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Abstract 
Reasons for the accelerated progression of liver fibrosis in HIV-1/HCV coinfection are not well defined. 
Increased microbial translocation and/or immune activation may play a role. The aim of this research was to 
investigate the relationship between Th17 and Th22 cells with microbial translocation, immune activation 
and liver fibrosis in HIV-1/HCV coinfection. 
HIV-1 infection led to a preferential reduction in peripheral Th17 and Th22 cells and a reduction in Th17:Treg 
and Th22:Treg cell ratios.  There was a negative correlation between Th17 and Th22 frequencies, Th17:Treg 
and Th22:Treg ratios with markers of microbial translocation and immune activation. In addition we found 
significant increases in the activity of the enzyme IDO, which promotes CD4 Treg development at the 
expense of Th17 cells. Alterations in the distribution of Th17, Th22 and Treg cells may be a mechanism 
through which immune activation promotes fibrogenesis. 
HIV-1/HCV coinfection led to increased immune activation and microbial translocation. There was a more 
marked depletion of Th17 cells than in HIV-1 monoinfection, and reduced Th22 cells, Th17:Treg ratio and 
Th22:Treg ratio, which were not seen in HCV monoinfection. Unlike HCV monoinfection there was no 
increase in Th1 cells in HIV-1/HCV coinfection. There was a stronger association between reduction in 
Th17:Treg, Th22:Treg ratios and markers of immune activation and microbial translocation in patients with 
HIV-1/HCV coinfection compared to  HCV monoinfection. Th1 cells displayed robust negative correlations 
with immune activation in HIV-1/HCV coinfection, but not in HCV monoinfection. There was no association 
between alterations in CD4 T cell subsets and liver fibrosis in HCV monoinfection. In HIV-1/HCV coinfection 
reduced Th17 cell and depleted Th1 responses were associated with liver fibrosis. Our research implicates 
HIV-1 driven depletion of Th1 and Th17 cells in the development of liver fibrosis in HIV-1/HCV co-infection.  
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Chapter 1 Background 
1.1 General introduction 
Acquired immunodeficiency syndrome (AIDS) due to human immunodeficiency virus (HIV) has caused 
significant mobidity and mortality since it was first described in 1981 (Centers for Disease Control, 1981). 
HIV, as the causative agent, was identified in 1983 by Francoise Barrè-Sinoussi and colleagues at the Pasteur 
Institute (Barre-Sinoussi et al., 1983). The earliest documented case of HIV infection is from Kinshasa; from a 
serum sample stored in 1959. Early reports demonstrated the depletion of cluster of differentiation (CD) 4 T 
cells and the consequential loss of immune control of multiple pathogens. The introduction of highly active 
antiretroviral therapy (HAART) in 1996 dramatically changed the clinical course and prognosis of HIV. In the 
developed world, where effective HAART is readily available, there has been a dramatic reduction in the 
numbers of deaths due to AIDS, while non AIDS related deaths have increased. Deaths due to liver disease 
have increased from 2% in 1995, to 13% in 2000 and 15% in 2005 (Rosenthal et al., 2009). 71% of the liver 
deaths in 2005 were related to hepatitis C virus (HCV) infection.  
HIV-1/HCV coinfected individuals have a more rapid and frequent progression to liver disease than their 
monoinfected counterparts (Soto et al., 1997). Thus HIV-1 coinfection of HCV may hold the key as to why 
some individuals with HCV develop liver fibrosis while others do not. This cohort of patients may serve to 
highlight significant deficiencies in the immune system that impact on the development of liver fibrosis. 
Recent studies have hypothesised that increased microbial translocation in HIV may, in the context of an 
HCV infected liver, result in enhanced lipopolysaccharide (LPS) signalling via toll-like receptor (TLR) 4 on 
hepatic stellate cells (HSC) and Kupffer cells leading to more rapid development of liver fibrosis and cirrhosis, 
with the consequential increased passage of microbial products to the systemic circulation where they 
contribute to the pathognomonic systemic immune activation of HIV-1 (see figure 1) (Balagopal et al., 2008). 
Other microbial products may be involved: with lipoteichoic acid (LTA) leading to up regulation of profibrotic 
genes in HSCs (Brun et al., 2005) and bacterial deoxyribonucleic acid (DNA) recognition by TLR-9 on HSCs 
leading to increased monocyte chemotactic protein (MCP)-1 messenger ribonucleic acid (RNA) expression 
and release (Gabele et al., 2008). Immune activation itself may drive the development of liver fibrosis via a 
number of mechanisms: induction of profibrotic cytokine release, T regulatory (Treg) cell transforming 
growth factor (TGF)-β1 induction with procollagen production (Zeng et al., 2011) and activated HIV-1-specific 
CD8 T cells leading to tumour necrosis factor (TNF)-α synthesis or tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) mediated hepatocyte apoptosis resulting in collagen deposition and development of 
fibrosis (Schacker et al., 2002)  Preferential depletion of helper T (Th) 17 cells, in the gastrointestional 
associated lymphoid tissue (GALT), has been suggested as a mechanism via which HIV-1 may accentuate 
microbial translocation and thus contribute to systemic immune activation (Brenchley et al., 2008). Th22 
cells have only recently been described as a CD4 T cell subset separate from Th17 cells, which produce 
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interleukin (IL)-22, but not IL-17 (Duhen et al., 2009) (Trifari et al., 2009). IL-22 functions to protect protect 
colonic epithelial integrity (Zheng et al., 2008) and therefore the depletion of Th22 cells in the GALT may 
drive increased microbial translocation. Their role in HIV, HCV and coinfection has yet to be investigated. The 
aim of this research is to investigate the effect of HIV-1/HCV coinfection on Th17 and Th22 cells and the 
presence of any association with microbial translocation, immune activation and / or liver fibrosis. 
Figure 1 HIV related gastrointestinal CD4 T cell depletion and microbial translocation contribute to HCV 
progression - adapted from (Balagopal et al., 2008) 
 
 
1.2 Overview of immune response to infection 
1.2.1 The innate immune response 
The innate immune response is the primary barrier against pathogens; it occurs within hours of infection in 
an antigen-non-specific manner. Pathogens express several signature molecules, known as pathogen-
associated molecular patterns (PAMPs) (Janeway and Medzhitov, 2002). PAMPs are recognised in the host 
by evolutionarily well conserved sensors known as pathogen recognition receptors (PRRs). Several families of 
PRRs exist and can be categorised into secreted, transmembrane, or cytosolic forms; including TLR, retinoic 
acid–inducible gene I (RIG-I) like receptors (RLRs), nucleotide oligomerization domain (NOD) like-receptors 
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(NLRs), and DNA receptors (cytosolic sensors for DNA). PRRs are expressed on innate immune cells (dendritic 
cells [DCs], macrophages, neutrophils and epithelial cells) (Kawai and Akira, 2010) (Takeuchi and Akira, 2010) 
(Medzhitov, 2007) (Blasius and Beutler, 2010). Each innate cell lineage expresses a defined set of PRRs 
allowing allocation of recognition responsibilities: phagocytosis, chemotaxis and production of effector 
molecules to influence both the innate and adaptive immune response. Recognition of PAMPs by PRRs 
rapidly triggers an array of anti-microbial inflammatory responses through the induction of various 
inflammatory cytokines, chemokines and type I interferons (IFNs) (Kumar et al., 2009a). The resulting 
inflammatory response leads to chemo-attraction of neutrophils to the area of infection, followed by 
monocytes which then mature into macrophages that engulf and destroy the pathogens.  
Secreted PRRs, which include pentraxins, collectins and ficolins, bind to microbial cell surfaces, activate the 
classical and lectin complement pathways and opsonize pathogens for phagocytosis by neutrophils and 
macrophages. The cytosolic PRRs include RLRs which detect RNA from RNA viruses. Recognition through 
RLRs leads to secretion of factors such as type I IFNs to activate dendritic cells. The NLRs, NOD1 and NOD2, 
are also cytosolic PRRs and detect breakdown products of intracellular bacteria.  
1.2.1.1 Toll like receptors 
TLRs, transmembrane PRRs, are the most widely studied (see figure 2). The human TLR family consists of at 
least 10 members (Rock et al., 1998). TLR1, 2, 4, 5 and 6 are expressed on the cell surface and recognise 
PAMPs derived from bacteria, fungi and protozoa, whereas TLR3, 7, 8 and 9 are exclusively expressed within 
endocytic compartments and primarily recognise nucleic acid PAMPs derived from various viruses and 
bacteria (Kawai and Akira, 2010) (Takeuchi and Akira, 2010) (Kumar et al., 2009a). TLR5 senses the flagellin 
protein expressed by flagellated bacteria. Endosomal TLRs predominantly detect microbial nucleic acids: 
TLR3 is stimulated by viral double stranded (ds) RNA, whilst CpG dsDNA derived from bacteria and viruses is 
recognised by TLR9 (Kumar et al., 2009b). Group B streptococci are recognised by TLR7 (Mancuso et al., 
2009) and RNA from RNA viruses is sensed by TLR7 and TLR8. Recognition of PAMPs by TLR1, TLR2, TLR4, 
TLR5 and TLR6 primarily induces the production of inflammatory cytokines, whereas TLR3, TLR7 and TLR9 
induce type I IFNs. 
TLR2 responds to cell wall components from predominantly gram-positive bacteria (LTA, peptidoglycan and 
bacterial lipoprotein) while LPS, a major cell wall component of gram negative bacteria, is primarily 
recognised by TLR4 (Chow et al., 1999). Recognition of LPS consists of complex interactions involving LPS-
binding protein (LBP) and soluble CD14 (sCD14) before binding to the CD14/TLR4/myeloid differentiation 2 
(MD2) receptor complex on the cell membrane of macrophages and monocytes (Shimazu et al., 1999, da 
Silva Correia et al., 2001). LBP is produced by gastrointestinal and hepatic epithelial cells (Schumann et al., 
1990), while sCD14 is secreted by monocytes and macrophages in response to LPS stimulation (Kitchens and 
Thompson, 2005). Activation of TLR4 by LPS activates the transcription factor nuclear factor kappa-light-
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chain-enhancer of activated B cells (NF-κB) and triggers several crucial intracellular signalling pathways 
leading to secretion of a number of pro-inflammatory cytokines such as TNF-α, sCD14, IL-1 and IL-6 
(Schletter et al., 1995).  
Figure 2 TLR families - adapted from (Rich, 1996) 
 
1.2.1.2 Type 1 interferons and viral infections 
Infection of cells with viruses induces the production of type I IFNs (IFN-α and IFN-β). Type I IFN synthesis is 
thought to occur in response to dsRNA. dsRNA forms the genome of some viruses and is formed as part of 
the life cycle for many viruses. dsRNA is recognised as a PAMP by TLR3 which signals through the adaptor 
molecule TIR-domain-containing adapter-inducing interferon-β (TRIF), to activate IFN regulatory factor (IRF) 
3 and IRF7. IRF3 and IRF7 can then form either homodimers or heterodimers that enter the nucleus and 
activate the transcription of a number of genes, principally those for IFN-α and IFN-β. IFN-α and IFN-β bind 
to the IFN receptor on infected and bystander cells. Binding to the IFN receptor activates the Janus Kinase – 
Signal Transducing Activators of Transcription (JAK-STAT) pathway which induces the synthesis of proteins 
(such as oligoadenylate synthetase and protein kinase R) which inhibit viral replication. In addition, IFNs 
induce the expression of co-stimulatory molecules on dendritic cells and macrophages to enable them to act 
as antigen presenting cells (APC) to fully activate T cells and hence initiate an adaptive immune response. 
Finally IFN-α and IFN-β stimulate the increased expression of major histocompatability complex (MHC) class I 
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molecules on all types of cells, which are recognised by the cytotoxic CD8 T cells, thus promoting the killing 
of virus-infected cells.  
1.2.2 The adaptive immune response 
The innate immune response initiates the development of the adaptive immune response; a pathogen-
specific, long-lasting, acquired immune response (Hoebe et al., 2004) (Iwasaki and Medzhitov, 2010). The 
main components are T lymphocytes, B lymphocytes and antibodies (Ab). A significant feature of the 
adaptive immune response is the ability to distinguish between self and non-self components, ensuring that 
self-antigens are tolerated while foreign/pathogen-antigens are recognised. The B and T lymphocytes 
express clonally rearranged receptors highly specific for unique antigens; B-cell antigen receptor (BCR), a 
transmembrane bound immunoglobulin (Ig) and T cells receptors (TCR). TCR recognise antigens as a complex 
of short linear peptides bound to MHC molecules on the surface of APCs (DCs, macrophages and B cells). 
1.2.2.1 T cell differentiation and T cell subsets 
T cells develop in the thymus. Thymocytes are initially double negative for CD4 and CD8 (TCR co-receptors), 
subsequently express both CD4 and CD8 (double positive), and finally mature into single positive T cells for 
CD4 or CD8.  During this process they undergo positive selection for recognition of self MHC, followed by 
negative selection with apoptosis of cells strongly reactive to self peptide. The mature T cells that emerge 
populate the peripheral organs. The two main T cell subsets are labelled according to the TCR co-receptor 
molecules they singularly express: CD4 T cells and CD8 T cells. T cells expressing CD4 are commonly referred 
to as Th cells whilst CD8 T cells are known as cytotoxic effector T cells (CTLs). CD4 and CD8 T cells bind to 
MHC class II and class I molecules respectively.   
Activated CD8 T cells undergo proliferation driven by IL-2. The effector function of CD8 T cells consists of 
both the production of cytokines (TNF-α and IFN-γ) that lead to clearance of viruses and cytolysis of infected 
cells. The release of cytotoxins forms pores in the infected host cell's plasma membrane causing the cell to 
lyse. Granzyme then enters host cells via the formed pores and induces apoptosis. Apoptosis can also be 
induced via interactions between the activated CD8 T cell’s Fas ligand and the infected host cell’s Fas 
receptor.  
Naive CD4 T cells may differentiate into several Th cell subsets which play a critical role in orchestrating 
adaptive immune responses to various pathogens (see figure 3).  The main determinants for Th cell 
differentiation are the cytokine milieu at the time of antigen encounter, the dose of antigen and route of 
antigen administration. Activation of naive CD4 T cells, by TCR and cytokine mediated signalling, results in 
the release of IL-2, which stimulates Th cell proliferation. Proliferating Th cells differentiate into Th cell 
subsets which are induced to produce specific cytokine profiles and stabilised by the presence of lineage-
specifying transcription factors and the signal transducer and activator of transcription (STAT) proteins. The 
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first two recognised effector T cell subtypes were Th1 and Th2 cells. Th1 cell development is driven by IFN-γ 
and IL-12. Th1 cells express the transcription factor T-bet and STAT-4; they secrete IFN-γ, TNF-α and IL-2 to 
promote neutrophil recruitment, macrophage activation, proliferation of CD8 T cells and inflammatory 
responses. Whereas Th2 cell differentiation is driven by IL-4 and they express the transcription factor GATA-
3 and STAT-6. Th2 cells secrete IL-4, IL-5 and IL-13 which stimulate B cell proliferation, antibody production 
and limits Th1-mediated inflammatory responses, thus preventing excessive tissue destruction.  
Recent work has shown that further CD4 T cell subsets may develop, governed by the expression of different 
transcription factors. They have different, possibly distinct, roles in the immune response, expressing 
different chemokine receptors, secreting different cytokines and localising to different sites in the body. 
Thus CD4 T cells represent a heterogeneous population of subsets that play an essential role in adaptive 
immunity and are made up of both effector and regulatory T cells.  
1.2.2.2 Th17 cells 
Th17 cells, a distinct T cell subset, are characterised by the expression of the transcription factor retinoic 
orphan receptor-c (RORc), STAT-3, IL-23 receptor and chemokine receptor (CCR) 4 and CCR6 (the receptors 
for chemokine ligand [CCL] 20 and β-defensins) (Acosta-Rodriguez et al., 2007) . They derive from CD161+ 
naive CD4 T cells in an environment rich in TGF-β, IL-1β and IL-6, with IL-21 or IL-23 (Yang et al., 2008) (Manel 
et al., 2008) . TGF-β is required to induce RORc, but its expression and function are inhibited by excess TGF-β. 
Only when IL-6 plus IL-21 or IL-23 are present is RORc relieved from inhibition and then naive CD4 T cells can 
begin transcribing IL-17 (Korn et al., 2009). Th17 cells are mainly localised in the mucosal tissue, likely driven 
by the chemokine homing receptor. Adenosine tri-phosphate from commensal bacteria triggers Th17 
differentiation in the colonic lamina propria (Round and Mazmanian, 2009). They secrete IL-17A, IL-17F, IL-
21, IL-22, and CCL20 (Wilson et al., 2007). IL-17A and IL-17F are also produced by other cell types from both 
the adaptive and innate immune system including: γδ T cells, natural killer (NK) T cells, NK cells and 
eosinophils (Korn et al., 2009). The main function of Th17 cells is the clearance of extracellular pathogens 
during infections, but they also promote inflammation and this has been implicated in the pathogenesis of 
some autoimmune and inflammatory conditions (Oukka, 2008) (Fouser et al., 2008). IL17A and IL17F have 
pro-inflammatory properties and act on a broad range of cell types to induce the expression of cytokines 
(TNF, IL-1β, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF], granulocyte colony 
stimulating factor [G-CSF]), chemokines (Chemokine (C-X-C motif) ligand [CXCL] 1, CXCL8, CXCL10) and 
metalloproteinases (Korn et al., 2009). IL-17A and IL-17F play a critical role in the recruitment, activation and 
differentiation of neutrophils, either directly through IL-8 production (Pelletier et al., 2010) or indirectly by 
inducing the production of colony-stimulatory factor and CXCL8 by tissue resident cells (Ouyang et al., 2008). 
IL-17 has been shown to enhance the expression of antimicrobial peptides (such as β defensin-2) (Liang et 
al., 2006) (Kao et al., 2004). IL-17 supports the production of tight junction proteins such as claudin and 
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stimulates the proliferation of gastrointestinal enterocytes. Thus Th17 cells prevent extracellular bacterial, 
viral and fungal mucosal infection and maintain the intestinal epithelial barrier (Aujla et al., 2007) (Dubin and 
Kolls, 2008). 
Figure 3 CD4 T cell differentiation model – adapted from  (King et al., 2008) 
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IL-21, a pleiotropic C γ-chain cytokine, is produced by a number of CD4 T cells; Th17 cells, follicular Th cells 
and NK T cells. It has the ability to act on multiple cells of both the innate and adaptive immune system. IL-21 
induces the development of Th17 cells via up regulation of IL-23R (Zhou et al., 2007), blocks the 
differentiation of regulatory T cells (Monteleone et al., 2008), maintains CD8 T cell function (limiting the 
exhaustion and loss of function of CD8 T cells in chronic viral infections) (Zeng et al., 2005), regulates B cell 
differentiation (Kuchen et al., 2007), and is important in regulating effector T cells in the gut (Fantini et al., 
2008). Studies in the murine lymphocytic choriomeningitis virus (LCMV) model showed that IL-21 produced 
by virus-specific CD4 T cells was critical in controlling chronic infection and in preventing exhaustion of CD8 T 
cells  (Yi et al., 2009b) (Frohlich et al., 2009) (Elsaesser et al., 2009). 
1.2.2.3 Th22 cells 
Th22 cells are a distinct CD4 T cell subset that produces IL-22, but neither IL-17 nor IFN-γ, which have only 
recently been described (Duhen et al., 2009) (Trifari et al., 2009). Differentiation is promoted by IL-6 and IL-
23, but not TGF-β, and is dependent on expression of aryl hydrocarbon receptor (Duhen et al., 2009) (Trifari 
et al., 2009). The human Th22 cell expresses CCR6 and the skin homing receptors CCR4 and CCR10. IL-22 
signals through the IL-22R/IL-10R2 receptor complex which is absent on immune cells, but is found on cells 
of the gastrointestinal tract, liver, respiratory tract and skin. IL-22 is instrumental in autoimmune disease and 
this has been demonstrated in psoriasis (Zheng et al., 2007). In mouse models IL-22 has been shown to be 
critical for host defence against attaching and effacing intestinal bacterial infections and has been 
demonstrated to protect colonic epithelial integrity (Zheng et al., 2008). Possible mechanisms are via the 
induction of antimicrobial peptides such as β-defensins (Liang et al., 2006) and Reg family proteins (Zheng et 
al., 2008) and regulation of tight junctions of colonic epithelial cells (Kebir et al., 2007). IL-22 has also been 
shown to play a role in liver disease. Injection of recombinant IL-22 into mice prior to administration of 
inflammatory molecules reduced the amount of hepatocyte damage, while injection of IL-22 neutralising 
antibodies immediately after inflammatory molecules exacerbated hepatic injury (Radaeva et al., 2004). 
Administration of IL-22 in mice has been shown to result in up regulation of hepatic LBP, reaching levels 
known to neutralise LPS (Wolk et al., 2007).  
1.2.2.4 Treg cells 
Regulation of the immune response is vital in maintenance of immune homeostasis. Treg cells are crucial in 
the development and maintenance of tolerance via cell-cell interaction with effector T cells and DCs as well 
as release of immunosuppressive cytokines such as TGF-β and IL-10, and the generation of adenosine 
catalysed by subset-specific expression of ectoenzymes (Tang and Bluestone, 2008) (Deaglio et al., 2007). 
Tregs are heterogeneous and most are defined by expression of the transcription factor forkhead box 
protein 3 (FoxP3) and STAT-5 (Hori et al., 2003). There are two major subsets. The large majority of Tregs are 
found within the CD4 Th cell population, constitutively express high levels of CD25 and are thymus-derived 
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(Fontenot et al., 2003). These are known as CD4+CD25+FoxP3+ Tregs or natural Tregs (nTregs). nTregs 
constitute about 5% to 10% of peripheral CD4 T cells in humans. nTregs have been shown to be stable and 
function via antigen-independent, contact dependent and cytokine-independent mechanisms (Shevach, 
2002) (Yamagiwa et al., 2001) (Kretschmer et al., 2005). However, Tregs can be induced in the periphery 
from naive CD4 T cells by exposure to TGF-β (Sakaguchi et al., 2008). Like nTregs, inducible Tregs (iTregs) 
express FoxP3, but may be less stable (Murphy and Stockinger, 2010). 
Specific cell surface markers to distinguish nTregs and iTreg cells have not currently been identified. CD25 is 
also expressed by effector T cells upon antigen activation (although only transiently), cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4) (Takahashi et al., 2000) and glucocorticoid-inducer tumour 
necrosis factor (McHugh et al., 2002) are also upregulated following activation of naïve CD4+CD25- T cells. 
Lymphocyte activation gene 3, an MHC class II binding CD4 homologue, was shown to be selectively 
expressed on Tregs upon activation and maybe involved in their suppressive function (Huang et al., 2004), as 
was glycoprotein A repetitions predominant (GARP) (Kinter et al., 2004).  Currently the intracellular marker 
Foxp3 is considered the optimal marker of nTregs; although it is also expressed by non T cells eg tumour 
cells. IL-7R (CD127) is expressed in low levels in both iTregs and nTregs and so in combination with Foxp3 
may allow more accurate identification (Hartigan-O'Connor et al., 2007) (Liu et al., 2006). FoxP3 can be 
upregulated on activated CD4 T cells and therefore controversy exisits about its use as a marker of Treg cells 
in HIV infection (Wang et al., 2009).  
1.2.2.5 Effector Th cell plasticity 
Ever since the discovery of Th1 and Th2 cells, it has been clear that there are human T cell clones that 
simultaneously produce both Th1 (IFN-γ) and Th2 (IL-4) cytokines, defined as Th0 cells. Now there are further 
examples of T cells with dual personality. Th1Th17 cells have recently been described. They are a population 
of CD4+ T cells capable of producing Th1 (IFN-γ) and Th17 (IL-17) cytokines and express both transcription 
factors T-bet and ROR-c as well as the chemokine receptors CXCR3 and CCR6 (Acosta-Rodriguez et al., 2007) 
(Annunziato et al., 2007). They were initially identified as memory T cells specific for Mycobacterium 
tuberculosis.  
Th17 and iTregs develop from a common progenitor cell and are thought to have a reciprocal relationship 
(see figure 4). TGF-β orchestrates Th17 and Treg cell differentiation depending on TGF-β levels and the 
cytokine environment. High levels of TGF-β, which repress IL-23R expression, in the absence of IL-6, promote 
the development of iTregs from naive CD4 T cells with the expression of the transcription factor FoxP3, while 
the presence of IL-6 and IL-23, with low levels of TGF-β inhibits iTregs and induces Th17 cells (Sakaguchi et 
al., 2008). Retinoic acid inhibits ROR-c while promoting Treg differentiation (Mucida et al., 2007). In addition 
IL-2 inhibits Th17 cell differentiation but is necessary for the generation and maintenance of Treg cells 
(Laurence et al., 2007). Recently a link between indoleamine 2,3-dioxygenase (IDO) metabolism and the 
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differentiation of Th17 and Tregs from naive CD4 T cells has been suggested. IDO is expressed by both 
epithelial and DCs and induced by the proinflammatory cytokines IFN-γ and TNF-α. It is the rate-limiting 
enzyme involved in the catabolism of the amino acid tryptophan (TRP) through the kynurenine (KYN) 
pathway (Mellor and Munn, 2004). TRP catabolites are able to induce the expression of FoxP3 and the 
generation of iTregs while suppressing the expression of ROR-c and the generation of Th17 cells (Sharma et 
al., 2009). Recent studies have suggested that Th cells can switch subset type with committed CD4 T cell 
subsets acquiring expression of alternative cytokines if stimulated under appropriate conditions. This has 
been demonstrated by Foxp3+ iTregs that become Th17 cells (Koenen et al., 2008) (Deknuydt et al., 2009). A 
significant number of iTregs in peripheral blood and lymphoid tissue which express CCR6 can develop into 
Th17 cells with the capacity to produce IL-17 on mucosal sites during inflammation (Voo et al., 2009).  
Figure 4 TGF-β mediated regulation of the differentiation and function of Th17 and iTreg cells - adapted 
from (Chen et al., 2011) 
 
TGF-β orchestrates Th17 and Treg cell differentiation depending on the concentration and cytokine environment. Low 
concentrations of TGF-β with IL-6 and IL-23 favor the differentiation of Th17, whereas Treg cell differentiation is favoured under high 
concentrations of TGF-β, which represses IL-23R expression, and the absence of IL-6. In addition retinoic acid is known to inhibit ROR-
c while promoting Treg differentiation. 
 
Further plasticity of CD4 T cell subsets is observed with the differentiation of Th17 to Th1 cells; IL-23 without 
TGF-β resulted in a progressive extinction of IL-17 and promoted the emergence of IFN-γ producing cells, 
with IL-12 stimulation inducing an extinction of ROR-c and STAT-3 with development of a Th1 phenotype (T-
bet and STAT-4) (Lee et al., 2009). 
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1.2.2.6 B cell differentiation 
B cell development involves the sequential differentiation of haematopoietic stem cell precursors into 
immature and transitional B cells in the bone marrow. To control autoreactivity, apoptosis of autoreactive B 
cells occurs in the bone marrow. Transitional B cells emerge into the peripheral blood with subsequent 
maturation to mature B cells consisting of multiple B cell populations including: mature naive, memory and 
terminally differentiated plasma. Mature B cells express surface IgM, IgD, CD19 and CD20. Their survival 
depends on recognition of their cognate antigen and subsequent differentiation.  
The BCR can bind a vast variety of structures: proteins, glycoproteins, polysaccharides, virus particles and 
bacterial cells by recognition of surface epitopes. B cell responses to antigen are enhanced by simultaneous 
signalling through the BCR complex made up of CD19, CD21 and CD81. Upon activation of the BCR 
intracellular signalling pathways are initiated which result in activation of transcription factors NF-κB, nuclear 
factor of activated T cells and activator protein-1 which act to induce specific gene transcription, leading to 
cell proliferation and differentiation. In addition the antigen is delivered to intracellular sites where it is 
degraded to give peptides that are returned to the cell surface bound to MHC class II molecules. Antigen 
specific Th cells recognise these peptides MHC class II complexes and are activated. Effector Th cells secrete 
cytokines to induce B cell proliferation and differentiation into memory B cells which persist after antigen 
challenge, expand quickly in response to secondary antigen responses and are able to differentiate into 
terminally differentiated plasma cells. Memory B cells comprise two subsets: IgM memory B cells which are 
important in T cell independent immune responses early in infection and class switched memory B cells 
which are important for adaptive T cell dependent humoral responses. Class switched memory B cells are so-
called because isotype-switching of the BCR has taken place; therefore these cells express IgG, IgA or IgE.  
Plasma cells are thought to be differentiated from both IgM memory and class switched memory B cells. 
Plasma cells secrete large amounts of specific immunoglobulin, are extremely long-lived and replenished 
from the pool of memory B cells only when required. 
Antibodies have three principal roles in immune defence: neutralisation, opsonisation and complement 
activation. Antibodies of different classes have distinct effector functions. The first antibodies synthesised in 
an infection are always IgM as they can be expressed before class switching. Although their affinity is low 
they form pentamers allowing them to bind simultaneously to multivalent antigens. IgM is especially 
effective in activating the complement system, along with IgG1 and IgG3. In neutralisation, IgG1, IgG2, IgG3, 
IgG4 or IgA antibodies typically bind to molecules such as viral surface proteins, surface glycoproteins or 
bacterial toxins and block pathogenic interaction with host cells, decreasing viral replication. IgG1 and IgG3 
drive opsonisation where antibody binds to receptors on the cell membrane of a pathogen to label it for 
rapid degradation and removal by phagocytosis.   
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1.3 Human Immunodeficiency Virus 
HIV is a lentivirus belonging to the retroviridae family and was initially identified in 1983 as a T lymphotropic 
retrovirus (Barre-Sinoussi et al., 1983). Infection in humans leads to chronic infection which results in 
progressive destruction of the immune system, ultimately resulting in AIDS which is characterised by 
susceptibility to opportunistic infections and tumours. Two strains of HIV cause infection in humans; HIV-1 
and HIV-2. Both are thought to have arisen from cross-species transmission from African non-human 
primates of simian immunodeficiency virus (SIV); HIV-1 from three transmissions of chimpanzee virus 
(SIVcpz) giving rise to groups M, N and O (Gao et al., 1999), and HIV-2 from eight transmissions of sooty 
mangabey virus (SIVsmm) giving rise to groups A to H (Damond et al., 2004) (Hirsch et al., 1989). For the 
purpose of this research, only HIV-1 has been examined and will be discussed. 
1.3.1 Epidemiology 
The pandemic of HIV is constantly evolving in magnitude, viral diversity, mode of transmission and 
geographically. Today all regions of the world are affected with 33.3 million people infected by the end of 
2009 (see figure 5) (UNAIDS, 2010). 2.6 million people became newly infected in 2009 and 1.8 million died of 
AIDS. Sub-Saharan Africa remains the epicentre of the pandemic with 68% of infections, but the pandemic 
here appears to be stabilising with the incidence of HIV falling by more than 25% in 22 countries within Sub-
Saharan Africa between 2001 and 2009. However it has increased by more than 25% in seven countries 
world wide, with Eastern Europe and Central Asia seeing the largest increase in HIV prevalence with a 
threefold increase between 2000 and 2009. The epidemic continues to grow in North America and Western 
and Central Europe with a 30% rise in prevalence between 2001 and 2009. 
In Sub-Saharan Africa heterosexual transmission is the dominant mode of transmission, closely followed by 
mother to child transmission (UNAIDS, 2010). Recently high levels of HIV infection have been demonstrated 
amongst groups of men who have sex with men (MSM) in Sub-Saharan Africa; the majority of these men will 
also have sex with women (Smith et al., 2009).  In Asia the epidemic is concentrated in individuals who inject 
drugs, MSM and sex workers and their clients. In Eastern Europe and Central Asia the rapid rise in HIV 
infections was driven by a surge in intravenous drug use (IDU), while MSM participating in unprotected sex 
dominates transmission in North America and Western and Central Europe. There is strong evidence of 
resurgent HIV epidemics among MSM in North America and Western and Central Europe (Bezemer et al., 
2008). The 3160 new HIV diagnoses among MSM in 2007 in the United Kingdom were the most ever 
reported up to that point (Lattimore et al., 2008).  
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Figure 5 Adults and children estimated to be living with HIV in 2009 - adapted from (UNAIDS, 2010) 
Total: 33.3 million [31.4 million – 35.3 million]
Western & 
Central Europe
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[720 000 – 910 000]
Middle East & North Africa
460 000
[400 000 – 530 000]
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Eastern Europe 
& Central Asia
1.4 million 
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South & South-East Asia
4.1 million
[3.7 million – 4.6 million]
Oceania
57 000
[50 000 – 64 000]
North America
1.5 million
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Central & 
South America
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[1.2 million – 1.6 million]
East Asia
770 000
[560 000 – 1.0 million]
Caribbean
240 000
[220 000 – 270 000]
Adults and children estimated to be living with HIV  2009 
 
1.3.2 Pathogenesis: structure and life cycle 
The HIV-1 virion is made up of a spherical envelope (120nm in diameter) around a conical shaped capsule 
enclosing two copies of single stranded (ss) RNA and two enzymes essential for replication and integration: 
reverse transcriptase and integrase. The envelope consists of two proteins forming spikes on the virions’s 
surface; the transmembrane protein gp41 and the external glycoprotein gp120 (Ray and Doms, 2006). The 
capsid comprises the protein p24. The RNA strands contain nine open reading frames encoding genes for 
structural proteins (gag, env, pol), regulatory proteins (tat, rev, nef) and accessory proteins (vif, vpr, vpu). 
The life cycle begins when gp120 binds to the CD4 receptor of the host cell (see figure 6). Gp41 then binds to 
the host cell co-receptor (CCR5 or CXCR4) resulting in irreversible conformational changes in the viral 
envelope allowing fusion (Eckert and Kim, 2001). Pores form in the host cell allowing the viral capsid to enter 
(Platt et al., 2005). Disassembly of the capsid allows viral reverse transcriptase to form viral DNA from the 
viral RNA genome (Coffin et al., 1997). HIV-1 reverse transcriptase is error prone, with no proof reading 
mechanism, resulting in high mutation rates and the development of quasi-species (Coffin et al., 1997). HIV-
1 integrase incorporates the viral DNA into the host DNA, where the host cell’s transcription and translation 
mechanisms are exploited. The capsid proteins (encoded by gag), viral enzymes (encoded by pol) and two ss 
RNA genomes are transported to the host cell membrane for assembly of progeny virus. Env encodes gp160 
which is constructed in the endoplasmic reticulum and glycosylated in the Golgi complex prior to cleavage 
into gp120 and gp41. The virion is then released via budding, incorporating a fragment of the host cell 
membrane within the envelope protein (Cantin et al., 2005). 
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Figure 6 HIV life cycle - adapted from (Ho and Bieniasz, 2008) 
 
1.3.3 Pathogenesis: acute infection 
The CCR5-tropic HIV-1 viral strain has selective transmission advantage and thus makes up the majority of 
founder virus, with CXCR4-tropic virus only rarely being transmitted, but emerging at later stages of infection 
associated with increased pathogenicity (Connor et al., 1997). In 80% of adults infected with HIV-1, infection 
initiates with transmission across a mucosal barrier (UNAIDS, 2010). Most evidence is based on vaginal 
transmission via research on human tissue explants and the rhesus macaque model (Haase, 2010) (Zhang et 
al., 1999) (Li et al., 2005).  CD4 T cells and Langerhans cells act as the earliest targets (Hladik et al., 2007) 
(Boggiano and Littman, 2007) (Lackner and Veazey, 2007). Early low-level propagation is thought to occur in 
partially activated CD4 T cells of the genital mucosa. At this stage the virus cannot be detected in the plasma.  
Recently the gut homing receptor intergin α4β7 has been identified as an additional receptor that gp120 
binds to and signals through (Arthos et al., 2008). In mucosal tissues a subset of CCR5+CD4 T cells expresses 
α4β7. α4β7+CCR5+ CD4 T cells are highly permissive to infection by HIV-1 and appear to be ideal targets for 
efficient transmission. Gp120-α4β7 interactions mediate the activation of lymphocyte function-associated 
antigen-1 which facilitates the formation of virological synapses and cell-to-cell spread of HIV-1. It has been 
suggested that gp120-α4β7 interactions play an important role in the very early events following sexual 
transmission of HIV-1 (Cicala et al., 2011). 
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It is likely to take three to six days for the virus to spread beyond the submucosal CD4 T cells. Irrespective of 
the transmission route the virus migrates via draining lymph nodes to the GALT of the lamina propria where 
memory CCR5+CD4 T cells are rapidly depleted (Haase, 2010, Paiardini et al., 2008). The preponderance of 
HIV-1 for the GALT is likely due to the concentrated numbers of CD4 T cells (5% of total body lymphocytes 
are found in the periphery, with 50% in the GALT) (Mowat and Viney, 1997) and a high frequency of CCR5 
expressing CD4 T cells (Anton et al., 2000) (Poles et al., 2001). This rapid expansion of HIV-1 in the GALT is 
swiftly followed by the dissemination of HIV-1 systemically to other secondary lymphoid tissues and the 
establishment of viral latency (silent integration of HIV-1 DNA into the genome of host resting T cells). 
Latently infected cells allow the proviral DNA to evade detection by the immune system, while being able to 
reactivate and continue replicating at any time. They are resistant to antiretroviral therapy (ART) and thus 
effectively thwart attempts at viral eradication (Perelson et al., 1997). Immune response lags behind this 
burst of viraemia resulting in an acute HIV syndrome which manifests as a flu-like illness with fevers and 
lymphadenopathy (Gurunathan et al., 2009). Plasma viraemia will peak at three to four weeks post exposure 
(up to 10 million copies per millilitre) (Little et al., 1999), before declining spontaneously over several 
months to reach a viral set point. The viral set point is an important predictor of disease progression (Mellors 
et al., 1996). 
Figure 7 Natural history of HIV infection - adapted from (Grossman et al., 2006) 
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The primary immune response to HIV-1 infection is an acute-phase reaction three to five days after 
transmission (Kramer et al., 2010). There is a surge of inflammatory cytokines (IFN-α and IL-15), excreted 
initially by DCs and later by monocytes, macrophages, NK cells and T cells. Paradoxically while inciting 
antiviral immune responses the cytokine storm likely induces immune activation and the consequential loss 
of CD4 T cells. The initial antibody response to the viral envelope is directed at gp41, but is non-neutralising, 
while protective antibodies (neutralising antibodies against gp120 and antibodies that mediate cellular 
cytotoxicity) do not develop for weeks, too late to influence the course of infection (Tomaras et al., 2008). 
Primary CD8 T cell responses, focused on one to three epitopes found in nef and gag, appear days prior to 
plasma viraemia (Lichterfeld et al., 2004). Lysis of HIV-1 infected cells occurs through perforin and granzyme 
B mediated apoptosis (Hersperger et al., 2011) and suppression of viral replication or viral entry into host 
cells via secretion of chemokines (macrophage inflammatory protein [MIP1] α, MIP1β, CCL5) (Cocchi et al., 
1995), as well as IFN-γ, IL-2 and TNF-α production. However HIV-1 is not eliminated. This is partially due to 
selection of escape mutants, with new CD8 T cell responses, to different epitopes, also often escaped. Later 
CD8 T cell responses however do appear to effectively focus on regions of the virus that can mutate and 
drive the formation of a less virulent virus (Leslie et al., 2004). In addition in progressive disease CD8 T cell 
exhaustion with up regulation of PD-1 is observed which results in reduced cytolytic capacity, reduced 
production of chemokines and absence of the formation of memory CD8 T cells (Rosignoli et al., 2007, Zhang 
et al., 2007). Despite this, these CD8 T cell responses are felt to be the most important cell mediated 
response and likely contribute to the control of HIV-1 as the viral load falls and a viral set point is found. This 
is highlighted firstly by research demonstrating that patients with HLA-B57 and HLA-B27 have better viral 
control and longer survival, as these HLA types present highly conserved parts of HIV-1 to CD8 T cells forcing 
the virus to escape control with viral strains of much reduced replicative fitness (International et al., 2010) 
and secondly by studies of pathogenic SIV infection where in vivo depletion of CD8 T cells leads to rapid viral 
replication with rapid progression to AIDS and death (Schmitz et al., 1999). 
During acute HIV-1 infection, once antiviral immune responses are established, the sharp decline in 
peripheral CD4 T cell counts soon recovers (see figure 7). However, the GALT memory CCR5+CD4 T cells mass 
depletion is irreversible and persists (Brenchley et al., 2004, Guadalupe et al., 2003) resulting in chronic 
locally impaired immune function. During acute SIV infection 60% of all memory CD4 T cells in the jejunum 
harbour SIV-Gag DNA, suggesting direct viral cytopathic effects are responsible for the mass depletion of 
GALT CD4 T cells (Mattapallil et al., 2005) in addition to bystander apoptosis (Li et al., 2005). The lack of 
recovery, and thus irreversible depletion, of GALT CD4 T cells may be explained by their short half life, 
depletion by ongoing direct infection and killing by HIV or HIV-specific T cells, and thymic dysfunction 
resulting in a finite source of naïve CD4 T cells from which pools of memory CD4 T cells are restored 
(Brenchley et al., 2006a). This rapid, early, irreversible loss of CD4 T cells probably accounts for the weak CD4 
T cell response in acute HIV-1 infection. 
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The effect of ART on GALT CD4 T cell restoration is unclear; in some studies reconstitution is delayed and 
incomplete  (Mehandru et al., 2004, Guadalupe et al., 2003) (Mehandru et al., 2006) (Guadalupe et al., 2006) 
(Tincati et al., 2009) (Gordon et al., 2010), while in others prolonged virus suppression is associated with 
GALT CD4 T cell levels similar to those in healthy controls (Sheth et al., 2008) (Ciccone et al., 2010).  
1.3.4 Pathogenesis: chronic infection - immune activation and microbial translocation 
The hallmarks of HIV-1 infection include chronic immune activation and loss of CD4 T cells, which eventually 
leads to susceptibility to opportunistic infections (Brenchley and Douek, 2008). While in acute infection 
direct infection of target cells and bystander apoptosis, leads to a severe selective CD4 T cell lymphopenia in 
the GALT, in chronic disease it is the persistence of immune activation that leads to peripheral CD4 T cell 
death and progressive disease.  
Immune activation is a pathognomonic feature of progressive HIV-1 infection and is a robust predictor of 
disease progression (Giorgi et al., 1999). It was first described in B cells over 25 years ago (Lane et al., 1983). 
In chronic HIV-1 infection immune activation is characterised by: polyclonal B cell activation (Lane et al., 
1983), increased turnover of CD4 and CD8 T cells (Hellerstein et al., 1999), a high frequency of ‘activated’ 
phenotype T cells (Hazenberg et al., 2000), and increased levels of pro-inflammatory cytokines and 
chemokines (Valdez and Lederman, 1997). This results in lymph node retention of effector T cells, clonal 
exhaustion, drainage of memory T cell pools, and generation of activated T cells allowing perpetuation of HIV 
replication.  
The causative factors of immune activation in HIV-1 disease are not fully understood and are likely 
multifactorial and interconnected. HIV-1 specific T cells are too infrequent to explain the numbers of 
activated and effector T cells witnessed in chronic HIV-1 disease. TLR triggering may play an important role 
(Mandl et al., 2008). TLR7 and TLR9 are differentially regulated in pathogenic versus (vs) non-pathogenic SIV 
infections. Triggering of TLR7 and TLR9, expressed by plasmacytoid DCs, results in the induction of 
downstream adaptor molecules and IFN-α-stimulated genes (ISGs). Binding of HIV proteins (Env 
[gp120/gp160] and Nef) to cellular proteins (CD4, CCR5 and CD3-TCR respectively) may induce immune 
activation (Arhel and Kirchhoff, 2009). In addition direct viral killing of Tregs may aggravate immune 
activation (Terzieva, 2008). However; the fact that although effective ART leads to undetectable plasma HIV-
1 viral loads, T cell activation is not fully suppressed suggests that other, non HIV-1 dependent, mechanisms 
are involved. In numerous settings including graft vs host disease (GvHD), inflammatory bowel disease (IBD) 
and gut surgery, products of microbial translocation are correlated with systemic immune activation (Cooke 
et al., 1998) (Caradonna et al., 2000) (Schietroma et al., 2006). Recent studies have suggested that increased 
microbial translocation in HIV-1 may be one of the main drivers of immune activation. 
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Microbial translocation is the process by which immunostimulatory gut-derived microbes or microbial 
products such as LPS, LTA and bacterial DNA fragments translocate from the intestinal lumen to the systemic 
circulation in the absence of overt bacteraemia (see figure 8). LPS and the well-conserved 16SrDNA subunit, 
common to most bacteria, can be used as indicators of microbial translocation (Cooke et al., 1998, 
Caradonna et al., 2000, Schietroma et al., 2006). Determination of LBP is felt to be a more reliable marker of 
microbial translocation than LPS because the half life of LBP is longer (Schumann and Latz, 2000). sCD14 can 
be measured to establish evidence for direct chronic LPS stimulation (Brenchley et al., 2006b). 
Figure 8 Microbial translocation may lead to immune activation in chronic HIV infection - adapted from 
(Haynes, 2006) 
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In healthy individuals immunological and structural barriers, of the gastrointestinal tract, act to limit 
translocation of potentially pathogenic microbes to the lamina propria and mesenteric lymph nodes, thus 
averting overwhelming local and systemic inflammation (see figure 8) (Macpherson and Harris, 2004). In the 
event of limited microbial translocation a number a mechanisms occur to prevent overwhelming sepsis:  
1. sCD14 can remove LPS from membrane CD14 and divert it to plasma lipoproteins (Kitchens and 
Thompson, 2005) (Cavaillon and Adib-Conquy, 2006).  
2. Naturally occurring IgM, IgA and IgG antibodies to the LPS core oligosaccharide (endotoxin-core 
antibodies [EndoCAb]), bind to and clear LPS from the circulation (Strutz et al., 1999).  
3. High levels of LBP neutralise LPS limiting their immune stimulatory activity (Lamping et al., 1998) 
(Zweigner et al., 2001).  
4. Repeated exposure to TLR ligands results in tolerance, a protective mechanism aimed at limiting 
inflammation (Pimentel-Nunes et al., 2010). 
HIV-1 infection results in local  impairment of immune function due to the mass irreversible depletion of 
GALT CD4 T cells (described above) and in damage to the integrity of the gastrointestinal epithelial barrier. 
HIV-1 associated enteropathy results in infiltration of lymphocytes, crypt hyperplasia, villous atrophy and 
blunting (Batman et al., 1989) with increased enterocyte apoptosis and transepithelial permeability (Kotler, 
2005, Bjarnason et al., 1996). Alterations in intestinal permeability are thought to be caused by: HIV-1 
exposure and/or local immune cell activation mediating cytokine production from infiltrating lymphocytes 
(Epple et al., 2009) (Li et al., 2008) (Sankaran et al., 2008). Exposure of intestinal and genital epithelial cell 
lines in vitro to HIV-1 surface glycoproteins results in inflammatory cytokine secretion by epithelial cells, loss 
of tight junctions and increased viral and bacterial translocation across epithelial cell monolayers (Nazli et al., 
2010) supporting previous data showing that HIV-1 gp120 protein may alter intestinal permeability through 
increased production of TNF-α secretion by gastrointestinal epithelial cells (Schmitz et al., 2002). There is 
down regulation of genes associated with cell cycle regulation, lipid metabolism, epithelial cell barrier and 
digestive functions leading to increased permeability (Sankaran et al., 2005). In addition impairment of 
barrier function in intestinal biopsies of HIV-1 infected patients is associated with increased IL-2, IL-4, IL-5 
and TNF-α in supernatants of cultured intestinal biopsies  (Epple et al., 2009). Thus the gastrointestinal 
mucosal barrier suffers both immunological and structural insults early in HIV infection. Alteration in these 
barriers is thought to increase microbial translocation. 
The evidence, firstly that microbial translocation is increased in HIV-1 disease and secondly that this may 
drive immune activation is growing. Brenchley et al have demonstrated that plasma LPS and LBP levels are 
increased in chronic HIV-1 (compared to acute HIV-1 or healthy controls [HCs]), while plasma levels of sCD14 
are increased in acute and chronic HIV-1 (Brenchley et al., 2006b). LPS levels in HIV-1 are correlated with 
increased frequencies of CD38+HLA-DR+CD8 T cells. LPS levels are dramatically reduced in pathogenic SIV 
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infection after the administration of ‘gut-sterilising’ antibiotics, strongly suggesting that the gut is the main 
source of LPS (Brenchley et al., 2006b). LPS levels were shown to reduce following initiation of ART, although 
at 48 weeks they remained elevated two fold compared to healthy controls (Brenchley et al., 2006b), and 
raised LPS levels are seen in immunologic-non-responders (Marchetti et al., 2008). These individuals have an 
increased risk of HIV-1 progression (Kaufmann et al., 2003). Treatment interruption results in stable LPS 
levels in the first six weeks, while frequencies of activated CD8 T cells increase (Papasavvas et al., 2009). It 
was suggested that initially LPS is cleared by EndoCAb until these titres decrease so that clearance is no 
longer effective due to increased microbial translocation or B cell dysfunction or both. Brenchley et al 
similarly demonstrated normal LPS levels in acute HIV-1 infection with increased titres of EndoCAb 
compared to chronic disease, suggesting that initial LPS is cleared by EndoCAb, but persistent LPS cannot be 
neutralised due to insufficient antibody titre levels (Brenchley et al., 2006b). A further study from the same 
group has confirmed the above findings using 16SrDNA as a marker for microbial translocation (Jiang et al., 
2009). More recently tissue level evidence of translocation of microbial products from the lumen of the 
intestine into the lamina propria and to draining and peripheral lymph nodes and liver, accompanied by local 
immune responses in affected tissues, has been demonstrated in SIV models (Estes et al., 2010).  
Results from Africa have been conflicting: a longitudinal study in Uganda (Redd et al., 2009) found no 
association between circulating LPS and progression to AIDS (CD4 T cell decline or death), while cross-
sectional studies in Kenya (Lester et al., 2009) and South Africa (Cassol et al., 2010) found significant 
associations between HIV-1 infection and plasma LPS. Only the South African study looked for a correlation 
between LPS and immune activation (CD38+HLA-DR+ CD8 T cells) and none was found. It is important to 
note that the majority of studies to date have been cross-sectional and therefore causality cannot be 
inferred.  
Whether endotoxaemia in HIV-1 is a cause or consequence of disease progression still needs to be defined. It 
is possible that both mechanisms coexist; immune activation results in a dysfunctional immune system 
unable to control translocation, while microbial products activate the immune system leading to progressive 
immunodeficiency.  Recent studies have shown that: HIV-1 RNA can enhance TLR4 mediated response to LPS 
(Lester et al., 2009), EndoCAb titres are reduced in chronic disease (Brenchley et al., 2006b) and it is possible 
that reduced IL-22 in HIV-1 leads to reduced LBP levels all causing dysregulation of endotoxin tolerance. The 
fact that natural hosts for SIV have low levels of LPS and immune activation and do not progress to AIDS 
(Brenchley et al., 2006b) emphasises the importance microbial translocation plays in the pathogenesis of SIV 
infection. Yet natural hosts do display mass depletion of mucosal CD4+ T cells in acute infection, with a 
stable plateau reached in sooty mangabeys and in African green monkeys a significant recovery is observed 
(Gordon et al., 2007) (Pandrea et al., 2007) suggesting that GALT immune function is not disrupted simply by 
CD4 T cell depletion, but more complex mechanisms are at play. 
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1.3.5 Pathogenesis: CD4 T cell subsets  
It is possible that preferential depletion of specific CD4 T cell subsets in HIV may play a role in impairing 
mucosal integrity, thus increasing microbial translocation and immune activation. Here we investigate the 
possible involvement of Th17 and Th22 cell subsets. 
1.3.5.1 Th17 cells 
As Th17 cells have been shown to play an important role in the maintenance of mucosal immunity loss in 
HIV-1 infection may contribute to microbial translocation and immune activation. In healthy animal models 
Th17 (CD4+IL17+) cells are found more commonly in the gut than in the periphery or other systemic 
compartments (Cecchinato et al., 2008). GALT Th17 (CD4+IL17+) cells are preferentially lost in SIV infected 
hosts with progressive disease (Favre et al., 2009, Raffatellu et al., 2008), while GALT Th1 (CD4+IFN-g+) cell 
frequencies are unaltered. In contrast natural hosts (Brenchley et al., 2008) maintain GALT Th17 (CD4+IL17+) 
cell frequencies despite the overall loss of GALT CD4 T cells. Reduced frequencies of Th17 (CD4+IL17+) cells 
are found in systemic and mucosal compartments early in SIV infection and are only restored in elite 
controllers (Cecchinato et al., 2008). Raffatellu et al demonstrated the importance of Th17 cells and their 
cytokines in limiting bacterial dissemination from the intestinal mucosa (Raffatellu et al., 2008). They 
demonstrated that SIV-infected rhesus macaques coinfected with Salmonella typhimurium have blunted IL-
17 responses with increased bacterial dissemination relative to SIV uninfected controls. IL-17 receptor 
deficient mice show increased systemic dissemination of S.typhimurium from the gut (Raffatellu et al., 2008). 
In SIV infection a marked and selective depletion of Th17 (CD4+IL17+) cells in blood, lymph nodes and GALT 
mucosa has been associated with increased T cell turnover (Ki67+CD8+ T cells) which is driven by systemic 
immune activation (Favre et al., 2009). Peripheral Th17 cells have been shown to be susceptible to SIV 
infection and frequency of Th17 cells at mucosal sites is negatively correlated with plasma viral load. 
Therefore it is possible that direct infection and killing by SIV leads to mucosal Th17 cell depletion 
(Cecchinato et al., 2008). Natural hosts of SIV may maintain their Th17 population through down regulation 
of CCR5 expression, however there are two other possibilities; natural hosts with their preserved bone-
marrow (Paiardini et al., 2009) may possess more effective maintenance of mucosal Th17 cell homeostasis or 
Th17 cell homing to the GALT may be more efficient (Favre et al., 2009). 
In humans whether HIV-1 disrupts or expands Th17 cells is not clear. The first description of Th17 cells in 
HIV-1 infection was reported by Maek et al in 2007 (Maek et al., 2007) where stimulation of peripheral blood 
mononuclear cells (PBMC) with phorbol myrisate acetate and ionomycin resulted in a significant increase in 
IL-17 producing CD4 T cells in HIV-1 positive individuals compared to healthy controls. Another study 
compared peripheral Th17 (CD4+IL-17) cell frequencies in acute HIV-1 compared to chronic HIV-1 infection 
(ART exposed and ART naive), long term non progressors (LTNP) and healthy controls and found increased 
frequencies in acute HIV-1 with no differences between the remaining groups (Yue et al., 2008). However in 
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children the frequencies of peripheral Th17 cells (IL-17+ PBMCs) have been shown to be reduced and 
correlated with the degree of HIV-1 viral load suppression, while Th1 (IFN-γ+ PBMCs) frequencies remained 
unchanged (Ndhlovu et al., 2008a). In this study Th17 cells did not express CCR5 and it was speculated that 
differentiation of Th17 cells was impaired. These findings have been repeated in adults with reduced 
frequencies of peripheral Th17 cells (IL-17+ CD4 T cells) and progenitor Th17 cells (CD161+ CD4 T cells) in 
chronic HIV-1 positive individuals naive to ART (Prendergast et al., 2010). Gosselin et al demonstrated a 
persistent reduced frequency of peripheral Th17 cells (CCR4+CCR6+ CD4 T cells) during chronic HIV-1 
infection despite successful ART and demonstrated the gut homing potential of Th17 cells via the high levels 
of expression of α4β7 integrin (Gosselin et al., 2010). The latter two studies and more recent publications 
have given evidence for direct viral infection and killing of Th17 cells as a cause of this CD4 T cell subset 
depletion (Prendergast et al., 2010) (Gosselin et al., 2010, El Hed et al., 2010). Recently LTNP have been 
shown to display greater Th17 cell (IL-17+ CD4 T cell) frequencies than typical progressors  (Salgado et al., 
2011). Pilot data from our group show that progressive HIV-1 infection is associated with loss of Th17 
(CXCR3-CCR4+CCR6+) cells in blood. Conflicting results may be explained by differences between studies in 
the: determination of Th17 cells, quantification of cells using total CD4 T cell counts or memory CD4 T cell 
counts, use of different stimulants/mitogens or duration of HIV-1 at time of sampling.  
Brenchley et al provide compelling evidence that Th17 cells (IL-17+ and IL-23R+ CD4 T cells), as opposed to 
Th1 cells (IFN-γ+ CD4 T cells), are significantly reduced in the gastrointestinal tract of HIV-1 infected ART 
naive individuals (Brenchley et al., 2008). This was not reflected in the periphery or at respiratory mucosal 
sites. In this study few remaining Th17 cells expressed CCR5, suggesting preferential loss of CCR5+Th17 cells 
and virus mediated depletion. A recent study has demonstrated a reduction in Th17 cells in both the 
periphery and gut (Chege et al., 2011). ART related CD4 T cell restoration in GALT has been shown to be 
associated with enhanced Th17 CD4 T cell accumulation in gut biopsies and the periphery (Macal et al., 
2008), however in this study there was no evidence of reduced Th17 cell (IL-17+ CD4 T cell) frequencies in 
the gut of HIV ART naive individuals. LTNP have been shown to maintain gut Th17 cell frequencies (Ciccone 
et al., 2011).It is important to note that the association between depleted Th17 cells and both immune 
activation and microbial translocation remains controversial. An inverse correlation between activated 
peripheral CD4 T cells and mucosal Th17 cells has recently been reported in HIV-1 positive individuals 
(Gordon et al., 2010). Cecchinato et al found no correlation between LPS levels and GALT Th17 (CD4+IL17+) 
cell count in SIV infected macaques (Cecchinato et al., 2008)  similar findings have been demonstared in HIV-
1 (Chege et al., 2011). The latter study did display a weak correlation between LPS levels and peripheral Th17 
cell frequencies, while LTNP have been shown to display no such correlation (Ciccone et al., 2011).  
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1.3.5.2 Th22 cells 
There is a marked paucity of data on Th22 cells and IL-22 in HIV-1 infection. It is possible that loss of Th22 
cells from the GALT results in loss of gastrointestinal mucosal integrity leading to increased microbial 
translocation and immune activation. Moreover, IL-22 induces LBP and thus reduced levels could increase 
immune activation by preventing neutralisation of increased LPS levels (Wolk et al., 2007). To date only one 
publication has addressed the role of Th22 cells in HIV-associated mucosal pathogenesis (Kim et al., 2012). In 
this study while Th17 and Th1 cells were not shown to be reduced in either gastrointestinal mucosal tissue or 
the periphery Th22 frequencies were. Gut Th22 frequencies were not shown to correlate with markers of 
microbial translocation (LPS and sCD14), while correlations with markers of immune activation was not 
investigated. 
1.3.5.3 Treg cells 
The role of Tregs in the pathogenesis of HIV-1 is controversial.  At present it is not clear if Tregs are increased 
in HIV-1 infection and  play a detrimental role by impairing T-cell responses and thus facilitating viral 
persistence, or conversely, if they are reduced and therefore unable to exert a protective effect by limiting 
immune activation. It is possible that they have a dual role depending on the disease stage. Studying the role 
of Tregs in HIV-1 is challenging for a number of reasons. Firstly as discussed in section 1.2.2.4 identification 
of Treg cells is problematic. In HIV-1 FoxP3 has been shown to be upregulated in activated T cells and thus 
may not be a marker specific to Treg cells. Secondly the majority of studies assessing the role of Treg cells 
have been phenotypic rather than functional. It is only complex, labour intensive T cell co-culture 
experiments that are able to identify the suppressive effects of Treg cells and thus clearly define their role. 
Finally it is difficult to know if results from the periphery can be extrapolated to tissues, as it is possible that 
function of Treg cells differs within these two departments. For these reasons our knowledge on the role of 
Treg cells in HIV-1 continues to be limited. 
 It has been demonstrated that in asymptomatic HIV-1 infected individuals, and those controlled with ART, 
Tregs are present in the peripheral blood and capable of suppressing numerous HIV specific T cell responses 
including cytokine production (IL-2 and IFN-γ) and proliferation (Weiss et al., 2004, Kinter et al., 2004). 
Tsunemi et al found a significant increase of Tregs in peripheral blood of untreated individuals, with normal 
levels in treated individuals, suggesting that increased levels of Tregs are associated with more severe stages 
of infection (Tsunemi et al., 2005). Increased numbers of Tregs have been shown in lymphoid tissue of 
untreated HIV-1 patients with progressive disease compared to LTNP (Nilsson et al., 2006).  
However other studies have suggested that Tregs are reduced in HIV-1 disease.  Tregs express the HIV-1 co-
receptor CCR5 and are susceptible to infection, giving a mechanism for reduced levels of Tregs in HIV-1 
positive patients compared to seronegative controls (Oswald-Richter et al., 2004). Those individuals with 
lower numbers of Tregs were shown to have higher levels of T cell activation and lower CD4 counts. There is 
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a negative correlation between Treg cell frequency and CD4+ and CD8+ T cell activation (Oswald-Richter et 
al., 2004, Eggena et al., 2005). This suggests that the presence of functional Tregs may be beneficial in HIV-1 
pathogenesis by controlling the immune activation and that depletion of this cell group could hasten 
progression to AIDS. However there remains the possibility that Tregs are not lost but redistributed from the 
peripheral blood to the lamina propria and lymphoid tissue, where HIV-1 is actively replicating, during 
periods of HIV-1 viraemia (Epple et al., 2006, Andersson et al., 2005). 
1.3.5.4 Effector Th cell plasticity 
A recent study demonstrated that the Th1Th17 cells express the HIV-1 coreceptors CCR5 and CXCR4 and are 
highly permissive to infection with HIV-1 (Gosselin et al., 2010). Our group has since confirmed that the 
frequency of Th1Th17 cells is reduced in HIV-1 infected individuals compared to healthy controls, with 
effective ART having little effect on restoring frequencies (Clark et al., 2011). 
SIV models have demonstrated an alteration in the balance between Th1 and Th17 cell frequencies, with a 
shift from Th17 to Th1 cells in both the periphery and mucosal sites in pathogenic SIV infection (Kader et al., 
2009, Cecchinato et al., 2008). More recently similar findings have been demonstrated; with HIV-1 infection 
leading to a shift towards Th1 cells and away from Th17 and Th1Th17 cells (Gosselin et al., 2010). In addition 
a shift in the Th17 to Treg ratio towards Tregs in the blood, lymphoid organs and mucosal tissue of SIV 
infected pigtail macaques was found to be predictive of systemic and sustained T cell activation (Favre et al., 
2009). An imbalance in Th17 to Treg cells has since been demonstrated in HIV-1 infection in both the 
periphery and the gut (Favre et al., 2010, Chege et al., 2011, Brandt et al., 2011, Li et al., 2011). In contrast 
elite controllers have been shown to maintain Th17:Treg cell ratios (Brandt et al., 2011, Li et al., 2011). 
Similar findings were demonstrated in a study of HIV-1 infected individuals with loss of Th17 cells and a 
reciprocal increase in Tregs in both peripheral blood and rectosigmoid biopsies being associated with 
induction of IDO and disease progression (Favre et al., 2010). Both peripheral and gut Th17:Treg cell ratios 
have been shown to inversely correlate with IDO activity (Favre et al., 2010). In HIV-1 infection some groups 
demonstrate inverse correlations with markers of systemic immune activation and microbial translocation 
while others do not (Favre et al., 2010, Chege et al., 2011). Longitudinal studies have suggested that a loss of 
balance between Th17 and Treg cells is associated with an earlier CD4 T cell decline while ART leads to 
partial resolution (Li et al., 2011, He et al.,2012). 
IL-21 has a role in promoting the development of Th17 cells while inhibiting Treg development. Recent 
reports (Elsaesser et al., 2009, Yi et al., 2009a, Frohlich et al., 2009) have demonstrated that mice infected 
with chronic LCMV produce increasing levels of IL-21 as the infection persists. IL-21R deficient mice were 
more susceptible to chronic infection and had more dramatic exhaustion of LCMV-specific CD8 T cells, while 
the magnitude of the CD4 T cell response was maintained. In HIV-1 infection IL-21 levels are reduced and 
shown to correlate positively with CD4 T cell counts and negatively with HIV-1 viral loads (Iannello et al., 
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2010). In keeping with the above murine models functional HIV-specific CD8 T cell responses tend to be 
greater in individuals with high serum levels of IL-21. Therefore alterations in IL-21 levels in HIV-1 infection 
may contribute to imbalances in the ratio of Th17 to Treg cells and have profound effects on HIV disease 
progression and pathogenesis. 
1.3.6 Pathogenesis: liver disease 
More than half of deaths in individuals with HIV-1 on ART are not AIDS related. Data from the DAD (data 
collection on adverse events of anti-HIV drugs) study demonstrated that mortality from liver disease was 
second only to AIDS related mortality. Of these liver-related deaths 66% were due to HCV, 17% to HBV and 
only three percent were directly attributable to ART. Other causes of liver disease in patients with HIV 
infection include alcohol, drug-induced hepatotoxicity and non-alcoholic fatty liver disease.  
1.4 Hepatitis C Virus 
The hepatitis C virus (HCV) is of the hepacivirus genus in the Flaviviridae family. It was identified as the major 
cause of non-A, non-B, hepatitis in 1989 (Choo et al., 1989). There are at least six major HCV genotypes, and 
100 subtypes, whose prevalence varies geographically. Genotype 1 accounts for the majority of infections in 
North America, South America, and Europe (Ghany et al., 2009). The majority of individuals infected (60%) 
with HCV will develop chronic disease (Jauncey et al., 2004). 
1.4.1 Epidemiology 
It is estimated that 130–170 million people world wide are living with HCV (WHO, 2011). HCV is a major 
cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). Only one fifth to one half 
(Maheshwari et al., 2008) of individuals infected with HCV spontaneously clear the virus. Of those who 
develop chronic HCV, 20% will develop cirrhosis after 20 years and risk liver failure (2% to 4% per annum) 
and HCC (1% to 7% per annum) (Fattovich et al., 1997).  More than 350,000 people die from HCV related 
liver diseases each year (WHO, 2011). Chronic infection is also associated with extrahepatic manifestations 
with a seven fold increase in membranoproliferative glomerulonephritis, an 11 fold increase in 
cryoglobulinaemia and a 12 fold increase in prophyria cutanea tarda.  
HCV infection is a global phenomenon occurring among all ages, genders, races and regions of the world. 
Published data on prevalence of HCV world wide is limited; with information from many countries being 
inadequate. Exposure to infectious blood is the most efficacious transmission route: receipt of contaminated 
blood transfusions, blood products, and organ transplants; injections given with contaminated syringes, 
needle-stick injuries in health-care settings; IDU; being born to an HCV-infected mother (WHO, 2011). 
Therefore some patient groups such as haemophiliacs, recipients of unscreened blood and blood products, 
inmates of correctional facilities and persons with a history of occupational exposure have a high incidence 
and prevalence of HCV (Lavanchy, 2011). Vertical transmission occurs in 2-8% of babies born to HCV-infected 
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mothers. Countries with high rates of chronic infection are Egypt (22%), Pakistan (4.8%) and China (3.2%) 
(WHO, 2011). The main mode of transmission in these countries is attributed to unsafe therapeutic 
injections using contaminated equipment. In low prevalence, western countries HCV is most commonly 
transmitted as a result of recreational IDU. HCV is less commonly transmitted through sex with an infected 
person and sharing of personal items.  
1.4.2 Pathogenesis: structure and life cycle 
HCV is an enveloped virus with a positive ss RNA genome of 9.6kb in length which encodes a single open 
frame flanked by 5’ and 3’ untranslated regions (UTRs) (Houghton et al., 1991). The usual route of HCV 
infection is parenteral. HCV reaches the liver, its major site of replication, via the hepatic artery or portal vein 
and infects hepatocytes. In addition to hepatocytes, HCV is able to replicate in immune cells such as 
monocytes, lymphocytes and B cells (Sung et al., 2003). 
Figure 9 HCV life cycle – adapted from (Fukasawa, 2010) 
 
The virus envelope glycoproteins, E1 and E2, are responsible for binding the cell surface receptors. Host 
entry receptors include: low-density lipoprotein receptor (LDLR), the tetraspanin CD81, and the tight 
junction proteins claudin 1 and occludin (Zhang et al., 2004, Evans et al., 2007, Ploss et al., 2009).  After 
clathrin-mediated endocytosis the uncoated virus RNA genome is released into the cytoplasm (see figure 9). 
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The RNA genome encodes a single polyprotein precursor of 3,010 amino acid residues replicated in the 
cytosol through a negative strand intermediate.  Translation is initiated through an internal ribosomal entry 
site in the 5’ UTR. After translation the polyprotein is cleaved by viral and host cell proteases into the 10 viral 
proteins (Sung et al., 2003) (see figure 10).  The first third of the polyprotein encodes the structural proteins 
that form the three-dimensional architecture of the virus. They include the core protein, two envelope 
glycoproteins (E1 and E2) and a protein of unknown function (P7). Non-structural (NS) proteins (NS2 
[protease], NS3 [serine protease & RNA helicase], NS4A [serine protease cofactor], NS4B [hydrophobic 
membrane protein], NS5A [hydrophilic phosphoprotein] and NS5B [RNA dependent RNA polymerase]) are 
derived from the remaining two-thirds of the polyprotein and have functions in HCV replication. Core along 
with E1 and E2, are released from the polyprotein by the endoplasmic reticulum signal peptidases of the 
host cell and form the structural constitutes of the virus particle together with the host-derived lipid bilayer. 
The non-structural proteins, released from the polyprotein after cleavage by HCV proteases NS2-3 and 
NS3/4A form a ribonucleoprotein complex with the virus genome that associates with intracellular 
membranes and is the site of RNA replication mediated by the NS5B protein. The viral proteins are packaged 
into viral particles by budding into the endoplasmic reticulum and released through the secretary pathway.   
Figure 10 HCV genome - adapted from (Rehermann and Nascimbeni, 2005) 
 
1.4.3 Pathogenesis: innate immune response 
Due to the asymptomatic nature of acute HCV infection, knowledge of early immune responses comes from 
animal models. During the first few days of primary HCV infection, RNA levels rapidly increase and continue 
to be high throughout the incubation period of up to 10-12 weeks. Within days of infection HCV stimulates 
the innate immune response. The PRRs: TLR3 (sensing dsRNA in endosomes), TLR7/8 (sensing ssRNA) and 
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RLR (recognising the polyuridine motif of HCV 3’ UTR in the cytoplasm) induce type I IFN production - usually 
in the form of IFN-β from hepatocytes (Saito et al., 2008). IFN-β induces ISGs, which degrade and inhibit 
translocation of viral RNA and amplify the IFN response. This anti-viral state extends to uninfected 
neighbouring cells. However the HCV viral load does not decrease in the early phase suggesting that HCV 
attenuates the IFN response at multiple levels:  
 NS3/4A protease cleaves the adaptor proteins, CARD adaptor inducing IFN-β (CARDIF) and TRIF, 
required for IFN induction via RLR and TLR3 signalling (Meylan et al., 2005) (Breiman et al., 2005).  
 Core protein interferes with the JAK-STAT signalling pathway blocking the induction of ISGs (de Lucas et 
al., 2005). 
 NS5A binds to oligoadenylate synthetase preventing viral inhibition (Taguchi et al., 2004) and induces IL-
8 (Polyak et al., 2001), which inhibits the antiviral actions of IFN by conferring a general attenuation of 
ISG expression and function. 
 E2 modifies protein kinase R activity (Taylor et al., 1999) and binds to CD81 on NK cells directly blocking 
the cell function, thus down regulating the NK cell response (Crotta et al., 2002, Tseng and Klimpel, 
2002).  The early inhibition of NK cells impairs DC priming and thus CD4 T cell induction and cytotoxic 
CD8 T cell development. Therefore T cell responses are delayed (detectable five to nine weeks after 
infection) and may never achieve the efficacy required to clear the virus. 
 Core and NS3 proteins activate monocytes via TLR2 to produce TNF-α, which in turn inhibits IFN-α 
production and induces pDC apoptosis (Dolganiuc et al., 2003).pDC frequency and ability to produce IFN-
α are reduced (Decalf et al., 2007, Dolganiuc et al., 2006).  
 
In addition there is enhanced expression of the inhibitory CD94-NKG2A receptor on NK cells in HCV 
(Nattermann et al., 2006), whether this is TGF-β or HCV driven is unknown (Ray et al., 2003). This results in 
secretion of IL-10 and TGFβ which attenuates the immune response (Jinushi et al., 2004). Host genetic 
factors also appear to play a role in NK cell responsiveness to HCV with protective KIR/HLA compound 
genotypes having a lower threshold for NK cell activation with faster cell degranulation and IFN-γ release in 
vitro (Khakoo et al., 2004).  
1.4.4 Pathogenesis: adaptive immune response 
1.4.4.1 Acute HCV infection 
Humoral responses in the form of neutralising antibodies appear late in infection with their titre and breadth 
increasing only once chronic infection is established (Logvinoff et al., 2004). Although unable to clear 
infection at this stage they exert selection pressure on viral variants, contributing to the evolution of HCV 
envelope sequences throughout the course of the infection (Farci et al., 2000). The hypervariable region 
(HVR) 1 of E2 appears to be a major target for neutralising antibodies, and mutations in E2 HVR1 account for 
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a significant degree of HCV sequence diversity in virus isolates from infected patients (Farci et al., 1996). 
Infection outcome in humans can be predicted by sequence changes in the E2 HVR1 (Farci et al., 2000). 
However spontaneous viral clearance after acute infection has been described in patients with 
hypogammaglobulinaemia (Christie et al., 1997) and independent studies in chimpanzees have shown that 
HVR1 sequence changes are not a prerequisite to establishing HCV persistence (Bassett et al., 1999).  
Control of acute primary viral replication is associated with expansion of antiviral CD4 and CD8 T cells and 
this determines viral clearance. HCV-specific CD4 T cells and CD8 T cells are detectable in both the liver and 
peripheral blood of HCV infected individuals. The initial decrease in viral titre coincides with the appearance 
of HCV-specific T cells and IFN-γ expression in the liver (Thimme et al., 2001). In both chimpanzee and human 
infection, clearance of HCV has been associated with a strong and sustained HCV-specific CD4 T cell response 
(Thimme et al., 2001, Shata et al., 2002). Chimpanzees deplete of CD4 T cells, re-infected with HCV develop 
persistent, low-level viraemia despite functional intrahepatic memory CD8 T cell responses, with emergence 
of viral escape mutations in Class I MHC restricted epitopes (Grakoui et al., 2003). Supporting this 
independent requirement of CD4 T cell response for HCV clearance is evidence that HCV-specific CD4 T cells 
contribute to viral clearance, but not necessarily by enhancing CD8 T cell or neutralising antibody responses 
(Kaplan et al., 2007). CD4 proliferative T cell response is maintained indefinitely after recovery from HCV 
infection (Chang et al., 2001) suggesting that the CD4 T cell response must be maintained permanently to 
achieve long-term control of HCV. In addition to a strong and sustained HCV-specific CD4 T cell response it 
has been shown that the breadth of response is important. An average of 10 different epitopes are targeted 
in persons with resolved infection including; HCV core, NS3, NS4 and NS5. An early and persistent Th1-
dominated CD4 T cell response appears to be critical in the prevention of chronic infection. A strong Th1 
response is integral in viral clearance (Ulsenheimer et al., 2003). 
The frequency of HCV-specific CD8 T cells is high during the acute phase of infection regardless of virological 
outcome (Kaplan et al., 2007). They appear stunted, with impaired proliferation, weakened IFN-γ production 
and cytotoxicity, and increased levels of PD-1 (Rehermann, 2009). However, this dysfunction resolves as 
soon as HCV-specific CD4 T cell responses develop and the HCV titre decreases. As with the CD4 T cell 
response polyclonal and multispecific CD8 T cell responses are associated with spontaneous HCV clearance 
in chimpanzees (Cooper et al., 1999) and humans (Gruner et al., 2000).  
1.4.4.2 Chronic HCV infection 
Loss of the virus specific CD4 memory T cell responses in patients who initially control the infection is 
immediately followed by recurrence of serum HCV RNA (Gerlach et al., 1999) suggesting that the CD4 T cell 
response must be maintained permanently to achieve long-term control of HCV. In those cases that directly 
progress to chronic infection CD4 T cell responses are weak, narrowly selected and short lived, with cellular 
immune responses barely detectable in the periphery once chronic HCV infection is established (Rosen et al., 
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2002). In chronic infection HCV-specific CD4 T cell responses are targeted to never more than one epitope 
(Day et al., 2002), usually to HCV core protein rather than the NS proteins (Chang et al., 2001, Schulze zur 
Wiesch et al., 2005, Rosen et al., 2002). CD4 T cell HCV specific responses tend to be shifted from a Th1 to a 
Th2 response (Tsai et al., 1997). In addition Th1 responses tend to be IFN-γ producing, rather than IFN-γ/IL-2 
producing (Semmo et al., 2007), resulting in weak HCV-specific CD4 T cell proliferative responses.  
If viraemia persists after acute infection CD8 T cell responses wane rapidly (Lechner et al., 2000). In chronic 
infection, HCV-specific CD8 T cells possess less capacity to proliferate and produce less IFN-γ in response to 
HCV antigens (Wedemeyer et al., 2002). Due to the high variability of HCV, escape mutations in CD8 T cells 
epitopes are common and are felt to play a major role in viral persistence; however other mechanisms of 
viral escape are likely to be important (Timm et al., 2004). Exhaustion of CD8 T cells, mediated by PD-1, has 
been demonstrated and is likely to impact persistence (Barber et al., 2006). Engagement of PD-1 by its 
ligand, PD-ligand 1, delivers a negative signal to the T cell preventing proliferation and IL-2 production. There 
is increased PD-1 expression on total and HCV-specific CD8+ T cells in both the peripheral and the 
intrahepatic compartments of those patients with longstanding HCV infection relative to those with 
spontaneous resolution (Urbani et al., 2006).  
There is emerging evidence that Tregs may contribute to down regulating the immune response to HCV. Treg 
cell function at the earliest time point of acute HCV infection does not differ in those who clear the virus and 
those who go on to develop chronicity. However frequency of Tregs is increased in the peripheral blood of 
chronically HCV infected individuals in comparison with those with resolved infections or healthy controls 
(Cabrera et al., 2004) (Boettler et al., 2005) (Sugimoto et al., 2003). Tregs exert immunomodulatory functions 
on virus-specific CD4 and CD8 T cells in chronically infected individuals, including suppression of effector 
functions (IFN-γ secretion) and inhibition of proliferation of CD4 and CD8 T cells (Boettler et al., 2005). 
Depletion of Tregs has been shown to enhance HCV-specific CD4 and CD8 T cell proliferation while addition 
of Tregs has been shown to suppress T cell proliferation (Rushbrook et al., 2005).  
1.4.5 Pathogenesis: liver disease 
Liver fibrosis, a reversible wound-healing response, is characterised by an excessive accumulation of 
extracellular matrix (ECM) proteins (predominantly collagen type I), the activation of pro-inflammatory cells, 
and tissue remodelling following liver injury. Persistence of viral infection leads to a progressive substitution 
of liver parenchyma by scar tissue resulting in cirrhosis.  
There is evidence that LPS and TLR4 play a key role in the pathogenesis of HCV infection. Interactions 
between TLR4 and HCV are complex. HCV appears to affect TLR4 signalling in two ways. Firstly, enhancing it 
through the action of NS5A protein, in cells (hepatocytes and B cells) that generate a chronic inflammatory 
state (Machida et al., 2006) (Machida et al., 2009), and secondly inhibiting it in cells that limit HCV 
49 | P a g e  
 
replication (DCs and macrophages) (Miyazaki et al., 2008, Abe et al., 2007). It has been demonstrated, in 
individuals with HCV monoinfection, that host-derived factors (IFN-γ and endotoxin) and viral factors (HCV 
core protein) act in tandem to induce loss of tolerance to LPS of TLR4 and maintain macrophage activation, 
thus favoring persistent inflammation (Dolganiuc et al., 2007). Recently, TLR4 was identified as one of seven 
genes associated with increased risk of developing cirrhosis in patients with chronic hepatitis C (Huang et al., 
2007). In a subsequent study examining the functional linkage of two ‘protective’ TLR4 SNPs; 
hyporesponsiveness to TLR4 was demonstrated when compared to HSCs expressing wild-type TLR4 (Guo et 
al., 2009).  
Patients with chronic HCV infection display increased serum levels of LPS even in the absence of significant 
fibrosis (Dolganiuc et al., 2007). Liver injury is known to result in increased microbial translocation owing to 
changes in the intestinal mucosal permeability due to reduced oncotic pressure, oxidant stress and 
enhanced intestinal oedema (Guarner and Soriano, 2005). Serum LPS levels are significantly elevated in 
patients with chronic hepatitis and cirrhosis (Lumsden et al., 1988, Lin et al., 1995). It is thought that changes 
in intestinal motility, subsequent alterations of intestinal microbiota, decreased mucosal integrity and 
suppressed immunity in hepatic fibrosis contribute to intestinal mucosal barrier failure and lead to increased 
translocation and LPS levels in later stages of hepatic fibrosis and cirrhosis (Wiest and Garcia-Tsao, 2005). 
1.5 Human Immunodeficiency Virus and Hepatitis C Virus coinfection 
As outlined above HIV-1 and HCV are two major viral global epidemics. Coinfection with HCV in HIV-1 
infection is common (15% to 30% of HIV-1 infected individuals are coinfected with HCV) and its impact on 
the morbidity and mortality of HIV-1 is increasing (Joshi et al., 2011). HIV-1 dramatically modifies the natural 
history of HCV. Spontaneous clearance is reduced with reports of anywhere from 0% to 40% (European, 
2011). There is a more frequent and accelerated progression to cirrhosis (median time 10 years), with 
greater rates of liver-related deaths (Soto et al., 1997). In addition to detectable HIV-1 viraemia and low CD4 
T cell counts (<200 cells/L), accelerated rates of liver fibrosis in this population are associated with age (>25 
years) at contracting HCV and heavy alcohol consumption (> 50g/d). A recent study has shown that despite 
the immunologic benefit of ART, HIV-1/HCV coinfected patients still have more advanced liver fibrosis than 
their HCV monoinfected counterparts (de Ledinghen et al., 2008). 
1.5.1 Epidemiology 
Due to shared routes of transmission HIV-1/HCV coinfection is common affecting an estimated 4-5 million 
individuals around the world (Alter, 2006). A third of individuals with HIV-1 infection in Europe, 16% in the 
USA and 9% in the UK are coinfected with HCV (Thomson and Main, 2008). The prevalence of coinfection 
does not only vary geographically but is also dependent on an individual’s risk for acquisition of HIV-1. 90% 
of intravenous drug users  with a greater than 10 year history of drug use are coinfected with HCV (Quaglio 
et al., 2003). IDU is likely to account for the high prevalence of coinfection seen in Eastern Europe. Prior to 
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the availability and introduction of diagnostic tests to screen blood products haemophiliac patients were 
frequently infected with both HIV and HCV from contaminated factor VIII. The risk of HIV and HCV 
acquisition in resource poor countries remains high due to the lack of blood product screening and the 
administration of unsafe therapeutic injections – in both westernised and traditional medical environments. 
The prevalence of HCV in HIV-1 infected MSM is 1% to 12%. 
1.5.2 Pathogenesis: effect of HCV on HIV 
There are several postulated mechanisms via which HCV may impact on the natural history of HIV infection; 
liver-related deaths and toxicity, progression of HIV disease and CD4 T cell responses after initiation of ART. 
Despite reduced morbidity and mortality in HIV-infected individuals on ART, liver-related deaths now 
represent a leading cause of mortality in this population, primarily due to HCV coinfection. In HIV-1/HCV 
coinfected individuals there is increased mortality due to liver-related disease as demonstrated by the 
‘Mortality 2000’ survey. 31% of deaths in HIV-1/HCV coinfected individuals were due to liver disease 
compared to 2% of HIV monoinfected individuals, despite better immunovirological status in the coinfected 
population (Salmon-Ceron et al., 2005). Coinfected individuals have a higher risk of hepatotoxicity on HAART 
(Sulkowski et al., 2002b). 
Evidence on the effect of HCV on the progression of HIV disease remains conflicting. Studies have shown that 
in the pre-HAART era HCV was not a determinant of the progression of HIV disease (Dorrucci et al., 2004). 
However in the post-HAART era numerous studies have shown discrepancies on the effect of HCV on the 
clinical course of HIV disease. In the Swiss Cohort Study, HCV was independently associated with an 
increased risk of progression to AIDS and death among patients initiating ART (Greub et al., 2000). Other 
studies have found no association between HCV infection and the progression of HIV disease or death. 
Analysis of data from 1998 to 2004 in the Adult and Adolescent Spectrum of HIV Disease Project found that 
HCV infection was not associated with an increased risk of developing AIDS-defining opportunistic illnesses, 
death or immunological disease progression when adjusted for alcoholic hepatitis and hepatitis B virus  
infection (Sullivan et al., 2006). The authors concluded that concurrent liver disease from aetiologies other 
than HCV confounds the association of HCV infection and the progression of HIV disease. Among 1955 
patients at an HIV clinic in Baltimore, Maryland, no difference was detected in the progression to AIDS or 
death after adjustment for exposure to ART (Sulkowski et al., 2002a). Recent studies have shown that HCV 
coinfection may increase immune activation, leading to more rapid progression to severe immunodeficiency 
(Kovacs et al., 2010). However the impact of these effects does not appear to be of clinical significance with 
no real evidence that HCV in HIV-1 infections leads to increased disease progression (Kim and Chung, 2009).  
The impact of HCV infection on CD4 T cell recovery following initiation of ART is conflicting; with some 
reports noting a blunted CD4 T cell response and others demonstrating no effect. The Swiss Cohort Study 
demonstrated a slower rise in CD4 T cell counts in coinfected individuals (Greub et al., 2000) but this was not 
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supported by a study at an HIV clinic in Baltimore, Maryland (Sulkowski et al., 2002a). More recent data 
remain conflicting with Potter et al demonstrating blunted CD4 T cell responses in coinfected individuals 
commencing ART (Potter et al., 2010), while the recent four year follow-up data from the Swiss HIV Cohort 
Study could not find any significant differences with regard to recovery of CD4 cell counts between HCV-
positive and HCV-negative individuals (Kaufmann et al., 2003). These findings were recently confirmed by 
Peters et al (Peters et al., 2009). 
The introduction of HAART in 1996 and its dominant effect on the natural history of HIV has complicated the 
understanding of the effect of HCV on the progression of HIV disease. No major differences in HIV-related 
mortality or immune progression appear to exist between HIV-1/HCV coinfected individuals and HIV-1 
monoinfected individuals. Although initial CD4-count recovery may be blunted after the introduction of ART 
in the coinfected population this resolves over time (Miller et al., 2005). There is however an increased risk 
of liver-related disease and morbidity but this may be due to confounding factors such as alcoholism, 
alcoholic hepatitis and drug-induced hepatitis.  
1.5.3 Pathogenesis: effect of HIV on HCV 
The effects of HIV-1 on the pathogensis of HCV infection include: a reduced rate of spontaneous clearance 
(European, 2011) and increased HCV RNA titres (Sulkowski and Thomas, 2003). One of the most striking 
effects of HIV-1 on the progression of HCV is the more frequent and rapid rate of fibrosis progression (Soto 
et al., 1997). A Spanish study followed up 44 HCV monoinfected and 32 HIV-1/HCV coinfected individuals for 
15 years during which time 25% of those with HIV developed cirrhosis compared to just 6.5% of those who 
were HIV negative (Sanchez-Quijano et al., 1995). More recently a meta-analysis demonstrated that 
coinfected individuals have a two-fold increased rate of cirrhosis compared to monoinfected individuals 
(Thein et al., 2008). Progression to liver disease is increased in HIV-1/HCV coinfected individuals with higher 
HIV viral loads and lower CD4 counts (Brau et al., 2006).  
Cytokine dysregulation may contribute to the weakened HCV-specific adaptive immune responses during 
HIV coinfection (Breen, 2002). Intrahepatic cytokines TNFα, IL-8 and IL-10 are lower among HCV/HIV-1 
coinfected individuals compared to those with HCV monoinfection, whereas the profibrogenic cytokine TGF-
β was found to be increased. Coinfection with HIV-1 may induce TGF-β expression, resulting in reduced IFN-γ 
response of CD8+ T-cells to viral infection, promoting HCV persistence. The enhancement of peripheral HCV-
specific T-cell responses with functional blockade of TGF-β secretion is attenuated in individuals with HIV-
1/HCV coinfection (Alatrakchi et al., 2007). Insufficient IFN-α production in HIV-1 infection results in impaired 
DCs with low IL-12 secretion and failure to induce T cell responses and activate NK cells.  
At a number of levels, HIV-1 is likely to affect CD4+ T-cell responses to HCV through alterations in CD4+ T-cell 
survival, antigen-presenting cell function and disruption of lymphoid architecture. Peripheral CD4+ T-cell 
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responses to HCV antigens are virtually nonexistent in HCV/HIV-1 coinfected individuals (Lauer et al., 2002), 
with a much narrower response to HCV in the coinfected population (Harcourt et al., 2006). This defect in 
cell mediated immunity occurs early during the course of HCV infection and probably explains the increased 
HCV persistence and higher HCV RNA levels during acute infection in HIV-1 infected individuals (Danta et al., 
2008). 
1.5.4 Pathogenesis: liver disease 
The disease mechanisms underlying progressive liver disease are complex in HIV-1/HCV coinfection are not 
well understood due to: the lack of a suitable animal model for HCV-related fibrosis, human liver studies 
being hampered by the limited frequency of sample collection and liver biopsy representing only a single 
snapshot of the liver. However several different mechanisms have been suggested: 
 HIV-1 induced immune suppression, CD4 T cell depletion and impaired anti-HCV immune responses 
(Rotman and Liang, 2009, Operskalski and Kovacs, 2011).  
 Increased apoptosis of hepatocytes through a Fas/FasL pathway (Roe and Hall, 2008). 
 Accumulation of cytotoxic CD8 T cells in the liver with increased inflammatory mediators such as TNF-α 
(Nakamoto et al., 2008, Vali et al., 2008).  
 HIV-1 infection of HSC and Kupffer cells promoting collagen expression and secretion of proinflammatory 
cytokines (Tuyama et al., 2010). 
 Increased insulin resistance with hyperinsulinaemia and hyperglycaemia leading to connective tissue 
growth and accumulation of ECM (Merchante et al., 2009).  
It has been suggested that increased microbial translocation in HIV-1 may contribute to increased rates of 
liver fibrosis. The role of microbial translocation in promoting liver fibrosis has been noted in several other 
conditions including alcoholic liver disease, GvHD and IBD (Cooke et al., 1998) (Caradonna et al., 2000, 
Thurman, 1998). In HIV-1/HCV coinfection microbial translocation is likely to promote liver fibrosis via two 
main mechanisms: direct LPS mediated activation of Kuppfer and HSC resulting in the secretion of pro-
fibrotic cytokines and type 1 collagen or indirectly via induction of systemic immune responses and 
promotion of local hepatocyte activation induced apoptotic death resulting in collagen deposition.   
1.5.4.1 Liver fibrosis: LPS and TLR4 
LPS appears to play a role in chronic liver disease. CD14 or LBP deficient mice are resistant to liver injury and 
fibrosis induced by bile duct ligation (Isayama et al., 2006), and hepatic inflammation and fibrosis are 
strongly decreased in the TLR4 mutant C3H/HeJ strain following bile duct ligation or carbon tetrachloride 
(CCl4) administration (Seki et al., 2007). Until recently Kupffer cells were the best characterised target of LPS 
in the liver (Schwabe et al., 2006). They are specialised macrophages thought to clear up microbial 
translocation products during passage through the portal circulation. They can be directly activated by LPS 
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and produce a wide variety of cytokines such as TNF-α, reactive oxygen species and TGF-β (Su, 2002, 
Thurman, 1998). TGF-β is a key cytokine in the mediation of hepatic fibrogenesis (Bataller and Brenner, 
2005). A critical role of Kupffer cells in hepatic fibrogenesis is enhancing HSC activation. A consequence of 
hepatic injury is HSC activation. Activated HSCs are the major source of scar-associated ECM proteins 
(Friedman, 1999). Although quiescent HSCs do not express the CD14/TLR4/MD2 receptor complex activated 
HSCs do and low concentrations of LPS induce activation of NF-κβ (Paik et al., 2003) which has been 
associated with the development and survival of activated HSCs (Hellerbrand et al., 1998, Lang et al., 2000).  
Animal models have demonstrated that while mice with TLR4 mutant Kupffer cells show the same degree of 
hepatic inflammation and fibrosis as their wild-type counterparts, those with TLR4 mutant HSCs have a 
resistance to experimental fibrosis (Seki et al., 2007). HSCs express the transmembranepseudoreceptor 
BAMBI (bone morphogenic protein and activin membrane-bound inhibitor) which silences TGF-β signalling. 
LPS down regulates BAMBI on quiescent HSCs augmenting TGF-β-mediated activation (Seki et al., 2007).  
Thus it appears LPS mediates its effect on the liver through various different mechanisms (see figure 11). LPS 
induces Kupffer cells to secrete mediators including TGF-β enhancing HSC activation and ECM production. 
Concurrently LPS acts on quiescent HSC to produce chemokines that attract Kupffer cells to the site of injury 
and simultaneously down regulates BAMBI thus augmenting TGF-β mediated activation. TLR4 is expressed in 
several liver cells and the liver is constantly confronted with gut derived LPS from the portal circulation. 
Despite this the normal liver does not show signs of inflammation likely due to multiple protective 
mechanisms:  
1. sCD14 can remove LPS from membrane CD14 (Kitchens and Thompson, 2005) (Cavaillon and Adib-
Conquy, 2006).  
2. EndoCAb bind to and clear LPS from the circulation (Strutz et al., 1999).  
3. High levels of LBP neutralise LPS (Lamping et al., 1998) (Zweigner et al., 2001).  
4. Negative regulation of TLR4 allows ‘liver tolerance’ to LPS (Pimentel-Nunes et al., 2010).  
In HIV-1/HCV coinfection the LPS/TLR4 signalling pathway may account for the more rapid and frequent 
progression to liver disease. As discussed above increased levels of LPS have been demonstrated in both HIV-
1 and HCV monoinfection. In addition the above safety mechanisms appear to fail. In HIV-1 monoinfection 
HIV-1 RNA can enhance TLR4 mediated response to LPS (Lester et al., 2009), EndoCAb titres are reduced 
(Brenchley et al., 2006b) and reduced IL-22 may lead to reduced LBP levels.  In HCV monoinfection TLR4 
signalling is enhanced in hepatocytes (Machida et al., 2006) (Machida et al., 2009) and there appears to be 
loss of TLR4 tolerance to LPS (Dolganiuc et al., 2007). In HIV-1/HCV coinfection a significant association 
between reduced Kupffer cell counts in liver histology sections and CD4 T cell depletion in peripheral blood 
has also been demonstrated (Balagopal et al., 2009). ART resulted in increases in both peripheral CD4 T cell 
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counts and Kupffer cell density.  Kupffer cell numbers were significantly higher in portal/periportal areas of 
the liver, the site where microbial products encounter the liver and the initial location of hepatic fibrosis in 
chronic HCV infection.  The findings reported suggest that Kupffer cell loss may make a significant 
contribution towards periportal fibrosis in HIV-1/HCV coinfection.   
Figure 11 Fibrogenic signalling induced by TLR4 in hepatic stellate cells and the role of Kupffer cells – 
adapted from (Friedman, 2007) 
 
1.5.4.2 Liver fibrosis: immune activation 
It has been demonstrated that local immune responses to HIV-1 result in collagen deposition and the 
development of fibrosis in lymphoid tissue (Schacker et al., 2002). This disruption of normal architecture by 
fibrosis may play an important role in the depletion of naive CD4 T cells in late HIV-1 disease. The amount of 
lymphatic tissue fibrosis appears to predict the magnitude of immune reconstitution after the initiation of 
ART (Schacker et al., 2005). The mechanism of fibrosis development has not been fully elucidated, but 
immune activation is thought to play a critical role and may augment the development of liver fibrosis in 
HIV-1/HCV coinfection.  
The induction of systemic inflammatory immune responses in HIV-1 is associated with secretion of pro-
fibrotic cytokines such as IL-4, IL-5, IL-13, and TGF-. In SIV models, TGF-β1 producing Tregs induce extensive 
collagen deposition in lymphoid tissues (Estes et al., 2007). The Treg immune responses to immune 
activation increases pro-collagen production via TGF-1 signalling pathways in the secondary lymphoid 
tissues of HIV-1 infected patients (Zeng et al., 2011). Activated HIV-1 specific CD8 T cells have been linked to 
distortion of lymph node architecture and fibrosis in progressive HIV-1 infection (Schacker et al., 2002). 
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Similar cells have been found in the livers of patients with HIV-1/HCV coinfection and may promote liver 
fibrosis via the secretion of TNF- (Vali et al., 2008). Immune activation in HIV-1 infection is also associated 
with increased circulating levels of TRAIL and TRAIL induced CD4 T cell apoptosis (Herbeuval et al., 2005a, 
Herbeuval et al., 2005b, Herbeuval and Shearer, 2007). The combination of chronic HIV-1 infection and HCV 
associated inflammatory changes may result in increased intrahepatic TRAIL levels, and susceptibility of 
hepatocytes, lymphocytes, Kupffer cells and HSC to TRAIL mediated apoptosis (Herbeuval and Shearer, 2007, 
Babu et al., 2009, Lan et al., 2008) (Jang et al., 2011) . The on-going cycle of cell death and regeneration is 
likely to promote increased rates of liver fibrosis.  
1.5.4.3 Discussion 
A number of studies have attempted to define the extent of microbial translocation in HIV-1/HCV coinfection 
using a number of biological markers (LPS, sCD14, LBP and EndoCAb). Ancuta et al demonstrated that HIV-
1/HCV coinfected individuals have increased serum LPS levels, but not sCD14 levels, compared to HIV-1 
monoinfected individuals  (Ancuta et al., 2008). However de Oca Arjona et al demonstrated increased levels 
of sCD14 and LBP in HIV-1/HCV coinfection in those with compensated cirrhosis compared to healthy 
controls and in those with decompensated cirrhosis compared to healthy controls, HIV-1 monoinfected 
individuals and coinfected individuals with compensated cirrhosis (de Oca Arjona et al., 2011). Compared to 
HCV monoinfection some studies have demonstrated no change in LBP levels while others have shown 
increased levels (Montes-de-Oca et al., 2011, Balagopal et al., 2008).  Balagopal et al demonstrated 
increased levels of LPS and LBP and lower levels of EndoCAb IgM in HIV-1/HCV coinfected individuals 
compared with HCV monoinfected individuals (Balagopal et al., 2008). These differences were more marked 
in HIV-1 positive individuals with CD4 counts of less than 350/mm. The risk of cirrhosis was six-fold higher in 
persons with CD4 lymphocyte counts of less than 350/mm3 and 18 fold higher in individuals with raised LPS 
levels. These studies suggest that microbial translocation is increased in HIV-1/HCV coinfection compared to 
both HIV-1 and HCV monoinfection. 
With regard to immune activation in HIV-1/HCV coinfection, recent studies have found increased levels 
compared to HIV-1 and HCV monoinfection. Kovacs et al demonstrated increased percentages of HLA-
DR+CD38+ CD8 T cells among HIV-1/HCV coinfected women compared with HIV-1 monoinfected women 
(Kovacs et al., 2008). While Gonzalez et al demonstrated increased percentages of CD38+CD4 and CD38+CD8 
T cells in HIV-1/HCV coinfected individuals compared to HIV-1 and HCV monoinfected individuals and healthy 
controls (Gonzalez et al., 2009). Hunt et al showed a relationship between HIV-1/HCV coinfection and 
increased levels of CD4 and CD8 T cell activation (Hunt et al., 2008), and there is a positive correlation 
between markers of T cell and B cell immune activation and HSC activation in HIV-1/HCV coinfection (Allison 
et al., 2009) especially in patients with CD4 T cell count less than 500cells/µl.    
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Thus in HIV-1/HCV coinfection increased levels of microbial translocation may act to drive the development 
of more frequent and more rapid liver fibrosis via both LPS signalling and immune activation. However a 
definitive relationship between HIV-1 induced microbial translocation and immune activation, and the 
development of liver fibrosis in HIV-1/HCV coinfection has not been fully established.  
1.6 Hypothesis 
Loss of Th17 and Th22 cells in HIV-1 infection is associated with microbial translocation and immune 
activation resulting in the rapid development of fibrotic liver disease in HIV-1/HCV coinfection. 
1.7 Aims 
 Determine any differences between HIV-1 monoinfection, HCV monoinfection and HIV-1/HCV 
coinfection and the:  
 presence of microbial translocation via: LPS, LBP, sCD14 and EndoCAb concentrations 
 presence of systemic immune activation via: frequencies of peripheral activated CD4 and CD8 T cells 
and neopterin concentrations 
 frequencies, ratios and function of peripheral Th17 and Th22 cells, compared to other CD4 T cell 
subsets 
 
 Evaulate any associations between: 
 markers of immune activation and microbial translocation  
 markers of immune activation and CD4 T cell subsets  
 markers of microbial translocation and CD4 T cell subsets  
 
 Assess the associations between liver stiffness and: 
 markers of microbial translocation  
 markers of immune activation  
 CD4 T cell subsets   
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Chapter 2 Materials and methods  
2.1 Ethical considerations 
Ethical approval to perform this study was obtained from the Outer North East London Research Ethics 
Committee (REC reference number 09/H0701/73).  Local Site Specific Approval was obtained from the 
Research and Development Office at Chelsea and Westminster NHS Foundation Trust (R&D reference 
number IIM09002NN). 
2.2 Study design 
Cross-sectional study. 
Study groups were as follows: 
 healthy controls not infected with HIV-1 or HCV recruited from research and clinical laboratory staff 
working at the Department of Immunology, Chelsea & Westminster Hospital 
 chronic HCV monoinfected individuals  
 HIV-1 monoinfected individuals on effective antiretroviral therapy 
 HIV-1 monoinfected individuals naive to antiretroviral therapy 
 chronic HCV/HIV-1 coinfected individuals on effective antiretroviral therapy 
 chronic HCV/HIV-1 coinfected individuals naive to antiretroviral therapy. 
2.2.1 Inclusion criteria 
HCV infected patients required a positive serum HCV RNA. Individuals who had previously failed treatment 
for HCV were not excluded. HIV infected individuals required detectable antibodies against HIV-1 and 
effective antiretroviral therapy was defined as an HIV viral load of < 50 copies/ml for at least 12 months prior 
to the date of study entry. HIV monoinfected individuals required a negative HCV antibody. HCV 
monoinfected individuals required a negative HIV antibody. 
2.2.2 Exclusion criteria 
Exclusion criteria included a body mass index of ≥30 kg/m2, the presence of ascites, the presence of HCC or 
previous/current clinical hepatic decompensation or coinfection with hepatitis B, the use of intravenous 
drugs, the use of hepatotoxic drugs, genetic liver disease, autoimmune hepatitis, vascular diseases of the 
liver, biliary tract disorders, age younger than 18 years or older than 70 years, pregnancy and existence of an 
in situ pacemaker. Those individuals with other immunosuppressive conditions including malignancy, chronic 
renal failure with haemodialysis, organ transplant or other co-morbid diseases requiring immunosuppressive 
therapy were excluded. 
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2.2.3 Recruitment and consent 
Patients were recruited from the HIV-1/HCV coinfection clinic and the Hepatitis clinic at Chelsea and 
Westminster Hospital NHS Foundation Trust. Written informed consent was obtained from all patients. At 
enrolment all participants had transient elastography performed via FibroScan (Echosens) to determine the 
degree of liver fibrosis and venesection to obtain 10ml EDTA blood, 10ml clotted blood and 36ml Lithium 
Heparin blood. 
2.3 Transient elastography 
To date liver biopsy has been regarded as the gold standard for detecting hepatic fibrosis. However there 
continues to be evidence that sampling error (up to 25% to 40%) remains a problem in accurate fibrosis 
staging for individual patients (Cholongitas et al., 2006, Standish et al., 2006). In addition the extent of 
variation between histopathologist interpretations for a particular stage may be as high as 20% (Bravo et al., 
2001). Furthermore the ability to procure an optimal specimen for assessment (biopsy length ≥25 mm with 
≥11 complete portal tracts) is not guaranteed with either percutaneous or transjugular approaches 
(Cholongitas et al., 2006). Therefore new non invasive detection methods for hepatic fibrosis have been 
developed. Transient elastography is a novel non invasive method that has been proposed for the 
assessment of liver fibrosis. The stiffness of the liver is measured in a volume that approximates a cylinder 1 
cm wide and 4 cm long, lying between 25 mm and 65 mm below the skin surface. The volume is at least 100 
times larger than a biopsy sample and is, therefore, far more representative of the hepatic parenchyma 
(Sandrin et al., 2003). It has been estimated that this evaluates 1/500 of the liver. 
Transient elastography was performed using the FibroScan (Echosens) apparatus. The main component of 
the FibroScan is a 3.5 MHz ultrasound transducer probe mounted on the axis of a vibrating device (piston). 
With the patient lying in the dorsal decubitus position, and the right arm maximally abducted, the tip of the 
transducer probe, covered with coupling gel, was placed on the skin in the mid-axillary line, between the 
ribs, aiming at the right lobe of the liver. The operator, assisted by ultrasound A-mode images provided by 
the system, located a portion of the liver at least 6cm thick, free of large vascular structures and the 
gallbladder. Once the area of measurement had been identified the operator acquired a reading. The piston 
induces elastic shear waves, with low frequency (50Hz) and small amplitude that propagate through the 
liver. The reflected waves are captured by the transducer, their velocity being directly related to the 
elasticity (stiffness) of the liver, with faster wave progression occurring through stiffer tissues. Measurement 
of liver stiffness is then performed and measured in kPa. 
The median value of ten valid readings was calculated to give a measurement. Only measurements with 
success rates (ratio of the number of successful acquisitions over the total number of acquisitions) of at least 
60% and an interquartile range (IQR) to median ratio of less than 30% were considered.  
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Liver stiffness measurements can be difficult in obese patients (BMI ≥30, gives OR 0.1) (Kettaneh et al., 2007) 
or in those with narrow intercostal space and impossible in patients with ascites (Sandrin et al., 2003). 
Reproducibility of transient elastography has been shown to be excellent for both interobserver and 
intraobserver agreement. However interobserver agreement was significantly reduced in patients with lower 
degrees of hepatic fibrosis, hepatic steatosis and increased BMI (Fraquelli et al., 2007).  
2.4 Plasma HIV-1 viral load and lymphocyte subset quantification 
The plasma HIV viral load of HIV infected subjects, performed by the Clinical Virology Department, St Mary’s 
Hospital, Imperial College Healthcare NHS Trust, was measured by PCR using branched DNA amplification 
technology (Bayer Healthcare, Tarrytown, NY, USA) with a lower limit of detection of 50 copies/ml.  
Quantification of lymphocyte subsets, performed by the Clinical Immunology Department, Chelsea and 
Westminster Hospital, Imperial College Healthcare NHS Trust, were determined using four colour flow 
cytometry.  Briefly, whole blood (EDTA) was stained with a panel of monoclonal antibodies (CD3, CD4, CD8 
and CD45 or CD3, CD56, CD19 and CD45) and was evaluated using a Cytomics FC500 flow cytometer 
(Beckman Coulter Inc., High Wycombe, UK). 
2.5 Flow cytometry 
2.5.1 Isolation of peripheral blood mononuclear cells 
PBMCs were isolated by gradient centrifugation from heparinised peripheral blood by overlaying equal 
volumes of whole blood directly over Histopaque (Sigma) in a 50ml conical centrifuge tube and centrifuging 
(20min, 1000xg, break off).  The PBMCs were carefully isolated from the plasma/histopaque interface and 
then washed twice (10min, 600xg, break off) in RPMI-1640 median (Sigma).  The pellet was resuspended in 
AIM-V complete median (Gibco).  Cell yield was established by the Trypan Blue (Sigma) stain enumeration 
method using a haemocytometer.  Cells were diluted in AIM-V complete median (Gibco) to a working 
concentration of 2X106 cells/ml. 
2.5.2 Immunophenotyping of T cell subsets by flow cytometry 
The phenotypic characterisation of T cell subsets was performed on whole blood and PBMCs with six colour 
flow cytometry (see figure 12). For each subject 150µl of whole blood was added to seven flow cytometry 
tubes and 500µl (1X106cells) of PBMCs to 11 flow cytometry tubes. Samples were washed in 2ml of 
phosphate buffered saline (PBS) (5 min, 400xg). Samples were resuspended in 100µl of red fluorescent 
reactive dye (Invitrogen L23102), diluted 1:1600 in PBS. All tubes were then incubated in the dark at room 
temperature for 30 minutes. All tubes were subsequently washed in 1ml PBS (5 min, 400xg). Monoclonal 
antibodies were added to each tube as outlined in table 1.  After incubation in the dark for 20 minutes, 300µl 
of 1:10 dilution of Cell Fix in dH20 (BD 340181) were added to the PBMC tubes followed by a further 15 
minute incubation period in the dark at room temperature. After the whole blood tubes had been incubated 
60 | P a g e  
 
at room temperature in the dark for 30minutes, lysis of erythrocytes and fixation of staining with 
paraformaldehyde was performed using an automated TQ Prep System (Beckman Coulter).  The whole blood 
tubes were washed twice and PBMC tubes once with 2ml PBS (5min, 400 x g) and resuspended in 300-500l 
PBS.  Acquisition was performed on an LSRII (BD Biosciences) and where possible at least 50,000 CD3+CD4+ 
lymphocytes were acquired from the whole blood tubes and 100,000 CD3+CD4+ lymphocytes from the 
PBMC tubes. Otherwise at least 100,000 lymphocytes were acquired.  Data were analysed using FlowJo Tree 
Star Inc. software and exported to Microsoft Excel (Microsoft). 
Figure 12 Phenotypic staining of whole blood and peripheral blood mononuclear cells 
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Table 1 Panels of monoclonal antibodies used for immunophenotyping of T cell subsets. 
 FITC PE PerCP PE-Cy7 APC APC-Cy7 
T cell activation 
Panel 
HLA-DR 
(BD:555560) 
CD38 
(BD:555460) 
DUMP CHANNEL 
(*CD14/
#
CD19) 
CD4 
(BC:737660) 
CD8 
(BD:555369) 
CD3 
(BD:557832) 
Stained Tube 10µl 10µl 1µl of each 2µl 10µl 5µl 
FMO-HLA-DR 0µl 10µl 1µl of each 2µl 10µl 5µl 
FMO-CD38 10µl 0µl 1µl of each 2µl 10µl 5µl 
       
Chemokine Receptor 
Panel 
CCR6 
(R&D:FAB195F) 
CCR5 
(BD:555993) 
DUMP CHANNEL 
(CD14/CD19) 
CD4 
 
CXCR3 
(BD:550967) 
CD3 
Stained Tube 20µl 5µl 1µl of each 2µl 5µl 5µl 
FMO-CCR6 0µl 5µl 1µl of each 2µl 5µl 5µl 
FMO-CCR5 20µl 0µl 1µl of each 2µl 5µl 5µl 
FMO-CXCR3 20µl 5µl 1µl of each 2µl 5µl 5µl 
       
Naive / Memory 
Panel 
CCR7 
(R&D:FAB197F) 
CD27 
(BD:555441) 
DUMP CHANNEL 
(CD14/CD19) 
CD4 CD45RA 
(eBio:17-0458) 
CD3 
Stained Tube 5µl 5µl 1µl of each 2µl 5µl 5µl 
FMO-CCR7 0µl 5µl 1µl of each 2µl 5µl 5µl 
FMO-CD27 5µl 0µl 1µl of each 2µl 5µl 5µl 
FMO-CD45RA 5µl 5µl 1µl of each 2µl 0µl 5µl 
       
Treg Panel X CD127 
(BD:557938) 
DUMP CHANNEL 
(CD14/CD19) 
CD4 CD25 
(eBio:17-0259) 
CD3 
Stained Tube  4µl 1µl of each 2µl 5µl 5µl 
FMO-CD127  0µl 1µl of each 2µl 5µl 5µl 
FMO-CD25  4µl 1µl of each 2µl 0µl 5µl 
       
Th17/Th22 Panel CCR6 
(R&D:FAB195F) 
CCR4 
(BD:551120) 
DUMP CHANNEL 
(CD14/CD19) 
CD4 CCR10 
(R&D:FAB3478A) 
CD3 
Stained Tube 20µl 5µl 1µl of each 2µl 10µl 5µl 
FMO-CCR6 0µl 5µl 1µl of each 2µl 10µl 5µl 
FMO-CCR4 20µl 0µl 1µl of each 2µl 10µl 5µl 
FMO-CCR10 20µl 5µl 1µl of each 2µl 0µl 5µl 
 
*CD14 – eBio:45-0149  
#
CD19 – eBio:45-0198 
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2.5.3 Stimulation and staining of PBMCs for detection of intracellular cytokines 
Figure 13 Intracellular cytokine staining of peripheral blood mononuclear cells 
 
The detection of intracellular cytokines was performed on PBMCs with six colour flow cytometry (see figure 
13). 750µl of PBMC / AIM-V mix (1.5x106 cells) were aliquoted into flow cytometry tubes. Cells were 
stimulated with SEB (Sigma, S4881) at a concentration of 300µg/ml for 20 hours in a humidified incubator 
(37C, 5% CO2).  Unstimulated cells were run concurrently as a negative control.  Brefeldin A (10g/ml; 
Sigma) was added for the final four hours of stimulation. The cells were washed twice with PBS (5min, 400xg) 
and samples were resuspended in 100µl of red fluroescent reactive dye (Invitrogen L23102), diluted 1:1600 
in PBS. All tubes were then incubated in the dark at room temperature for 30 minutes. All tubes were 
subsequently washed in 2ml PBS (5 min, 400xg). Monoclonal antibodies were added to each tube as outlined 
in table 2. Staining of surface markers (CD3, CD4, CD14, CD19) was performed at room temperature for 15 
minutes. Fixation and permeabilization was carried out using Fix and Perm Cell Permeabilization Reagents 
from Invitrogen (GAS-004). After the incubation 100µl of Reagent A was added to each tube followed by 
further 15 minutes incubation in the dark at room temperature.  The cells were washed in 2ml 5% foetal 
bovine serum (5min, 400xg) and resuspended in 100µl of Reagent B.  Antibodies to accumulated intracellular 
cytokines (IFN-γ, IL-2, IL-17A, IL-17F, IL-21 and IL-22) were added and the tubes were incubated in the dark at 
room temperature for 20 minutes.  Cells were washed once in 2ml 5% foetal bovine serum (5min, 400 x g) 
and resuspended in 300l PBS.  Acquisition was performed on an LSRII (BD Biosciences) and where possible 
at least 20,000 CD3+CD4+ lymphocytes were acquired, otherwise at least 100,000 lymphocytes were 
acquired.  Data were analysed using FlowJo Tree Star Inc. software and exported to Microsoft Excel 
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(Microsoft). IL-17F producing CD4+ T cells were not identified from the first 30 individuals included in the 
study, therefore staining for this cytokine was discontinued and the results have not been analysed.  
Table 2 Panels of monoclonal antibodies used for the detection of intracellular cytokines on CD4 T cells.   
 FITC PE PerCP PE-Cy7 APC APC-Cy7 
Functional Panel 1 IFN-γ 
(eBio:11-7391) 
IL-17A 
(eBio:12-7178) 
DUMP CHANNEL 
(CD14/CD19) 
CD4 
(BC:737660) 
IL-2 
(BD:341116) 
CD3 
(BD:557832) 
Stimulated Tube 2µl 5µl 1µl of each 2µl 5µl 5µl 
Unstimulated Tube 2µl 5µl 1µl of each 2µl 5µl 5µl 
       
Functional Panel 2 IL-17F 
(R&D:IC13351F) 
IL-22 
(eBio:12-7229) 
DUMP CHANNEL 
(CD14/CD19) 
CD4 IL-21 
(BD:341116) 
CD3 
Stimulated Tube 10µl 5µl 1µl of each 2µl 20µl 5µl 
Unstimulated Tube 10µl 5µl 1µl of each 2µl 20µl 5µl 
2.5.4 Flow cytometry - optimising experiments 
Optimisation experiments were completed before performing flow cytometric measurements to ensure high 
quality data collection. Some of the populations of interest were relatively rare and thus it was important to 
ensure that adequate controls were used in the flow cytometry panels to ensure the cells detected were a 
true population. 
2.5.4.1 Monoclonal antibody titration 
Titration experiments were performed to determine the optimal volume of each monoclonal antibody 
required for the flow cytometric experiments. An example of a titration experiment is shown in figure 14. 
Monoclonal antibody to human CCR7 conjugated to FITC (anti-CCR7-FITC) was added in increasing volumes 
(0µl, 2µl, 3µl, 5µl, 7.5µl, 10µl and 20µl) to whole blood along with previously determined volumes of anti-
CD3-APC-Cy7 and anti-CD4-PC7. Initially the lymphocyte population was selected on a forward scatter (FSC) 
vs side scatter (SSC) plot. This was followed by doublet discrimination and then sequential gating of the CD3+ 
population (T cells) followed by the CD4+ population (CD4 T cells). Fluorescence of anti-CCR7-FITC on both 
the negative (CCR7-) and positive (CCR7+) cell populations were then measured. This allowed calculation of 
the Stain Index [(geometric mean fluorescence intensity of the positive population – geometric mean 
fluorescence intensity of the negative population)/standard deviation of the negative population] which was 
plotted against the log antibody volume. In this instance 5µl is the lowest volume giving the highest ratio and 
is therefore the volume used in the panel. All other optimal antibody volumes were determined using the 
same technique. 
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Figure 14 Example of titration experiment 
a) 
 
 
b) 
 
Monoclonal antibody to CCR7 conjugated to Fluorescein was added in increasing volumes to whole blood a) Fluorescence was 
measured after gating on the lymphocyte population by FSC vs SSC, followed by doublet discrimination, a CD3 gate and a CD4 gate b) 
The graph shows the Stain Index [(geometric mean of the positive population – geometric mean of the negative 
population)/standard deviation of the negative population] against the log antibody concentration. 5ul (Log of 5=0.7) is the lowest 
volume giving the highest ratio and is therefore the volume used in the panel. 
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2.5.4.2 Whole blood versus peripheral blood mononuclear cells 
Immunophenotyping experiments were carried out, in three healthy controls, for each phenotype panel 
using both PBMCs and whole blood to determine which panels would benefit from use of whole blood and 
which from PBMCs. Sole use of PBMCs required large volumes of blood and time intensive separation before 
staining could commence. However their use allowed rapid acquisition of greater cell numbers which was 
important, especially for rare event analysis. In addition some antibody staining differed between whole 
blood and PBMCs. It was decided to use whole blood for both the activation and chemokine receptor panels. 
Within the activation panel initially a CD38 vs SSC dot plot was used to aid gate positioning: the monocyte 
population is an internal positive control for cells that strongly express CD38 (CD38bright) and the granulocyte 
population for cells that weakly express CD38 (CD38dim). Use of PBMCs would not allow application of these 
internal controls. In the chemokine receptor panel superior staining with both anti-CCR5-PE and anti-CXCR3-
APC were seen in whole blood experiments (see figure 15). Anti-CD25-APC staining was superior with PBMCs 
compared to whole blood in the Treg panel. Due to the need for rare event analysis in the Th17/Th22 panel 
PBMCs were chosen over whole blood. There was minimal difference between whole blood and PBMC 
staining in the naive memory panel, PBMCs were chosen to allow faster acquisition on the flow cytometer. 
Figure 15 Example PBMC vs whole blood experiments  
 
The contour plots above demonstrate enhanced anti-CXCR3-APC staining staining in whole blood compared to peripheral blood 
mononuclear cells in the Th1 panel.FMO tubes are used as controls to allow accurate positioning of the gate in the stained tube to 
differentiate between positive and negative cell populations. 
2.5.5 Gating strategy 
The sequential gating strategy for the immunophenotyping of T cell subsets is shown in figure 16. For T cell 
immunophenotyping a timed dot plot is used to ensure laser stability during real time acquisition to 
guarantee cells are being acquired continuously. The lymphocyte population is selected on a FSC vs SSC plot. 
Plotting FSC height vs FSC area then allows for doublet discrimination. This is important as cells can adhere 
to each other to form clumps or doublets, therefore producing inaccurate results. Doublets can be reliably 
gated out by plotting FSC area vs FSC height, as the readout for these values from a single cell should be 
proportional. 
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Figure 16 Sequential gating strategy for identification of CD4+ T cells  
 
A timed dot plot is followed by selection of the lymphocyte population on FSC vs SSC. This is followed by doublet discriminat ion, 
before the dump channel is utilised to exclude CD14
+
, CD19
+
 and dead cells. T cells are selected with a CD3gate and finally CD4+ T 
cells with a CD4 gate. 
 
Monocytes (CD14+), B cells (CD19+) and dead cells (ViRed+) are then excluded as they fluoresce within the 
same PerCP Cy5.5 ‘dump channel’. ‘Dump channels’ can be used to exclude irrelevant cell populations from 
analysis.  Non-specific binding of monoclonal antibodies to dead cells can lead to significant measurement 
errors. A viability dye, such as an amine reactive dye, can be used to identify and gate out dead cells. These 
dyes penetrate the dead cell’s damaged membrane and bind to amine groups in the cytoplasm. They also 
bind to amine groups on the cell surface but at a much lower intensity. Their use has been validated for cell 
surface immunophenotyping and they have therefore been included in the staining methods used here. Anti-
CD19 and anti-CD14 labelled with a fluorochrome that reads in the same fluorescence channel as the amine 
reactive dye has been used to allow exclusion of monocytes and B cells in the same channel as dead cells.  
Following exclusion of the irrelevant cell populations in the ‘dump channel’, anti-CD3-APC-Cy7 is used to 
identify T cells, followed by anti-CD4-PC7 to identify CD4 cells. Once CD4 T cells have been identified 
different markers are used in each of the panels to identify the particular CD4 T cell subsets of interest. 
These individual gating strategies are demonstrated in each results section.  
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Figure 17 Comparison of gating strategies 
a) Dot plots demonstrating gating strategies with and without the use of a CD3 gate 
 
 
b) Bland-Altman plots to compare number and frequency of CD4 T cells using gating strategies with and without the use of 
a CD4 gate 
 
 
 
 
 
 
 
 
 
 
 
 
Comparisons were made between two gating strategies: 
a) one including a CD3 gate and one excluding a CD3 gate  
b) the Bland-Altman Plots demonstrates the close agreement in CD4 T cell numbers and frequencies between the use of a 
CD3 gate and exclusion of a CD3 gate. 
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During interim analysis a different gating strategy was also applied – where the CD3 gate was excluded and a 
direct CD4 gating strategy was used. The reason for investigating this new gating strategy was to attempt to 
identify an effective alternative that was more cost-efficient. Figure 17a shows the effect on the CD4 T cell 
population if the CD3 gate is excluded. A new, distinct CD4lo population is seen, which can be excluded from 
the CD4 gate. Data for 36 individuals were analysed using both gating strategies. CD4 T cell numbers and 
frequencies were almost identical. Bland-Altman plots (see figure 17b) were constructed to determine the 
agreement between the two gating strategies in determining numbers and frequencies of CD4 T cell subsets. 
For absolute counts of CD4T cells; the average of the differences (average bias) was 10cells/µl, and for 
frequencies of CD4 T cells; the average of the differences (average bias) was -0.0142%. Within the Clinical 
Immunology Department, Chelsea and Westminster Hospital, Imperial College Healthcare NHS Trust a 
variation in absolute counts of 10cells/µl and percentages of 3% are acceptable and thus the direct CD4 
gating was felt to be well with in acceptable limits to allow this strategy to be adopted and used for analysis 
of all further data. 
2.5.6 Controls 
2.5.6.1 Gating controls 
Controls are necessary when there is no clear division of positive from negative expression of a cell surface 
marker to allow accurate gating of positive and negative cell populations. In order to correctly position a 
control gate, levels of background fluorescence of individual cell populations should be identified. In this 
study fluorescence minus one tubes (FMOs) (leaving out a single antibody of interest in a control tube) were 
included where distinct positive and negative cell populations did not exist to allow discrimination between 
the negative population and truly positive cells.  A further advantage of FMOs is that they can be useful to 
ensure accurate compensation has been applied particularly in multicolour panels. Examples of FMOs as 
controls can be seen in figure 15.  
Further gating options exist for the analysis of intracellular cytokine production following stimulation. The 
first option is to use either FMOs as described above. The second option is to use unstimulated controls 
(PBMCs prepared in exactly the same way as the PBMCs of interest, however SEB is left out). Initially both 
methods were examined, but in contrast to unstimulated controls FMOs were found to overestimate the 
positive population and therefore were discarded. 
2.5.6.2 Compensation controls 
In order to accurately compensate for fluorescence spillover it is relatively common practice to use single 
stained cells as compensation controls. This is only really accurate, however, if using the same monoclonal 
antibody/fluorochrome combination in the single stain compensation tube as in the complete panel. If the 
expression of the marker on the cell type of interest is not clearly positive or negative, this becomes 
inaccurate. In this instance, it is possible to use the same fluorochrome conjugated to an antibody specific 
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for a surface antigen with a clear positive/negative population (e.g. CD8). However this adds an element of 
inaccuracy as the fluorochrome may behave differently when bound to another antibody or if the 
manufacturing process is not the same. This is especially true for tandem dyes. Compensation beads provide 
a solution to this problem as they are designed to bind any fluorochrome/antibody combination with a 
distinct positive and negative population. This allows use of the same monoclonal antibodies being used in 
the panel, irrespective of the pattern of expression on cells. Compensation beads were therefore used as 
compensation controls for flow cytometry in this project with unstained whole blood and PBMCs used to 
define the negative populations in determining the overspill and compensation required.  
2.6 ELISAs 
Plasma and serum were separated from cells by centrifugation (10 min, 2500rpm, 20oC, brake on) of EDTA 
and clotted blood respectively.  2ml of each, in 0.5ml aliquots, were stored at -80°C for future studies.  
Unless otherwise stated all ELISAs were carried out by Dr Emma Elizabeth Page. 
For each ELISA the average absorbance values were calculated for each set of duplicate standards, samples 
and controls. If individual absorbance values differed by more than 15% from the corresponding mean value, 
the result was considered suspect and the sample was re-assayed. The mean absorbance values of the 
controls were less than 10%. A standard curve was constructed by plotting the logarithmic mean absorbance 
for each standard on the Y-axis vs the corresponding standard linear concentration on the X-axis. Using the 
mean absorbance value for each sample, the corresponding concentration was determined from the 
standard curve. The concentration determined from the standard-curve was multiplied by the dilution 
factor.  
2.6.1 Soluble CD14 
Plasma samples stored at -80oC were used to determine sCD14 concentrations. A commercially available kit 
was utilised (R&D Systems: Quantikine, Human sCD14 Immunoassay, Catalog number DC140). All reagents 
and plasma samples were brought to room temperature. Plasma samples were diluted 200X into ‘calibrator 
diluent RD5P (1X)’. ‘Soluble CD14 standard’ was prepared by reconstituting it with 5ml ‘calibrator diluent 
RD5P (1X)’, giving a stock solution of 16,000 pg/ml. The stock solution was gently agitated for 15 minutes 
prior to using double dilutions with ‘calibrator diluent RD5P (1X)’ to produce a dilution series. The resulting 
standard concentrations were as follows: 16,000 pg/ml, 8,000 pg/ml, 4,000 pg/ml, 2,000 pg/ml, 1,000 pg/ml, 
500 pg/ml, 250 pg/ml, 0 pg/ml. 100ul of ‘assay diluent RD1W’ was added to each of the microplate wells, 
followed by 100µl of either ‘standard’, ‘sample’ or ‘control’ per well. Each ‘standard’, ‘sample’ and ‘control’ 
was run in duplicate. The microplate was covered with an adhesive strip and incubated at room temperature 
for three hours. The microplate was aspirated and washed four times, before 200µl of ‘sCD14 conjugate’ 
were added to each well. The microplate was covered with an adhesive strip and incubated at room 
temperature for one hour. The microplate was aspirated and washed four times, before 200µl of ‘substrate 
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solution’ was added to each well. The microplate was covered with an adhesive strip and incubated in the 
dark at room temperature for 30 minutes. 50µl of ‘stop solution’ was added to each well and the microplate 
reader was used within 30 minutes. Measurement of the optical density was carried out at wavelength of 
450nm.  
2.6.2 Lipopolysaccharide binding protein 
Plasma samples stored at -80oC were used to determine LBP concentrations. A commercially available kit 
was utilised (Hycult Biotech: LBP, Human, ELISA kit HK315). All reagents and plasma samples were brought to 
room temperature. Plasma samples were diluted 1000 times into ‘dilution buffer’. ‘LBP standard’ was 
prepared by reconstituting it with 1ml of distilled water giving a stock solution of 50 ng/ml. One and a half 
times dilutions with ‘dilution buffer’ were used to produce a dilution series. The resulting standard 
concentrations were as follows: 50ng/ml, 33.3ng/ml, 22.2ng/ml, 14.8ng/ml, 9.9ng/ml, 6.6ng/ml, 3.3ng/ml, 
0ng/ml. 100µl of either ‘standard’, ‘sample’ or ‘control’ were added to each well of the microplate. Each 
‘standard’, ‘sample’ and ‘control’ was run in duplicate. The microplate was covered with an adhesive strip 
and incubated at room temperature for one hour. The microplate was aspirated and washed four times, 
before 100µl of ‘diluent tracer’ was added to each well. The microplate was covered with an adhesive strip 
and incubated at 37oC for one hour. The microplate was aspirated and washed four times, before 100µl of 
‘streptavidin-peroxidase’ was added to each well. The microplate was covered with an adhesive strip and 
incubated at 37oC for one hour. The microplate was aspirated and washed four times, before 100µl of ‘TMB 
substrate solution’ was added to each well. The microplate was covered with an adhesive strip and 
incubated in the dark at room temperature for 30 minutes. 100µl of ‘stop solution’ was added to each well 
and the microplate reader was used within 30 minutes. Measurement of the optical density was carried out 
at wavelength of 450nm.  
2.6.3 Endotoxin core antibodies 
Plasma samples stored at -80oC were used to determine EndoCab concentrations. A commercially available 
kit was utilised (Hycult Biotech: EndoCab, Human, ELISA kit HK504). All reagents and plasma samples were 
brought to room temperature. Plasma samples were diluted 100 times into ‘dilution buffer’. ‘EndoCab IgM 
standard’ was prepared by reconstituting it with 1.075ml ‘dilution buffer’ giving a stock solution of 
3.50MMU/ml. Double dilutions with ‘dilution buffer’ were used to produce a dilution series. The resulting 
standard concentrations were as follows: 3.50MMU/ml, 1.7MMU/ml, 0.88MMU/ml, 0.44MMU/ml, 
0.22MMU/ml, 0.11MMU/ml, 0.05MMU/ml, 0MMU/ml. The microplate was aspirated and washed four 
times, before 100µl of either ‘standard’ or ‘sample’ were added to each well of the microplate. Each 
‘standard’, ‘sample’ and ‘control’ was run in duplicate. The microplate was covered with an adhesive strip 
and incubated at 37oC for one hour. The microplate was aspirated and washed four times, before 100µl of 
‘endotoxin core antibody IgM conjugate’ were added to each well. The microplate was covered with an 
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adhesive strip and incubated at 37oC for one hour. The microplate was aspirated and washed four times, 
before 100µl of ‘TMB substrate solution’ were added to each well. The microplate was covered with an 
adhesive strip and incubated in the dark at room temperature for 30 minutes. 100µl of ‘stop solution’ were 
added to each well and the microplate reader was used within 30 minutes. Measurement of the optical 
density was carried out at wavelength of 450nm.  
2.6.4 Lipopolysaccharide  
ELISAs to determine the presence of LPS were carried out by Louise Greathead, PhD student, Immunology 
Department, Chelsea and Westminster Campus, Imperial College London. The Hycult Biotech Limulus 
Amoebocyte Lysate (LAL) assay (HIT 302) was used with serum samples stored at -80oC to determine levels 
of bacterial endotoxin. This test is based on the observation that endotoxin causes opacity and gelatinisation 
of LAL, an aqueous extract of amoebocytes from the American horseshoe crab (Limulus polyphemus). In the 
presence of a colourless substrate an enzymatic reaction causes cleavage of the chromophore, p-nitroaniline 
which results in a yellow colour development. Addition of acetic acid stops the reaction and absorbance is 
measured at 405nm on a spectrophotometer, comparison of the sample value against a standard curve 
allows endotoxin concentration to be determined. This kit has a minimum detection limit of 0.01 endotoxin 
units (EU)/ml and a measurable concentration range of 0.01 to 10 EU/ml. Before performing the assay 
samples were brought to room temperature and mixed gently. As serum may contain endotoxin-inhibiting 
compounds all samples were heated to 75oC for five minutes in a water bath prior to testing. Endotoxin free 
pipette tips and plastics were used throughout the procedure. All samples were run in duplicate with the 
addition of individual sample controls.  The standard was reconstituted in the required amount of endotoxin 
free water (EFW) and vortexed for five minutes, LAL reagent was reconstituted in 4ml EFW and covered with 
parafilm and 10ml of stop solution was diluted in 15ml distilled water. 50µl of each sample was diluted in 
200µl EFW (20% or 1/5 dilution). 50µl of reconstituted standard was added to to 35µl EFW in an LP4 tube 
(final concentration 30EU/ml) and vortexed for 30 seconds. Serial dilutions were then performed to establish 
a standard curve. In triplicate 50µl of patient samples, or 50µl of EFW for control wells, were mixed with 50µl 
of reconstituted LAL reagent. The plate was then covered with a plate sealer and incubated for 15 minutes at 
room temperature in the dark. The plate was read to assess progression of the standard curve, when the top 
standard had reached 0.8 optical density (OD) the reaction was stopped by the addition of 50µl diluted stop 
solution. The plate was read on a spectrophotometer and the concentration in each sample was calculated 
from the standard curve after the subtraction of the OD values of each sample’s individual blank control and 
after correcting for the sample dilutions. 
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2.6.5 Tissue growth factor beta 
ELISAs to determine the presence of TGF-β were carried out by Louise Greathead, PhD student, Immunology 
Department, Chelsea and Westminster Campus, Imperial College London. Serum samples stored at -80oC 
were used to determine TGF-β concentrations. A commercially available kit was utilised (R&D Systems, 
Quantikine, Human TGF- β1 Immunoassay, DB100B). All reagents and serum samples were brought to room 
temperature before use. Latent TGF-β1 was activated to the immunoreactive form, detectable by this assay, 
by the addition of 20ul of 1N HCL to 40ul of serum followed by mixing and a 10 minute incubation. The 
acidified samples were then neutralised by the addition of 20µl of 1.2 NaOH/0.5M HEPES. Calibrator diluent 
was prepared by diluting 20ml concentrate into 60ml of distilled water, TGF- β1 standard was reconstituted 
in 2ml of calibrator diluent and mixed thoroughly, wash buffer was prepared by adding 25ml concentrate to 
600ml of distilled water. Activated samples were then diluted 20-fold in calibrator diluent, giving a final 
dilution factor of 40. Using polypropylene tubes the standard curve was prepared by pipetting 200µl diluent 
into six tubes followed by 200µl standard into tube one followed by doubling dilutions to give a curve value 
of 1000, 500, 250, 125, 62.5, 31.2 pg/ml. 50ul of assay diluent RD1-73 was added to each well followed by 
50ul of standard, control or diluted activated sample and the plate was incubated on a shaking platform at 
room temperature for two hours. The plate was then washed four times with wash buffer and blotted dry on 
clean paper towels. 100µl of conjugate was then added to each well, the plate covered and incubated at 
room temperature on a shaking platform for two hours then washed as before. 100µl of substrate were then 
added and incubated for 30 minutes at room temperature in the dark, the reaction was stopped with 100µl 
of stop solution and the plate read on a spectrophotometer within 30 minutes at 450nm and TGF-β 
concentrations calculated for each sample from the standard curve after correcting for the dilution factor. 
2.6.6 Neopterin 
Neopterin levels were measured by Professor Dietmar Fuchs’ laboratory, Division of Biological Chemistry, 
Biocenter, Innsbruck Medical University, Fritz Pregl Strasse 3, A-6020 Innsbruck, Austria. Serum samples 
stored at -80oC were transported to the above laboratory and used to determine neopterin levels. A 
commercially available ELISA kit was utilised (ELItest Neopterin, BRAHMS Diagnostica, Henningsdorf, 
Germany). 
2.7 Kynurenine and tryptophan 
KYN and TRP levels were measured by Professor Dietmar Fuchs’ laboratory, Division of Biological Chemistry, 
Biocenter, Innsbruck Medical University, Fritz Pregl Strasse 3, A-6020 Innsbruck, Austria. Serum samples 
stored at -80oC were transported to the above laboratory and high-performance liquid chromatography was 
used to determine KYN and TRP levels, via methods previously described (Widner et al., 1997). 
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2.8 Statistical analysis 
Statistical calculations were performed with GraphPad Prism version 5 software. Comparisons for categorical 
data were made using the Chi-square test with a threshold for statistical significance set at a p value less 
than 0.05. Differences between two groups were tested for using a two-tailed Mann Whitney test with 95% 
confidence intervals. The threshold for statistical significance was set at a P value less than 0.05. If multiple 
non parametric T tests were carried out to look at a single variable then a Bonferroni multiple-significance-
test correction was applied to the two-tailed Mann Whitney test and the threshold for statistical significance 
was set at a p value of less than 0.05 divided by the number of T tests carried out for each variable (0.05/7= 
P<0.007). Differences between three or more groups were tested for statistical significance using the Kruskal 
Wallis test with Dunn’s Multiple Comparison post test applied to identify which groups differed.   
2.8.1 Methods and statistical analysis for determining correlations 
Chapters 5 and 6 look for the presense of correlations between variables examined. To allow for separate 
determination of correlations within both HCV and HIV-1 (treated and untreated) monoinfection we initially 
looked for correlations in individuals with HCV monoinfection (HCV group), in those individuals with HIV-1 
monoinfection, irrespective of ART status, (HIV ART and HIV NAIVE groups) and finally in those individuals 
with untreated HIV (HIV NAIVE group). Finally for all correlations, we looked at either all individuals with HIV-
1/HCV coinfection (HCV HIV ART and HCV HIV NAIVE groups) or just those with untreated HIV-1/HCV 
coinfection (HCV HIV NAIVE group) [depending on whether ART influenced the correlation]  to determine if 
any correlation was maintained or enhanced in the context of coinfection. 
The presence of a correlation between two variables was determined using Spearman’s rank correlation 
coeffient. A Spearman r value of ≥ +/- 0.4000 was taken to denote a significant correlation. To correct for 
multiple correlations performed a significant P value was determined using the Bonferroni multiple-
significance-test.  In Chapter 5 when observing for correlations between immune activation and three 
markers of microbial translocation a P value of <(0.05/3) 0.0167 was taken as significant, whilst when 
observing for correlations between immune activation or microbial translocation the following P values were 
taken as significant; P <(0.05/5) 0.01 for the five CD4 T cell subsets, P <(0.05/6) 0.0083 for the six CD4 T cell 
subset shifts and P <(0.05/5) 0.01 for the five CD4 T cell cytokines. Finally, with correlations between IDO 
activity and three markers of immune activation or microbial translocation a P value of <(0.05/3) 0.0167 was 
taken as significant, while correlations between IDO activity or IL-21+ CD4 T cell frequency and the four CD4 
T cell subset shifts lead to a P value of <(0.05/4) 0.0125 being taken as significant. In Chapter 6 when 
observing for correlations with liver stiffness the following P values were taken as significant; P < (0.05/3) 
0.0167 for three markers of microbial translocation and three markers of immune activation, P < (0.05/1) 
0.05 for IDO, P < (0.05/7) 0.0071 for the seven CD4 T cell subsets, P < (0.05/5) 0.01 for the five CD4 T cell 
cytokines and P < (0.05/6) 0.0083 for the six CD4 T cell subset shifts.  
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Chapter 3 Results (1): Patient characteristics and immunophenotyping of T 
cell subsets 
3.1 Introduction 
To begin to answer our hypothesis that loss of Th17 and Th22 cells is associated with microbial translocation 
and immune activation resulting in the rapid development  of fibrotic liver disease in HIV-1/HCV coinfection, 
we recruited individuals into the following six study groups: healthy controls (HC), HCV monoinfected 
patients (HCV), HIV-1 monoinfected patients on ART (HIV ART), HIV-1 monoinfected patients naïve to HIV 
treatment (HIV NAÏVE), HIV-1/HCV coinfected patients on ART (HCV HIV ART) and HIV-1/HCV coinfected 
patients naïve to HIV treatment (HCV HIV NAÏVE). This chapter outlines the patient characteristics and the 
results of the immunophenotyping of T cell subsets. 
 In an attempt to characterise the HIV-1 disease stage of individuals recruited, a number of standard 
immunological parameters were determined including:  CD4 T cell absolute count and frequency 
(Schellekens et al., 1995) (the most frequently used markers of HIV-1 disease progression), CD4:CD8 T cell 
ratio and nadir CD4 T cell counts and frequencies. In addition naive/memory CD4 T cell subsets are known to 
alter with disease progression; there is a decrease in the proportion of naive and memory CD4 T cells, and an 
increase in the proportion of activated effector T cells (Gorochov et al., 1998). Most recently the surface 
markers CD45RA, CD27 and CCR7 have been shown to discriminate effectively between naive, central 
memory, transitional memory, effector memory and terminally differentiated CD4 and CD8 T cells (Ferrando-
Martinez et al., 2010).  
Immune activation, a pathognomonic feature of HIV-1 infection (Giorgi et al., 1999), was studied by 
determining the frequency of ‘activated’ phenotype CD4 and CD8 T cells. With regard to T cell activation 
numerous surface markers have been utilised to assess this in HIV-1 disease (Steel, 2010). We have utilised 
two commonly used parameters: the expression of CD38 and HLA-DR, and the CD38 antibody binding 
capacity (ABC) of CD4 T cells and CD8 T cells. HCV monoinfection is known to result in immune activation 
with increased percentages of CD38+ CD4 and CD8 T cells (Gonzalez et al., 2009). In HIV-1/HCV coinfection, 
recent studies have found increased levels of immune activation compared to HIV-1 and HCV monoinfection. 
Kovacs et al demonstrated increased percentages of HLA-DR+CD38+ CD8 T cells among HIV-1/HCV 
coinfected women compared with HIV-1 monoinfected women (Kovacs et al., 2008). While Gonzalez et al 
demonstrated increased percentages of CD38+ CD4 and CD8 T cells in HIV-1/HCV coinfected individuals 
compared to HIV-1 and HCV monoinfected individuals and healthy controls (Gonzalez et al., 2009). 
The chemokine receptors CXCR3, CCR5 and CCR6 have been used by a number of investigators to define pre-
Th1, Th1 and Th1Th17 cells (Gosselin et al., 2010, Syrbe et al., 1999). Th1 responses are known to be 
important and increased in HCV infection (Sobue et al., 2001). Published literature has demonstrated that 
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HIV-1 infection does not lead to a reduction in Th1 cells (Clark et al., 2011), and in some studies an increase 
in frequency has been demonstrated (Gosselin et al., 2010). Th1Th17 cells have previously been shown to be 
reduced in the periphery of HIV-1 infected individuals with ART conferring only partial if any restoration of 
this CD4 T cell subset (Gosselin et al., 2010, Clark et al., 2011), but to our knowledge they have not yet been 
studied in either HCV monoinfection or HIV-1/HCV coinfection. 
As discussed in section 1.3.5.1 data on Th17 cell frequency in HIV-1 infection are conflicting. SIV and HIV-1 
models suggest that Th17 cells are preferentially depleted from the GALT and there is some evidence to 
suggest that this may be reflected in the periphery. Conflicting results may be explained by differences 
between studies in the determination of Th17 cells. Many authors have classified Th17 cells using the 
functional marker of IL-17, which we studied in Chapter 4. Studies using phenotypic markers for Th17 cells 
are less common and limited to HIV-1 rather than SIV studies. Reduced frequencies of peripheral progenitor 
Th17 cells (CD161+ CD4 T cells) in chronic HIV-1 positive individuals naive to ART have been demonstrated 
(Prendergast et al., 2010). Gosselin et al demonstrated a persistent reduced frequency of peripheral Th17 
cells (CCR4+CCR6+ CD4 T cells) during chronic HIV-1 infection despite successful ART (Gosselin et al., 2010) 
and pilot data from our group shows that progressive HIV-1 infection is associated with loss of Th17 (CXCR3-
CCR4+CCR6+) cells in blood (Clark et al., 2011).  
In this study identification of Th17 and Th22 cells was determined using the chemokine receptors CCR4, 
CCCR6 and CCR10. Two Nature Immunology papers in 2009 identified a new subset of T helper cells that 
produced IL-22, but not IL-17, in humans. These cells were termed Th22 cells and were found to express the 
cell surface markers CCR4, CCR6 and CCR10 (Duhen et al., 2009, Trifari et al., 2009). While Th17 cells had 
previously been established to express CCR4 and CCR6 (Acosta-Rodriguez et al., 2007), to ensure mutually 
exclusive identification of these two Th cell subsets Th17 cells have been defined as CCR4+CCR6+CCR10-, 
while Th22 cells have been defined as CCR4+CCR6+CCR10+. 
While the difficulties posed in truly identifying Treg cells, especially in HIV-1 infection where FoxP3 can be 
upregulated on activated CD4 T cells, have been discussed in section 1.2.2.4 the surface markers CD25+ and 
CD127lo were used to identify Treg cells for the purpose of this research project. The role of Tregs in the 
pathogenesis of HIV is not well understood.  It is unclear whether Tregs are increased (Tsunemi et al., 2005, 
Nilsson et al., 2006) (Oswald-Richter et al., 2004) or reduced in HIV infection (Oswald-Richter et al., 2004) 
and whether they play a beneficial or detrimental role (Oswald-Richter et al., 2004, Eggena et al., 2005). Treg 
cells are thought to be increased in the periphery (Cabrera et al., 2004, Boettler et al., 2005, Rushbrook et 
al., 2005, Sugimoto et al., 2003) and liver (Sturm et al., 2010) in chronic HCV infection. There is evidence that 
Tregs may contribute to down-regulating the immune response to HCV (Boettler et al., 2005, Rushbrook et 
al., 2005). A recent study in HIV-1/HCV coinfection has shown increased Tregs compared to HCV 
monoinfected individuals (Rallon et al., 2011). 
76 | P a g e  
 
Current data suggests flexibility within CD4 T cell responses with an ability to shift from one predominant Th 
cell response to another, as discussed in section 1.3.5.4. A recent study has suggested an association 
between immune activation and a shift in the ratio of peripheral Th17 to Th1 cells in HIV-1 infection 
(Gosselin et al., 2010). In addition the reciprocal relationship between Th17 cells and Treg cells is now well 
documented. An imbalance in Th17 to Treg cells been demonstrated in HIV-1 infection in the periphery 
(Favre et al., 2010, Chege et al., 2011, Brandt et al., 2011, Li et al., 2011).  
To date there is no phenotypic data on Th22 cells in HIV-1 nor Th17 and Th22 cells in HCV or HIV-1/HCV 
coinfection. 
3.2 Aims 
Within the six study groups: 
 Assess the severity of HIV-1 infection via: 
 The absolute counts and frequencies of current and nadir CD4 T cells and the CD4:CD8 T cell 
ratio 
 The frequencies of peripheral naive, memory and terminally differentiated CD4 T cells 
 Assess the presence of systemic immune activation via: 
 The frequencies of peripheral activated CD4 and CD8 T cells 
 Establish any preferential depletion of Th17 or Th22 cells  via: 
 The frequencies of peripheral pre-Th1, Th1, Th1Th17, Treg, Th17 and Th22 cells 
 Establish any CD4 T cell subset shifts between: 
 Effector Th cells and Treg cells 
 Th17 or Th22 cells and Th1 cells 
3.3 Patient characteristics 
The baseline demographic data of the patients recruited to the six study groups: HC, HCV, HIV ART, HIV 
NAÏVE, HCV HIV ART and HCV HIV NAÏVE are summarised in Table 3. We recruited 16 HCs and 85 HIV and/or 
HCV infected individuals: 21 in the HCV group, 16 in the HIV ART group, 20 in the HIV NAIVE group, 18 in the 
HCV HIV ART group and 10 in the HCV HIV NAIVE group. The individuals in the HCV group were significantly 
older (mean 52.4 years) than the individuals in the HC group (mean 40.5 years, P < 0.01). However there was 
no significant difference in age between the remaining groups. There was no difference between groups in 
either gender or ethnicity with the majority of individuals recruited to each group being male (76%-100%) 
and of white ethnicity (62-94%). The frequency and number of CD4+ T cells was significantly lower in the HIV 
NAÏVE group (median: 15.7% and 283 cells/µl) compared to both the HC (median: 48.2%, P < 0.001 and 777 
cells/µl, P < 0.001) and HIV ART (median: 37.7%, P < 0.001 and 619 cells/µl, P < 0.001) groups. In addition the 
frequency of CD4+ T cells was significantly lower in the HCV HIV NAÏVE group (median 27.8%) compared to 
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the HC (P < 0.01) and HCV (median 45.1%, P < 0.01) groups. Although not significant there was a trend to the 
HCV HIV NAÏVE group having a higher frequency and number of CD4+ T cells than the HIV NAÏVE group. CD8+ 
T cell frequency and number were increased in the HIV NAÏVE (median: 63.2%, P < 0.0001 and 819 cells/µl, P 
< 0.01) and HCV HIV NAÏVE (median: 51.4%, P < 0.01 and 945cells/µl, P < 0.01) groups compared to the HC 
group (median: 27% and 439 cells/µl), while they were also increased in the HCV HIV NAIVE (P < 0.001 and P 
< 0.01) and HCV HIV ART (median: 42.1%, P < 0.01 and 831 cells/µl, P < 0.05) groups compared to the HCV 
(median: 21.6% and 398 cells/µl) group.  
When looking at CD4:CD8 cell ratios and nadir CD4 T cell counts and frequencies (see figure 18), the HCV HIV 
NAIVE group appeared to have less advanced HIV disease than the HIV NAIVE group. CD4:CD8 cell ratios 
were significantly reduced in the HIV NAIVE group (median: 0.25) compared to the HC group (median: 1.72, P 
< 0.001). Ratios were also significantly reduced in the HCV HIV NAIVE group (median: 0.46) compared to the 
HC group (P < 0.001) and HCV group (median: 1.99, P < 0.001). Although not quite reaching significance the 
CD4:CD8 ratio in the HCV HIV NAIVE group was almost double that in the HIV NAIVE group. ART did result in 
some ‘normalisation’ of the ratios, however this was less marked in the coinfected group with the ratio in 
the HCV HIV ART group (median: 0.80) being significantly reduced compared to those in the HC (median: 
1.72, P < 0.05) and HCV (median: 1.99, P < 0.05) group. Nadir CD4 T cell frequencies were significantly higher 
in the HCV HIV NAIVE group (median: 24.9%) compared to the HIV NAIVE group (median: 15.5%, P < 0.05). 
While a similar pattern was seen with absolute counts this did not reach significance. The HCV HIV NAIVE 
group (median: 363 cells/µl) had a significantly higher nadir CD4 T cell count than the HCV HIV ART group 
(median: 227 cells/µl, P < 0.01) 
Those individuals naive to ART tended to have been diagnosed with HIV more recently than those on ART. 
This reached significance with the HIV ART group having a median time since HIV diagnosis of 12.7 years 
compared to 5.1 years in the HIV NAIVE group (P < 0.01). There was no difference between the HIV ART and 
HCV HIV ART groups in the duration of ART exposure. All patients on ART had an HIV viral load of < 50 
copies/ml. The HIV NAÏVE and HCV HIV NAÏVE groups had similar median HIV viral loads at the time of study 
entry. There were differences between groups in the years since HCV diagnosis. Those in the HCV group had 
been diagnosed with HCV over twice as long as those individuals in the HCV HIV NAIVE group (median: 11.0 
years vs 4.5 years, P < 0.001). The majority of HCV infected individuals recruited were infected with genotype 
1 virus, six individuals were infected with genotype 4 virus and one with genotype 3 virus. There was no 
difference in baseline HCV RNA levels. 
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Table 3 Baseline demographic, immunological and virological data. 
 HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*AGE in years 
Mean (StdDev)  
 
40.5(12.35) 
 
52.4 (8.39) 
 
47.7 (11.44) 
 
40.3 (8.09) 
 
44.9 (6.39) 
 
43.7 (7.81) 
GENDER 
Male: n (%) 
 
15 (94) 
 
16 (76) 
 
16 (100) 
 
16 (80) 
 
17 (94) 
 
9 (90) 
ETHNICITY 
White: n (%) 
Hispanic: n (%) 
Black: n (%) 
Other: n (%) 
 
15 (94) 
0(0) 
0(0) 
1 (6) 
 
13 (62) 
3 (14) 
1 (5) 
4 (19) 
 
13 (81) 
2 (13) 
1 (6) 
0 (0) 
 
16 (80) 
1 (5) 
2 (10) 
1 (5) 
 
14 (77) 
3 (17) 
0 (0) 
1 (6) 
 
7 (70) 
3 (30) 
0 (0) 
0 (0) 
CD4 
*%: Median  
(IQR) 
*cells/µl: Median  
(IQR) 
 
48.2  
(42.1-52.1) 
777  
(561-950) 
 
45.1  
(35.4-56.1) 
781 
(501-1081) 
 
37.7  
(29.2-42.5) 
619  
(542-880) 
 
15.7  
(13.5-20.7) 
283  
(169-338) 
 
35.2  
(13.5-20.7) 
646  
(519-919) 
 
27.8  
(17.4-32.5) 
434  
(369-709) 
CD8 
*%: Median  
(IQR) 
*cells/µl: Median  
(IQR) 
 
27.0  
(18.5-36.4) 
439  
(290-471) 
 
21.6  
(17.7-30.3) 
398  
(304-601) 
 
41.0  
(31.1-47.1) 
675  
(499-995) 
 
63.2  
(53.1-70.9) 
819  
(610-1482) 
 
42.1  
(33.3-49.6) 
831  
(521-1414) 
 
51.4  
(44.3-61.2) 
945  
(766-1550) 
*CD4:CD8 
Median 
(IQR) 
 
1.72 
(1.51-2.75) 
 
1.99 
(1.14-3.19) 
 
0.96 
(0.64-1.33) 
 
0.25 
(0.19-0.39) 
 
0.80 
(0.57-1.22) 
 
0.46 
(0.36-0.74) 
*Years since HIV diagnosis 
Median (IQR)  
 
NA 
 
NA 
 
12.7 (8.3-16.2) 
 
5.1 (2.8-9.0) 
 
9.6 (7.4-15.5) 
 
4.9 (2.8-9.4) 
HIV Viral Load 
Median  
(IQR) 
 
NA 
 
NA 
 
50  
(50-50) 
 
85,505 
(53,351-276,173) 
 
50 
(50-50) 
 
45,813 
(2.868-117,225) 
Years on ART 
Median (IQR) 
 
NA 
 
NA 
 
8.0 (3.2-11.3) 
 
NA 
 
9.6 (3.7-11.6) 
 
NA 
Nadir CD4 
*%: Median  
(IQR) 
*cells/µl: Median  
(IQR)  
 
NA 
 
NA 
 
18.2 
(11.2-25.4) 
206 
(143-264) 
 
15.5 
(12.9-18.0) 
267 
(178-328) 
 
14.0 
(10.5-24.3) 
227 
(153-259) 
 
24.9 
(20.1-29.2) 
363 
(290-485) 
*Years since HCV diagnosis 
Median (IQR) 
 
NA 
 
11.0 (7.5-16.0) 
 
NA 
 
NA 
 
8.0 (5.0-10.3) 
 
4.5 (2.4-6.0) 
HCV Genotype 
1: n (%) 
2: n (%) 
3: n (%) 
4: n (%) 
 
NA 
 
15 (71) 
0 (0) 
1 (5) 
5 (24) 
 
NA 
 
NA 
 
17 (94) 
0 (0) 
0 (0) 
1 (6) 
 
8 (80) 
1 (10) 
1 (10) 
0 (0) 
HCV RNA Level 
IU/ml: Median  
(IQR) 
 
NA 
 
558,138 
(190,875-
3,889,000) 
 
NA 
 
NA 
 
1,590,000 
(821,398-
5,409,000) 
 
1,089,000  
(112,918- 
4,780,000) 
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Table 3 Legend 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment, StdDev: standard deviation, IQR: interquartile range.   
 
*Comparison between groups was determined using the Kruskal Wallis test with Dunn’s post test applied:  
Age: HC vs HCV P< 0.01 
CD4 %: HC vs HIV NAÏVE P<0.001, HC vs HCV HIV NAÏVE P<0.01, HCV vs HCV HIV NAÏVE P<0.01, HIV ART vs HIV NAÏVE P<0.001 
CD4 count: HC vs HIV NAÏVE P<0.001, HIV ART vs HIV NAÏVE P<0.001 
CD8 %: HC vs HIV NAÏVE P<0.001, HC vs HCV HIV NAÏVE P<0.01, HCV vs HCV HIV ART P<0.01, HCV vs HCV HIV NAÏVE P<0.001, HIV ART 
vs HIV NAIVE P<0.01 
CD8 count: HC vs HIV NAÏVE P<0.01, HC vs HCV HIV ART P<0.05, HC vs HCV HIV NIAVE P< 0.01, HCV vs HCV HIV ART P<0.05, HCV vs 
HCV HIV NAÏVE P<0.01 
CD4:CD8: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV ART P < 0.05, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV ART P < 0.05, HCV 
vs HCV HIV NAÏVE P < 0.001, HIV ART vs HIV NAIVE P<0.01 
Years since HIV diagnosis: HIV ART vs HIV NAIVE P < 0.01 
Nadir CD4%: HIV NAIVE vs HCV HIV NAIVE P < 0.05 
Nadir CD4 count: HCV HIV ART vs HCV HIV NAIVE P < 0.01 
Years since HCV diagnosis: HCV vs HCV HIV NAIVE P < 0.001 
 
Comparison for variables relevant for only two groups were analysed using the Mann Whitney U test. No significant differences. 
 
Comparisons for categorical data were made using Chi-square test. No significant differences. 
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Figure 18 The ratio of CD4:CD8 cells and nadir CD4 T cell count and frequency 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
 
3.4 Immunophenotyping of T cell subsets 
3.4.1 Immunophenotyping of naive, memory, terminally differentiated CD4 T cell subsets 
The markers CD45RA, CCR7 and CD27 were used to characterise naive, central memory, transitional 
memory, effector memory and terminally differentiated subsets of CD4 T cells (see figure 19). Cells 
expressing CD45RA and CCR7 brightly were defined as naive Th cells (Thn) while those expressing CD45RA 
brightly, but not expressing CCR7 were defined as terminally differentiated Th cells (Thtd). The memory 
subsets did not express CD45RA; central memory Th cells (Thcm) were defined as CD45RA-CCR7+CD27+, 
transitional memory Th cells (Thtm) as CD45RA-CCR7-CD27+, and effector memory Th cells (Them) as 
CD45RA-CCR7-CD27-. 
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Figure 19 The gating strategy for the determination of naive (Thn), central memory (Thcm), transitional 
memory (Thtm), effector memory (Them) and terminally differentiated (Thtd) CD4 T cell subsets 
 
 
All but one HIV NAIVE patient was included in the following analysis. The patient was excluded due to failure 
of the panel to acquire correctly. Analysis of naive, memory and terminally differentiated CD4 T cells did not 
reveal any differences between the HC and HCV groups (see table 4). The HIV NAIVE group displayed 
reduced absolute counts of Thn, Thcm and Thtm cells (median: 101.6cells/µl; 67.10cells µl; 25.11 cells µl) 
compared to the HC group (median: 396.2cells/µl, P < 0.001; 211.1cells/µl, P < 0.001; 61.18cells/µl, P < 0.01) 
(see figures 20 & 21). There were no differences between these two groups in the frequencies of Thn, Thcm, 
Thtm or Thtd cells. Them cell frequencies differed, with the HIV NAIVE group having increased frequencies 
with a median of 11.40% compared to the HC group with a median of 3.34% (P < 0.001). Analysis of naive, 
memory and terminally differentiated CD4 T cells did not reveal any differences between the HC and HIV 
HCV NAIVE groups.  
Comparison between the HCV and HCV HIV NAIVE groups only demonstrated differences in the Thcm CD4 T 
cell subset. The HCV HIV NAIVE group was shown to have reduced absolute counts and frequencies (median: 
100.0 cells/µl; 23.60%) compared to the HCV group (median: 236.4, P < 0.01; 32.20%, P < 0.05).  
Effective ART was shown to restore CD4 T cell subsets to ‘normal’ values with no differences between the 
HC, HIV ART and HCV HIV ART groups in either absolute counts or frequencies of naive, memory and 
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terminally differentiated CD4 T cells. In addition the HIV ART group demonstrated increased absolute counts 
of Thn, Thcm and Thtm cells (median: 342.2cells/µl, P < 0.001; 185.3 cells/µl, P < 0.001; 41.56cells/µl, P < 
0.05) and reduced frequencies of Them cells (median: 5.06%, P < 0.05) compared to the HIV NAIVE group. 
Table 4 The frequency (%) and number (cells/µl) of naive (Thn), central memory (Thcm), transitional 
memory (Thtm), effector memory (Them) and terminally differentiated (Thtd) CD4 T cell subsets. 
 HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
Thn% 
 
53.40 
(45.35-67.05) 
44.40 
(37.20-55.80) 
54.35 
(47.35-62.78) 
43.60 
(25.50-53.10) 
47.10 
(33.33-60.15) 
52.50 
(39.55-60.65) 
*Thn cells/µl 
 
396.2 
(290.1-588.5) 
321.4 
(237.8-496.0) 
342.2 
(261.5-468.2) 
101.6 
(58.6-151.0) 
312.3 
(164.9-389.7) 
224.4 
(147.0-391.6) 
*#Thcm % 
 
27.85 
(21.35-33.40) 
32.20 
(27.00-41.70) 
27.80 
(22.70-31.78) 
25.60 
(20.70-30.40) 
29.45 
(24.03-37.30) 
23.60 
(14.90-28.18) 
*Thcm cells/µl 
 
211.1 
(127.6-266.0) 
236.4 
(171.3-350.9) 
185.3 
(121.7-264.7) 
67.10 
(33.1-90.7) 
181.4 
(124.6-313.3) 
100.0 
(67.4-148.7) 
Thtm % 
 
7.73 
(6.15-10.43) 
10.10 
(7.24-14.45) 
7.04 
(5.06-9.17) 
9.53 
(6.98-11.70) 
8.29 
(4.97-12.05) 
9.32 
(5.96-11.95) 
*Thtm cells/µl 
 
61.18 
(33.13-85.53) 
93.03 
(54.96-128.10) 
41.56 
(35.67-52.18) 
25.11 
(16.71-35.38) 
46.23 
(37.93-78.81) 
41.32 
(26.78-56.88) 
*#Them % 
 
3.34 
(1.62-5.80) 
4.96 
(2.16-8.27) 
5.06 
(2.57-7.62) 
11.40 
(5.90-22.60) 
6.31 
(3.21-10.50) 
7.99 
(5.18-18.60) 
Them cells/µl 
 
23.81 
(14.17-41.17) 
37.99 
(15.49-45.44) 
30.16 
(18.50-48.03) 
29.51 
(8.65-63.69) 
33.37 
(18.91-85.28) 
46.42 
(24.79-82.07) 
Thtd % 
 
1.57 
(1.20-4.70) 
1.83 
(0.83-2.59) 
2.90 
(1.55-4.19) 
3.87 
(1.07-7.64) 
1.83 
(1.30-2.86) 
2.63 
(1.21-7.24) 
Thtd cells/µl 
 
10.90 
(8.33-39.64) 
11.91 
(9.01-22.24) 
14.80 
(10.14-37.49) 
7.21 
(2.09-21.47) 
11.09 
(7.42-24.95) 
18.88 
(5.17-37.50) 
 
Median values are shown with the interquartile range in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: 
HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV 
coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.   
 
*Comparison between groups was determined using the Kruskal Wallis test with Dunn’s post test applied: 
Thn cells/µl: HC vs HIV NAÏVE P < 0.001, HIV ART vs HIV NAÏVE P < 0.001  
Thcm %: HCV vs HCV HIV NAÏVE P < 0.05  
Thcm cells/µl: HC vs HIV NAÏVE P < 0.001, HCV vs HCV HIV NAÏVE P < 0.01, HIV ART vs HIV NAÏVE P < 0.001  
Thtm cells/µl: HC vs HIV NAÏVE P < 0.01, HIV ART vs HIV NAÏVE P < 0.05  
Them %: HC vs HIV NAÏVE P < 0.001, HIV ART vs HIV NAÏVE P < 0.05 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
Thcm %: HCV vs HCV HIV NAÏVE P < 0.0022 
Them %: HC vs HIV NAÏVE P = 0.0003, HIV ART vs HIV NAÏVE P = 0.0024. 
  
83 | P a g e  
 
Figure 20 The frequency (%) and number (cells/µl) of central memory (Thcm), transitional memory 
(Thtm) and effector memory (Them) CD4 T cell subsets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range.  
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Figure 21 The frequency (%) and number (cells/µl) of naive (Thn) and terminally differentiated (Thtd) 
CD4 T cell subsets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile  
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3.4.2 Immunophenotyping of activated CD4 T cells and CD8 T cells 
The expression of markers CD38 and/or HLA-DR was used to characterise activation of CD4 and CD8 T cells. 
In HIV-1 infection, coexpression of both these antigens or just CD38 on memory CD8 T cells has been used to 
characterise disease progression and response to treatment (Steel, 2010). While HLA-DR expression tends to 
be determined using isotype controls or FMOs a number of flow cytometric methods including isotype 
controls, FMOs, internal controls and commercially available fluorescence quantification kits 
(QunatibriteTM) can be used to determine CD38 expression (Steel, 2010).  
In this study: 
1) FMO tubes were used to define singular expression of CD38 on CD4 and CD8 T cells. FMOs were also 
used to identify CD38med expression when defining HLA-DR+CD38med CD4 and CD8 T cells (see 
figures 22 & 23). Initial analysis revealed very similar results to HLA-DR+CD38lo expression on CD4 
and CD8 T cells and therefore further analysis of HLA-DR+CD38med CD4 and CD8 T cells was 
discontinued.  
2) CD38hi and CD38lo expression was determined using the monocyte and granulocyte populations 
respectively, as internal positive controls for cells that strongly express CD38 (CD38hi) and those that 
weakly express CD38 (CD38lo) (Tilling et al., 2002) (see figures 22 & 23). It has been demonstrated 
that it is within the CD45RO subset of memory CD8 T cells where the prognostic CD38 expressing 
cells of interest can be found (Bofill et al., 1996), and these tend to be the cells with CD38hi 
expression (Tilling et al., 2002). Thus as HLA-DR+CD38hi expression uses the most stringent criteria 
only these findings will be discussed here. 
3) In addition the CD38 ABC of CD4 T cells and CD8 T cells was determined using BD QuantibriteTM PE 
beads (Catalogue Number 340495). The beads supplied are conjugated to four different, known 
numbers of phycoerythrin (PE) molecules. The beads are run at the same instrument settings as the 
sample, where PE is conjugated to the cell marker for which the ABC is required (in this case CD38).  
Analysis allows determination of the four geometric means (low, median low, median high and high) 
of the beads with the known numbers of PE molecules bound per bead. A standard curve can then 
be constructed which allows determination of research sample CD38 ABC by determining the PE 
geometric mean of the sample (Iyer et al., 1998).   
  
86 | P a g e  
 
Figure 22 The gating strategy for the determination of activated CD4 T cells 
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Figure 23 The gating strategy for the determination of activated CD8 T cells 
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All participants in the study were included in the following analyses. There were no demonstrable 
differences between study groups when assessing CD38 ABC of CD4 T cells (see table 5). Analysis of CD4 T 
cell activation markers described above did not reveal any differences between the HC and HCV groups. 
Frequency of expression of HLA-DR or CD38 on CD4 T cells was higher in the HIV NAÏVE group (median: 
7.720%; 71.10%) compared to the HC group (median: 1.700%, P < 0.001; 54.14%, P < 0.05) (see figure 24). 
Findings were similar when comparing the HC group to the HCV HIV NAÏVE group (median: 6.880%, P < 0.01; 
69.56%, P > 0.05), but the difference in CD38 expression did not quite meet significance. Both HIV NAÏVE 
(median: 3.140%) and HCV HIV NAÏVE (median: 2.110%) groups had higher frequencies of HLA-DR+CD38hi 
CD4 T cells compared to HCs (median: 0.310%, both P < 0.001) (see figure 25). The only demonstrable 
difference between the HIV NAIVE (median: 185.9cells/µl) and HCV HIV NAIVE (median: 293.0cells/µl, P < 
0.05) groups was observed when examining CD38+CD4 T cell absolute counts. Increased frequency of 
expression of HLA-DR or CD38 on CD4 T cells was higher in the HCV HIV NAÏVE group (median: 6.880% and 
69.56%) compared to the HCV group (median: 2.510%, P < 0.01; 48.90%, P < 0.05). The HCV HIV NAIVE group 
(median: 2.110%) was also shown to have higher frequencies of HLA-DR+CD38hi CD4 T cells compared to the 
HCV group (median: 0.450%, P < 0.01). 
Effective ART reverses these changes with there being no difference in expression in both the HIV ART or 
HCV HIV ART groups compared to the HC and HCV groups. The HIV ART group (median: 3.460%, P < 0.05; 
59.15%, P < 0.05; 0.560%, P < 0.001) drives reduced frequency of HLA-DR+, CD38+ and HLA-DR+CD38hi CD4 
T cells compared to the HIV NAÏVE group. A similar trend is seen with coinfection with all markers of 
activation except HLA-DR+CD38hi CD4 T cells where the HCV HIV ART group (median: 0.925%) is shown to 
have increased frequencies compared to the HC group, with a Mann Whitney U test P value of 0.0021. 
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Table 5 The frequency (%) and number (cells/µl) of activated CD4 T cells 
CD4 T cells HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#HLA-DR+ % 
 
1.700 
(1.205-2.798) 
2.510 
(1.365-3.585) 
3.460 
(1.538-5.640) 
7.720 
(4.040-11.300) 
3.025 
(2.208-6.870) 
6.880 
(4.660-11.100) 
HLA-DR+ cells/µl 
 
12.11 
(7.01-23.0) 
14.99 
(9.94-29.24) 
27.68 
(8.57-37.51) 
17.95 
(7.19-28.92) 
21.00 
(11.36-40.36) 
31.87 
(19.43-75.73) 
*#CD38+ % 
 
54.15 
(47.98-66.95) 
48.90 
(40.30-61.05) 
59.15 
(49.00-66.38) 
71.10 
(65.43-79.68) 
56.00 
(43.08-64.78) 
69.65 
(55.88-74.30) 
*CD38+ cells/µl 
 
408.9 
(275.8-536.7) 
356.3 
(224.8-543.3) 
361.1 
(297.2-415.9) 
185.9 
(130.0-233.7) 
372.2 
(194.9-530.7) 
293.0 
(258.4-456.1) 
CD38+ ABC 
 
2338 
(2053-2739) 
2719 
(1995-2915) 
2658 
(2085-3040) 
2827 
(2542-3255) 
2465 
(1972-2752) 
2817 
(2658-3287) 
*#HLA-DR+CD38lo % 
 
1.005 
(0.748-1.380) 
1.340 
(0.815-2.085) 
1.590 
(0.918-3.228) 
5.370 
(3.110-8.318) 
2.015 
(1.333-2.815) 
4.650 
(3.598-7.518) 
*HLA-DR+CD38lo cells/µl 
 
7.18 
(4.25-10.45) 
9.80 
(6.73-19.22) 
14.16 
(5.35-18.34) 
11.25 
(6.91-21.55) 
10.50 
(8.16-16.85) 
25.86 
(13.51-43.18) 
*#HLA-DR+CD38hi % 
 
0.310 
(0.223-0.435) 
0.450 
(0.315-0.815) 
0.560 
(0.398-0.930) 
3.140 
(1.905-4.073) 
0.925 
(0.513-1.070) 
2.110 
(1.090-4.433) 
*HLA-DR+CD38hi cells/µl 
 
2.270 
(1.413-3.760) 
3.920 
(2.555-6.765) 
4.670 
(2.253-5.735) 
5.985 
(4.993-10.64) 
4.610 
(3.128-6.988) 
13.66 
(6.415-21.94) 
 
Median values are shown with the interquartile range in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: 
HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV 
coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment, ABC: antibody binding 
capacity.   
 
*Comparison between groups was determined using the Kruskal Wallis test with Dunn’s post test applied:  
CD4+HLA-DR+ %: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAIVE P < 0.01, HCV vs HCV HIV NAIVE P < 0.01, HIV ART vs HIV NAIVE P 
< 0.05 
CD4+CD38+ %: HC vs HIV NAÏVE P < 0.05: HCV vs HCV HIV NAIVE P < 0.05, HIV ART vs HIV NAIVE P < 0.05 
CD4+CD38+ cells/µl: HC vs HIV NAIVE P < 0.001, HIV ART vs HIV NAIVE P < 0.001, HIV NAIVE vs HCV HIV NAIVE P < 0.05 
CD4+HLA-DR+CD38
lo
 %: HC vs HCV NAIVE P < 0.001, HC vs HCV HIV NAIVE P < 0.001, HCV vs HCV HIV NAIVE P < 0.01, HIV ART vs HIV 
NAIVE P < 0.01  
CD4+HLA-DR+CD38
lo
cells/µl: HC vs HCV HIV NAIVE P < 0.01 
CD4+HLA-DR+CD38
hi
 %: HC vs HIV NAIVE P < 0.001, HC vs HCV HV NAIVE P < 0.001, HCV vs HCV HIV NAIVE P < 0.01, HIV ART vs HIV 
NAIVE P < 0.001 
CD4+HLA-DR+CD38
hi
cells/µl: HC vs HIV NAIVE P < 0.01, HC vs HCV HIV NAIVE P < 0.001 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
CD4+HLA-DR+ %: HC vs HIV NAÏVE P < 0.0001, HC vs HCV HIV NAIVE P = 0.0017, HCV vs HCV HIV NAIVE P = 0.0009, HIV ART vs HIV 
NAIVE P = 0.0026 
CD4+CD38+ %: HC vs HIV NAÏVE P = 0.0025, HCV vs HCV HIV NAIVE P = 0.0033, HIV ART vs HIV NAIVE P = 0.0010 
CD4+HLA-DR+CD38
lo
 %: HC vs HCV NAIVE P < 0.0001, HC vs HCV HIV NAIVE P = 0.0008, HCV vs HCV HIV NAIVE P = 0.0012, HIV ART vs 
HIV NAIVE P < 0.0001  
CD4+HLA-DR+CD38
hi
 %: HC vs HIV NAIVE P < 0.0001, HC vs HCV HIV ART P = 0.0021, HC vs HCV HV NAIVE P = 0.0006, HCV vs HCV HIV 
NAIVE P = 0.0009, HIV ART vs HIV NAIVE P < 0.0001 
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Figure 24 The frequency (%) and number (cells/µl) of HLA-DR+ and CD38+ CD4 T cells 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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Figure 25 The CD38 ABC of CD4 T cells and the frequency (%) and number (cells/µl) of activated CD4 T 
cells 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range.  
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Analysis of CD8 T cell activation markers described revealed an increase in CD38 ABC of CD8 T cells in the 
HCV group (median: 1488) compared to the HC group (median: 1162), with a Mann Whitney U test P value 
of 0.0008 (see table 6). There were no further differences in CD8 T cell immune activation markers between 
these two groups, however the HCV group did consistently give higher values for all markers of CD8 T cell 
activation. 
Frequencies and absolute counts of HLA-DR+CD8 T cells and CD38+CD8 T cells were expanded in HIV NAIVE 
(median: 23.05%; 140.20cells/µl and 82.00%; 628.6cells/µl) and HCV HIV NAÏVE (median: 25.85%; 
199.30cells/µl and 80.00%; 725.2cells/µl) groups compared to the HC group (median: 2.97%, both P < 0.001; 
8.23cells/µl, both P < 0.001 and 36.25% both P < 0.001; 127.2cells/µl both P < 0.001) (see figure 26). The 
CD38 ABC of CD8 T cells was markedly increased in HIV NAÏVE (median: 3060) and HCV HIV NAÏVE (median: 
2722) groups compared to the HC group (median: 1162, both P < 0.001) (see figure 27). The frequencies and 
absolute counts of HLA-DR+CD38hi CD8 T cells were closely comparable to those of the CD38 ABC of CD8 T 
cells with increased values in the HIV NAÏVE (median: 10.48%; 82.66cells/µl) and HCV HIV NAÏVE (median: 
12.00%; 108.90cells/µl) groups compared to the HC group (median: 0.57%, both P < 0.001; 1.76cells/µl, both 
P < 0.001). There were no demonstrable differences between the HIV NAIVE and HCV HIV NAIVE groups.  
The HCV HIV NAIVE group had expanded frequencies and absolute counts of HLA-DR+CD8 T cells and 
CD38+CD8 T cells compared to the HCV group (median: 3.61%, P < 0.01; 17.00cells/µl, P < 0.001 and 45.00% 
P < 0.01; 172.80cells/µl P < 0.001). The HCV HIV NAIVE group had increased CD38 ABC of CD8 T cells 
compared to the HCV group (median: 1488, P < 0.05). Similarly the frequencies and absolute counts of HLA-
DR+CD38hi CD8 T cells were expanded in the HCV HIV NAIVE group compared with the HCV group (median: 
0.91%, P < 0.001; 3.31cells/µl, P < 0.001). 
Effective ART leads to a reduction in CD8 T cell activation markers.  However the HCV HIV ART group 
continues to display increased absolute counts of HLA-DR+CD8 T cells (median: 44.67 cells/µl, P < 0.05), 
CD38+CD8 T cells (median: 325.1cells/µl, P < 0.01) and HLA-DR+CD38hi CD8 T cells (median: 12.48 cells/µl, P 
< 0.05) compared to the HC group.  In addition frequencies of HLA-DR+CD38hi CD8 T cells were increased in 
HIV ART (median: 1.47%) and HCV HIV ART (median: 1.67%) groups compared to the HC group, with Mann 
Whitney U test P values of 0.0031 and 0.0011 respectively. Thus effective ART does not appear to fully 
reverse each aspect of immune activation.   
93 | P a g e  
 
Table 6 The frequency (%) and number (cells/µl) of activated CD8 T cells 
CD8 T cells HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#HLA-DR+ % 
 
2.97 
(0.79-6.17) 
3.61 
(1.95-8.35) 
10.70 
(3.61-14.30) 
23.05 
(11.98-35.60) 
6.60 
(2.72-13.13) 
25.85 
(19.43-31.75) 
*HLA-DR+ cells/µl 
 
8.23 
(3.73-21.91) 
17.00 
(6.60-29.95) 
61.95 
(16.65-146.90) 
140.20 
(102.00-426.00) 
44.67 
(15.44-190.40) 
199.30 
(142.60-399.50) 
*#CD38+ % 
 
36.25 
(24.28-41.08) 
45.00 
(33.05-56.50) 
43.15 
(32.98-49.90) 
82.00 
(65.13-88.83) 
45.05 
(39.95-59.08) 
80.00 
(61.35-85.03) 
*CD38+ cells/µl 
 
127.2 
(89.4-215.9) 
172.8 
(106.8-219.2) 
270.9 
(209.9-442.6) 
628.6 
(452.2-1236.0) 
325.1 
(237.0-566.0) 
725.2 
(554.5-1075.0) 
*#CD38+ ABC 
 
1162 
(1076-1294) 
1488 
(1287-1843) 
1388 
(1285-1532) 
3060 
(2205-3652) 
1519 
(1268-1694) 
2722 
(2006-3177) 
*#HLA-DR+CD38
lo
 % 
 
1.74 
(0.58-3.92) 
2.63 
(1.19-5.10) 
6.27 
(2.73-9.00) 
20.75 
(10.69-32.18) 
4.87 
(1.84-8.50) 
24.30 
(17.93-27.95) 
*HLA-DR+CD38
lo
 cells/µl 
 
4.39 
(2.57-11.53) 
11.84 
(4.57-21.46) 
38.37 
(11.85-94.74) 
137.10 
(97.54-352.40) 
35.10 
(9.19-122.30) 
189.30 
(130.10-359.90) 
*#HLA-DR+CD38
hi
 % 
 
0.57 
(0.19-0.99) 
0.91 
(0.42-1.92) 
1.47 
(0.70-2.69) 
10.48 
(6.79-16.13) 
1.67 
(0.62-2.79) 
12.00 
(9.04-15.45) 
*HLA-DR+CD38
hi
 cells/µl 
 
1.76 
(1.05-3.68) 
3.31 
(2.14-7.94) 
12.81 
(3.96-22.66) 
82.66 
(56.59-127.40) 
12.48 
(4.02-26.38) 
108.90 
(69.57-167.70) 
Median values are shown with the interquartile range in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: 
HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV 
coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups) was determined using the Kruskal Wallis test with Dunn’s post test applied:  
CD8+HLA-DR+ %: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV NAÏVE P < 0.01 
CD8+HLA-DR cells/µl: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV ART P < 0.05, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV NAÏVE 
P < 0.001 
CD8+CD38+ %: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV NAÏVE P < 0.01, HIV ART vs HIV NAÏVE P < 
0.001, HCV HIV ART vs HCV HIV NAÏVE P < 0.05 
CD8+CD38 cells/µl: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV ART P < 0.01, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV ART P < 
0.05, HCV vs HCV HIV NAÏVE P < 0.001, HIV ART vs HIV NAÏVE P < 0.05 
CD8+CD38 ABC: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV NAÏVE P < 0.05, HIV ART vs HIV NAÏVE P 
< 0.001, HCV HIV ART vs HCV HIV NAÏVE P < 0.05 
CD8+HLA-DR+CD38
lo
 %: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV NAÏVE P < 0.001, HIV ART vs HIV 
NAÏVE P < 0.05, HCV HIV ART vs HCV HIV NAÏVE P < 0.05  
CD8+HLA-DR+CD38
lo
cells/µl: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV ART P < 0.05, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV 
HIV NAÏVE P < 0.001, HIV ART vs HIV NAÏVE P < 0.05 
 CD8+HLA-DR+CD38
hi
 %: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV NAÏVE P < 0.001, HIV ART vs HIV 
NAÏVE P < 0.001, HCV HIV ART vs HCV HIV NAÏVE P < 0.05 
CD8+HLA-DR+CD38
hi
cells/µl: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV ART P < 0.05, HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV 
HIV NAÏVE P < 0.001, HIV ART vs HIV NAÏVE P < 0.01, HCV HIV ART vs HCV HIV NAÏVE P < 0.05 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
CD8+HLA-DR+ %: HC vs HIV NAÏVE P < 0.0001, HC vs HCV HIV NAÏVE P = 0.0004, HCV vs HCV HIV NAÏVE P = 0.0006, HIV ART vs HIV 
NAIVE P = 0.0015, HCV HIV ART vs HCV HIV NAIVE P = 0.0025 
CD8+CD38+ %: HC vs HIV NAÏVE P < 0.0001, HC vs HCV HIV NAÏVE P < 0.0001, HCV vs HCV HIV NAÏVE P = 0.0002, HIV ART vs HIV 
NAÏVE P < 0.0001, HCV HIV ART vs HCV HIV NAÏVE P = 0.0001 
CD8+CD38 ABC: HC vs HCV P = 0.0008, HC vs HIV NAÏVE P < 0.0001, HC vs HCV HIV NAÏVE P < 0.0001, HCV vs HCV HIV NAÏVE P = 
0.0007, HIV ART vs HIV NAÏVE P < 0.0001, HCV HIV ART vs HCV HIV NAÏVE P = 0.0002 
CD8+HLA-DR+CD38
lo
 %: HC vs HIV ART P = 0.0039, HC vs HIV NAÏVE P < 0.0001, HC vs HCV HIV NAÏVE P = 0.0002, HCV vs HCV HIV 
NAÏVE P = 0.0005, HIV ART vs HIV NAÏVE P = 0.0002, HCV HIV ART vs HCV HIV NAÏVE P = 0.0020  
CD8+HLA-DR+CD38
hi
 %: HC vs HIV ART P = 0.0031, HC vs HIV NAÏVE P < 0.0001, HC vs HCV HIV ART P = 0.0011, HC vs HCV HIV NAÏVE 
P = 0.0002, HCV vs HCV HIV NAÏVE P = 0.0004, HIV ART vs HIV NAÏVE P < 0.0001, HCV HIV ART vs HCV HIV NAÏVE P = 0.0004 
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Figure 26 The frequency (%) and number (cells/µl) of HLA-DR+ and CD38+ CD8 T cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range.  
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Figure 27 The CD38 ABC of CD8 T cells and the frequency (%) and number (cells/µl) of activated CD8 T 
cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range.  
Frequency (%) of CD8+HLA-DR+CD38 lo Tcells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
10
20
30
40
50
%
Absolute Count (cells/ l) of CD8+HLA-DR+CD38 lo Tcells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
200
400
600
800
ce
ll
s/

l
Frequency (%) of CD8+HLA-DR+CD38 hi Tcells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
5
10
15
20
25
30
%
Absolute Count (cells/ l) of CD8+HLA-DR+CD38 hi Tcells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
100
200
300
400
500
ce
ll
s/

l
CD38 Antibody Binding Capacity of CD8+ Tcells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
2000
4000
6000
8000
A
B
C
96 | P a g e  
 
3.4.3 Expression of the chemokine receptors CXCR3+, CCR5+, CCR6+ on CD4 T cells. 
The chemokine receptors CXCR3, CCR5 and CCR6 were used to identify: pre-Th1 (CXCR3+CCR6-) cells, Th1 
(CXCR3+CCR5+) cells and Th1Th17 (CXCR3+CCR6+) cells. The gating strategy used is shown below in figure 
28. CCR6 was added to this panel after recruitment had commenced and consequently there are reduced 
patient numbers when analysing pre-Th1 and Th1Th17 cell frequencies and absolute counts.  
Figure 28 The gating strategy for the determination of pre-Th1 (CXCR3+CCR6-), Th1 (CXCR3+CCR5+) and 
Th1Th17 (CXCR3+CCR6+) 
 
Frequencies of Th1 cells differed between groups (Kruskal-Wallis P < 0.0001) (see table 7). Th1 cell 
frequencies appeared increased in the HCV group (median: 5.920%) compared to the HC group (median: 
3.050%) with a Mann Whitney U test P value of 0.0039. Frequencies in the HIV NAIVE group (median: 
1.690%, P > 0.05) did not significantly differ from the HC group, while the HCV HIV NAIVE (median: 0.795%, P 
< 0.05 and P < 0.001) group had markedly depressed frequencies compared to both HC and HCV groups. The 
HIV NAIVE group had higher Th1 frequencies than the HCV HIV NAIVE group with a Mann Whitney U test P 
value of 0.0031. In HIV-1/HCV coinfection effective ART appeared to result in restoration of Th1 cell 
frequencies. The HCV HIV ART group (median: 2.130%, P < 0.05) had significantly increased frequencies 
compared to the HCV HIV NAIVE group and did not differ significantly from either the HC or HCV group. 
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Pre-Th1 cell frequencies were also increased in the HCV group (median: 31.75%) compared to the HC group 
(median: 20.50%) with a Mann Whitney U test P value of 0.0043 (see figure 29). However differences 
between the HC group and either the HIV NAIVE or HCV HIV NAIVE groups were not observed. The HCV HIV 
NAIVE group (median: 12.60%) did display reduced frequencies compared to the HCV group (median: 
31.75%, P < 0.001). In HIV-1/HCV coinfection effective ART appeared to result in restoration of pre-Th1 cell 
frequencies. 
Differences from the HC group in the frequencies of Th1Th17 cells were not demonstrated in the HCV group. 
In this study HIV-1 infection was not shown to lead to lower Th1Th17 cell frequencies compared to the HC 
group. However Th1Th17 cell frequencies were depleted significantly in the HCV HIV NAIVE group (median: 
2.095%), compared to both the HC (median: 5.725%, P < 0.05) and HCV groups (median: 7.540, P < 0.01). 
ART leads to only partial recovery of Th1Th17 frequency with the HCV HIV ART group (median: 2.940%, P < 
0.05) having a significant depletion compared to the HCV group, with a tendency to increased frequencies 
compared to the HCV HIV NAIVE group although this did not reach significance. 
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Table 7 The frequency (%) and number (cells/µl) of Th1, pre-Th1 and Th1Th17 cells 
 HC 
(n=15) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*
#
Th1 (%) 
 
3.050 
(1.370-3.840) 
5.920 
(3.445-9.925) 
2.905 
(1.423-3.648) 
1.690 
(1.050-5.450) 
2.130 
(0.817-5.393) 
0.795 
(0.185-1.130) 
*Th1 (cells/ µl) 
 
22.14 
(12.11-32.64) 
54.05 
(19.58-97.31) 
15.35 
(10.18-23.66) 
3.71 
(2.22-14.01) 
15.63 
(7.37-22.29) 
3.00 
(1.51-6.03) 
 HC 
(n=12) 
 
HCV 
(n=18) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=15) 
HCV HIV NAÏVE 
(n=10) 
*
#
pre-Th1 (%) 
 
20.50 
(16.68-26.08) 
31.75 
(25.08-38.73) 
23.25 
(18.68-28.35) 
18.30 
(12.68-23.88) 
21.90 
(15.08-34.10) 
12.60 
(8.22-14.98) 
*pre-Th1(cells/ µl) 
 
153.4 
(112.7-210.4 
221.6 
(151.5-317.3) 
154.5 
(90.2-186.8) 
47.4 
(23.2-63.6) 
159.7 
(81.7-218.2) 
58.2 
(31.4-102.9) 
*
#
Th1Th17 (%) 
 
5.725 
(4.485-8.528) 
7.540 
(4.275-9.305) 
4.100 
(3.083-5.013) 
4.845 
(2.768-5.883) 
2.940 
(1.910-6.730) 
2.095 
(0.953-3.523) 
*Th1Th17 (cells/ µl) 
 
40.48 
(28.95-66.48) 
50.96 
(37.93-81.01) 
25.11 
(13.24-41.23) 
11.04 
(7.12-16.97) 
18.61 
(16.05-25.10) 
12.99 
(3.52-21.87) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: 
Th1 %: HC vs HCV HIV NAÏVE P < 0.05, HCV vs HCV HIV NAÏVE P < 0.001, HCV HIV ART vs HCV HIV NAÏVE P < 0.05  
Th1 cells/µl: HC vs HIV NAÏVE P < 0.05, HC vs HCV HIV NAÏVE P < 0.01, HCV vs HCV HIV NAÏVE P < 0.001, HCV HIV ART vs HCV HIV 
NAÏVE P < 0.05 
pre-Th1 %: HCV vs HCV HIV NAÏVE P < 0.001  
pre-Th1 cells/µl: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAÏVE P < 0.05, HCV vs HCV HIV NAÏVE P < 0.001, HIV ART vs HIV NAÏVE P 
< 0.001, HCV HIV ART vs HCV HIV NAÏVE P < 0.05 
Th1Th17 %: HC vs HCV HIV NAIVE P < 0.05, HCV vs HCV HIV ART P < 0.05, HCV vs HCV HIV NAÏVE P < 0.01 
Th1Th17 cells/µl: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAÏVE P < 0.01, HCV vs HCV HIV NAÏVE P < 0.001 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
Th1 %: HC vs HCV P = 0.0039, HC vs HCV HIV NAÏVE P = 0.0002, HCV vs HCV HIV NAÏVE P < 0.0001, HIV NAÏVE vs HCV HIV NAÏVE P = 
0.0031, HCV HIV ART vs HCV HIV NAÏVE P = 0.0043: 
pre-Th1 %: HC vs HCV P = 0.0043, HCV vs HCV HIV NAÏVE P < 0.0001,  
Th1Th17 %: HC vs HCV HIV NAÏVE P = 0.0041, HCV vs HCV HIV NAÏVE P = 0.0043 
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Figure 29 The frequency (%) and number (cells/µl) of pre-Th1, Th1 and Th1Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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3.4.4 Immunophenotyping of CD25+ and regulatory CD4 T cell subsets 
CD4+ T regulatory (Treg) cells were defined as CD25+ and CD127 lo, in keeping with other recent studies 
(Hunt et al., 2011) (see figure 30). Differences seen in absolute counts between groups in CD4+CD25 + T cell 
and Treg cell subsets were driven by absolute CD4 T cell counts. The HIV ART group showed a slight increase 
in CD4+CD25+ T cell frequency compared to the HIV NAIVE group, but there were no other differences 
between groups. No significant differences in frequency were demonstrated between groups for the Treg 
cell subset (see table 8 & figure 31).  
Figure 30 The gating strategy for the determination of Treg (CD4+CD25+CD127lo) cells 
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Table 8 The frequency (%) and number (cells/µl) of CD25+ and regulatory CD4+ T helper cell subsets 
  HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#CD25+ (%) 
 
27.20 
(23.35-37.75) 
32.00 
(29.30-38.90) 
35.00 
(28.33-41.55) 
26.25 
(23.35-28.05) 
29.60 
(20.40-34.45) 
25.90 
(21.95-33.50) 
*CD25+ (cells/ µl) 
 
203.9 
(175.2-298.2) 
254.4 
(188.8-349.1) 
214.3 
(165.5-337.8) 
69.82 
(33.58-85.74) 
194.3 
(100.8-264.6) 
114.1 
(85.52-191.8) 
Treg (%) 
 
6.600 
(5.858-8.110) 
7.060 
(5.715-9.780) 
8.360 
(7.315-10.450) 
8.070 
(5.820-10.900) 
8.550 
(6.573-9.500) 
7.670 
(6.090-10.550) 
*Treg(cells/ µl) 
 
53.38 
(44.34-62.26) 
64.47 
(42.53-82.56) 
58.43 
(43.71-68.28) 
19.98 
(10.20-25.94) 
56.32 
(32.41-65.63) 
33.84 
(27.85-65.85) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: 
CD4+CD25+ %: HIV ART vs HIV NAIVE P < 0.05 
CD4+CD25+ cells/µl: HC vs HIV NAIVE P < 0.001, HIV ART vs HIV NAIVE P < 0.001 
Treg cells/µl: HC vs HIV NAIVE P < 0.001, HIV ART vs HIV NAIVE P < 0.001 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
CD4+CD25+ %: HIV ART vs HIV NAIVE P = 0.0042 
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Figure 31 The frequency (%) and number (cells/µl) of CD25+ and regulatory CD4 T cell subsets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
 
3.4.5 Immunophenotyping of CD4 T cell subsets: Th17 and Th22 cells 
While Th17 cells have been defined as expressing CCR4 and CCR6, Th22 cells are known to express CCR4, 
CCR6, and CCR10. Therefore we have defined Th17 cells as CCR4+CCR6+CCR10-, while Th22 cells have been 
defined as CCR4+CCR6+CCR10+. The gating strategy for assessing the expression of these three chemokine 
receptors on CD4 T cells is shown below in figure 32. The expression of CCR6 on CD4 T cells was investigated 
in all study groups along with the frequency and number of Th17 (CCR4+CCR6+CCR10-) and Th22 
(CCR4+CCR6+CCR10+) cells. 
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Figure 32 The gating strategy for the determination of Th17 (CCR4+CCR6+CCR10-) and Th22 
(CCR4+CCR6+CCR10+) cells 
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Of the 101 individuals in this study, 96 are included in the following analysis due to failures in processing or 
acquisition of five of the samples for this panel. There were no differences between the HC group and the 
HCV group for CCR6+CD4 T cells, Th17 cells and Th22 cells (see table 9). 
Frequencies of CCR6+CD4 T cells differed between groups (Kruskal-Wallis P = 0.0003). The HIV NAIVE group 
(median: 8.22%) did not differ significantly from the HC group (median: 11.00%), however frequencies of 
CCR6+CD4 T cells were halved in the HCV HIV NAÏVE group (median: 7.23%) compared to both the HC group 
(median: 11.00%, Mann Whitney U test P < 0.001) and the HCV group (median: 13.75%, P < 0.01). Effective 
ART appeared to reverse these changes with the HCV HIV ART group (median: 11.30%) having similar 
frequencies to both the HC and HCV group.  
There were no significant differences in Th17 and Th22 cell frequencies between the HC (median: 7.41% and 
1.440%) and HCV (median: 7.81% and 1.430%) groups (see figure 33). While Th17 cell frequencies were 
reduced in the HIV NAIVE group (median: 5.09%) compared to the HC group the difference did not reach 
statistical significance. Th22 cell frequencies demonstrated a significant reduction in frequencies (median: 
0.800%, P < 0.01). Both Th17 and Th22 cell frequencies were strikingly reduced in the HCV HIV NAÏVE group 
(median: 4.54% and 0.630%) compared to both the HC group (median: 7.41%, P<0.05; and 1.440%, P < 0.01) 
and the HCV group (median: 7.81%, P < 0.01 and 1.430%, P < 0.01).  
On observing the dot plots it was clear that individuals within the HC group rarely had Th17 and Th22 cell 
frequencies of less than 5% and 1% respectively. Using this cut off to form a contingency table and 
conducting a Chi-square test revealed significant differences between groups, with a P value of less than 
0.0004 and 0.0002 (see figure 34). The majority of individuals in the HC (93%), HCV (90%) and HIV ART (93%) 
groups had Th17 frequencies of greater than 5%, 53% and 66% of individuals in the HIV NAIVE and HCV HIV 
ART groups had frequencies of greater than 5%, whereas 30% of individuals in the HCV HIV NAIVE group had 
frequencies of greater than 5%. The majority of individuals in the HC (100%) group and 70%, 71% and 61% of 
individuals in the HCV, HIV ART and HCV HIV ART groups respectively had Th22 frequencies of greater than 
1%,  whereas 32% and 20% of individuals in the HIV NAIVE and HCV HIV NAIVE groups had frequencies of 
greater than 1%.  
Significant differences were not demonstrated for either CD4 T cell subset between the HIV NAIVE and HCV 
HIV NAIVE groups. Effective ART appeared to return Th17 and Th22 cell frequencies to near ‘normal’ levels 
with no discernable difference between the HIV ART and HCV HIV ART groups and either the HC or HCV 
groups. 
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Table 9 The frequency (%) and number (cells/µl) of CCR6+ CD4 T cells, Th17 and Th22 cells 
 HC 
(n=15) 
 
HCV 
(n=20) 
HIV ART 
(n=14) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*
#
CCR6+ % 
 
11.00 
(9.27-15.10) 
13.75 
(11.03-18.20) 
13.10 
(12.50-16.28) 
8.22 
(5.79-14.220) 
11.30 
(5.74-14.53) 
7.23 
(4.88-8.80) 
*CCR6+ cells/µl 
 
73.13 
(52.67-98.08) 
83.87 
(43.21-133.00) 
65.87 
(46.95-81.13) 
18.08 
(6.62-31.91) 
49.30 
(30.19-72.46) 
25.62 
(18.93-29.81) 
*
#
Th17 % 
 
7.41 
(5.52-9.23) 
7.81 
(6.38-11.33) 
8.00 
(7.15-9.95) 
5.09 
(4.02-7.55) 
6.49 
(4.25-10.40) 
4.54 
(2.65-5.14) 
*Th17 cells/µl 
 
58.84 
(40.48-81.20) 
70.74 
(37.67-111.20) 
55.70 
(39.95-67.24) 
15.54 
(6.03-25.44) 
39.12 
(25.34-62.60) 
19.95 
(16.24-27.13) 
*
#
Th22 % 
 
1.440 
(1.240-1.930) 
1.430 
(0.953-2.935) 
1.435 
(0.960-1.763) 
0.800 
(0.420-1.160) 
1.120 
(0.823-1.420) 
0.630 
(0.240-0.935) 
*Th22 cells/µl 
 
12.01 
(8.91-15.63) 
11.77 
(5.79-27.01) 
9.84 
(6.06-12.47) 
2.19 
(0.61-3.35) 
7.04 
(4.04-10.50) 
3.066 
(1.65-5.10) 
 
Median values are shown with the interquartile range in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: 
HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV 
coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: 
CD4+CCR6+ %: HCV vs HCV HIV NAÏVE P < 0.01 
CD4+CCR6+ cells/µl: HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV NAÏVE P < 0.01, HCV vs HCV HIV NAÏVE P < 0.001, HIV ART vs HIV 
NAÏVE P < 0.001 
Th17 %: HC vs HCV HIV NAÏVE P < 0.05, HCV vs HCV HIV NAÏVE P < 0.01 
Th17 cells/µl: HC vs HIV NAÏVE  P< 0.001, HC vs HCV HIV NAÏVE P < 0.01, HCV vs HCV HIV NAÏVE P < 0.001, HIV ART vs HIV NAÏVE P < 
0.001  
Th22 %: HC vs HIV NAÏVE P < 0.01, HC vs HCV HIV NAÏVE P < 0.01, HCV vs HCV HIV NAÏVE P < 0.05  
Th22 cells/µl: HC vs HIV NAÏVE P < 0.001; HC vs HCV HIV NAÏVE P < 0.001, HCV vs HCV HIV NAÏVE P < 0.01, HIV ART vs HIV NAÏVE P < 
0.001 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
CD4+CCR6+ %: HC vs HCV HIV NAÏVE P = 0.001, HCV vs HCV HIV NAÏVE P = 0.0002 
Th17%: HC vs HCV HIV NAÏVE P= 0.0005, HCV vs HCV HIV NAÏVE P = 0.0003 
Th22 %: HC vs HIV NAÏVE P = 0.0002, HC vs HCV HIV NAÏVE P = 0.0006 
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Figure 33 The frequency (%) and number (cells/µl) of CCR6+ CD4 T cells, Th17 and Th22 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range.  
  
Frequency (%) of Th17 (CCR4+CCR6+CCR10-) cells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
5
10
15
20
%
Absolute Count (cells/ l) of Th17 (CCR4+CCR6+CCR10-) cells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
50
100
150
250
ce
ll
s/

l
Frequency (%) of Th22 (CCR4+CCR6+CCR10+) cells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
1
2
3
4
%
Absolute Count (cells/ l) of Th22 (CCR4+CCR6+CCR10+) cells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
10
20
30
40
ce
ll
s/

l
Frequency (%) of CD4+CCR6+ Tcells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
5
10
15
20
25
%
Absolute Count (cells/ l) of CD4+CCR6+ Tcells
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
100
200
300
ce
ll
s/

l
107 | P a g e  
 
Figure 34 Number of participants with frequencies (%) of Th17 cells greater or less than 5% and Th22 
cells greater or less than 1% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparisons for categorical data were made using the Chi-square test:  
Th17 cells: P = 0.0004 
Th22 cells: P = 0.0002  
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3.5 Phenotypic CD4 T cell subset shifts 
3.5.1 The ratios of Th1:Treg, Th1Th17:Treg, Th17:Treg and Th22:Treg cells 
Despite no significant differences in Treg cell frequencies between groups, ratios of CD4 T cell subsets to 
Treg cells demonstrated a shift towards a Treg cell response in HIV-1 and HIV-1/HCV coinfection (see table 
10). There were no demonstrable differences between the HC group and HCV group in CD4 T cell subset to 
Treg cell ratios, except for a trend to a shift towards Th1 cells in the HCV group. 
No significant differences were observed between the HC group and HIV NAIVE group for Th1:Treg and 
Th17:Treg ratios (see figure 35). However there was a trend to reduced Th17:Treg ratios with median ratios 
of 1.153 in the HC group and 0.636 in the HIV NAIVE group (Mann Whitney U test P = 0.0125). Significant 
differences were demonstrated in coinfected individuals. The HCV HIV NAIVE group (median: 0.088 and 
0.529) had reduced ratios of Th1:Treg cells and Th17: Treg cells compared to both the HC (median: 0.431, P < 
0.001 and 1.153, P < 0.05) and HCV groups (median: 0.677, P < 0.001 and 1.144, P < 0.01). Effective ART 
reversed any shifts in Th1:Treg and Th17:Treg cell ratios. 
Th1Th17:Treg cell ratios were reduced in the HIV NAIVE (median: 0.546) and HIV ART (median: 0.490) groups 
compared to the HC group (median: 0.811, P > 0.05 and < 0.05). The reduced ratio in the HIV NAIVE group 
did not reach significance. Th1Th17:Treg cell ratios were also depleted in the HCV HIV NAIVE (median: 0.376) 
and HCV HIV ART (median: 0.348) groups compared to the HC group (median: 0.811, P < 0.01 and P < 0.05) 
and HCV group (median: 0.980, P < 0.01 and P < 0.05). Effective ART did not reverse any shifts in 
Th1Th17:Treg cell ratios. 
Th22:Treg cell ratios were reduced in the HIV NAIVE (median: 0.099) and HIV ART (median: 0.137) groups 
compared to the HC group (median: 0.227, P < 0.001 and P < 0.05). Cell ratios were also depleted in the HCV 
HIV NAIVE group (median: 0.088) compared to the HC (P < 0.001) and HCV (median: 0.192, P < 0.05) groups. 
The HCV HIV ART group (median: 0.130) had reduced ratios compared to the HC group (P < 0.05). Thus 
effective ART did not reverse Th22:Treg cell ratio shifts. 
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Table 10 The ratios of Th1:Treg, Th1Th17:Treg, Th17:Treg and Th22:Treg cells 
 HC 
(n=15) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#Th1:Treg 
 
0.431 
(0.238-0.533) 
0.677 
(0.481-1.171) 
0.338 
(0.143-0.433) 
0.218 
(0.114-0.605) 
0.277 
(0.125-0.636) 
0.088 
(0.023-0.177) 
 
 
HC 
(n=12) 
HCV 
(n=18) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=16) 
HCV HIV NAÏVE 
(n=10) 
*#Th1Th17:Treg 
 
0.811 
(0.686-1.38) 
0.980 
(0.620-1.256) 
0.490 
(0.217-0.604) 
0.546 
(0.358-0.764) 
0.348 
(0.219-0.705) 
0.376 
(0.066-0.432) 
 
 
HC 
(n=15) 
HCV 
(n=20) 
HIV ART 
(n=14) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#Th17:Treg 
 
1.153 
(0.871-1.298) 
1.144 
(0.853-1.470) 
0.937 
(0.667-1.218) 
0.636 
(0.353-1.124) 
0.835 
(0.504-1.077) 
0.529 
(0.309-0.786) 
*#Th22:Treg 
 
0.227 
(0.184-0.282) 
0.192 
(0.107-0.274) 
0.137 
(0.075-0.167) 
0.099 
(0.041-0.155) 
0.130 
(0.097-0.176) 
0.088 
(0.034-0.138) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: 
Th1:Treg: HC vs HCV HIV NAIVE P < 0.01, HCV vs HCV HIV NAIVE P < 0.001 
Th1Th17:Treg: HC vs HIV ART P < 0.05, HC vs HCV HIV ART P < 0.05, HC vs HCV HIV NAIVE P < 0.01, HCV vs HCV HIV ART P < 0.05, HCV 
vs HCV HIV NAIVE P < 0.01 
Th17:Treg: HC vs HCV HIV NAIVE P < 0.05, HCV vs HCV HIV NAIVE P < 0.01  
Th22:Treg: HC vs HIV ART P < 0.05, HC vs HIV NAIVE P < 0.001, HC vs HCV HIV ART P < 0.05, HC vs HCV HIV NAIVE P < 0.001, HCV vs 
HCV HIV NAIVE P < 0.05 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
Th1:Treg: HC vs HCV HIV NAIVE P < 0.0001, HCV vs HCV HIV NAIVE P < 0.0001 
Th1Th17:Treg: HC vs HIV ART P = 0.0009, HC vs HCV HIV ART P = 0.0024, HC vs HCV HIV NAIVE P = 0.0017, HCV vs HCV HIV ART P = 
0.0023, HCV vs HCV HIV NAIVE P = 0.0032 
Th17:Treg: HC vs HCV HIV NAIVE P = 0.0010, HCV vs HCV HIV NAIVE P = 0.0008  
Th22:Treg: HC vs HIV ART P = 0.0016, HC vs HIV NAIVE P < 0.0001, HC vs HCV HIV ART P = 0.0004, HC vs HCV HIV NAIVE P < 0.0001, 
HCV vs HCV HIV NAIVE P = 0.0030 
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Figure 35 The ratios of Th1:Treg, Th1Th17:Treg, Th17:Treg and Th22:Treg cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment.  The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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3.5.2 The ratios of Th1:Th17 and Th1:Th22 cells 
There were no significant differences in Th1:Th17 and Th1:Th22 cell ratios between the HC group and either 
the HIV ART or HIV NAIVE groups. There was a trend to increased Th1:Th17 and Th1:Th22 cell ratios in the 
HCV group (0.658, P > 0.05 and 0.634, P > 0.05) compared to the HC group (0.402; 1.965)  (see table 11 & 
figure 36). Coinfection with HIV-1 led to a reduction in these CD4 T cell ratios with the HCV HIV NAIVE group 
(0.154, P < 0.001; 1.405, P < 0.05) having reduced ratios compared to the HCV group. Effective ART reversed 
these changes (see figure 35) with no difference in Th1:Th17 and Th1:Th22 cell ratios between the HCV 
group and the HCV HIV ART group (0.400, P > 0.05; 2.311, P > 0.05). 
Table 11 The ratios of Th1:Th17 and Th1:Th22 cells 
 
 
HC 
(n=15) 
 
HCV 
(n=20) 
HIV ART 
(n=14) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*
#
Th1:Th17 
 
0.402 
(0.250-0.568) 
0.658 
(0.426-1.201) 
0.345 
(0.241-0.515) 
0.414 
(0.189-0.758) 
0.400 
(0.138-0.935) 
0.154 
(0.0578-0.265) 
*Th1:Th22 
 
1.965 
(0.978-2.455) 
3.634 
(1.946-7.351) 
2.301 
(1.299-3.415) 
3.042 
(1.221-7.396) 
2.311 
(0.822-6.074) 
1.405 
(0.481-2.091) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied:  
Th1:Th17: HCV vs HCV HIV NAIVE P < 0.001 
Th1:Th22: HCV vs HCV HIV NAIVE P < 0.05 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
Th1:Th17: HCV vs HCV HIV NAIVE P = 0.0002 
 
Figure 36 The ratios of Th1:Th17 and Th1:Th22 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment.  The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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3.6 Conclusions 
3.6.1 Key findings 
In untreated HIV-1 monoinfection phenotypic studies have demonstrated a reduction in Th22 cells and Th17 
cells compared to healthy individuals (see table 12). In addition there was a shift towards Treg cells from 
Th1Th17, Th17 and Th22 cells, while shifts towards Th1 cells away from Treg, Th17 and Th22 cells were not 
demonstrated. Phenotypic studies revealed that HIV-1/HCV coinfection led to a number of complex changes 
in the CD4 T cell subset milieu with reduced frequencies of Th1, Th1Th17, Th17 and Th22 cells compared to 
HCV monoinfection and healthy individuals. Given that the majority of Th1, Th17 and Th22 cells are found in 
the Thcm compartment these results are consistent with our finding of reduced Thcm cells in HIV-1/HCV 
coinfection compared to HCV monoinfection. Additionally HIV-1/HCV coinfection was shown to lead to a 
reduction in Th1 to Treg, Th17 and Th22 cell ratios compared to HCV monoinfection, while leading instead to 
a shift towards Treg cells from Th1, Th1Th17, Th17 and Th22 cells, compared to HCs. 
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Table 12 Summary of key findings: chapter 3 
Variable Control group for 
comparison 
HCV 
 
 
HIV NAIVE 
 
HCV HIV NAIVE 
 
HCV HIV ART 
Thcm HC 
HCV 
HIV NAIVE 
= =* = 
↓ 
= 
= 
= 
= 
 
CD38 ABC of CD8 T cells HC 
HCV 
HIV NAIVE 
↑ ↑ (HIV ART =) ↑ 
↑ 
= 
= 
= 
= 
 
HLA-DR+CD38hi CD8 T cells HC 
HCV 
HIV NAIVE 
= ↑ (HIV ART ↑) ↑ 
↑ 
↑ 
= 
= 
 
=** 
Th1 HC 
HCV 
HIV NAIVE 
↑ = ↓ 
↓ 
↓ 
= 
= 
= 
 
Th1Th17 HC 
HCV 
HIV NAIVE 
= =*** ↓ 
↓ 
= 
= 
↓ 
= 
 
Treg HC 
HCV 
HIV NAIVE 
= = = 
= 
= 
= 
= 
= 
 
Th17 HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART =) ↓ 
↓ 
= 
= 
= 
= 
 
Th22 HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART ↓) ↓ 
↓ 
= 
↓ 
↓ 
= 
 
Th1:Treg HC 
HCV 
HIV NAIVE 
↑ = ↓ 
↓ 
= 
= 
= 
= 
 
Th1Th17:Treg HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART ↓) ↓ 
= 
= 
↓ 
↓ 
= 
 
Th17:Treg HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART =) ↓ 
↓ 
= 
= 
= 
= 
 
Th22:Treg HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART ↓) ↓ 
↓  
= 
↓ 
↓ 
= 
 
Th1:Th17 HC 
HCV 
HIV NAIVE 
  ↑ =**** = 
↓ 
= 
= 
= 
= 
 
Th1:Th22 HC 
HCV 
HIV NAIVE 
↑ = = 
↓ 
= 
= 
= 
= 
 
 
↑ variable increased compared to control group 
↓ variable reduced compared to control group 
= variable unchanged compared to control group 
 
Novel findings highlighted in green 
Different findings to previous highlighted in orange 
* ↓ Okoye et al., 2007 
** ↑ Kovacs et al., 2008 
*** ↓ Gosselin et al., 2010, Clark et al., 2011 
**** ↑ Gosselin et al., 2010 
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3.6.2 Discussion  
We have confirmed previous findings that immune activation is increased in HIV-1 (section 1.3.4). We 
established that HIV-1 infection resulted in higher expression of all markers of immune activation (HLA-DR+, 
CD38+, CD38 ABC and HLA-DR+CD38hi), more marked in CD8 T cells than CD4 T cells. The exception was 
CD38 ABC of CD4 T cells which did not differ for any disease group. Effective ART resulted in reversal of 
immune activation, but this was only partial especially for CD8 T cells. As previously reported there was a 
tendency to consistently higher markers of immune activation in HCV infection compared to healthy controls 
( Gonzalez et al., 2009). This was most marked with CD38 ABC of CD8 T cells where significance was reached. 
HIV-1/HCV coinfection led to a further significant increase in immune activation compared to HCV 
monoinfection, which was demonstrable in a broad number of activation markers in both CD4 and CD8 T 
cells. In contrast to recent studies we did not demonstrate increased immune activation in coinfection 
compared to HIV-1 monoinfection (Kovacs et al., 2008, Gonzalez et al., 2009). The difference in these 
findings might be explained by the less advanced HIV disease in the HIV-1/HCV ART naive individuals 
compared with the HIV-1 ART naive individuals in this study. 
In this study HIV-1 infection did not alter pre-Th1, Th1 or Th1Th17 cell frequencies. Published literature has 
demonstrated that HIV-1 infection does not lead to a reduction in Th1 cells (Clark et al., 2011), but in some 
studies an increase in frequency has been demonstrated (Gosselin et al., 2010). Th1Th17 cells have 
previously been shown to be reduced in the periphery of HIV-1 infected individuals with ART conferring only 
partial if any restoration of this CD4 T cell subset (Gosselin et al., 2010, Clark et al., 2011). While evidence to 
date suggests that Th17 cells are reduced in the periphery in HIV-1 infection (section 1.3.5.1), phenotypic 
Th22 cells have not yet been studied. We demonstrated a trend to reduced Th17 cell frequencies and a 
significant reduction in the frequencies of Th22 cells in untreated HIV-1 infection, with restoration to normal 
levels with effective ART. We did not demonstrate an altered balance between Th1 cells and Th17 or Th22 
cells in HIV-1 infection, unlike previous studies which have shown a shift towards Th1 cells away from Th17 
cells (Gosselin et al., 2010). However while Treg cell frequencies did not alter, we did demonstrate a shift 
towards Treg cells away from Th1Th17, Th17 or Th22 cells, but an altered balance between Treg cells and 
Th1 cells was not observed. ART did not reverse these shifts. Recent literature has demonstrated a shift 
towards Treg cells away from Th17 in peripheral blood (Favre et al., 2010 Chege et al., 2011, Brandt et al., 
2011, Li et al., 2011) while elite controllers, but not therapy controllers, have been shown to maintain the 
balance between Tregs and Th17 cells (Brandt et al., 2011, Li et al., 2011). 
HCV monoinfection led to an increase in pre-Th1 and Th1 cells compared to healthy individuals. This 
upregulation in Th1 cells was substantiated by the demonstration of shifts towards Th1 cells from Treg, Th17 
and Th22 cells. HCV monoinfection did not lead to further phenotypic CD4 T cell subset (Th1Th17, Th17 or 
Th22) varitations. Th1 responses are known to be important and increased in HCV infection (Sobue et al., 
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2001). HCV infection has been shown to induce increased Th17 responses but to our knowledge, frequencies 
of phenotypic Th1Th17, Th17 and Th22 cells have not previously been reported. In HCV monoinfection an 
intrahepatic shift from Th1 to Th17 responses is potentially disadvantageous, with stronger Th17 responses 
being associated with higher HCV plasma levels, increased serum transaminases and enhanced activation of 
monocytes and Kupffer cells (Hammerich et al., 2011). Treg cells are thought to be increased in the periphery 
(Cabrera et al., 2004, Boettler et al., 2005, Rushbrook et al., 2005, Sugimoto et al., 2003) and liver (Sturm et 
al., 2010) in chronic HCV infection however we did not demonstrate an alteration in the frequency or subset 
shifts of Treg cells. 
Phenotypic studies revealed that HIV-1/HCV coinfection led to a number of complex changes in the CD4 T 
cell subset milieu with reduced frequencies of Th1, Th1Th17, Th17 and Th22 cells compared to HCV 
monoinfection and healthy individuals. Effective ART resulted in restoration of all CD4 T cell subsets except 
for Th1Th17 cells where only partial restoration was demonstrated. Frequencies of phenotypic Th1, 
Th1Th17, Th17 and Th22 cells, to our knowledge, have not yet been studied in HIV-1/HCV coinfection. 
Additionally HIV-1/HCV coinfection was shown to lead to a reversal in Th1 to Treg, Th17 and Th22 cell ratios 
compared to HCV monoinfection which was normalised with ART. In addition a shift towards Treg cells from 
Th1, Th1Th17, Th17 and Th22 cells compared to HCV monoinfection and healthy controls was shown. ART 
did not normalise shifts away from Th1Th17 or Th22 cells.  
3.6.3 Study limitations 
The main limitation of this study is its cross-sectional, rather than longitudinal, nature so that causality 
cannot be determined. In addition, due to difficulties in obtaining organ tissue, we have only analysed 
peripheral blood samples and it is unknown if events in the periphery mirror those in either gastrointestinal 
mucosal tissue or the liver.  
When recruiting participants into this study an attempt was made to match controls and patients with 
respect to demographic features and severity of HIV-1 disease. However individuals in the HCV group tended 
to be older than those in the HC group and this should be borne in mind when analysing the results. In 
addition the HCV HIV NAIVE group appeared to have less advanced HIV-1 infection than the HIV NAIVE 
group. Nadir CD4 T cell frequencies were higher in the HCV HIV NAIVE group than the HIV NAIVE group. 
There was a trend to increased absolute counts and frequencies of CD4 T cells and CD4:CD8 T cell ratios in 
the HCV HIV NAIVE group compared to the HIV NAIVE group. The HCV HIV NAIVE group did not demonstrate 
reduced Tn and increased Thtm and Them cells reflecting the less advanced HIV disease in this group. This 
was due to present day clinical guidelines advising the initiation of ART at a higher CD4 T cell count in 
individuals with HCV coinfection. The HCV HIV NAIVE group was therefore difficult to recruit to and 
individuals with higher CD4 counts were thus included.  
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As discussed in section 1.2.2.4 identification of Treg cells is problematic due to the lack of standardised 
assays to measure levels and function of Treg cells and this study is open to criticism in the way in which we 
have identified Treg cells. As no consensus exists as to the definitive strategy to identify Treg cells we 
decided to adopt the approach our study group has the most experience with and one which has been used 
by other research groups (Hunt et al., 2011).  
3.6.4 Conclusion 
These results have added to the literature to confirm that Th17 cells appear to be preferentially reduced in 
HIV-1 infection, compared to other CD4 T cell subsets (pre-Th1, Th1, Th1Th17 and Treg cells). We have also 
demonstrated a significant depletion of a newly defined CD4 T cell subset; Th22 cells. In addition we have 
demonstrated a shift towards Treg cells from Th1Th17, Th17 and Th22 cells, while the balance in Treg to Th1 
cells was not altered. The effect of HIV-1 infection on peripheral and GALT Th17 cells is still uncertain and the 
effect on Th22 cells has yet to be described. Th17 cells prevent extracellular bacterial, viral and fungal 
mucosal infection and maintain the intestinal epithelial barrier (Aujla et al., 2007) (Dubin and Kolls, 2008). 
Along with the skin homing chemokine receptors CCR4 and CCR10, human Th22 cells are known to express 
the gut homing receptor CCR6. Th22 cells produce IL22 which has been shown to be essential during early 
host defence against attaching and effacing bacterial gastrointestinal infections and induce LBP to LPS 
neutralising levels. It is possible that loss of Th17 and Th22 cells, in HIV-1 infection, as suggested by the 
above pilot data, plays an important role in increased microbial translocation and immune activation.  
In addition to increased immune activation HIV-1/HCV coinfection results in a more complex and broad 
alteration of CD4 T cell subsets with reduced frequencies of Th1Th17, Th17 and Th22 cells compared to both 
healthy controls and HCV monoinfection and lack of Th1 cell up regulation compared to HCV monoinfection. 
There was a revesal in the balance of Th1 to Th17 and Th22 cells compared to HCV monoinfection. In 
addition there was a shift towards Treg cells and away from all other CD4 T cell subsets (Th1, Th1Th17, Th17 
and Th22). These changes appear to be HIV-1 rather than HCV driven as HCV infection does not lead to a 
depletion in or altered balance of any CD4 T cell subsets. It is possible that increased immune activation in 
HIV-1/HCV coinfection plays a role in the rapid development of liver disease, however; how or if these CD4 T 
cell subset alterations affect the pathogenesis of liver disease in HIV-1/HCV coinfection is unclear.  
The focus of the next results chapter [Chapter 4 Results (2)] is to determine any alterations in the 
functionality of these CD4 T cell subsets, to further analyse immune activation using alternative markers and 
to assess the extent of microbial translocation within our study groups.   
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Chapter 4 Results (2): Analysis of CD4 T cell cytokine secretion, soluble 
markers of immune activation and microbial translocation 
4.1 Introduction 
This chapter describes our findings with regard to the functionality of Th1 (IFN-γ+ and IL-2+ CD4 T cells), 
Th17 (IL-17A+ and IL-21+ CD4 T cells) and Th22 (IL-22+ CD4 T cells) cells, compared to their phenotypic 
frequency as determined in Chapter 3 Results (1). It outlines the results of a soluble marker of immune 
activation; neopterin (as opposed to T cell markers of immune activation described in Chapter 3) and 
illustrates the results of microbial translocation assays (LPS, sCD14, LBP and EndoCAb). Finally we depict the 
outcome of an assay to determine the activity of IDO as a biological marker of Treg cell activity. 
IFN-γ is the only member of the type II IFNs. It is expressed by CD4 and CD8 T cells and NK cells. It is the 
primary cytokine which defines Th1 cells and functions to induce differentiation from naive CD4 T cells into 
Th1 cells and inhibits differentiation into Th2 cells. It is critical for immunity against viral and intracellular 
bacterial infections. IL-2 is expressed primarily by primed Th cells and Th1 cells, and its primary function is 
the induction of CD4 and CD8 T cell proliferation, differentiation and survival. IL-2 along with TGF-β drives 
the development of Treg cells from naive CD4 T cells. T cell activation in HIV-1 infection is associated with 
chronically elevated levels of IFN-γ (Schroecksnadel et al., 2007). Impaired IL-2 production has long been 
recognised as a consequence of HIV-1 infection. HCV infection as been shown to induce increased Th1 
responses as determined by increased serum IFN-γ and IL-2 levels (Jimenez-Sousa et al., 2010, Fathy et al., 
2011). 
The effect of HIV on GALT and peripheral IL-17+ CD4 T cells remains under investigation. Initial studies 
reported increased peripheral IL-17+ CD4 T cells in HIV infection (Maek et al., 2007, Yue et al., 2008). More 
recent studies have found reduced frequencies of peripheral IL-17+ CD4 T cells in chronic HIV positive 
individuals naive to ART (Prendergast et al., 2010, Gosselin et al., 2010, Chege et al., 2011), with LTNP 
displaying greater IL-17+ CD4 T cell frequencies than typical progressors (Salgado et al., 2011). Brenchley et 
al. provide evidence that GALT IL-17+ CD4 T cells are significantly reduced in HIV-infected ART naive 
individuals, but this was not reflected in the periphery (Brenchley et al., 2008). ART related CD4 T cell 
restoration in GALT has been shown to be associated with enhanced IL-17+ CD4 T cell accumulation in gut 
biopsies and the periphery (Macal et al., 2008), however in this study there was no evidence of baseline 
reduced IL-17+ CD4 T cell frequencies in the GALT. A more recent study has suggested that ART results in 
only partial resolution of peripheral IL-17+ CD4 T cells and extent of restoration is dependent on stage of 
disease at initiation of ART (Chege et al., 2011). The effect of HCV infection on IL-17+ CD4 T cells has been 
less extensively investigated.  Antigen specific IL-17+ CD4 T cells appear to be induced by HCV infection 
(Rowan et al., 2008), while serum IL-17 levels (Jimenez-Sousa et al., 2010, Fathy et al., 2011) and frequencies 
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of hepatic portal IL-17+ T cells are increased in chronic HCV infection (Harada et al., 2009). IL-17 receptors 
are detected on a number of liver cells including; hepatocytes, HSC and Kupffer cells and thus IL-17 may 
contribute to the pathogenesis of liver disease.   
In progressive HIV infection there are decreased levels of plasma IL-21 (Iannello et al., 2008). ART only 
partially restores IL-21 levels (Iannello et al., 2010), while elite controllers maintain normal levels. Yue et al 
showed that in chronic progressors, higher frequencies of IL-21 producing CD4 T cells correlated with lower 
viral load (Yue et al., 2010). However, the control of viraemia in elite controllers and in ART-treated 
individuals has been associated with low frequencies of IL-21 secreting HIV specific CD4 T cells. In contrast, 
Chevalier et al found higher levels of IL-21 secretion by HIV-specific CD4 T cells in elite controllers than in 
ART-controlled individuals, with the lowest levels detected in chronic progressors (Chevalier et al., 2011). IL-
21 has not been extensively investigated in HCV infection. 
To date only one publication has addressed the role of IL-22+IL-17-IFN-γ- CD4 T cells in HIV-associated 
mucosal pathogenesis (Kim et al., 2012). In this study while Th17 and Th1 cells were not shown to be 
reduced in either gastrointestinal mucosal tissue or the periphery IL-22+IL-17-IFN-γ- CD4 T cells were. ART 
was demonstrated to lead to restoration of Th22 cell frequencies. IL-22 has also been shown to play a role in 
protecting against the development of liver disease (Radaeva et al., 2004). There is little published data on 
IL-22 in HCV infection. IL-22 mRNA expression has been shown to be increased in chronic HCV infection; 
however IL-22 serum levels were similar to that of controls (Dambacher et al., 2008). 
Neopterin, a pteridine, was measured as a marker of immune activation (Murr et al., 2002). Neopterin, along 
with reactive oxygen species (ROS), is mainly synthesised by macrophages and to some extent DC. The most 
potent inducer of neopterin is IFN-γ produced by Th1 cells (Schroecksnadel et al., 2007). Other potent 
inducers of macrophage activity such as colony stimulating factor, granulocyte/monocyte colony-
stimulating-factor and IFN-β, do not induce the release of significant amounts of neopterin, however 
neopterin is inducible upon stimulation of TLR4 on monocytes/macrophages with LPS (Werner-Felmayer et 
al., 1990, Werner-Felmayer et al., 1989). Stimulation of monocytes with LPS has been shown to result in a 
dose dependent increase in neopterin (Schroecksnadel et al., 2010) and high neopterin concentrations are 
found in septicaemia (Strohmaier et al., 1987) due to gram-negative, LPS producing bacteria like 
Pseudomonas pseudomallei  (Brown et al., 1990) or Brucella melitensis  (Diez-Ruiz et al., 1993). HIV-1 
infection leads to elevated serum concentrations of neopterin and ROS (Fuchs et al., 1991, Huengsberg et al., 
1998, Look et al., 2000). In HIV-1 infection neopterin is not only a marker of immune activation, but acts as 
an independent prognostic factor of disease progression (Gisslen et al., 1997, Hutterer et al., 1992). Levels of 
neopterin are known to be increased in HCV infection (Fuchs et al., 1992, Quiroga et al., 1994).  
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LPS, sCD14, LBP and EndoCAb concentrations were measured as markers of microbial translocation. 
Determination of LBP is felt to be a more reliable marker of microbial translocation than LPS because the half 
life of LBP is longer (Schumann and Latz, 2000). sCD14 can be measured to establish evidence for direct 
chronic LPS stimulation (Brenchley et al., 2006b). Naturally occurring EndoCAb bind to and clear LPS from the 
circulation, but are thought to reach saturation with increased microbial translocation (Strutz et al., 1999). 
LPS levels have been shown to be increased in advanced HIV disease in a number of studies (Brenchley et al., 
2006b, Ancuta et al., 2008, Lester et al., 2009, Cassol et al., 2010) with some resolution in the context of 
effective ART (Papasavvas et al., 2009, Marchetti et al., 2008). Similarly sCD14 and LBP concentrations have 
been shown to be increased in advanced HIV disease (Ancuta et al., 2008, Montes-de-Oca et al., 2011, 
Brenchley et al., 2006b), although ART has not been shown to have a restorative effect on sCD14 
concentrations (Cassol et al., 2010).  LTNP do not demonstrate increased LPS or sCD14 concentrations 
(Ciccone et al., 2011). Meanwhile EndoCAb titres are reduced in advanced HIV-1 infection (Ancuta et al., 
2008, Brenchley et al., 2006b). Patients with chronic HCV infection display increased serum levels of LPS, LBP 
and sCD14 (Dolganiuc et al., 2007, Jirillo et al., 1998, de Oca Arjona et al., 2011). In the context of HIV-1/HCV 
coinfection there is less evidence available. Bagalopal et al and Ancuta et al demonstrate increased levels of 
LPS in HIV-1/HCV coinfection compared to HCV and HIV-1 monoinfection respectively (Balagopal et al., 2008, 
Ancuta et al., 2008).  Ancuta et al did not demonstrate increased sCD14 levels in HIV-1/HCV coinfection 
compared with HIV-1 monoinfection. However de-Oca Arjona et al demonstrated increased levels in HIV-
1/HCV coinfection in those with compensated cirrhosis compared to healthy controls and in those with 
decompensated cirrhosis compared with healthy controls, HIV-1 monoinfected individuals and coinfected 
individuals with compensated cirrhosis  (de Oca Arjona et al., 2011). In addition increased levels have been 
demonstrated in HIV-1/HCV coinfection compared with HCV monoinfection (Balagopal et al., 2008). In HIV-
1/HCV coinfection LBP levels have been shown to be increased compared to healthy controls (de Oca Arjona 
et al., 2011, Montes-de-Oca et al., 2011). Compared with HCV monoinfection some studies have 
demonstrated no change while others have shown increased LBP levels (de Oca Arjona et al., 2011, 
Balagopal et al., 2008). Compared to HIV-1 monoinfection increased levels have been demonstrated in those 
with decompensated liver disease, but not in those with compensated liver disease (de Oca Arjona et al., 
2011). Bagalopal et al revealed reduced EndoCAb levels in HIV-1/HCV coinfection compared to HCV 
monoinfection  
IDO was measured as a biological marker of Treg cell activity. It promotes the development of Treg cells and 
thus inhibits T cell immune responses and upregulates the expression of other inhibitor immune proteins 
such as IL-4. IDO expression is induced in a broad variety of cells (monocytes, macrophages, DCs, epithelial 
cells) via IFN-γ (Schroecksnadel et al., 2007). It is the rate-limiting enzyme involved in the catabolism of the 
amino acid TRP through the KYN pathway (Mellor and Munn, 2004). TRP withdrawal from the 
microenvironment arrests protein biosynthesis and subsequently cell proliferation. TRP catabolites are able 
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to induce the expression of FoxP3 and the generation of iTregs while suppressing the expression of ROR-c 
and the generation of Th17 cells (Sharma et al., 2009). HIV-1 infection leads to increased IDO activity (Fuchs 
et al., 1991, Huengsberg et al., 1998, Look et al., 2000). Here IDO may play a prominent role in immune 
regulation, serving as a negative feedback mechanism, with TRP depletion leading to T cell proliferation 
arrest and apoptosis and TRP metabolites being immunosuppressive  (Fallarino et al., 2002, Frumento et al., 
2002, Terness et al., 2002). In addition IDO may play a role in the loss of Th17 cells and a reciprocal increase 
in the fraction of Treg cells in HIV-1 (Favre et al., 2010). Thus enhanced IDO activity in HIV-1 infection is 
thought to contribute to disease progression via: CD4 T cell apoptosis, inhibition of CD4 and CD8 T cell 
responses, and altered Th cell subtype balance (Boasso, 2011). In chronic HCV there is up regulation of IDO 
expression in the liver and increased serum IDO activity (Larrea et al., 2007). Induction of IDO may dampen 
T-cell reactivity to viral antigens in chronic HCV infection. 
4.2 Aims 
Within the six study groups: 
 Assess the function of Th1, Th17 and Th22 cells via: 
 The frequencies of IFN-γ+ and IL-2+ CD4 T cells 
 The frequencies of IL-17A+ and IL-21+ CD4 T cells 
 The frequencies of IL-22+ CD4 T cells 
 Determine the level of immune activation via: 
 The concentrations of serum neopterin 
 Establish the presence of microbial translocation through measurement of: 
 LPS, sCD14, LBP and EndoCAb 
 Determine the level of Treg activity via: 
 The activity of IDO (estimated by the KTR determined via concentrations of serum TRP and 
KYN) 
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4.3 Intracellular cytokine assays 
Intracellular cytokine staining was employed in an attempt to determine the functionality of Th1 (IFN-γ+ and 
IL-2+ CD4 T cells), Th17 (IL-17A+ and IL-21+ CD4 T cells) and Th22 (IL-22+ CD4 T cells) cells. IFN-, IL-2, IL-17A, 
IL-21 and IL-22 produced by CD4 T cells following 20 hour stimulation with SEB were measured by 
intracellular flow cytometry.  Unstimulated tubes were used as controls to aid gate positioning to allow the 
identification of cells producing the cytokine of interest. 
4.3.1 Interferon-gamma and interleukin-2 
Figure 37 below outlines the gating strategy used to identify CD4 T cells producing either IFN-γ or IL-2. 
Figure 37 The gating strategy for the determination of IFN-γ+ and IL-2+ CD4 T cells 
 
 
 
There were significant differences between groups in frequency of IFN-γ+ CD4 T cells with a Kruskal-Wallis P 
value of 0.0218 (see table 13). There was no difference between the HCV or HIV NAIVE groups and the HC 
group. The principal difference existed between the HCV group and the HCV HIV NAIVE group with median 
frequencies of 4.268% and 2.404% respectively (P < 0.05) (see figure 38). There were no other significant 
differences between groups with ART appearing to ‘normalise’ frequencies in the HCV HIV ART group. It is 
worth noting that the HIV NAIVE group of individuals had disparate frequencies of IFN-γ+ CD4 T cells ranging 
from 0.560% to 13.980%. The two individuals with the highest frequencies of IFN-γ+ CD4 T cells were both 
extensively immunocompromised with CD4:CD8 T cell ratios of 0.24.  
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Frequencies of IL-2+ CD4 T cells varied greatly between groups, in keeping with previous published literature, 
with a Kruskal-Wallis P value of < 0.0001. There was no difference in frequencies between the HC and HCV 
groups. The HIV NAIVE group had a reduced median frequency of 1.066% compared to 5.851% in the HC 
group (P < 0.001). The HCV HIV NAIVE group (median: 1.384%) had reduced frequencies compared to both 
the HC group (median: 5.851%, P < 0.01) and the HCV group (median: 4.023%, P < 0.05). There was no 
difference in frequencies between the HIV NAIVE group and HCV HIV NAIVE group. Established ART resulted 
in partial restoration of frequencies in both HIV ART and HCV HIV ART groups.  
Table 13 Frequency (%) of IFN-γ+ and IL-2+ CD4 T cells 
 
 
HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#CD4+IFN-γ+ 
 
4.600 
(2.235-5.912) 
4.268 
(3.596-5.447) 
2.766 
(1.580-4.199) 
5.006 
(1.414-6.672) 
3.393 
(2.212-4.386) 
2.404 
(0.867-4.159) 
*#CD4+IL-2+ 
 
5.851 
(3.116-8.631) 
4.023 
(3.233-4.907) 
2.678 
(1.687-3.838) 
1.066 
(0.473-2.164) 
2.617 
(1.446-3.282) 
1.384 
(1.084-2.694) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied:  
% CD4+IFN-γ+: HCV vs HCV HIV NAIVE P < 0.05  
% CD4+IL-2+: HC vs HIV NAIVE P < 0.001, HC vs HCV HIV ART P < 0.05, HC vs HCV HIV NAIVE P < 0.01, HCV vs HCV HIV NAIVE P < 0.05 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:   
% CD4+IFN-γ+: HCV vs HCV HIV NAIVE P = 0.0033  
% CD4+IL-2+: HC vs HIV NAIVE P < 0.0001, HC vs HCV HIV ART P = 0.0008, HC vs HCV HIV NAIVE P = 0.0007, HCV vs HCV HIV ART P = 
0.0022, HCV vs HCV HIV NAIVE P = 0.0009 
 
Figure 38 Frequency (%) of IFN-γ+ and IL-2+ CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment.  The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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4.3.2 Interleukin-17A, interleukin-21 and interleukin-22 
Figure 39 below outlines the gating strategy used to identify CD4 T cells producing IL-17A, IL-21 or IL-22. A 
lower limit of detection was defined as 0.1 for CD4+IL-17A+ cell frequencies and 0.01 for CD4+IL-21+ and 
CD4+Il-22+ cell frequencies; any values less than this were arbitrarily assigned the value of 0.001. 
Figure 39 The gating strategy for the determination of IL-17A+, IL-21+ and IL22+ CD4 T cells 
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There was no difference in CD4+IL-17A+ frequencies between the HC and HCV groups (see table 14). The HIV 
NAIVE group had a median of 0.191% compared to 0.225% in the HC group (P > 0.05), which did not differ 
significantly. The HCV HIV NAIVE group (median: 0.063%) had significantly reduced CD4+IL-17A+ frequencies 
compared with both the HC (median: 0.225%, P < 0.05) and HCV (median: 0.225%, P < 0.01) groups. The HCV 
HIV ART group did not differ significantly from either the HC or HCV group. However on observing the dot 
plots it was clear that individuals within the HC group rarely had CD4+IL-17A+ frequencies of less than 0.15%. 
Using this cut off to form a contingency table and conducting a Chi-square test revealed significant 
differences between groups with a P value of 0.0010 (see figure 40).  The majority of individuals in the HC 
(93%), HCV (81%) and HIV ART (69%) groups had CD4+IL-17A+ frequencies of greater than 0.15%, 47% and 
44% of individuals in the HIV NAIVE and HCV HIV ART groups respectively had frequencies of greater than 
0.15% whereas only 20% of individuals in the HCV HIV NAIVE group had frequencies of greater than 0.15%.  
CD4+IL-21+ T cell frequencies did not differ between the HC and HCV groups (see figure 40). Frequencies 
were significantly reduced in the HIV NAIVE group (median: 0.148%) compared with the HC group (median: 
0.419%, P < 0.01). The HCV HIV NAIVE group (median: 0.181%) displayed reduced frequencies compared 
with the HC (median: 0.419%, P < 0.05) and HCV (median: 0.410%, P < 0.05) groups. In both NAIVE groups, 
ART resulted in restoration of CD4+IL-21+ T cell frequencies with median frequencies of 0.317 in the HIV ART 
group and 0.317 in the HCV HIV ART group.  
The HCV group did not differ from the HC group in terms of frequencies of CD4+IL-22+ T cells. The HIV NAIVE 
group had reduced frequencies compared to the HC group with median values of 0.053% and 0.130% 
respectively (P < 0.01). In HIV-1 monoinfection effective ART appeared to lead to partial restoration of 
CD4+IL-22+ T cells. Coinfection did appear to lead to reduced CD4+IL-22+ T cells  with the HCV HIV ART group 
(median: 0.088%) having a reduced frequency compared to the HCV group (median: 0.137%) with a Mann 
Whitney P value of 0.0042. There was a trend to reduced frequencies of CD4+IL-22+ T cells in the HCV HIV 
NAIVE group (median 0.073%) compared to both the HC (median: 0.130%, P > 0.05) and HCV (median: 
0.137%, P > 0.05) groups, but this did not reach significance. The difference between the HCV HIV ART group 
and HCV HIV NAIVE group may be due to fewer patient numbers.  On observing the dot plots it was clear 
that individuals within the HC group rarely had CD4+IL-22+ frequencies of less than 0.1%. Using this cut off to 
form a contingency table and conducting a Chi-square test revealed significant differences between groups, 
with a P value of less than 0.0001 (see figure 41). The majority of individuals in the HC (100%) and HCV (90%) 
groups had CD4+IL-22+ frequencies of greater than 0.1%. 44%, 39% and 40% of individuals in the HIV ART, 
HCV HIV ART and HCV HIV NAIVE groups had frequencies of greater than 0.1%, whereas 28% of individuals in 
the HIV NAIVE group had frequencies of greater than 0.1%.  
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Table 14 Frequency (%) of IL-17A+, IL-21+ and IL-22+ CD4 T cells 
 
 
HC 
(n=15) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#CD4+IL-17A+ 
 
0.225 
(0.180-0.311) 
0.225 
(0.176-0.396) 
0.198 
(0.135-0.279) 
0.191 
(0.001-0.382) 
0.131 
(0.001-0.262) 
0.063 
(0.001-0.152) 
 
 
HC 
(n=16) 
 
HCV 
(n=20) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=19) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#CD4+IL-21+ 
 
0.419 
(0.229-0.710) 
0.410 
(0.261-0.724) 
0.317 
(0.146-0.460) 
0.148 
(0.034-0.221) 
0.316 
(0.116-0.494) 
0.181 
(0.090-0.256) 
 
 
HC 
(n=16) 
 
HCV 
(n=20) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=18) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*#CD4+IL-22+ 
 
0.130 
(0.116-0.172) 
0.137 
(0.110-0.158) 
0.091 
(0.065-0.141) 
0.053 
(0.036-0.114) 
0.088 
(0.057-0.128) 
0.073 
(0.041-0.164) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied:  
% CD4+IL-17A+: HC vs HCV HIV NAIVE P < 0.05, HCV vs HCV HIV NAIVE P < 0.01 
% CD4+IL-21+: HC vs HIV NAIVE P < 0.01, HC vs HCV HIV NAIVE P < 0.05, HCV vs HCV HIV NAIVE P < 0.05 
% CD4+IL-22+: HC vs HIV NAIVE P < 0.01 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
% CD4+IL-17A+: HC vs HCV HIV NAIVE P = 0.0003, HCV vs HCV HIV NAIVE P = 0.0012 
% CD4+IL-21+: HC vs HIV NAIVE P = 0.0003, HC vs HCV HIV NAIVE P = 0.0017, HCV vs HCV HIV NAIVE P = 0.0006 
% CD4+IL-22+: HC vs HIV NAIVE P = 0.0018, HCV vs HCV HIV ART P = 0.0042 
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Figure 40 Frequency (%) of IL-17A+, IL-21+ and IL-22+ CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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Figure 41 Number of participants with frequencies (%) of CD4+IL-17A T cells greater or less than 0.15% 
and CD4+IL-22 T cells greater or less than 0.1% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparisons for categorical data were made using the Chi-square test:  
CD4+IL-17A T cells: P = 0.0010 
CD4+IL-22 T cells: P < 0.0001 
 
4.4 Soluble marker of immune activation 
4.4.1 Neopterin assay 
Serum neopterin levels were determined on serum samples. Levels differed significantly between groups 
with a Kruskal-Wallis P value of < 0.0001 (see table 15 & figure 42). There was a propensity to an almost two 
fold increase in concentrations in the HCV group (median: 8.90nmol/L) compared to the HC group (median: 
4.90nmol/L) with a Mann Whitney U test P value of 0.0011. HIV monoinfection was shown to drive a more 
dramatic increase in neopterin concentrations with the HIV NAIVE group having a median concentration of 
21.05 nmol/L (P < 0.001). The HCV HIV NAIVE group (median: 16.60nmol/L) had increased levels compared 
to the HC group (P < 0.001). Comparison of the HCV HIV NAIVE group (median: 16.60nmol/L) and HCV group 
(median: 8.90nmol/L) demonstrated a significant difference with a Mann Whitney U test P value of 0.0035. 
There was no significant difference between the concentrations in the HIV NAIVE and HCV HIV NAIVE groups. 
Effective ART appeared to partially, but not completely, restore concentrations of neopterin. The HIV ART 
group (median: 8.80nmol/L, P < 0.001) had significantly lower levels than the HIV NAIVE group. Comparison 
of the HIV ART group (median: 8.80nmol/L) and HC group (median: 4.90nmol/L) demonstrated a significant 
difference with a Mann Whitney U test P value of 0.0041. The HIV HCV ART group (median: 9.30nmol/L, P < 
0.05) had significantly higher concentrations than the HC group (median: 4.90nmol/L). 
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Table 15 The concentration of serum neopterin (nmol/L) 
 HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*
#
Neopterin (nmol/L) 
 
4.90 
(4.60-5.55) 
8.90 
(5.95-13.70) 
8.80 
(6.73-9.85) 
21.05 
(15.83-31.08) 
9.30 
(5.60-14.60) 
16.60 
(12.30-19.43) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied:  
Neopterin (nmol/L): HC vs HIV NAIVE P < 0.001, HC vs HCV HIV ART P < 0.05, HC vs HCV HIV NAIVE P < 0.001, HIV ART vs HIV NAIVE P 
< 0.001 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
Neopterin (nmol/L): HC vs HCV P = 0.0011, HC vs HIV ART P = 0.0041, HC vs HIV NAIVE P < 0.0001, HC vs HCV HIV ART P = 0.0012, HC 
vs HCV HIV NAIVE P < 0.0001, HCV vs HCV HIV NAIVE P = 0.0035, HIV ART vs HIV NAIVE P < 0.0001  
 
Figure 42 The concentration of serum neopterin (nmol/L) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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4.5 Microbial translocation assays 
4.5.1 Lipopolysaccharide 
This study revealed no differences in LPS levels between healthy controls or individuals with HCV 
monoinfection, HIV monoinfection or HIV-1/HCV coinfection (see table 16 & figure 43). Even those 
individuals naive to ART did not have appreciably increased LPS levels compared to either healthy controls or 
those on effective ART.  
Table 16 The concentration of lipopolysaccharide (EU/ml) 
 HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=17) 
HCV HIV NAÏVE 
(n=10) 
LPS (EU/ml) 
 
0.00 
(0.00-0.57) 
0.15 
(0.00-0.42) 
0.19 
(0.00-0.71) 
0.12 
(0.01-0.46) 
0.11 
(0.00-0.41) 
0.11 
(0.00-0.60) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: No significant differences 
were found. 
 
Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045: No significant differences were found. 
 
Figure 43 The concentration of lipopolysaccharide (EU/ml) 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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4.5.2 Soluble CD14 
Differences between the study groups were significant with a Kruskal-Wallis P value of 0.0001 (see table 17 
& figure 44).  All patient groups had increased concentrations of sCD14 compared with the HC group 
(median: 1800 ng/ml). Patient groups had similar concentrations although the HCV group (median: 2360 
ng/ml) appeared to have slightly lower concentrations that the rest of the patient groups. There were no 
differences between HIV and HCV HIV groups. ART did not lead to a significant reduction in sCD14 
concentrations.  
Table 17 The concentration of soluble CD14 (ng/ml) 
 HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*
#
sCD14(ng/ml) 
 
1800 
(1625-2138) 
2360 
(2080-2900) 
2670 
(2283-3350) 
2715 
(2250-3818) 
2650 
(2340-2853) 
2760 
(2235-3680) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: 
sCD14 (ng/ml): HC vs HCV P < 0.05, HC vs HIV ART  P < 0.01, HC vs HIV NAÏVE P < 0.001, HC vs HCV HIV ART P < 0.01, HC vs HCV HIV 
NAÏVE P < 0.01. 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
sCD14 (ng/ml): HC vs HCV P = 0.0025, HC vs HIV ART P = 0.0002, HC vs HIV NAÏVE P < 0.0O01, HC vs HCV HIV ART P = 0.0004, HC vs 
HCV HIV NAÏVE P = 0.0008 
 
Figure 44 The concentration of soluble CD14 (ng/ml) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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4.5.3 Lipopolysaccharide binding protein 
There were no significant differences in LBP concentrations when comparing the original six study groups 
(see table 18 & figure 45). Analysis of the HC group with the HCV group, all HIV monoinfected individuals 
(HIV ART and HIV NAIVE groups) and all HCV HIV coinfected individuals (HCV HIV ART and HCV HIV NAIVE 
groups) found increased LBP concentrations in HIV monoinfected individuals with a median concentration of 
38.50 µg/ml (IQR: 33.53µg/ml - 47.55µg/ml) compared with 30.35 µg/ml (IQR: 26.53µg/ml – 36.08µg/ml) in 
the HC group (P < 0.05).  There was a trend to increased levels in the HCV group (median: 36.80µg/ml) and 
all HCV HIV co infected individuals (median: 38.90µg/ml) compared to the HC group (30.35 µg/ml), but this 
did not reach significance.  
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Table 18 The concentration of lipopolysaccharide binding protein 
 HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
LBP (µg/ml) 
 
30.35 
(26.53-36.08) 
36.80 
(33.75-50.30) 
44.50 
(31.35-55.18) 
37.80 
(33.60-47.55) 
38.90 
(29.40-46.35) 
39.95 
(31.25-52.12) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: No significant differences 
were found. 
 
Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045: No significant differences were found. 
 
Figure 45 The concentration of lipopolysaccharide binding protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
 
4.5.4 Endotoxin core antibodies 
There were no discernable differences in EndoCAb concentrations when comparing the original six study 
groups (see table 19 & figure 46). Analysis of the HC group with the HCV group, all HIV monoinfected 
individuals (HIV ART and HIV NAIVE groups) and all HCV HIV coinfected individuals (HCV HIV ART and HCV 
HIV NAIVE groups) did not find any differences.  
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Table 19 The concentration of endotoxin core antibodies 
 HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
EndoCAb IgM (MMU/ml) 
 
46.56 
(36.12-65.24) 
41.86 
(30.24-63.59) 
28.78 
(14.44-58.21) 
36.40 
(26.62-66.05) 
31.33 
(14.41-59.12) 
46.99 
(21.47-57.11) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment.  
 
Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: No significant differences 
were found. 
 
Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045: No significant differences were found. 
 
Figure 46 The concentration of endotoxin core antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
 
4.6 Biological marker of T regulatory cell activity 
4.6.1 Indoleamine 2,3-dioxygenase activity assay 
Decreasing plasma TRP concentrations in parallel with increasing plasma levels of KYN are indicative of 
enhanced IDO activation (Taylor and Feng, 1991, Carlin et al., 1987, Heyes, 1991). Thus, calculation of the 
KYN to TRP ratio (KTR) allows an estimation of IDO activity. Serum KYN and TRP levels were determined on 
serum samples.  
There was no significant difference in KYN concentrations between the HC group (median: 2.625 µmol/L) 
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4.465 µmol/L, P < 0.01) and the HCV HIV NAÏVE group (median: 4.825 µmol/L, P < 0.05) had increased 
EndoCAb IgM MMU/ml
HC HC
V
HI
V 
AR
T
HI
V 
NA
IV
E
HC
V 
HI
V 
AR
T
HC
V 
HI
V 
NA
IV
E
0
30
60
90
120
150
350
M
M
U
/m
l
134 | P a g e  
 
concentrations compared to the HC group. The HCV HIV NAÏVE group had a tendency to higher KYN 
concentrations than the HCV group. There were no differences between the HIV NAIVE group and the HCV 
HIV NAIVE group. Effective ART appeared to resolve the changes in concentration to near normal in both the 
HIV ART (median: 3.600µmol/L) and HCV HIV ART (median: 2.870µmol/L) groups. There were no significant 
differences between any of the groups for TRP concentrations with a Kruskal-Wallis test P value of 0.1335. 
The kynurenine/tryptophan ratio (KTR), a marker of IDO activity, differed between the five study groups with 
a Kruskal-Wallis test P value of< 0.0001. While ratios were similar between the HC (median: 39.40) and HCV 
groups (median: 41.40), HIV infection appeared to drive increased ratios. Compared with the HC group, the 
HIV NAÏVE group had a median ratio of 72.00 (P<0.001) and the HCV HIV NAÏVE group a median ratio of 
69.40 (P < 0.001). The HCV HIV NAÏVE group also had increased values compared with the HCV group (P < 
0.05). ART resulted in a return to ‘normal’ ratios as demonstrated by the ‘normal’ HIV ART group median 
value of 46.60 and the ‘normal’ HCV HIV ART group median value of 45.75. 
Table 20 Kynurenine & tryptophan concentrations (µmol/L) and kynurenine/tryptophan ratio 
 HC 
(n=16) 
 
HCV 
(n=21) 
HIV ART 
(n=16) 
HIV NAÏVE 
(n=20) 
HCV HIV ART 
(n=18) 
HCV HIV NAÏVE 
(n=10) 
*
#
kynurenine (µmol/L) 
 
2.625 
(2.235-3.920) 
3.410 
(2.415-4.290) 
3.600 
(2.820-4.108) 
4.465 
(3.650-6.603) 
2.870 
(2.450-3.883) 
4.825 
(3.130-5.538) 
#
tryptophan (µmol/L) 
 
70.60 
(66.20-87.15) 
77.00 
(56.70-88.30) 
70.10 
(58.83-82.33) 
61.35 
(47.65-79.83) 
63.80 
(53.90-74.25) 
66.35 
(59.73-78.88) 
*
#
kynurenine / tryptophan 
 
39.40 
(34.03-46.28) 
41.40 
(35.20-53.45) 
46.60 
(43.08-52.20) 
72.00 
(54.48-118.70) 
45.75 
(39.40-57.48) 
69.40 
(51.08-86.73) 
 
Median values are shown with the interquartile range shown in brackets. HC: healthy controls, HCV: HCV monoinfected patients, HIV 
ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected patients who are HIV treatment naïve, HCV HIV ART: HIV-
1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected patients who are naïve to HIV treatment. 
  
*Comparison between groups was determined using the Kruskal-Wallis test with Dunn’s post test applied: 
kynurenine µmol/L: HC vs HIV NAIVE P < 0.01, HC vs HCV HIV NAIVE P < 0.05  
kynurenine:tryptophan ratio: HC vs HIV NAIVE P < 0.001, HC vs HCV HIV NAIVE P < 0.001, HCV vs HCV HIV NAIVE P < 0.05, HIV ART vs 
HIV NAIVE P < 0.01 
 
# Comparison between two groups was determined using the Mann Whitney U test where application of the Bonferroni multiple-
significance-test correction set a threshold for statistical significance at P < 0.0045:  
kynurenine µmol/L: HC vs HIV NAIVE P = 0.0020, HC vs HCV HIV NAIVE P = 0.0034 
kynurenine:tryptophan ratio: HC vs HIV NAIVE P < 0.0001, HC vs HCV HIV NAIVE P = 0.0003, HIV ART vs HIV NAIVE P < 0.0001, HCV 
HIV ART vs HCV HIV NAIVE P = 0.0078. 
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Figure 47 Kynurenine & tryptophan concentrations (µmol/L) and kynurenine/tryptophan ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HC: healthy controls, HCV: HCV monoinfected patients, HIV ART: HIV monoinfected individuals on ART, HIV NAÏVE: HIV monoinfected 
patients who are HIV treatment naïve, HCV HIV ART: HIV-1/HCV coinfected patients on ART, HCV HIV NAÏVE: HIV-1/HCV coinfected 
patients who are naïve to HIV treatment. The middle horizontal line denotes the median of each group, while the vertical line 
denotes the interquartile range. 
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4.7 Conclusions 
4.7.1 Key findings 
In this study HIV-1 infection led to a significant reduction in IL-17A+, IL-21+ and IL-22+ CD4 T cell frequencies 
and an increase in IDO activity (a marker of Treg cell activity) (see table 21). These results are consistent with 
data in Chapter 3 which demonstrated a reduction in Th17 and Th22 cell frequencies and a shift towards 
Treg from Th17 and Th22 cells. In addition two markers of microbial translocation (sCD14 and LBP) were 
increased. In keeping with phenotypic data from the prevous chapter HIV-1/HCV coinfection led to a 
reduction in Th1 (IFN-γ+ and IL-2+ CD4 T cells) cytokine responses compared to HCV monoinfection and a 
reduction in Th17 (IL-17A+ and IL-21+ CD4 T cells) and Th22 (IL-22+ CD4 T cells) cytokine responses 
compared to HCV monoinfection and healthy individuals. IDO activity was increased compared to HCV 
monoinfection, consistent with a shift towards Treg and away from Th17 cells. Neopterin (a soluble marker 
of immune activation) was increased compared to HCV monoinfection and sCD14 (a marker of microbial 
translocation) was increased compared to healthy individuals. 
4.7.2 Discussion 
We have confirmed that HIV-1 infection leads to a significant reduction in IL-2+ CD4 T cell frequencies (Fan et 
al., 1993). IFN-γ+ CD4 T cell frequencies appeared unchanged, except for those with severe HIV-1 infection 
who were noted to have increased frequencies. T cell activation in HIV-1 infection has been associated with 
chronically elevated levels of IFN-γ (Schroecksnadel et al., 2007). While evidence suggests that IL-21 is 
reduced in HIV-1 infection (Iannello et al., 2008,) the effect on frequencies of peripheral IL-17+ CD4 T cells 
remains under investigation with conflicting results (Maek et al., 2007, Yue et al., 2008, Prendergast et al., 
2010, Brenchley et al., 2008). In this study HIV-1 infection led to a higher proportion of individuals with IL-
17A+ CD4 T cell frequencies of less than 0.15% and a significant reduction in IL-21+ CD4 T cells. IL-22+ CD4 T 
cells were also depleted, in keeping with current literature (Kim et al., 2012). These findings are in keeping 
with the trend to reduced phenotypic Th17 cells and depleted phenotypic Th22 cells in HIV-1 infection seen 
in the previous chapter. In this study the frequencies of IFN-γ+ and IL-2+ CD4 T cells (Th1 cytokines), IL-17A+ 
and IL-21+ CD4 T cells (Th17 cytokines) and IL-22+ CD4 T cells (Th22 cytokines) in HCV monoinfection did not 
differ from healthy controls. In contrast previous reports have shown increased Th1 responses in HCV 
infection (Jimenez-Sousa et al., 2010, Fathy et al., 2011). IL-17A, IL-21 and IL-22 are less well studied; there is 
the suggestion that serum IL-17 levels (Jimenez-Sousa et al., 2010, Fathy et al., 2011) may be increased while 
IL-22 levels are unchanged (Dambacher et al., 2008).   
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Table 21 Summary of key findings: chapter 4 
Variable Control group for 
comparison 
HCV 
 
 
HIV NAIVE 
 
HCV HIV NAIVE 
 
HCV HIV ART 
IFN-γ+ CD4 T cells HC 
HCV 
HIV NAIVE 
= = = 
↓ 
= 
= 
= 
= 
 
IL-2+  CD 4 T cells HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART ↓) ↓ 
↓ 
= 
↓ 
↓ 
= 
 
IL-17A+ CD4 T cells HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART =) ↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
 
IL-21+ CD4 T cells HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART =) ↓  
↓ 
= 
= 
= 
= 
 
IL-22+ CD4 T cells HC 
HCV 
HIV NAIVE 
= ↓ (HIV ART ↓) ↓ 
↓ 
= 
↓ 
↓ 
= 
 
Neopterin 
(nmol/L) 
HC 
HCV 
HIV NAIVE 
↑ ↑ (HIV ART ↑) ↑ 
↑ 
= 
↑ 
↑ 
= 
 
LPS  
(EU/ml) 
HC 
HCV 
HIV NAIVE 
=* =*** =
#
 
=
#
 
=
#
 
=
#
 
=
#
 
=
#
 
 
sCD14 
(ng/ml) 
HC 
HCV 
HIV NAIVE 
↑ ↑ (HIV ART ↑) ↑ 
= 
= 
↑ 
= 
= 
 
LBP 
(µg/ml) 
HC 
HCV 
HIV NAIVE 
=** ↑ =
##
 
= 
= 
=
##
 
= 
= 
 
EndoCAb 
((MMU/ml) 
HC 
HCV 
HIV NAIVE 
= =**** = 
= 
= 
= 
= 
= 
 
IDO activity 
(KTR) 
HC 
HCV 
HIV NAIVE 
= ↑ (HIV ART =) ↑ 
↑ 
= 
= 
= 
= 
 
 
↑ variable increased compared to control group 
↓ variable reduced compared to control group 
= variable unchanged compared to control group 
 
Novel findings highlighted in green 
Different findings to previous highlighted in orange 
* ↑ Jirillo et al., 1998 
** ↑ de Oca Arjona., 2011 
*** ↑ Brenchley et al., 2006b, Ancuta et al., 2008, Lester et al., 2009, Cassol et al., 2010 
**** ↓ Brenchley et al., 2006b, Ancuta et al., 2008  
# 
↑ Ancuta et al., 2008, Bagalopal et al., 2008 
## 
↑ de Oca Arjona., 2011, Montes-de-Oca et al., 2011 
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The effect of HIV-1/HCV coinfection on Th1, Th17 and Th22 cytokines has not previously been extensively 
investigated. As with phenotypic CD4 T cells in Chapter 3 HIV-1/HCV coinfection demonstrated a widespread 
reduction in functional CD4+ T cells. HIV-1/HCV coinfection demonstrated a reduction of IFN-γ+ CD4 T cell 
frequencies compared with HCV monoinfected individuals. IL-2+ CD4 T cells were depleted compared to 
both healthy controls and HCV monoinfected individuals. Both IL-17A+ and IL-21+ CD4 T cells were reduced 
compared to healthy controls and HCV monoinfection. HIV-1/HCV coinfection demonstrated the highest 
proportion of individuals with IL-17A+ CD4 T cell frequencies of less than 0.15% suggesting a more marked 
deletion of  functional Th17 cells in HIV-1/HCV coinfection than HIV-1 monoinfection. Consistent with 
phenotypic data HIV-1/HCV coinfection demonstrated a reduction in IL-22+ CD4 T cells; with a significant 
proportion of individuals having a frequency of less than 0.1%. Effective ART led to resolution of IFN-γ+ and 
IL-21+ CD4 T cells, with partial restoration of IL-2+, IL-17A+ and IL-22+ CD4 T cells. 
Neopterin concentrations are known to be increased in HCV (Fuchs et al., 1992, Quiroga et al., 1994) and 
HIV-1 monoinfection (Fuchs et al., 1991, Huengsberg et al., 1998, Look et al., 2000). Our study confirmed 
these findings. HIV-1/HCV coinfection led  to increased neopterin levels compared to HCV monoinfection. 
Effective ART in both monoinfection and coinfection led to only partial resolution of neopterin levels. 
In this study we demonstrated increased markers of microbial translocation in the form of sCD14 in HCV 
monoinfection, and in the form of sCD14 and LBP in HIV-1 infection. Whereas LBP levels appeared to be 
restored to normal levels with effective ART, sCD14 levels were not. There was a trend to increased LBP 
levels in HCV monoinfection and HIV-1/HCV coinfection, but this did not reach significance. sCD14 levels 
were significantly increased in HIV-1/HCV coinfection compared to healthy controls and tended to increased 
levels compared to HCV monoinfection. These results add to the literature which suggests increased 
microbial translocation in HIV-1 infection ( section 1.3.4) and gives some evidence for increased microbial 
translocation in HIV-1/HCV coinfection compared to HCV monoinfection (Balagopal et al., 2008, Ancuta et 
al., 2008, de Oca Arjona et al., 2011, Montes-de-Oca et al., 2011). LPS and EndoCAb assays did not determine 
any significant differences between the study groups. This differs from some published literature (section 
4.1). Other studies have had fewer study groups, with larger group numbers and significant overlap in results 
between study groups. Therefore this pilot study may be underpowered to demonstrate differences. 
However it is possible that these variables do not differ between study groups. Redd et al, in a longitudinal 
study from Uganda, found no significant changes in LPS and EndoCAb during HIV-1 disease progression 
(Redd et al., 2009). 
IDO activity is known to be increased in HCV (Larrea et al., 2007) and HIV-1 monoinfection (Fuchs et al., 
1991, Huengsberg et al., 1998, Look et al., 2000). In this study IDO activity did not appear to be altered by 
HCV monoinfection, but was increased in HIV-1 monoinfection. HIV-1/HCV coinfection resulted in levels 
similar to HIV-1 monoinfection. ART led to normalisation of enzyme activity in both HIV-1 monoinfection and 
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HIV-1/HCV coinfection. These findings are in keeping with the shifts towards Treg cells away from Th17 cells 
demonstrated in Chapter 3 in HIV-1 monoinfection and HIV-1/HCV coinfection, but not HCV monoinfection. 
4.7.3 Study limitations 
As previously mentioned the main limitation of this study is that it is cross-sectional rather than longitudinal 
so that causality cannot be determined. In addition, due to difficulties in obtaining organ tissue, we have 
only analysed peripheral blood samples and it is unknown if events in the periphery mirror those in either 
the gastrointestinal mucosal tissue or the liver.  
As discussed in Chapter 3, individuals in the HCV group tended to be older than those in the HC group and 
this should be borne in mind when analysing the results. In addition, the HCV HIV NAIVE group appeared to 
have less advanced HIV-1 infection than the HIV NAIVE group and was difficult to recruit to resulting in small 
patient numbers in this group. This may impact on the power of this pilot study. It is possible that due to this 
any differences in variables between HIV-1 infected individuals naive to ART and HIV-1/HCV coinfected 
individuals naive to ART are not discernable in this study. 
It has been beyond the scope of this thesis to observe for differences between study groups in HCV specific 
polyfunctional T cell responses. This would be an important component to carry out in future studies.  
4.7.4 Conclusions 
The above results have added to the literature to confirm that HIV-1 infection leads to suppression of Th1 
responses and a reduction in peripheral functional Th17cells, with a reduction in the frequencies of IL-17A+ 
and IL-21+ CD4 T cells. As previously established, immune activation (neopterin) and microbial translocation 
(sCD14 and LBP) have been shown to be increased in HIV-1 infection. Current literature identifies 
preferential loss of GALT IL-17+ CD4 T cells as a possible mechanism via which microbial translocation is 
increased in HIV-1. Loss of IL-17A production would lead to reduced intestinal mucosal integrity with loss of: 
tight junctions, antimicrobial peptides, neutrophil recruitment and regulation of effector T cells in the gut. 
While loss of IL-21 might lead to reduced Th17 cell and increased Treg cell differentiation with exhaustion 
and loss of function of CD8 T cells critical for control of chronic viral infections. In addition, we demonstrate 
that functional Th22 cells (IL-22+ CD4 T cells) are reduced in HIV-1 monoinfection. IL-22 has been shown to 
be essential during early host defence against attaching and effacing bacterial gastrointestinal infections and 
to induce LBP to LPS neutralising levels. Therefore evidence for depletion of IL-22+ CD4 T cells in HIV-1 
infections leads to the possibility that this may add to the presence of increased microbial translocation seen 
in HIV-1, which in turn may contribute to high levels of immune activation and progressive HIV-1 disease. 
In HIV-1/HCV coinfection we have demonstrated reduced IFN-γ+ and IL-2+ CD4 T cells compared to HCV 
monoinfection, which appears to be driven by HIV-1 infection. Th1 responses are known to be important in 
HCV infection and loss of these may explain the reduced rates of spontaneous seroconversion and the 
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increased HCV RNA levels seen in coinfected individuals. In addition we have demonstrated increased 
immune activation (neopterin) compared to healthy controls and HCV monoinfection, and increased 
microbial translocation (sCD14 and LBP) compared to healthy controls which is in keeping with the limited 
published data. Thus in keeping with our hypothesis, increased microbial translocation and immune 
activation may be components of the complex mechanisms which lead to more frequent and rapid 
development of liver fibrosis in HIV-1/HCV coinfection. The demonstration of reduced frequencies of IL-
17A+, IL-21+ and IL-22+ CD4 T cells in HIV-1/HCV coinfection, compared to healthy controls and HCV 
monoinfected individuals further supports the complex and broad alteration of CD4 T cell subsets seen in 
HIV-1/HCV coinfection described in Chapter 3. Loss of these effector CD4 T cell cytokines in the context of 
HCV coinfection is likely to be deleterious. In addition to the possible contribution to microbial translocation 
and immune activation, discussed in the paragraph above, which could lead to more rapid progression of 
liver disease, reduced IL-21 may contribute to chronic HCV infection with increased loss and exhaustion of 
CD8 T cells, while reduced IL-22 may contribute to the development of liver disease with loss of its apparent 
protective effect.  
However, how or if these CD4 T cell subset alterations affect the pathogenesis of liver disease in HIV-1/HCV 
coinfection is unclear. In Chapter 5 Results (3) we look for correlations between these CD4 T cell subsets, 
microbial translocation and immune activation to allow identification of any relationships which may suggest 
the involvement of Th17 and Th22 cells in this complex interaction.  
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Chapter 5 Results (3): Correlations between markers of immune activation, 
microbial translocation and CD4 T cell subsets 
5.1 Introduction 
In the previous two results chapters we observed the effects of HIV-1 monoinfection, HCV monoinfection 
and HIV-1/HCV coinfection on multiple markers of microbial translocation, cellular and soluble markers of 
immune activation and both phenotypic and functional CD4 T cell subsets. We have confirmed increased 
microbial translocation and immune activation in HIV-1 infection and have provided evidence to suggest 
increased levels in HIV-1/HCV coinfection. A complex and broad alteration of CD4 T cell subsets in HIV-1/HCV 
coinfection has been demonstrated. In this chapter we present correlations between markers of microbial 
translocation (sCD14, LBP and LPS) and markers of immune activation (HLA-DRCD38hi CD8 T cells, CD38 ABC 
of CD8 T cells and neopterin). In addition we observe correlations between these variables and CD4 T cell 
subsets (Th1, Th17Th1, Treg, Th17 and Th22), CD4 T cell cytokines (IFN-γ, IL-2, IL-17A, IL-21, IL-22) and CD4 T 
cell subset shifts (Th1:Treg, Th1Th17:Treg, Th17:Treg, Th22:Treg, Th1:Th17, Th1:Th22) to determine any 
inter-relationships. Lastly we define correlations between IL-21 or IDO activity and CD4 T cell subset shifts.  
Brenchley et al have shown that LPS levels in HIV are correlated with increased frequencies of CD38+HLA-
DR+CD8 T cells (Spearman r value 0.48, P =0.0019) (Brenchley et al., 2006b). A further study from the same 
group has confirmed the above findings using 16SrDNA as a marker for microbial translocation (Spearman r 
value 0.18, P=0.047) (Jiang et al., 2009). However a study from South Africa looked for a correlation between 
LPS and immune activation (CD38+HLA-DR+ CD8 T cells) and none was found (Cassol et al., 2010). The 
presence of correlations between immune activation and microbial translocation in the context of HCV 
monoinfection and HIV-1/HCV coinfection has yet to be fully assessed. 
Inverse correlations between immune activation and Th17 cells have been reported. In pathogenic SIV 
infection, the frequency of Th17 cells is an independent predictor of T cell turnover (Ki67+CD8+) which is 
driven by immune activation (Favre et al., 2009). In HIV-1 infection, peripheral and GALT Th17 cell 
frequencies have been inversely correlated with immune activation. Peripheral Th17 cells correlated with 
CD4+CD38+ cells with a Spearman r value of -0.5530 (P<0.01) (El Hed et al., 2010), while GALT Th17 cells 
correlated with CD4+Ki67+ cells with a Spearman r value of -0.5292 (P=0.0065) (Gordon et al., 2010). The 
association between depleted Th17 cells and microbial translocation has not yet been clearly defined. 
Cecchinato et al found no correlation between LPS levels and GALT Th17 cell count in SIV infected macaques 
(Cecchinato et al., 2008). A more recent study has demonstrated an inverse correlation between plasma LPS 
levels and gut Th17 cell frequencies, but not peripheral Th17 cell frequencies (Chege et al., 2011). Gut Th22 
frequencies were not shown to correlate with markers of microbial translocation (LPS and sCD14) (Kim et al., 
2012).  The presence of correlations between immune activation and Th22 cells in HIV-1 infection and 
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microbial translocation and immune activation with Th17 and Th22 cells in the context of HCV 
monoinfection and HIV-1/HCV coinfection has to our knowledge not yet been investigated. 
Recent studies have suggested that Th cells can switch subset type with committed CD4 T cell subsets 
acquiring the expression of alternative cytokines if stimulated under appropriate conditions. This has been 
demonstrated by Foxp3+ iTregs that become Th17 cells (Koenen et al., 2008, Deknuydt et al., 2009). IDO 
activity results in TRP catabolites which are able to induce the expression of FoxP3 and the generation of 
iTregs, while suppressing the expression of ROR-c and the generation of Th17 cells (Sharma et al., 2009). A 
significant number of iTregs in peripheral blood and lymphoid tissue, which express CCR6, can develop into 
Th17 cells with the capacity to produce IL-17 on mucosal sites during inflammation (Voo et al., 2009). In 
pathogenic SIV infection a shift from Th17 to Treg cells in blood, lymphoid organs and mucosal tissue was 
found to be predictive of systemic and sustained T cell activation (Favre et al., 2009). Similar findings were 
demonstrated in a study of HIV-1 infected individuals where gut Th17:Treg cell ratios were inversely 
correlated with markers of  microbial translocation (16S ribosomal DNA) and IDO activity, while peripheral 
Th17:Treg cell ratios were inversely correlated with markers of  immune activation and IDO activity (Favre et 
al., 2010). A more recent study has not demonstrated a correlation between gut Th17:Treg cell ratios and 
markers of microbial translocation (Chege et al., 2011). In addition IL-21 induces the development of Th17 
cells via up regulation of IL-23R (Zhou et al., 2007) and blocks the differentiation of regulatory T cells 
(Monteleone et al., 2008).  
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5.2 Aims 
Within the six study groups: 
 Assess the presence of correlations  between: 
 Markers of immune activation and microbial translocation 
 Markers of immune activation and CD4 T cell subsets 
 Markers of immune activation and CD4 T cell cytokines 
 Markers of immune activation and CD4 T cell subset shifts 
 Markers of microbial translocation and CD4 T cell subsets 
 Markers of microbial translocation and CD4 T cell cytokines 
 Markers of microbial translocation and CD4 T cell subset shifts 
 Assess the presence of correlations between IDO activity and: 
 Markers of immune activation 
 Markers of microbial translocation 
 CD4 T cell subset shifts towards the Treg phenotype 
 Assess the presence of correlations between IL21 and: 
 CD4 T cell subset shifts towards theTreg phenotype 
  
144 | P a g e  
 
5.3 Immune activation and microbial translocation 
In order to identify any correlations between immune activation and microbial translocation; HLA-DR+CD38hi 
CD8 T cells, CD38 ABC of CD8 T cells and neopterin were used as markers of immune activation while LPS and 
LBP were used as direct markers of microbial translocation and sCD14 was used as an indirect marker 
demonstrating chronic LPS stimulation. 
Table 22 Correlations between markers of immune activation and microbial translocation 
   HCV HIV HIV NAIVE HCV HIV NAIVE   r p 
sCD14 % HLA-DR+ CD38hi CD8  T cells ++ - - - 0.5284 0.0138 
 CD38 ABC of CD8 T cells - - ++
1
 +
2
 
1
0.5260 
1
0.0172 
 Neopterin (nmol/L) ++
3
 - - +
4
 
3
0.6225 
3
0.0026 
        
LBP % HLA-DR+ CD38hi CD8  T cells - - - + 0.5289 0.1231 
 CD38 ABC of CD8 T cells - - +
5
 ++
6
 
6
0.6606 
6
0.0438 
 Neopterin (nmol/L) - - - + 0.5030 0.1440 
        
LPS % HLA-DR+ CD38hi CD8  T cells - - - -   
 CD38 ABC of CD8 T cells - - - -   
 Neopterin (nmol/L) - - - -   
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART  
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.0167) 
 
2 
r 0.4424, P = 0.2004 
4 
r 0.5636, P = 0.0963 
5 
r 0.5130, P = 0.0207 
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5.3.1 Immune activation and soluble CD14 
Figure 48 Correlation of frequency of HLA-DR+CD38hi CD8 T cells and soluble CD14 concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, all HCV groups: includes HCV group, HCV HIV ART group and HCV HIV NAIVE group. 
 
HCV infection, rather than HIV infection, drove a correlation between sCD14 and HLA-DR+CD38hi CD8 T cells. 
Evaluating the HCV group alone gave a Spearman r value of 0.5284 (P = 0.0138), while only HIV (HIV ART and 
HIV NAIVE) groups and the HIV NAIVE group did not demonstrate a significant correlation  with Spearman r 
values of -0.0715 (P = 0.6785) and 0.0365 (P = 0.8786) respectively. Observing all HCV (HCV, HCV HIV ART 
and HCV HIV NAIVE) groups conferred a strongly significant correlation with a Spearman r value of 0.4621 (P 
= 0.0008).  
All HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups had a Spearman r value of 0.3475 (P = 0.0700), while 
the HCV HIV NAIVE group had a Spearman r value of 0.3343 (P = 0.3450) suggesting that in HIV-1/HCV 
coinfection the correlation was no longer present. 
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Figure 49 Correlation of CD38 ABC of CD8+ T cells and soluble CD14 concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE group, HIV NAIVE group: includes HIV NAIVE 
group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
When analysing correlations between sCD14 and CD38 ABC of CD8 T cells, no correlation was found in the 
HCV group (Spearman r 0.2859, P = 0.2090) or the only HIV (HIV ART and HIV NAIVE) groups (Spearman r 
0.1434, P = 0.4041). However a correlation between sCD14 and CD38 ABC of CD8 T cells did appear to exist 
in untreated HIV-1 infection; the HIV NAIVE group revealed a Spearman r of 0.5260 (P = 0.0172). The 
strongest correlation was observed when all HIV NAIVE (HIV NAIVE and HCV HIV NAIVE) groups were 
evaluated together (Spearman r 0.5143, P = 0.0036).  
The HCV HIV NAIVE group displayed a correlation with a Spearman r of 0.4424 (P = 0.2004). Although 
nonsignificant, likely due to small patient numbers meaning it is underpowered, the strong r value does 
suggest the correlation holds in coinfection but is not enhanced.  
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Figure 50 Correlation of neopterin concentration and soluble CD14 concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Neopterin is the immune activation marker that appeared to demonstrate the strongest correlation with 
sCD14. The HCV group had the strongest correlation with a Spearman r value of 0.6225 (P = 0.0026). HIV-1 
monoinfection did not show a correltion with only HIV (HIV ART and HIV NAIVE) groups displaying a 
Spearman r value of 0.2935 (P = 0.0824) and the HIV NAIVE group demonstrating a Spearman r value of 
0.4056 (P = 0.0760).  
The HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups revealed a Spearman r value of 0.3333 (P = 0.0831) 
while the HCV HIV NAIVE group presented a more robust Spearman r value of 0.5636 (P = 0.0963). Although 
nonsignificant, likely due to small patient numbers meaning it is underpowered, the strong r value does 
suggest the correlation holds in coinfection but is not enhanced. 
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5.3.2 Immune activation and lipopolysaccharide binding protein 
Figure 51 Correlation of frequency of HLA-DR+CD38hi CD8 T cells and lipopolysaccharide binding protein 
concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, HIV NAIVE group: includes HIV NAIVE group, all HIV NAIVE groups: includes HIV ART group and HIV 
NAIVE group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No significant correlations were demonstrated between LBP concentration and frequency of HLA-DR+CD38hi 
CD8 T cells when analysing the HCV group (Spearman r 0.1147, P = 0.6206), the only HIV (HIV ART and HIV 
NAIVE) groups (Spearman r 0.0243, P = 0.880) and the HIV NAIVE group (Spearman r 0.3138, P = 0.1779).  
Only the HCV HIV NAIVE group conferred a robust Spearman r value of 0.5289 (P = 0.1231). Although 
nonsignificant, likely due to small patient numbers meaning it is underpowered, the strong r value does 
suggest some synergism in the context of HCV coinfection of untreated HIV-1.    
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Figure 52 Correlation of CD38 ABC of CD8 T cells and lipopolysaccharide binding protein concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, HIV NAIVE group: includes HIV NAIVE group, all HIV NAIVE groups: includes HIV ART group and HIV 
NAIVE group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
On analysing for an association between LBP concentration and CD38 ABC of CD8 T cells, any correlation 
appeared to be driven by untreated HIV infection. The HCV group (Spearman r 0.2319, P = 0.3118) and only 
HIV (HIV ART and HIV NAIVE) groups (Spearman r 0.2651, P = 0.1182) did not demonstrate correlations, 
while the HIV NAIVE group revealed a Spearman r value of 0.5130 with a P value of 0.0207. Together the HIV 
NAIVE (HIV NAIVE and HCV HIV NAIVE) groups displayed a strong positive correlation with a Spearman r 
value of 0.5275 (P = 0.0027).  
Coinfection with HCV did appear to enhance this correlation with the HCV HIV NAIVE group demonstrating a 
strong Spearman r value of 0.6606 (P = 0.0438). Although nonsignificant, likely due to small patient numbers, 
the strong r value does suggest some synergism in the context of HCV coinfection of untreated HIV-1. 
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Figure 53 Correlation of neopterin concentration and lipopolysaccharide binding protein concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, HIV NAIVE group: includes HIV NAIVE group, all HIV NAIVE groups: includes HIV ART group and HIV 
NAIVE group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between LBP concentration and neopterin concentration were relatively weak. The HCV group 
demonstrated no correlation (Spearman r 0.0625, P = 0.7880). The only HIV (HIV ART and HIV NAIVE) groups 
and the HIV NAIVE group did not display correlations giving Spearman r values of 0.3350 (P = 0.0458) and 
0.4363 (P = 0.0545) respectively. Evaluation all HIV NAIVE (HIV NAIVE and HCV HIV NAIVE) groups showed a 
significant Spearman r value of 0.4414 with a P value of 0.0146. This correlation was likely driven by the HCV 
HIV NAIVE group. 
The HCV HIV NAIVE group demonstrating a Spearman r value of 0.5030 (P = 0.1440). Although nonsignificant, 
likely due to small patient numbers, the strong r value does suggest some synergism in the context of HCV 
coinfection of untreated HIV-1. 
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5.3.3 Immune activation and lipopolysaccharide 
No correlations were demonstrated between HLA-DR+CD38hi CD8 T cells, CD38 ABC of CD8 T cells, neopterin 
concentrations and LPS concentrations in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection 
(Appendix 1). 
5.4 Immune activation and CD4 T cell subsets 
In order to identify any correlations between immune activation and T cell subsets; HLA-DR+CD38hi CD8 T 
cells, CD38 ABC of CD8 T cells and neopterin were used as markers of immune activation. 
Table 23 Correlations between markers of immune activation and CD4 T cell subsets 
   HCV HIV HIV NAIVE HCV HIV NAIVE   r p 
Th1 % HLA-DR+ CD38hi CD8  T cells - - - + -0.4098 0.2396 
 CD38 ABC of CD8 T cells - - - + -0.4634 0.1786 
 Neopterin (nmol/L) - - - ++ -0.5793 0.0793 
        
Th1Th17 % HLA-DR+ CD38hi CD8  T cells - - - -   
 CD38 ABC of CD8 T cells - - - -   
 Neopterin (nmol/L) - - - -   
        
Treg % HLA-DR+ CD38hi CD8  T cells - - - -   
 CD38 ABC of CD8 T cells - - - -   
 Neopterin (nmol/L) - - - -   
        
Th17 % HLA-DR+ CD38hi CD8  T cells - + - - -0.4177 0.0156 
 CD38 ABC of CD8 T cells - ++
1
 +++
2
 - 
2
-0.8070 
2
<0.0001 
 Neopterin (nmol/L) - ++
3
 ++
4
 - 
3
-0.6506 
3
<0.0001 
        
Th22 % HLA-DR+ CD38hi CD8  T cells - - - + -0.5000 0.1411 
 CD38 ABC of CD8 T cells - ++
5
 ++
6
 - 
6
-0.6561 
6
0.0023 
 Neopterin (nmol/L) +
7
 ++
8
 ++
9
 - 
8
-0.6662 
8
<0.0001 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.01) 
 
1 
r -0.6707, P < 0.0001 
4 
r -0.5737, P = 0.0102 
5 
r -0.6197, P = 0.0002 
7
 r -0.4776, P = 0.0332 
9 
r -0.5316, P = 0.0192 
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5.4.1 Immune activation and Th1 cells  
Figure 54 Correlation of frequency of HLA-DR+CD38hiCD8 T cells and frequency of Th1 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, all HCV groups: includes HCV group, HCV 
HIV ART group and HCV HIV NAIVE group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were observed between Th1 cell frequency and HLA-DR+CD38hi CD8 T cell frequency in 
either HIV-1 or untreated HIV-1 infection. Evaluating only HIV (HIV ART and HIV NAIVE) groups and the HIV 
NAIVE group gave Spearman r values of -0.0989 (P = 0.5720) and -0.1667 (P = 0.4951) respectively. Although 
not significant there was a suggestion of a negative correlation in HCV infection. Studying the HCV group 
gave a Spearman r value of -0.3385 (P = 0.1333), while all HCV (HCV, HCV HIV ART, HCV HIV NAIVE) groups 
displayed a Spearman r value of -0.4332 (P = 0.0019).  
Coinfection with untreated HIV-1 enhanced this association. All HCV HIV (HCV HIV ART and HCV HIV NAIVE) 
groups displayed a non significant Spearman r value of -0.3169 (P = 0.1004) while the HCV HIV NAIVE group 
demonstrating a stronger Spearman r value of -0.4098 (P = 0.2396). Although nonsignificant, likely due to 
small patient numbers, the strong r value does suggest some synergism in the context of HCV coinfection of 
untreated HIV-1. 
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Figure 55 Correlation of CD38 ABC of CD8 T cells and frequency of Th1 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between Th1 cell frequency and CD38 ABC of CD8 T cells when 
evaluating the HCV group, only HIV (HIV ART and HIV NAIVE) groups or the HIV NIAVE group. All HCV (HCV, 
HCV HIV ART and HCV HIV NAIVE) groups did not display a true correlation (Spearman r -0.2663, P = 0.0644). 
Thus neither HIV-1 infection nor HCV infection led to a correlation between Th1 cell frequency and CD38 ABC 
of CD8 T cells.  
While all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups did not display a correlation (Spearman r -
0.2300, P = 0.2389), there was a suggestion that with larger numbers coinfection, in the context of untreated 
HIV-1, may lead to a correlation with the HCV HIV NAIVE group displaying a nonsignificant Spearman r value 
of -0.4634 (P = 0.1789). This suggests that ART naive HIV-1/HCV coinfection may play a synergistic role in 
enhancing this correlation. 
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Figure 56 Correlation of neopterin and frequency of Th1 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, all HCV groups: includes HCV group, HCV 
HIV ART group and HCV HIV NAIVE group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
There was no true correlation between Th1 cell frequency and neopterin when evaluating HIV-1 infection 
with only HIV (HIV ART and HIV NAIVE) groups displaying a Spearman r value of -0.1542 (P = 0.3764) and the 
HIV NAIVE group displaying a Spearman r value of 0.1667 (P = 0.4935). Although not significant there was a 
suggestion of a negative correlation in HCV infection. Analysing the HCV group gave a Spearman r value of -
0.4236 (P = 0.0557), while all HCV (HCV, HCV HIV ART, HCV HIV NAIVE) groups displayed a correlation with a 
Spearman r value of -0.3560 (P= 0.0121).  
Coinfection with untreated HIV-1 did appear to play some role. All HCV HIV (HCV HIV ART and HCV HIV 
NAIVE) groups did not dispay a correlation (Spearman r -0.2073, P = 0.2897), however the HCV HIV NAIVE 
group demonstrated a strong, although nonsignificant, Spearman r value of -0.5793 (P = 0.0793). Although 
nonsignificant, likely due to small patient numbers, the strong r value does suggest some synergism in the 
context of HCV coinfection. On the other hand the HCV HIV ART group displayed a Spearman r value of 
0.1828 (P = 0.4679). 
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5.4.2 Immune activation and Th1Th17 cells 
No correlations were observed between Th1Th17 cell frequencies and HLA-DR+CD38hi CD8 T cell 
frequencies, CD38 ABC of CD8 T cells or neopterin concentrations in HCV monoinfection, HIV-1 
monoinfection or HIV-1/HCV coinfection (Appendix 1). 
5.4.3 Immune activation and Treg cells 
No correlations where demonstrated between Treg cell frequencies and HLA-DR+CD38hi CD8 T cells, CD38 
ABC of CD8 T cells neopterin concentrations in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV 
coinfection (Appendix 1). 
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5.4.4 Immune activation and Th17 cells 
Figure 57 Correlation of frequency of HLA-DR+CD38hi CD8 T cells and frequency of Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, all HCV groups: includes HCV group, HCV HIV ART group and HCV HIV NAIVE group. 
 
Only a very weak correlation was demonstrated between Th17 cell and HLA-DR+CD38hi CD8 T cell 
frequencies in HIV-1 monoinfection with a Spearman r value of -0.4177 (P = 0.0156). This correlation was not 
affected by ART with both HIV ART and HIV NAIVE groups displaying similar Spearman r values. No 
correlation was shown in HCV monoinfection. 
The correlation was not held in HIV-1/HCV coinfection with the HCV HIV NAIVE and HCV HIV ART groups 
displaying a Spearman r values of -0.3465 (P = 0.3267) and 0.1579 (P = 0.5315) respectively. It is possible the 
correlation is lost due to the less advanced HIV disease stage of the individuals in the HCV HIV NAIVE group 
compared to the HIV NAIVE group.   
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Figure 58 Correlation of CD38 ABC of CD8 T cells and frequency of Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE group, HIV NAIVE group: includes HIV NAIVE 
group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
Strong inverse correlations were demonstrated between Th17 cell frequencies and CD38 ABC of CD8 T cells. 
The driving factor appeared to be untreated HIV-1 infection. The HCV group demonstrated no correlation 
with a Spearman r value of 0.0797 (P = 0.7384). Meanwhile studying only HIV (HIV ART and HIV NAIVE) 
groups conferred a robust Spearman r value of -0.6707 with a P value of < 0.0001. It was the HIV NAIVE 
group alone that demonstrated the strongest inverse correlation with a Spearman r value of -0.8070 and a P 
value of < 0.0001. While all HIV NAIVE (HIV NAIVE and HCV HIV NAIVE) groups display a Spearman r value of -
0.6540 with a P value of 0.0001.  
Co-infection did not appear to result in a correlation with all HCV HIV (HCV HIV ART and HCV HIV NAIVE) 
groups displaying a Spearman r value of -0.2061 (P = 0.2927) and the HCV HIV NAIVE group giving a 
Spearman r value of -0.3455 (P = 0.3282). It is possible the correlation is lost due to the less advanced HIV 
disease stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.   
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Figure 59 Correlation of neopterin and frequency of Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Although strong inverse correlations were demonstrated between Th17 cell frequencies and other markers 
of immune activation the strongest association was demonstrated with neopterin. The predominant driving 
factor appeared to be untreated HIV-1 infection. Studying only HIV (HIV ART and HIV NAIVE) groups 
conferred a compelling Spearman r value of -0.6506 with a P value of < 0.0001, with the HIV NAIVE group 
displaying a similar Spearman r of -0.5737 (P = 0.0102). The HIV ART group did not show a similar correlation 
with a Spearman r of -0.3036 (P = 0.2913). Meanwhile the HCV group did not demonstrated a correlation 
with a Spearman r value of -0.4339 (P = 0.0093).  
Coinfection did not appear to enhance or hold this correlation with all HCV HIV (HCV HIV ART and HCV HIV 
NAIVE) groups giving a Spearman r value of -0.1267 (P = 0.5206) and the HCV HIV NAIVE group displaying a 
Spearman r value of 0.1515 (P = 0.6821). It is possible the correlation is lost due to the less advanced HIV 
disease stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.   
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5.4.5 Immune activation and Th22 cells 
Figure 60 Correlation of frequency of HLA-DR+CD38hi CD8 T cells and frequency of Th22 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HJIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
HCV monoinfection, HIV-1 monoinfection and untreated HIV-1 monoinfection did not display correlations 
between Th22 cell and HLA-DR+CD38hi CD8 T cell frequencies with the HCV group conferring a Spearman r 
value of -0.2730 (P = 0.2441), the only HIV (HIV ART and HIV NAIVE) groups a Spearman r value of -0.4310 (P 
= 0.0138) and the HIV NAIVE group a Spearman r value of -0.2878 (P = 0.2321).  
All HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups did not display a correlation with a Spearman r value 
of -0.2325 (P = 0.2339). However coinfection of untreated HIV-1 with HCV did display a correlation with a 
robust, though nonsignificant, Spearman r value of -0.5000 (P = 0.1441). Although nonsignificant, likely due 
to small patient numbers, the strong r value does suggest some synergism in the context of HCV coinfection 
of untreated HIV-1. 
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Figure 61 Correlation of CD38 ABC of CD8 T cells and frequency of Th22 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE group, HIV NAIVE group: includes HIV NAIVE 
group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
Strong inverse correlations were demonstrated between Th22 cell frequencies and CD38 ABC of CD8 T cells. 
The driving factor appeared to be untreated HIV-1 infection rather than HCV infection. Studying only HIV 
(HIV ART and HIV NAIVE) groups conferred a robust Spearman r value of -0.6197 (P = 0.0002) and the HIV 
NAIVE group showed a Spearman r of -0.6561 (P = 0.0023). The HIV ART group displayed a Spearman r value 
of 0.2198 (P = 0.4706). Meanwhile the HCV group demonstrated no correlation with a Spearman r value of -
0.0271 with a P value of 0.9098.  
HCV coinfection did not appear to hold this correlation with all HCV HIV (HCV HIV ART and HCV HIV NAIVE) 
groups displaying a Spearman r value of 0.0060 (P = 0.9757) and the HCV HIV NAIVE group displaying a 
Spearman r value of -0.3891 (P = 0.2665). It is possible the correlation is lost due to the less advanced HIV 
disease stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.   
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Figure 62 Correlation of neopterin and frequency of Th22 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HJIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
As with Th17 cells the strongest inverse correlation between Th22 cell frequencies and immune activation 
markers was seen with neopterin. The predominant driving factor appeared to be untreated HIV-1 infection, 
with HCV infection being less dominant. Studying only HIV (HIV ART and HIV NAIVE) groups conferred a 
robust Spearman r value of -0.6662 with a P value of <0.0001. While the HIV NAIVE group displayed a 
Spearman r of -0.5316 (P = 0.0192), the HIV ART group did not demonstrate a correlation (Spearman r -
0.3494, P = 0.2420). Meanwhile the HCV group demonstrated a weaker inverse correlation with a Spearman 
r value of -0.4776 with a P value of 0.0332.  
HCV coinfection did not enhance this correlation with all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups 
displaying a Spearman r value of 0.0060 (P = 0.9757) and the HCV HIV NAIVE group displaying a Spearman r 
value of 0.1459 (P = 0.6821). It is possible the correlation may is lost due to the less advanced HIV disease 
stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.   
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5.5 Immune activation and CD4 T cell cytokines 
In order to identify any correlations between immune activation and CD4 T cell cytokines; HLA-DR+CD38hi 
CD8 T cells, CD38 ABC of CD8 T cells and neopterin were used as markers of immune activation. 
Table 24 Correlations between markers of immune activation and CD4 T cell cytokines 
   HCV HIV HIV NAIVE HCV HIV  NAIVE  r p 
IFN-γ % HLA-DR+ CD38hi CD8  T cells - - - -   
 CD38 ABC of CD8 T cells - - - -   
 Neopterin (nmol/L) - - - -   
        
IL-2 % HLA-DR+ CD38hi CD8  T cells - - - ++ -0.5410 0.1063 
 CD38 ABC of CD8 T cells - + - - -0.4213 0.0117 
 Neopterin (nmol/L) - ++ - - -0.5029 0.0021 
        
IL-17A % HLA-DR+ CD38hi CD8  T cells - - - -   
 CD38 ABC of CD8 T cells ++ - - - -0.5670 0.0074 
 Neopterin (nmol/L) - - - -   
        
IL-21 % HLA-DR+ CD38hi CD8  T cells - - - + -0.4238 0.2223 
 CD38 ABC of CD8 T cells - - - +* -0.4134 0.0288 
 Neopterin (nmol/L) - - - -   
        
IL-22 % HLA-DR+ CD38hi CD8  T cells - - - ++ 0.5593 0.0928 
 CD38 ABC of CD8 T cells - - - + 0.4788 0.1615 
 Neopterin (nmol/L) - - - ++ 0.5152 0.1276 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.01) 
 
* this correlation is for all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups 
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5.5.1 Immune activation and IFN-γ+ CD4 T cells 
No correlations where demonstrated between HLA-DR+CD38hi CD8 T cells, CD38 ABC of CD8 T cells 
neopterin concentrations and IFN-γ+ CD4 T cell frequencies in HCV monoinfection, HIV-1 monoinfection or 
HIV-1/HCV coinfection (Appendix 1). 
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5.5.2 Immune activation and IL-2+ CD4 T cells 
Figure 63 Correlation of frequency of HLA-DR+CD38hiCD8 T cells and frequency of IL-2+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HJIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
HCV monoinfection and HIV monoinfection, irrespective of ART status, did not display correlations between 
HLA-DR+CD38hi CD8 T cells and IL-2+ CD4 T cells.  The HCV group displayed a Spearman r value of 0.3092 (P 
= 0.1726), the only HIV (HIV ART and HIV NAIVE) groups a Spearman r value of -0.3825 (P = 0.0233) and the 
HCV HIV NAIVE group a Spearman r value of -0.2440 (P = 0.3142). 
The only correlation was demonstrated in HIV-1/HCV coinfected individuals naive to ART where a weak 
negative correlation with a Spearman r value of -0.5410 (P = 0.1063) was demonstrated. Although 
nonsignificant, likely due to small patient numbers, the strong r value does suggest a correlation in the 
context of HCV coinfection of untreated HIV-1. 
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Figure 64 Correlation of frequency of CD38 ABC of CD8 T cells and frequency of IL-2+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, all HIV groups: includes HIV ART, HIV NAIVE, HCV HIV ART and HCV HIV NAIVE groups. 
 
HIV-1 infection did demonstrate a negative correlation between IL-2+ CD4 T cell frequencies and CD38 ABC 
of CD8 T cells. Only HIV (HIV ART and HIV NAIVE) groups gave a Spearman r value of -0.4213 (P = 0.0117). 
This correlation appeared to be driven irrespective of ART status with the HIV NAIVE (Spearman r -0.3421, P 
= 0.1517) and HIV ART (Spearman r = 0.3382, P = 0.2001) groups not demonstrating significant correlations 
when reviewed alone. The most significant correlation was seen with in all HIV (HIV ART, HIV NAIVE, HCV HIV 
ART and HCV HIV NAIVE) groups with a Spearman r value of -0.4031 (P = 0.0011). 
 Neither the HCV (Spearman r 0.2753, P = 0.2271) nor the HCV HIV NAIVE group (Spearman r -0.333, P = 
0.3466) demonstrated significant correlations. 
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Figure 65 Correlation of frequency of neopterin and frequency of IL-2+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, all HIV groups: includes HIV ART, HIV NAIVE, HCV HIV ART and HCV HIV NAIVE groups. 
 
HIV-1 infection did demonstrate a negative correlation between IL-2+ CD4 T cell frequency and neopterin 
concentrations that appeared to be present independent of ART status. Only HIV (HIV ART and HIV NAIVE) 
groups gave a Spearman r value of -0.5029 (P = 0.0021), with the HIV NAIVE (Spearman r -0.3193, P = 0.1827) 
and HIV ART (Spearman r 0.0294, P = 0.9138) groups alone not displaying significant correlations. The most 
significant correlation was seen with in all HIV (HIV ART, HIV NAIVE, HCV HIV ART and HCV HIV NAIVE) groups 
with a Spearman r value of -0.4249 (P = 0.0005). 
Neither HCV nor HIV-1/HCV coinfection demonstrated significant correlations. 
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5.5.3 Immune activation and IL-17A+ CD4 T cells 
No correlations where demonstrated between HLA-DR+CD38hi CD8 T cells or neopterin concentrations and 
IL-17A+ CD4 T cell frequencies in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection 
(Appendix 1). 
Figure 66 Correlation of frequency of CD38 ABC of CD8 T cells and frequency of IL-17A+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, all HCV HIV groups: includes HCV HIV ART and HCV HIV NAIVE groups. 
 
HCV monoinfection appeared to display correlations between IL-17A+ CD4 T cell frequencies and CD38 ABC 
of CD8 T cells with a Spearman r value of -0.5670 (P = 0.0074). HIV-1 monoinfection did not demonstrate a 
correlation with the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group displaying Spearman r 
values of -0.1398 (P = 0.4233)and -0.4063 (P = 0.0843).  
HIV-1/HCV coinfection did not hold this correlation with all HCV HIV ( HCV HIV ART and HCV HIV NAIVE) 
groups displaying a Speaman r value of -0.0228 (P = 0.9083), while the HCV HIV NAIVE group displayed a 
Spearman r value of -0.0065 (0.9859). 
 
a) Correlation of immune activation and CD4+IL-17A+ cells
(HCV group)
0 1000 2000 3000 4000 5000
0.0
0.2
0.4
0.6
0.8
1.0
CD38 ABC of CD8+ T cells
%
 C
D
4
+I
L-
1
7
A
+ 
ce
lls
b) Correlation of immune activation and CD4+IL-17A+ cells
(only HIV groups)
0 1000 2000 3000 4000 5000 6000
0.0
0.2
0.4
0.6
0.8
1.0
CD38 ABC of CD8+ T cells
%
 C
D
4
+I
L-
1
7
A
+ 
ce
lls
c) Correlation of immune activation and CD4+IL-17A+ cells
(HIV NAIVE group)
0 1000 2000 3000 4000 5000 6000
0.0
0.2
0.4
0.6
0.8
1.0
CD38 ABC of CD8+ T cells
%
 C
D
4
+I
L-
1
7
A
+ 
ce
lls
d) Correlation of immune activation and CD4+IL-17A+ cells
(all HCV HIV groups)
0 1000 2000 3000 4000 5000 6000
0.0
0.1
0.2
0.3
0.4
0.5
CD38 ABC of CD8+ T cells
%
 C
D
4
+I
L-
1
7
A
+ 
ce
lls
Spearman r -0.5670
P = 0.0074
Spearman r -0.1398
P = 0.4233
Spearman r -0.4063
P = 0.0843
Spearman r -0.0228
P = 0.9083
168 | P a g e  
 
5.5.4 Immune activation and IL-21+ CD4 T cells 
No correlations where demonstrated between neopterin concentrations and IL-21+ CD4 T cell frequencies in 
HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 67 Correlation of frequency of HLA-DR+CD38hiCD8 T cells and frequency of IL-21+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between frequencies of HLA-DR+CD38hi CD8 T cells and IL-21+ CD4 T cells were not 
demonstrated for either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of 0.2962 (P = 
0.2047), while the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of 
-0.2935 (P = 0.0870) and -0.0211 (P = 0.9318) respectively. 
The only correlation was seen in the HCV HIV NAIVE group with a Spearman r value of -0.4238 (P = 0.2223). 
Although non significant, likely due to small patient numbers, it suggests some synergism between untreated 
HIV-1 infection and HCV coinfection. 
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Figure 68 Correlation of frequency of CD38 ABC of CD8 T cells and frequency of IL-21+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, all HCV HIV NAIVE groups: includes HCV HIV ART and HCV HIV NAIVE groups. 
 
Correlations between frequencies of HLA-DR+CD38hi CD8 T cells and IL-21+ CD4 T cells were not 
demonstrated for either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of 0.3023 (P = 
0.1952), while the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of 
-0.2938 (P = 0.0867) and -0.1000 (P = 0.6836) respectively. 
The only correlation was a weak neagative correlation seen in the HIV-1/HCV coinfection with all HCV HIV 
(HCV HIV ART and HCV HIV NAIVE) groups displaying a Spearman r value of -0.4134 (P = 0.0288). This 
suggests some synergism between untreated HIV-1 infection and HCV coinfection. 
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5.5.5 Immune activation and IL-22+ CD4 T cells 
Figure 69 Correlation of frequency of HLA-DR+CD38hiCD8 T cells and frequency of IL-22+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between frequencies of HLA-DR+CD38hi CD8 T cells and IL-22+ CD4 T cells were not 
demonstrated for either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of 0.0609 (P = 
0.7968), while the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of 
-0.3759 (P = 0.0284) and -0.4192 (P = 0.0833) respectively. 
A positive correlation was seen in the HCV HIV NAIVE group with a Spearman r value of 0.5593 (P = 0.0928), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of -
0.0227 (P = 0.4032). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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Figure 70 Correlation of frequency of CD38 ABC of CD8 T cells and frequency of IL-22+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between CD38 ABC of CD8 T cells and IL-22+ CD4 T cell frequencies were not demonstrated for 
either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of 0.0888 (P = 0.7098), while the 
only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of -0.3877 (P = 
0.0235) and -0.3540 (P = 0.1496) respectively. 
A positive correlation was seen in the HCV HIV NAIVE group with a Spearman r value of 0.4788 (P = 0.1615), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of -
0.1823 (P = 0.3362). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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Figure 71 Correlation of neopterin and frequency of IL-22+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between neopterin concentration and IL-22+ CD4 T cell frequencies were not demonstrated for 
either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of 0.1417 (P = 0.5513), while the 
only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of -0.3441 (P = 
0.0463) and -0.3767 (P = 0.1234) respectively. 
A positive correlation was seen in the HCV HIV NAIVE group with a Spearman r value of 0.5152 (P = 0.1276), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of -
0.0738 (P = 0.7090). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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5.6 Immune activation and CD4 T cell subset shifts  
In order to identify any correlations between immune activation and CD4 T cell subset shifts; HLA-DR+CD38hi 
CD8 T cells, CD38 ABC of CD8 T cells and neopterin were used as markers of immune activation. 
Table 25 Correlations between markers of immune activation and CD4 T cell subset shifts 
   HCV HIV HIV NAIVE HCV HIV NAIVE  r p 
Th1:Treg % HLA-DR+ CD38hi CD8  T cells - - - + -0.4255 0.2182 
 CD38 ABC of CD8 T cells - - - + -0.4545 0.1869 
 Neopterin (nmol/L) - - - + -0.4424 0.2004 
        
Th1Th17:Treg % HLA-DR+ CD38hi CD8  T cells - - - -   
 CD38 ABC of CD8 T cells - - - -   
 Neopterin (nmol/L) - - - -   
        
Th17:Treg % HLA-DR+ CD38hi CD8  T cells - - - + -0.5350 0.1111 
 CD38 ABC of CD8 T cells - ++
1
 +++
2
 +++
3
 
2
-0.7175 
2
0.0005 
 Neopterin (nmol/L) - ++
4
 ++
5
 - 
5
-0.5526 
5
0.0141 
        
Th22:Treg % HLA-DR+ CD38hi CD8  T cells - - - +++ -0.7173 0.0195 
 CD38 ABC of CD8 T cells - +
6
 ++
7
 ++
8
 
7
-0.6561 
7
0.0023 
 Neopterin (nmol/L) - ++
9
 ++
10
 - 
9
-0.5770 
9
0.0004 
        
Th1:Th17 % HLA-DR+ CD38hi CD8  T cells - - - -   
 CD38 ABC of CD8 T cells - - + - 0.5645 0.0147 
 Neopterin (nmol/L) - - +
11
 (positive) ++
12
 (negative) 
12
-0.5515 
12
0.0984 
        
Th1:Th22 % HLA-DR+ CD38hi CD8  T cells - - - -   
 CD38 ABC of CD8 T cells - - + - 0.4675 0.0504 
 Neopterin (nmol/L) - - + (positive) + (negative) -0.4788 0.1615 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.008) 
 
1
 r -0.5077, P = 0.0026 
3 
r -0.6970, P = 0.0251 
4 
r -0.5118, P = 0.0023 
6 
r -0.4823, P = 0.0045 
8 
r -0.6121, P = 0.0600 
10 
r -0.5474, P = 0.0153 
11 
r 0.5170, P = 0.0280 
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5.6.1 Immune activation and Th1:Treg cell ratio 
Figure 72 Correlation of frequency of HLA-DR+CD38hiCD8 T cells and Th1:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between HLA-DR+CD38hi CD8 T cell frequencies and Th1:Treg cell ratios were not 
demonstrated for either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of -0.2377 (P 
= 0.2994), while the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values 
of -0.0429 (P = 0.8009) and -0.1448 (P = 0.5542) respectively. 
The only correlation was seen in the HCV HIV NAIVE group with a Spearman r value of -0.4255 (P = 0.2182), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of –
0.3096 (P = 0.1089). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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Figure 73 Correlation of frequency of CD38 ABC of CD8 T cells and Th1:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between CD38 ABC of CD8 T cells and Th1:Treg cell ratios were not demonstrated for either 
HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of -0.2286 (P = 0.3190), while the only 
HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of -0.1552 (P = 0.3734) 
and –0.1000 (P = 0.6838) respectively. 
The only correlation was seen in the HCV HIV NAIVE group with a Spearman r value of -0.4545 (P = 0.1869), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of –
0.2091 (P = 0.2856). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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Figure 74 Correlation of neopterin and Th1:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between neopterin concentration and Th1:Treg cell ratios were not demonstrated for either 
HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of -0.3285 (P = 0.1460), while the only 
HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of -0.1614 (P = 0.3544) 
and 0.0088 (P = 0.9710) respectively. 
The only correlation was seen in the HCV HIV NAIVE group with a Spearman r value of -0.4424 (P = 0.2004), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of –
0.19541 (P = 0.3189). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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5.6.2 Immune activation and Th1Th17:Treg cell ratio 
No correlations where demonstrated between Th1Th17:Treg cell ratios and HLA-DR+CD38hi CD8 T cells, 
CD38 ABC of CD8 T cells or neopterin concentrations in HCV monoinfection, HIV-1 monoinfection or HIV-
1/HCV coinfection (Appendix 1). 
5.6.3 Immune activation and Th17:Treg cell ratio 
Figure 75 Correlation of frequency of HLA-DR+CD38hiCD8 T cells and Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between HLA-DR+CD38hi CD8 T cell frequencies and Th17:Treg cell ratios were not 
demonstrated for either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of -0.3415 (P 
= 0.1406), while the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values 
of -0.2022 (P = 0.2591) and 0.0281 (P = 0.9091) respectively. 
The only correlation was seen in the HCV HIV NAIVE group with a Spearman r value of -0.5350 (P = 0.1111), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of –
0.3082 (P = 0.1106). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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Figure 76 Correlation of frequency of CD38 ABC of CD8 T cells and Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between CD38 ABC of CD8 T cells and Th17:Treg cell ratios were demonstrated in HIV-1 
monoinfection. This negative correlation appeared to be driven by untreated HIV-1 with only HIV (HIV ART 
and HIV NAIVE) groups displaying a Spearman r value of -0.5077 (P = 0.0026), while the HIV NAIVE group 
displayed a stronger correlation with a Spearman r value of -0.7175 (P = 0.0005). HCV monoinfection did not 
display a correlation. 
Coinfection with HIV-1/HCV was shown to hold but not enhance this correlation with the HCV HIV NAIVE 
group displaying a Spearman r value of -0.6970 (P = 0.0251). 
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Figure 77 Correlation of neopterin and Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between neopterin concentration and Th17:Treg cell ratios were demonstrated in HIV-1 
monoinfection. This negative correlation appeared to be driven by HIV-1 irrespective of ART status. The only 
HIV (HIV ART and HIV NAIVE) groups displayed a Spearman r value of -0.5118 (P = 0.0023), with the HIV ART 
and HIV NAIVE groups displaying similar Spearman r values of -0.5677 (P = 0.0342) and -0.5526 (P = 0.0141). 
HCV monoinfection did not display a significant correlation (Spearman r = -0.4799, P = 0.0323).  
HIV-1/HCV coinfection did not appear to hold the correlation seen in HIV-1 mononinfection with all HCV HIV 
groups displaying a Spearman r value of -0.2970 (P = 0.4047) and the HCV HIV NAIVE group displaying a 
Spearman r value of -0.2970 (P = 0.4047). 
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5.6.4 Immune activation and Th22:Treg cell ratio 
Figure 78 Correlation of frequency of HLA-DR+CD38hiCD8 T cells and Th22:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between HLA-DR+CD38hi CD8 T cell frequencies and Th22:Treg cell ratios were not 
demonstrated for either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of -0.3001 (P 
= 0.1986), while the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values 
of -0.2492 (P = 0.1620) and -0.1790 (P = 0.4634) respectively. 
The only correlation was seen in the HCV HIV NAIVE group with a Spearman r value of -0.7173 (P = 0.0839), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of -
0.2699 (P = 0.1649). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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Figure 79 Correlation of frequency of CD38 ABC of CD8 T cells and Th22:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between CD38 ABC of CD8 T cells and Th22:Treg cell ratios were demonstrated in HIV-1 
monoinfection. This negative correlation appeared to be driven by untreated HIV-1 with only HIV (HIV ART 
and HIV NAIVE) groups displaying a Spearman r value of -0.4823 (P = 0.0045), while the HIV NAIVE group 
displayed a stronger correlation with a Spearman r value of -0.6561 (P = 0.0023). HCV monoinfection did not 
display a correlation. 
Coinfection with HIV-1/HCV was shown to hold but not enhance this correlation with the HCV HIV NAIVE 
group displaying a Spearman r value of -0.6121 (P = 0.0600). 
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Figure 80 Correlation of neopterin and Th22:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between neopterin concentration and Th22:Treg cell ratios were demonstrated in HIV-1 
monoinfection. This negative correlation appeared to be driven by HIV-1 irrespective of ART status. The only 
HIV (HIV ART and HIV NAIVE) groups displayed a Spearman r value of -0.5770 (P = 0.0004), with the HIV ART 
and HIV NAIVE groups displaying similar Spearman r values of -0.6293 (P = 0.0159) and -0.5474 (P = 0.0153). 
HCV monoinfection did not display a significant correlation (Spearman r = -0.5281, P = 0.0167).  
HIV-1/HCV coinfection did not appear to hold the correlation seen in HIV-1 mononinfection with all HCV HIV 
groups displaying a Spearman r value of -0.0080 (P = 0.6860) and the HCV HIV NAIVE group displaying a 
Spearman r value of -0.0061 (P = 0.9867). 
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5.6.5 Immune activation and Th1:Th17 cell ratio 
No correlations where demonstrated between Th1:Th17 cell ratios and HLA-DR+CD38hi CD8 T cells in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 81 Correlation of frequency of CD38 ABC of CD8 T cells and Th1:Th17 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between CD38 ABC of CD8 T cells and Th1:Th17 cell ratios were demonstrated in HIV-1 
monoinfection. This positive correlation appeared to be driven by untreated HIV-1 with only HIV (HIV ART 
and HIV NAIVE) groups displaying a Spearman r value of 0.2496 (P = 0.1682), while the HIV NAIVE group 
displayed a strong correlation with a Spearman r value of 0.5645 (P = 0.0147). HCV monoinfection did not 
display a correlation. 
Coinfection with HIV-1/HCV was not shown to hold this correlation with the HCV HIV NAIVE group displaying 
a Spearman r value of -0.2485 (P = 0.4888). 
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Figure 82 Correlation of neopterin and Th1:Th17 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between neopterin concentration and Th1:Th17 cell ratios were demonstrated in HIV-1 
monoinfection. This positive correlation appeared to be driven by untreated HIV-1 with only HIV (HIV ART 
and HIV NAIVE) groups displaying a Spearman r value of 0.2642 (P = 0.1440), while the HIV NAIVE group 
displayed a positive correlation with a Spearman r value of 0.5170 (P = 0.0280). HCV monoinfection did not 
display a correlation. 
Coinfection with HIV-1/HCV was appeared to reverse the correlation with the HCV HIV NAIVE group 
displaying a Spearman r value of -0.5515 (P = 0.0984). This suggests a synergistic effect between HCV and 
untreated HIV-1 in coinfection. 
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5.6.6 Immune activation and Th1:Th22 cell ratio 
No correlations where demonstrated between Th1:Th17 cell ratios and HLA-DR+CD38hi CD8 T cells in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 83 Correlation of frequency of CD38 ABC of CD8 T cells and Th1:Th22 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between CD38 ABC of CD8 T cells and Th1:Th22 cell ratios were demonstrated in HIV-1 
monoinfection. This positive correlation appeared to be driven by untreated HIV-1 with only HIV (HIV ART 
and HIV NAIVE) groups displaying a Spearman r value of 0.2609 (P = 0.1563), while the HIV NAIVE group 
displayed a positive correlation with a Spearman r value of 0.4675 (P = 0.0504). HCV monoinfection did not 
display a correlation. 
Coinfection with HIV-1/HCV was not shown to hold this correlation with the HCV HIV NAIVE group displaying 
a Spearman r value of -0.0546 (P = 0. 8810). 
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Figure 84 Correlation of neopterin and Th1:Th22 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between neopterin concentration and Th1:Th22 cell ratios were demonstrated in HIV-1 
monoinfection. This positive correlation appeared to be driven by untreated HIV-1 with only HIV (HIV ART 
and HIV NAIVE) groups displaying a Spearman r value of 0.3170 (P = 0.0823), while the HIV NAIVE group 
displayed a positive correlation with a Spearman r value of 0.4386 (P = 0.0686). HCV monoinfection did not 
display a correlation. 
Coinfection with HIV-1/HCV was appeared to reverse the correlation with the HCV HIV NAIVE group 
displaying a Spearman r value of -0.4788 (P = 0.1612). This suggests a synergistic effect between HCV and 
untreated HIV-1 in coinfection. 
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5.7 Microbial translocation and CD4 T cell subsets 
In order to identify any correlations between microbial translocation and CD4 T cell subsets; LPS and LBP 
were used as direct markers of microbial translocation and sCD14 as an indirect marker demonstrating 
chronic LPS stimulation. 
Table 26 Correlations between markers of microbial translocation and CD4 T cell subsets 
   HCV HIV HIV NAIVE HCV HIV NAIVE  r p 
Th1 LPS EU/ml - - - -   
 sCD14 ng/ml - - - -   
 LBP µg/ml - - - -   
        
Th1Th17 LPS EU/ml - - - -   
 sCD14 ng/ml - - - -   
 LBP µg/ml - - - -   
        
Treg LPS EU/ml - - - -   
 sCD14 ng/ml - - - -   
 LBP µg/ml - - - +++ 0.7091 0.0217 
        
Th17 LPS EU/ml - - - -   
 sCD14 ng/ml +
1
 +
2
 +++
3
 - 
3
-0.7073 
3
0.0007 
 LBP µg/ml +
4
 (positive) - ++
5
 (negative) - 
5
-0.5029 
5
0.0282 
        
Th22 LPS EU/ml - - - -   
 sCD14 ng/ml ++
6
 +
7
 +
8
 - 
6
-0.6220 
6
0.0034 
 LBP µg/ml +
9
 (positive) +
10
 (negative) +
11
 - 
9
0.4468 
9
0.0483 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.01) 
 
1 
r -0.4784, P = 0.0329 
2 
r -0.4336, P = 0.0117 
4 
r 0.3829, P = 0.0957 
7 
r -0.4443, P = 0.0108 
8 
r -0.4642, P = 0.0452 
10 
r -0.3640, P = 0.0405 
11 
r -0.3800, P = 0.1085 
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5.7.1 Microbial translocation and Th1 cells 
No correlations were observed between Th1 cell subsets and LPS, sCD14 or LBP concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
5.7.2 Microbial translocation and Th1Th17 cells  
No correlations were observed between T cell subsets and LPS, sCD14 or LBP concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
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5.7.3 Microbial translocation and Treg cells 
No correlations were observed between Treg cells and LPS or sCD14 concentrations in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 85 Correlation of lipopolysaccharide binding protein and frequency of Treg cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
Correlations between between concentrations of LBP and frequency of Treg cells were not demonstrated for 
either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of 0.1182 (P = 0.6098), while the 
only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of 0.3573 (P = 
0.0324) and 0.3896 (P = 0.0895) respectively. 
The only correlation was seen in the HCV HIV NAIVE group with a Spearman r value of 0.7091 (P = 0.0217), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of –
0.0682 (P = 0.7303). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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5.7.4 Microbial translocation and Th17 cells 
No correlations were observed between T cell subsets and LPS in HCV monoinfection, HIV-1 monoinfection 
or HIV-1/HCV coinfection (Appendix 1). 
Figure 86 Correlation of soluble CD14 and frequency of Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, HCV HIV NAIVE group: HCV HIV NAIVE group. 
 
Correlations between Th17 cell frequencies and sCD14 concentrations appeared to be driven by untreated 
HIV-1 infection to a lesser extent by HCV infection. The HCV group demonstrated a negative correlation with 
a Spearman r value of -0.4784 (P = 0.0329), but only HIV (HIV ART and HIV NAIVE) groups display a more 
robust Spearman r value of -0.4336 with a P value 0.0117. This correlation was driven by untreated HIV-1 
infection with the strongest inverse correlation shown by the HIV NAIVE group with a Spearman r of -0.7073 
and a P = 0.0007.  
Coinfection with HIV-1/HCV coinfection did not hold this correlation with all HCV HIV (HCV HIV ART and HCV 
HIV NAIVE) groups displaying a Spearman r value of 0.0709 (P = 0.7198) and the HCV HIV NAIVE group 
demonstrating a Spearman r value of -0.0061 (P = 1.000). 
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Figure 87 Correlation of lipopolysaccharide binding protein and frequency of Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, HCV HIV NAIVE group: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
While HCV monoinfection appeared to drive a weak positive correlation between Th17 cell frequencies and 
LBP concentrations, untreated HIV-1 infection drove a negative correlation.  The HCV group demonstrated a 
Spearman r value of 0.3829 (P = 0.0957). While only HIV (HIV ART and HIV NAIVE) groups displayed a 
Spearman r value of -0.3053 (P = 0.0840),  the strongest correlation was observed in the HIV NAIVE group 
with a Spearman r value of -0.5029 and a P value of 0.0282.  
Coinfection did not enhance or hold the correlation. All HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups 
displayed a Spearman r value of -0.2396 (P = 0.2195) and the HCV HIV NAIVE group had a Spearman r value 
of -0.0303 (P = 0.9338). With HCV infection driving a positive correlation and HIV-1 infection a negative 
correlation, coinfection would be unlikely to enhance or hold the correlation. 
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5.7.5 Microbial translocation and Th22 cells 
No correlations were observed between T cell subsets and LPS in HCV monoinfection, HIV-1 monoinfection 
or HIV-1/HCV coinfection (Appendix 1). 
Figure 88 Correlation of soluble CD14 and frequency of Th22 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, HIV ART group: includes HIV ART group. 
 
Th22 cell frequencies correlated inversely with sCD14 concentrations. The correlation appeared to be driven 
by both HIV-1 infection and HCV infection with the only HIV (HIV ART and HIV NAIVE) groups and the HCV 
group having Spearman r values of -0.444 and -0.6220 respectively (P = 0.0108 and 0.0034). Untreated HIV-1 
infection did not appear to affect the correlation, with the HIV NAIVE group displaying a Spearman r value of 
-0.4642 (P = 0.0452) and the HIV ART group displaying a similar Spearman r value of -0.4890 with a P value of 
0.0899.  
HCV coinfection did not hold this correlation with all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups 
displaying a Spearman r value of 0.0824 (P = 0.6766) and the HCV HIV NAIVE group a Spearman r value of 
0.0121 (P = 0.9730). 
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Figure 89 Correlation of lipopolysacchardie binding protein and frequency of Th22 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
While HCV monoinfection appeared to drive a weak positive correlation between Th22 cell frequencies and 
LBP concentrations, untreated HIV-1 infection drove a weak negative correlation.  The HCV group displayed a 
Spearman r value of 0.4468 (P = 0.0483) while only HIV (HIV ART and HIV NAIVE) groups demonstrated a 
Spearman r value of -0.3640 (P = 0.0405). Effecitve ART did not appear to have an effect, with the HIV ART 
and HIV NAIVE groups displaying similar Spearman r values of -0.3800 (P = 0.1085) and -0.3800 (P = 0.2341).  
Coinfection did not enhance or hold the correlation. All HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups 
displayed a Spearman r value of 0.2651 (P = 0.1728) and the HCV HIV NAIVE group gave a Spearman r value 
of -0.0973 (P = 0.7892). With HCV infection driving a positive correlation and HIV-1 infection a negative 
correlation, coinfection would be unlikely to enhance or hold the correlation. 
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5.8 Microbial translocation and CD4 T cell cytokines 
No correlations where demonstrated between any CD4 T cell cytokines and LPS, LBP or sCD14 in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
5.9 Microbial translocation and CD4 T cell subset shifts 
In order to identify any correlations between microbial translocation and CD4 T cell subset shifts; LPS and 
LBP were used as direct markers of microbial translocation and sCD14 as an indirect marker demonstrating 
chronic LPS stimulation. 
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Table 27 Correlations between markers of microbial translocation and CD4 T cell subset shifts 
   HCV HIV HIV NAIVE HCV HIV NAIVE  r p 
Th1:Treg LPS EU/ml - - - -   
 sCD14 ng/ml - - - -   
 LBP µg/ml - - - ++ -0.5879 0.0739 
        
Th1Th17:Treg LPS EU/ml - - - -   
 sCD14 ng/ml - - - -   
 LBP µg/ml - - - -   
        
Th17:Treg LPS EU/ml - - - -   
 sCD14 ng/ml - ++
1 
+++
2
 - 
2
-0.8188 
2
<0.0001 
 LBP µg/ml - +
3 
++
4 
++
5 4
-0.6047 
4
0.0061 
        
Th22:Treg LPS EU/ml - - - -   
 sCD14 ng/ml ++
6 
++
7 
+++
8 
- 
8
-0.7416 
8
0.0003 
 LBP µg/ml - ++
9 
++
10 
++
11 10
-0.5502 
10
0.0146 
        
Th1:Th17 LPS EU/ml - - - -   
 sCD14 ng/ml - - - -   
 LBP µg/ml ++ (negative)
12 
- + (positive)
13 
+ (negative)
14 12
-0.6311 
12
0.0028 
        
Th1:Th22 LPS EU/ml - - - -   
 sCD14 ng/ml - - - -   
 LBP µg/ml ++ (negative)
15 
- + (positive)
16 
- 
15
-0.5604 
15
0.0102 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.0083) 
 
1 
r -0.5318, P = 0.0014 
3
 r -0.4284, P = 0.0129 
5 
r -0.5152, P = 0.1276 
6
 r -0.6032, P = 0.0049
 
7 
r -0.5076, P = 0.0026 
9 
r -0.5015, P = 0.0029 
11
 r -0.4909, P = 0.1497 
13 
r 0.4688, P = 0.0497  
14 
r -0.5758, P = 0.0816 
16 
r -0.4399, P = 0.0678 
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5.9.1 Microbial translocation and Th1:Treg cell ratio  
No correlations were observed between Th1:Treg cell ratios and LPS or sCD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 90 Correlation of lipopolysaccharide binding protein and Th1:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between between concentrations of LBP and Th1:Treg cell ratios were not demonstrated for 
either HIV-1 or HCV monoinfection. The HCV group gave a Spearman r value of -0.4683 (P = 0.0323), while 
the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group gave Spearman r values of -0.2893 (P = 
0.0918) and -0.0448 (P = 0.8556) respectively. 
The only correlation was seen in the HCV HIV NAIVE group with a Spearman r value of -0.5879 (P = 0.0739), 
while all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups gave a non significant Spearman r value of -
0.2247 (P = 0.2502). Although non significant, likely due to small patient numbers, it suggests some 
synergism between untreated HIV-1 infection and HCV coinfection. 
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5.9.2 Microbial translocation and Th1Th17:Treg cell ratio  
No correlations were observed between Th1Th17:Treg cell ratios and LPS, sCD14 or LBP concentrations in 
HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
5.9.3 Microbial translocation and Th17:Treg cell ratio  
No correlations were observed between Th17:Treg cell ratios and LPS concentrations in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 91 Correlation of soluble CD14 and Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, HCV HIV NAIVE group: HCV HIV NAIVE group. 
 
Correlations between sCD14 concentrations and Th17:Treg cell ratios were driven by untreated HIV-1 
monoinfection. With the only HIV (HIV ART and HIV NAIVE) groups displaying Spearman r value of -0.5318 (P  
= 0.0014), and the HIV NAIVE group displaying a robust correlation with a Spearman r value of -0.8188 (P < 
0.0001). HCV monoinfection did not display a correlation. 
Coinfection with HIV-1/HCV did not appear to hold this correlation with the HCV HIV NAIVE group 
demonstrating a Spearman r value of -0.1030 (P = 0.7770). 
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Figure 92 Correlation of lipopolysaccharide binding protein and Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE group, HIV NAIVE group: includes HIV NAIVE 
group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
Strong inverse correlations were demonstrated between LBP concentration and Th1:Th17 cell ratios. The 
driving factor appeared to be untreated HIV-1 infection. The HCV group demonstrated no correlation with a 
Spearman r value of 0.3513 (P = 0.1289). Meanwhile studying only HIV (HIV ART and HIV NAIVE) groups 
conferred a robust Spearman r value of -0.4284 (P = 0.0129). It was the HIV NAIVE group alone that 
demonstrated the strongest inverse correlation with a Spearman r value of -0.6047 (P = 0.0061).  
The HCV HIV NAIVE group gave a Spearman r value of -0.5152 (P = 0.1276). Although non significant, likely 
due to small patient numbers, it suggests that coinfection with HCV in untreated HIV-1 holds, but does not 
enhance, the correlation. 
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5.9.4 Microbial translocation and Th22:Treg cell ratio 
No correlations were observed between Th22:Treg cell ratios and LPS concentrations in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 93 Correlation of soluble CD14 and Th22:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, HCV HIV NAIVE group: HCV HIV NAIVE group. 
 
Correlations between sCD14 concentrations and Th22:Treg cell ratios were displayed in HIV-1 
monoinfection. This negative correlation appeared to be driven by untreated HIV-1 infection with the only 
HIV (HIV ART and HIV NAIVE) groups displaying Spearman r value of -0.5076 (P  = 0.0026), and the HIV NAIVE 
group displaying a robust correlation with a Spearman r value of -0.7416 (P = 0.0003). HCV monoinfection 
displayed a weaker correlation with a Spearman r value of -0.6032 (P = 0.0049). 
Coinfection with HIV-1/HCV did not appear to hold this correlation with all HCV HIV (HCV HIV ART and HCV 
HIV NAIVE) groups and the HCV HIV NAIVE group demonstrating Spearman r values of -0.0008 (P = 0.9967) 
and 0.1273 (P = 0.7261). 
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Figure 94 Correlation of lipopolysaccharide binding protein and Th22:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE group, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: HCV HIV NAIVE group. 
 
Strong inverse correlations were demonstrated between LBP concentration and Th1:Th22 cell ratios. The 
driving factor appeared to be untreated HIV-1 infection. The HCV group demonstrated no correlation with a 
Spearman r value of 0.4235 (P = 0.0628). Meanwhile studying only HIV (HIV ART and HIV NAIVE) groups 
conferred a robust Spearman r value of -0.5015 (P = 0.0029). It was the HIV NAIVE group alone that 
demonstrated the strongest inverse correlation with a Spearman r value of -0.5502 (P = 0.0146).  
The HCV HIV NAIVE group gave a Spearman r value of -0.4909 (P = 0.1497). Although non significant, likely 
due to small patient numbers, it suggests that coinfection with HCV in untreated HIV-1 holsd, but does not 
enhance, the correlation. 
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5.9.5 Microbial translocation and Th1:Th17 cell ratio  
No correlations were observed between Th1:Th17 cell ratios and LPS or sCD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 95 Correlation of lipopolysaccharide binding protein and Th1:Th17 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between LBP concentrations and Th1:Th17 cell ratios were demonstrated. HCV monoinfection 
displayed a negative correlation with a Spearman r value of -0.6311 (P = 0.0028), while untreated HIV-1 
monoinfection displayed a positive correlation with the HIV NAIVE groupd displaying a correlation of 0.4688 
(P = 0.0497).  
Coinfection with HIV-1/HCV coinfection resulted in a negative correlation with the HCV HIV NAIVE group 
displaying a Spearman r value of -0.5758 (P = 0.0816). 
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5.9.6 Microbial translocation and Th1:Th22 cell ratio  
No correlations were observed between Th1:Th22 cell ratios and LPS or sCD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Correlation of lipopolysaccharide binding protein and Th1:Th22 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations between LBP concentrations and Th1:Th22 cell ratios were demonstrated for HCV 
monoinfection displayed a negative correlation with a Spearman r value of -0.5604 (P = 0.0102). Untreated 
HIV-1 infection displayed a positive correrlation with the HIV NAIVE group displaying a Spearman r value of 
0.4399 (P = 0.0678). 
This correlation did not appear to hold in coinfection HIV-1 with all HCV HIV (HCV HIV ART and HCV HIV 
NAIVE) groups displaying a Spearman r value of 0.0027 (P = 0.9890) and the HCV HIV NAIVE group displaying 
a Spearman r value of -0.2727 (0.4458). 
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5.10 Indoleamine 2,3-deoxygenase activity  
Table 28 Correlations between IDO activity and immune activation, microbial translocation and CD4 T cell 
subsets shifts 
   HCV HIV HIV NAIVE HCV HIV NAIVE   r p 
IDO % HLA-DR+ CD38hi CD8  T cells +
1 
++
2 
- +++*
3 3
0.7150 
3
<0.0001 
 CD38 ABC of CD8 T cells - +++
4 
+++
5 
+++
6 5
0.7913 
5
<0.0001 
 Neopterin (nmol/L) ++
7 
+++
8 
+++
9 
+++
10 10
0.8667 
10
0.0012 
        
IDO LPS EU/ml - - - -   
 sCD14 ng/ml ++
11 
+
12 
++
13 
++
14 11
0.6064 
11
0.0036 
 LBP µg/ml - - - ++ 0.6242 0.0537 
        
IDO Th1:Treg - - - -   
 Th1Th17:Treg - - - -   
 Th17:Treg - +
15 
+++
16 
++
17 16
-0.6959 
16
0.0009 
 Th22:Treg ++
18 
+
19 
++
20 
- 
20
-0.6792 
20
0.0014 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.0167 for 
immune activation and microbial translocation and P < 0.0125 for CD4 T cell subset shifts) 
 
* this correlation is for all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups 
1 
r 0.5325, P = 0.0130 
2
 r 0.5648, P = 0.0003 
4 
r 0.7500, P < 0.0001 
6 
r 0.7818, P = 0.0075 
7 
r 0.6012, P = 0.0039 
8 
r 0.8814, P < 0.0001 
9 
r 0.8477, P < 0.0001 
12 
r 0.4082, P = 0.0135 
13 
r 0.6022, P = 0.0050 
14 
r 0.5879, P = 0.0739 
15 
r -0.4924, P = 0.0036 
17 
r -0.5515, P = 0.0984 
18 
r -0.5701, P = 0.0087 
19 
r -0.4603, P = 0.0070 
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5.10.1 Indoleamine 2,3-dioxygenase activity and immune activation 
Figure 96 Correlation of frequency of HLA-DR+CD38hi CD8 T cells and IDO activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, all HCV HIV groups: includes HCV HIV ART group and HCV HIV NAIVE group. 
 
When observing HLA-DR+CD38hi CD8 T cell frequencies and IDO activity a strong positive correlation was 
driven by both HCV and HIV-1 infection; the HCV group displayed a correlation with a Spearman r value of 
0.5325 (P = 0.0130), while only HIV (HIV ART and HIV NAIVE) groups displayed a similar correlation with a 
Spearman r value of 0.5648 (P = 0.0003). The correlation driven by HIV-1 infection was not affected by ART 
with no difference in correlations displayed by the HIV ART (Spearman r -0.3076, P = 0.2465) and HIV NAIVE 
(Spearman r 0.1347, P = 0.5713) groups. Coinfection with HCV did appear to enhance this correlation with 
the most robust correlation seen in all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups, with a Spearman r 
value of 0.7150 (P < 0.0001). Again ART did not appear to effect the correlation in the context of coinfection 
with the HCV HIV NAIVE group displaying a Spearman r value of 0.6626 (P = 0.0368). 
  
a) Correlation of immune activation and IDO activity
(HCV group)
0 1 2 3 4
0
20
40
60
80
6 7
130
132
19 20
% CD8+HLA-DR+CD38hi T cells
K
TR
 (

m
o
l/
L)
b) Correlation of immune activation and IDO activity
(only HIV groups)
0 5 10 15 20 25 30
0
40
80
120
160
% CD8+HLA-DR+CD38hi T cells
K
TR
 (

m
o
l/
L)
c) Correlation of immune activation and IDO activity
(HIV NAIVE group)
0 5 10 15 20 25 30
0
40
80
120
160
% CD8+HLA-DR+CD38hi T cells
K
TR
 (

m
o
l/
L)
d) Correlation of immune activation and IDO activity
(all HCV HIV groups)
0 5 10 15 20 25 30
0
40
80
120
160
% CD8+HLA-DR+CD38hi T cells
K
TR
 (

m
o
l/
L)
Spearman r 0.5325
P =  0.0130
Spearman r 0.5648
P =  0.0003
Spearman r 0.1347
P =  0.5713
Spearman r 0.7150
P < 0.0001
205 | P a g e  
 
Figure 97 Correlation of CD38 ABC of CD8+ T cells and IDO activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, HCV HIV NAIVE grous: includes HCV HIV NAIVE group. 
 
When observing CD38 ABC of CD8 T cells and IDO activity a strong positive correlation was driven by 
untreated HIV-1 infection. The HCV group did not display a correlation with a Spearman r value of 0.3118 (P 
= 0.1689), while only HIV (HIV ART and HIV NAIVE) groups displayed a strong positive correlation with a 
Spearman r value of 0.7500 (P < 0.0001). The HIV ART group did not demonstrate a correlation, while the HIV 
NAIVE group demonstrated a Spearman r value of 0.7913 (P < 0.0001).  
Coinfection in the context of untreated HIV-1 did hold but did not enhance the correlation, with the HCV HIV 
NAIVE group displaying a Spearman r value of 0.7818 with a P value of 0.0075.  
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Figure 98 Correlation of neopterin concentration and IDO activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
The strongest correlation between IDO activity and immune activation were seen when observing neopterin 
concentrations. This correlation was driven by HCV infection and more dominantly by untreated HIV-1 
infection. The HCV group displayed a correlation with a Spearman r value of 0.6012 (P = 0.0039). Only HIV 
(HIV ART and HIV NAIVE) groups displayed a correlation with a Spearman r value of 0.8814 (P < 0.0001), 
while the HIV NAIVE group (Spearman r 0.8477, P < 0.0001) had a more robust correlation than the HIV ART 
group (Spearman r 0.5022, P < 0.0474).  
Coinfection in the context of untreated HIV-1 held, but did not enhance, the correlation with the HCV HIV 
NAIVE group displaying a Spearman r value of 0.8667 with a P value of 0.0012.  
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5.10.2 Indoleamine 2,3-dioxygenase activity and microbial translocation 
No correlations were observed between T cell subsets and LPS in HCV monoinfection, HIV-1 monoinfection 
or HIV-1/HCV coinfection (Appendix 1). 
Figure 99 Correlation of soluble CD14 and IDO activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
Robust positive correlations were demonstrated between sCD14 concentrations and IDO activity. This 
correlation appeared to be driven by both HCV and untreated HIV-1 infection. The HCV group displayed a 
Spearman r value of 0.6064 (P = 0.0036). The only HIV (HIV ART and HIV NAIVE) groups displayed a Spearman 
r value of 0.4082 (P = 0.0135), which strengthened when observing the HIV NAIVE group to give a Spearman 
r value of 0.6022 (P = 0.0050).  
The HCV HIV NAIVE group demonstrated a Spearman r value of 0.5879 (P = 0.0739). Although non significant, 
likely due to small patient numbers, it suggests that the correlation is held in untreated HIV-1 and HCV 
coinfection. 
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Figure 100 Correlation of lipopolysaccharide binding protein and IDO activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, all HIV NAIVE groups: includes HIV 
NAIVE group and HCV HIV NAIVE group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Correlations were not demonstrated between LBP concentrations and IDO activity in the HCV group 
(Spearman r -0.3298, P = 0.1443). HIV-1 monoinfection did not drive any correlations. Only HIV (HIV ART and 
HIV NAIVE) groups demonstrated a nonsignificant Spearman r value of 0.1574 (P = 0.3592), while the HIV 
NAIVE group displayed a Spearman r value of 0.4319 (P = 0.0572).  
The only correlation was demonstrated with coinfection of HCV in the context of untreated HIV-1. The HCV 
HIV NAIVE group displayed the most robust correlation with a Spearman r value of 0.6242 (P = 0.0537). 
Although non significant, likely due to small patient numbers, it suggests some synergism between untreated 
HIV-1 infection and HCV coinfection. 
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5.10.3 Indoleamine 2,3-dioxygenase activity CD4 T cell subset shifts 
No correlations where demonstrated between KTR and Th1:Treg cell ratios or Th1Th17:Treg cell ratios in 
HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
Figure 101 Correlation of IDO activity and Th17:Treg cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
There were strong inverse correlations between KTR and Th17:Treg cell ratios. The inverse correlation was 
strongest when observing HIV infection with only HIV (HIV ART and HIV NAIVE) groups revealing a Spearman 
r value of -0.4924 (P = 0.0036), compared to a non significant Spearman r value of -0.3798 (P = 0.0986) 
within the HCV group. Untreated HIV-1 infection appeared to be the main driving factor with no correlation 
demonstrated in the HIV ART group and the HIV NAIVE group displaying a Spearman r of -0.6959 (P = 
0.0009).  
Coinfection with HCV in the context of untreated HIV-1 held, but did not appear to enhance the correlation, 
with the HCV HIV NAIVE group displaying a correlation with a Spearman r value of -0.5515 (P = 0.984). 
Although non significant this is likely due to the small patient numbers meaning it is under powered. 
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Figure 102 Correlation of IDO activity and Th22:Treg cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
There were strong inverse correlations between KTR and Th22:Treg cell ratios. Both HCV and HIV appeared 
to demonstrate strong correlations with a Spearman r of -0.5701 in the HCV group (P = 0.0087) and in the 
HIV NAIVE group a Spearman r of -0.6792 (P = 0.0014).  
Coinfection with HCV in the context of untreated HIV did not appear to hold or enhance the correlation with 
all HCV HIV (HCV HIV ART and HCV HIV NAIVE) groups displaying a Spearman r value of -0.05069 (P = 0.7980) 
and the HCV HIV NAIVE group displaying a correlation with a Spearman r value of -0.1515 (P = 0.6821). This is 
possibly due to the less advanced HIV disease in the individuals in the HCV HIV NAIVE group.  
5.11 IL-21 and CD4 T cell subset shifts  
No correlations where demonstrated between IL-21 and CD4 T cell subset shifts in HCV monoinfection, HIV-1 
monoinfection or HIV-1/HCV coinfection (Appendix 1). 
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5.12 Conclusions 
5.12.1 Key findings 
Untreated HIV-1 infection led to positive correlations between markers of microbial translocation (sCD14 
and LBP) and cellular markers of immune activation (CD38 ABC of CD8 T cells) (see table 29). In HIV-1 
infection phenotypic Th17 and Th22 cells were the only CD4 T cell subsets to correlate (inversely) with 
markers of immune activation and microbial translocation. This relationship was highlighted by shifts away 
from Th17 and Th22 cells towards either Treg or Th1 cells being associated with increased immune activation 
and microbial translocation with shifts towards Treg cells displaying the strongest correlations. IDO, as a 
marker of Treg cell activity, was associated with immune activation, most strongly, and microbial 
translocation (LBP). IDO appeared to drive shifts towards Tregs from Th17 and Th22 cells, but not Th1 or 
Th1Th17 cells. 
In HIV-1/HCV coinfection the correlation between markers of microbial translocation (sCD14 and LBP) and 
immune activation were enhanced compared to HIV-1 with associations demonstrated for both cellular and 
soluble markers of immune activation (HLA-DR+CD38hi CD8 T cells, CD38 ABC of CD8 T cells and neopterin). 
HCV monoinfection only demonstrated correlations between sCD14 and immune activation (HLA-DR+CD38hi 
CD8 T cells and neopterin). Th1 cells were the CD4 T cell subset most strongly associated with immune 
activation, displaying an inverse correlation. This was not seen in either HIV-1 or HCV monoinfection. 
Phenotypic Th22 and functional Th17 cells were inversely correlated with immune activation in HCV 
monoinfection and HIV-1/HCV coinfection. There was also a significant association between Th17:Treg and 
Th22:Treg ratios and immune activation in HIV-1 monoinfection which was enhanced in HIV-1/HCV 
coinfection. In addition the importance of Th1 cells in HIV-1/HCV coinfection was stressed by the finding that 
shifts away from Th1 cells towards Th17, Th22 or Treg cells were associated with increased immune 
activation. The shifts away from Th1 cells were weakly associated with microbial translocation. While HCV 
monoinfection demonstrated weak associations between IDO and immune activation or microbial 
translocation, in coinfection correlations were stronger and mirrored those in HIV-1 monoinfection. IDO 
appeared to drive shifts towards Tregs from: Th22 cells in HCV monoinfection and Th17 cells in HIV-1/HCV 
coinfection. 
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Table 29 Summary of key findings: chapter 5 
Correlation HCV HIV NAIVE HCV HIV NAIVE 
immune activation translocation pos pos pos 
immune activation Th1  × × neg 
Th1Th17 × × × 
Treg × × × 
Th17 neg neg neg 
Th22 neg neg neg 
Th1:Treg × × neg 
Th17:Treg × neg neg 
Th22:Treg × neg neg 
Th1:Th17 × pos neg 
Th1:Th22 × pos neg 
microbial translocation Th1 × × × 
Th1Th17 × × × 
Treg × × pos 
Th17 neg neg × 
Th22 neg neg × 
Th1:Treg × × neg 
Th17:Treg × neg neg 
Th22:Treg neg neg neg 
Th1:Th17 neg pos neg 
Th1:Th22 neg pos × 
IDO activity immune activation pos pos pos 
translocation pos pos pos 
Th1:Treg × × × 
Th1Th17:Treg × × × 
Th17:Treg × neg neg 
Th22:Treg neg neg × 
 
× correlation does not exist 
pos positive correlation exisits 
neg negative correlation exists 
= variable unchanged compared to control group 
 
Novel findings highlighted in green 
Different findings to previous highlighted in orange 
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5.12.2 Discussion 
There are conflicting data with regard to correlations between immune activation and microbial 
translocation in HIV-1 infection (section 5.1), and correlations in HCV monoinfection and HIV-1/HCV 
coinfection have yet to be fully assessed. In this study untreated HIV-1 infection drove positive correlations 
between CD38 ABC of CD8 T cells (a cellular marker of immune activation) and markers of microbial 
translocation (sCD14 and LBP). Correlations in HIV-1/HCV co-infection were more prevalent involving all 
three markers of immune activation (HLA-DR+CD38hi CD8 T cells, CD38 ABC of CD8  T cells, neopterin) and 
markers of microbial translocation (sCD14 and LBP), while HCV monoinfection only displayed correlations 
between sCD14, not LBP, and  HLA-DR+CD38hi CD8 T cells and neopterin concentrations. Thus our data 
suggests that coinfection with HIV-1/HCV enhances positive correlations between markers of microbial 
translocation and immune activation compared to both HIV-1 and HCV monoinfection. LPS concentrations 
were not shown to correlate with any variables. It is possible that this assay was unsuccessful due to sample 
collection, handling methods or methodological errors. However it is also possible correlations do not exist. 
Some researches have demonstrated correlations between LPS and immune activation, but others have not 
(Brenchley et al., 2006b) (Cassol et al., 2010). 
The relationships between Th1 and Th1Th17 cells with immune activation in HIV-1, HCV and HIV-1/HCV 
coinfection have not been fully elucidated. Treg cells have been shown to positively correlate with HLA-
DR+CD38hi CD8 T cell frequencies in elite controllers (Hunt et al., 2011), while other studies have shown 
positive correlations in early HIV-1 infection and negative correlations in chronic HIV-1 infection (Ndhlovu et 
al., 2008b). Published literature has shown peripheral Th17 cells to correlate with CD4+CD38+ cells (r -
0.5530, P < 0.01) (El Hed et al., 2010), and GALT Th17 cells to correlate with CD4+Ki67+ cells (r -0.5292, P = 
0.0065) (Gordon et al., 2010). In this study when looking for correlations between markers of immune 
activation and frequencies of CD4 T cell subsets (Th1, Th1Th17, Treg, Th17 and Th22), Th1Th17 and Treg cells 
were not shown to demonstrate any correlations. Th17 and Th22 cells were the CD4 T cell subsets which 
exhibited the strongest correlations with markers of immune activation (CD38 ABC of CD8 T cells r -0.8070, P 
< 0.0001 and r -0.6197, P = 0.0002; neopterin concentrations r -0.5737, P = 0.0102 and r -0.6662, P < 0.0001). 
This was seen in HIV-1 infection and driven by ART navie individuals. HCV monoinfection and HIV-1/HCV 
coinfection demonstrated only weak negative correlations between Th22 cells and neopterin concentrations 
and HLA-DR+CD38hi CD8 T cells respectively. Correlations between functional Th17 (IL-17A+ and IL-21+ CD4 
T cells) and Th22 (IL-22+ CD4 T cells) cells when present were much weaker than those seen with phenotypic 
Th17 and Th22 cells. As these cytokines are expressed by multiple cell types this is not unexpected. No 
correlations were seen in HIV-1 monoinfection. In HCV monoinfection and HIV-1/HCV coinfection functional 
Th17 cells (IL-17A+ and IL-21+ CD4 T cells respectively) correlated inversely with markers of immune 
activation. In contrast to the negative association between Th22 proportions and immune activation; IL-22 
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secretion by CD4 Th22 cells were shown correlate positively with three markers of immune activation in HIV-
1/HCV coinfection.  
Th1 cells were not shown to correlate with immune activation in either HIV-1 or HCV monoinfection. In HIV-
1/HCV coinfection however these CD4 T cell subsets exhibited the strongest correlations with all three 
markers of immune activation: HLA-DR+CD38hi CD8 T cell frequencies, CD38 ABC of CD8 T cells and neopterin 
concentrations (r -0.4098, P = 0.2396; -0.4634, P = 0.1789; -0.5793, P = 0.0793). Despite strong r values these 
correlations did not reach significance due to limited patient numbers. Functional Th1 studies (IFN-γ+ and IL-
2+ CD4T cells) did not show as strong correlations. IFN-γ+ CD4 T cells were not shown to correlate with 
immune activation. IL-2+ CD4 T cells displayed inverse correlations with HLA-DR+CD38hi CD8 T cells in HIV-
1/HCV coinfection, but not in HCV monoinfection. In keeping with known literature HIV-1 monoinfection, 
irrespective of ART status, was shown to drive a negative correlation between IL-2+ CD4 T cells and immune 
activation (CD38 ABC of CD8 T cells: r -0.4031, P = 0.0011; neopterin concentrations: -0.5029, P = 0.0021).  
Associations between CD4 T cell subset shifts and either microbial translocation or immune activation have 
not been widely investigated. Favre et al have demonstrated inverse correlations between peripheral 
Th17:Treg cell ratios and immune activation (CD38+ CD8 T cells) and gut Th17:Treg cell ratios and microbial 
translocation (16S ribosomal DNA) in HIV-1 monoinfection (Favre et al., 2010). However Chege et al did not 
demonstrate any correlation between LPS and peripheral Th17:Treg cell ratios (Chege et al., 2011). To our 
knowledge this has not yet been investigated in either HCV monoinfection or HIV-1/HCV coinfection. HCV 
monoinfection did not lead to any correlations between CD4 T cell subset shifts and immune activation. The 
strongest correlations were seen in HIV-1 monoinfection with Th17:Treg and Th22:Treg cell ratios: where a 
shift away from Th17 and Th22 cells was associated with increased immune activation. Associations with 
CD38 ABC of CD8 T cells were driven by untreated HIV-1, while those with neopterin were present 
irrespective of ART status. Similar associations were seen in HIV-1/HCV coinfection naive to ART but while 
neopterin did not correlate, HLA-DR+CD38hi CD8 T cells did. Associations between shifts in Th1 cell subsets 
and immune activation stressed the importance of Th1 cells in coinfection. While HIV-1/HCV coinfection 
demonstrated correlations between immune activation and shifts away from Th1 cells towards Treg cells, 
HIV-1 monoinfection did not. In addition while HIV-1 monoinfection displayed positive correlations between 
immune activation and both Th1:Th17 and Th1:Th22 cell ratios, coinfection of HCV with untreated HIV-1 
displayed negative correlations. 
Associations between CD4 T cell subsets and markers of microbial translocation have not yet been clearly 
defined. In HIV-1 infection one study demonstrated no correlation between LPS and gut Th17 cells while 
another demonstrated a weak association between LPS and peripheral Th17 cells (Cecchinato et al., 2008, 
Chege et al., 2011). Kim et al did not demonstrate a correlation with gut Th22 cells and either LPS or sCD14 
(Kim et al., 2012). In this study the only CD4 T cell subsets to consistently display correlations with markers of 
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microbial translocation were Th17 and Th22 cells. Functional cells (IFN-γ+, IL-2+, IL-17A+, IL-21+, IL-22+) did 
not display correlations with microbial translocation. This may be explained by the production of these 
cytokines by other immune cells in response to different stimuli. In HIV-1 infection Th17 and Th22 cells 
demonstrated negative correlations with sCD14 (r -0.7073, P = 0.0007 and r -0.4443, P = 0.0108) and LBP (r -
0.5029, P = 0.0282 and r -0.3640, P=0.0405). These correlations were driven by untreated HIV-1 for Th17 
cells, but were seen irrespective of ART status for Th22 cells. While HCV monoinfection demonstrated similar 
correlations for sCD14, LBP was shown to correlate positively with Th17 and Th22 cells (r 0.3829, P = 0.0957; 
r 0.4468, P = 0.0483). Unsurprisingly in coinfection any correlation was lost. This reversal in correlation may 
be due to the complex role of LBP. In low concentrations it acts to bind and transport LPS to the CD14/TLR4/ 
MD2 receptor complex thus acting as a marker of microbial translocation (Shimazu et al., 1999, da Silva 
Correia et al., 2001), however high concentrations of LBP neutralise LPS (Lamping et al., 1998) (Zweigner et 
al., 2001). IL-22 has been shown to up regulate LBP (Wolk et al., 2007). Thus in HCV monoinfection where 
functioning Th17 and Th22 cells are at normal levels and functioning to secrete IL-22 LBP may be 
upregulated, while in HIV-1 infection where Th17 and Th22 cells are reduced and possibly not secreting 
adequate IL-22 LBP remains a marker of microbial translocation. Similar associations were seen with 
Th1:Th17 and Th1:Th22 cell ratios which in HCV monoinfection were negatively associated with LBP and in 
untreated HIV-1 monoinfection were positively associated with LBP. In the case of HIV-1/HCV coinfection a 
negative correlation was maintained for Th1:Th17 cells, while no correlation was shown for Th1:Th22 cells. 
The strongest correlations between CD4 T cell subset shifts and microbial translocation were seen with 
Th17:Treg and Th22:Treg cell ratios. In untreated HIV-1 infection a shift away from Th17 and Th22 cells was 
associated with increased microbial translocation (sCD14: r -0.8188, P < 0.0001 and -0.7416, P = 0.0003 and 
LBP: r -0.6047, P = 0.0061 and -0.5502, P = 0.0146). The correlation with LBP was held in HIV-1/HCV 
coinfection. 
IDO, which promotes the development of Treg cells while suppressing the generation of Th17 cells (Sharma 
et al., 2009), was measured as a biological marker of Treg cell activity. Induction of IDO has been associated 
with reduced Th17:Treg cell ratios in both the periphery and GALT of HIV-1 infected individuals (Favre et al., 
2010). In addition IL-21 is known to induce the development of Th17 cells via up regulation of IL-23R (Zhou et 
al., 2007) and blocks the differentiation of regulatory T cells (Monteleone et al., 2008). Strong positive 
correlations were demonstrated between IDO activity and HLA-DR+CD38hi CD8 T cell frequencies, CD38 ABC 
of CD8 T cells and neopterin concentrations in both untreated HIV-1 and HIV-1/HCV coinfection. HCV 
monoinfection demonstrated weaker correlations with only HLA-DR+CD38hi CD8 T cells and neopterin 
concentrations.  Weaker positive correlations were demonstrated between IDO and markers of microbial 
translocation in HIV-1, HCV and HIV-1/HCV coinfection, while only HIV-1/HCV coinfection led to a positive 
correlation between Treg cells and LBP concentrations. Correlations between IDO activity and CD4 T cell 
subset shifts were only demonstrated with Th17:Treg and Th22:Treg cell ratios. In HIV-1 and HIV-1/HCV 
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coinfection Th17:Treg cell ratios negatively correlated with IDO activity, confirming that increased IDO 
activity promotes the development of Tregs and inhibits the  development of Th17 cells. Similar findings 
were seen with Th22:Treg cell ratios in HCV and HIV-1 monoinfection suggesting that Th22 development 
may also be inhibited by IDO activity. IL-21+ CD4 T cells did not correlate with any CD4 T cell shifts. 
5.12.3 Study limitations 
The main limitation of this study is its cross-sectional, rather than longitudinal, nature so that causality 
cannot be determined. In addition, due to difficulties in obtaining organ tissue, we have only analysed 
peripheral blood samples and it is unknown if events in the periphery mirror those in either gastrointestinal 
mucosal tissue or the liver.  
As in the previous chapters the fact that individuals recruited to the HCV HIV NAIVE group appeared to have 
less advanced HIV-1 infection than the HIV NAIVE group means that correlations may not have been 
exposed. In addition the difficulty in recruiting to this group meant that statistical analyses may have been 
under powered.  
5.12.4 Conclusions  
The results of this study add to previous literature suggesting that in HIV-1 infection markers of microbial 
translocation are positively correlated with markers of immune activation, supporting the evidence that 
microbial translocation may be one of the drivers of immune activation. In this study, as in previous studies, 
correlations were modest but this is unsurprising as multiple other factors such as; HIV, depletion of Treg 
cells, coinfection with opportunistic infections and lymph node fibrosis, are likely to contribute to immune 
activation. Th17 and Th22 cells were the only CD4 T cell subsets to correlate with both immune activation 
and microbial translocation intimating that loss of these subsets may directly or indirectly drive these 
processes. This was supported by the association of shifts away from Th17 and Th22 cells towards Treg cells 
(and to a lesser extent Th1 cells) with both immune activation and microbial translocation. IDO, but not IL-
21+CD4 T cells, was associated with shifts towards Treg cells away from Th17 and Th22 cells implying that 
increased IDO in HIV-1 may drive upregulation of Treg cells with a reciprocal down regulation of Th17 and 
Th22 cells.  
HIV-1/HCV coinfection, naive to ART, displays the broadest, and in the context of LBP enhanced associations 
compared to HIV-1 and HCV monoinfection. This implies a stronger association between microbial 
translocation and immune activation in HIV-1/HCV coinfection. While weak negative correlations were seen 
between immune activation and functional Th17 or phenotypic Th22 cells in HCV and HIV-1/HCV coinfection, 
robust negative correlations were seen between immune activation and Th1 cells in untreated HIV-1 
coinfection with HCV. This indicates a more prominent role for Th1 cells compared to Th17 and Th22 cells in 
the development of immune activation in coinfection. This was supported by the reversal from positive to 
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negative correlations between Th1:Th17 or Th1:Th22 cell ratios and immune activation in HIV-1/HCV 
coinfection compared to HIV-1 monoinfection, while HCV monoinfection demonstrated no correlations. The 
shift from Th1 towards Th17 cells also correlated with microbial translocation. However an ongoing role for 
Th17 and Th22 cells was indicated by the strong correlations between shifts away from Th17 and Th22 cells 
towards Treg cells and both immune activation and microbial translocation. In addition Th22 cell frequencies 
in HCV monoinfection were shown to have a positive correlation with LBP concentrations which is in keeping 
with previous studies demonstrating that IL-22 stimulates production of LBP to LPS neutralising levels (Wolk 
et al., 2007). Thus a depletion of Th22 cells and the negative correlation with LBP in HIV-1 and and loss or 
correlation in HIV-1/HCV coinfection suggests that LBP levels known to neutralise LPS may not be reached 
allowing LPS to lead to immune activation unhindered. As in HIV-1 monoinfection increased IDO, but not IL-
21, may explain the reduction in Th17 and Th22 cells. 
However, how or if these CD4 T cell subset alterations affect the pathogenesis of liver disease in HIV-1/HCV 
coinfection is unclear. In Chapter 6 Results (4) we look for correlations between liver stiffness and immune 
activation, microbial translocation and CD4 T cell subsets. 
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Chapter 6 Results (4): Correlates of liver stiffness 
6.1 Introduction 
Chapter 5 Results (3) demonstrated an enhanced correlation between microbial translocation and immune 
activation in HIV-1/HCV coinfection compared to either HIV-1 or HCV monoinfection, implying a closer 
association between microbial translocation and immune activation. Th17 and Th22 cells and their reciprocal 
relationship with Treg cells were shown to play a pivotal role in immune activation and microbial 
translocation. However Th1 cells, their shifts towards Th17 and Th22 cells, and associations with immune 
activation highlight the complex mechanisms at play in the pathogenesis of HIV-1/HCV coinfection. In this 
chapter we aim to elucidate any variables studied which may drive the development of liver fibrosis in HIV-
1/HCV coinfection. The extent of liver fibrosis in study participants was determined using transient 
elastography (section 2.3).  
The disease mechanisms underlying progressive liver disease in HIV-1/HCV coinfection are complex and not 
well understood. Several different mechanisms have been suggested (section 1.5.4). Microbial translocation 
may contribute either directly (section 1.5.4.1) via LPS mediated activation of Kuppfer and HSC or indirectly 
(section 1.5.4.2) via induction of systemic immune activation and local hepatocyte activation induced 
apoptotic death with collagen deposition. Immune activation in the context of HIV-1 appears to augment the 
development of fibrosis in secondary lymphoid tissues. The causative factors of immune activation in HIV-1 
disease are not fully understood and are likely multifactorial, but include triggering of TLR7 and TLR9, binding 
of HIV proteins to cellular protein, direct viral killing of Treg cells or Treg cells leading to impaired T-cell 
responses (section 1.3.4). It is possible that in HIV-1 infection disruption of the requisite CD4 T cell subset 
composition in the periphery and GALT may drive increased microbial translocation (eg loss of Th17 or Th22 
cells) and/or systemic immune activation (eg shifts towards Treg cell responses) which in the context of an 
already injured liver, such as the case of HIV-1/HCV coinfection, may drive a more rapid development of liver 
fibrosis. 
In this chapter we aim to identify correlates of liver fibrosis in HIV-1 monoinfection, HCV monoinfection and 
HIV-1/HCV coinfection, as identified by transient elastography, from variables studied in the previous 
chapters (markers of microbial translocation, markers of immune activation and CD4 T cell subsets) (see 
Appendix 2 for review of literature on transient elastography as a tool to define severity of liver fibrosis). 
Previous studies of HCV monoinfection have demonstrated correlations between sCD14 and markers of 
hepatic inflammation (aspartate aminotransferase and ferritin) and fibrosis (γ glutamyl transpeptidase, 
alkaline phosphatise and α fetoprotein) (Sandler et al., 2011). Balagopal et al demonstrated an association 
between markers of microbial translocation (LPS and sCD14) and liver disease progression in HIV-1/HCV 
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coinfected individuals. Correlations between markers of immune activation and CD4 T cell subsets have not 
been extensively researched in HIV-1 monoinfection, HCV monoinfection and HIV-1/HCV coinfection. 
6.2 Aims 
Within the six study groups: 
 Assess the presence of correlations  between liver stiffness and : 
 Markers of microbial translocation (LPS, LBP and sCD14 concentrations) 
 Markers of immune activation (CD8+HLA-DR+CD38hi T cell frequencies, CD38 ABC of CD8 T 
cells and neopterin concentrations) 
 IDO activity (KTR) 
 CD4 T cell subsets (CD4, Thn, Th1, Th1Th17, Th17 and Th22 cell frequencies) 
 CD4 T cell cytokines (IFN-γ, IL-2, IL-17, IL-21 and IL-22) 
 CD4 T cell subset shifts (Th1:Th17, Th1:Th22, Th17:Treg, Th22:Treg) 
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6.3 Liver stiffness correlations 
6.3.1 Liver stiffness and microbial translocation, immune activation and 2,3- deoxygenase 
activity 
In order to identify any correlations between liver stiffness and: 
1) microbial translocation: LPS and LBP were used as direct markers and sCD14 as an indirect marker.  
2) immune activation: HLA-DR+CD38hi CD8 T cells, CD38 ABC of CD8 T cells and neopterin were used as 
markers. 
3) IDO activity: KTR was used as a marker. 
Table 30 Correlations between liver stiffness and microbial translocation, immune activation and 2,3-
deoxygenase activity 
   HCV HIV HIV NAIVE HCV HIV NAIVE   r p 
Liver stiffness LPS EU/ml - - - -   
 sCD14 ng/ml - - - -   
 LBP µg/ml - - - -   
Liver stiffness % HLA-DR+ CD38hi CD8  T cells ++ - - - 0.5575 0.0086 
 CD38 ABC of CD8 T cells - ++ - - 0.5385 0.0007 
 Neopterin (nmol/L) - + - - 0.4717 0.0037 
Liver stiffness KTR (µmol/L) - +
1 
- ++
2 2
0.5228 
2
0.1210 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.0167 for 
immune activation and microbial translocation and P < 0.05 for KTR) 
 
1 
r 0.4705, P = 0.0038 
 
6.3.1.1 Liver stiffness and microbial translocation 
No correlations were demonstrated between liver stiffness and markers of microbial translocation in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1)  
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6.3.1.2 Liver stiffness and immune activation 
Figure 103 Correlation of liver stiffness and frequency of HLA-DR+CD38hi CD8 T cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
There was a robust positive correlation between HLA-DR+CD38hi CD8 T cells and liver stiffness only when 
observing HCV monoinfected individuals (Spearman r = 0.5575, P = 0.0086). HIV-1 monoinfection did not 
demonstrate a correlation with the only HIV (HIV ART and HIV NAIVE) groups and HIV NAIVE group displaying 
Spearman r values of 0.3514 (P = 0.0356) and -0.2272 (P = 0.3354) respectively.  
There was no evidence of coinfection with HIV-1 holding this correlation with the HCV HIV NAIVE group 
demonstrating a Spearman r values of 0.3476 (P = 0.3251). It is possible the correlation is lost due to the less 
advanced HIV disease stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.   
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Figure 104 Correlation of liver stiffness and CD38 ABC of CD8+ T cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Only HIV- 1 infection demonstrated a correlation between CD38 ABC of CD8 T cells and liver stiffness. The 
only HIV (HIV ART and HIV NAIVE) groups demonstrated a Spearman r value of 0.5385 (P = 0.0007). This 
correlation appeared to be driven by untreated HIV-1 infection with the HIV NAIVE and HIV ART groups 
displaying significant Spearman r values of r 0.4323 (P = 0.0570) and  r -0.0534 (P = 0.8442) respectively. The 
HCV group displayed a Spearman r value of 0.4196 (P = 0.0583).  
There was no evidence of coinfection with HCV enhancing the correlation, with the HCV HIV NAIVE group 
demonstrating a Spearman r value of 0.1824 (P = 0.6141). It is possible the correlation is lost due to the less 
advanced HIV disease stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.   
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Figure 105 Correlation of liver stiffness and neopterin concentration  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
Only HIV- 1 infection demonstrated a correlation between neopterin concentrations and liver stiffness. The 
only HIV (HIV ART and HIV NAIVE) groups demonstrated a Spearman r value of 0.4717 (P = 0.0037). This 
correlation appeared to be driven by HIV-1 infection irrespective of ART status with neither the HIV NAIVE 
group nor the HIV ART groups displaying significant Spearman r values (Spearman r 0.3289, P = 0.1567 and  r 
= -0.1767, P = 0.5127). The HCV group displayed a Spearman r value of 0.2941 (P = 0.1957).  
There was no evidence of coinfection with HCV enhancing the correlation, with the HCV HIV NAIVE group 
demonstrating a Spearman r value of 0.3222 (P = 0.3693). It is possible the correlation is lost due to the less 
advanced HIV disease stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.   
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6.3.1.3 Liver stiffness and indoleamine 2,3-deoxygenase activity 
Figure 106 Correlation of liver stiffness and IDO activity 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
HCV monoinfection did not lead to a correlation between IDO activity and liver stiffness. A positive 
correlation was seen in HIV-1 monoinfected individuals with only HIV (HIV ART and HIV NAIVE) groups 
demonstrating a Spearman r value of 0.4705 (P = 0.0038). Having untreated HIV-1 infection appeared to 
drive this correlation with the HIV NAIVE group displaying a Spearman r value of 0.4159 (P = 0.0682), while 
the HIV ART group displayed a Spearman r value of -0.1158 (P = 0.6693).  
Coinfection with HCV appeared to enhance the correlation, with the HCV HIV NAIVE group demonstrating a 
Spearman r value of 0.5228 (P = 0.1210). 
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6.3.2 Liver stiffness and CD4 T cell subsets 
Table 31 Correlations between liver stiffness and CD4 T cell subsets 
   HCV HIV HIV NAIVE HCV HIV NAIVE  r p 
Liver stiffness % CD4 T cells - + - - -0.4289 0.0091 
 % Thn cells - - - -   
 % Th1 cells - - - ++ -0.6239 0.0539 
 % Th1Th17 cells - - - -   
 % Treg cells - - - -   
 % Th17 cells - - + - -0.4306 0.0197 
 % Th22 cells - + - - -0.4303 0.0140 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.0071) 
 
 
No correlations were demonstrated between liver stiffness and frequencies of Thn cells, Th1Th17 cells or 
Treg cells in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1). 
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Figure 107 Correlation of liver stiffness and frequency of CD4 T cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
The HCV group did not display a correlation between CD4 T cell frequency and liver stiffness (Spearman r 
0.2968, P = 0.1913). HIV-1 infection, irrespective of ART status, appeared to drive a negative correlation 
between CD4 T cell frequency and liver stiffness. The only HIV (HIV ART and HIV NAIVE) groups 
demonstrated a Spearman r value of -0.4289 (P = 0.0091). Effective ART did not appear to affect the 
correlation with the HIV NAIVE group and HIV ART group displaying similar correlations; Spearman r values 
of -0.2910 (P = 0.2116) and 0.3249 (P = 0.2195) respectively.  
Coinfection with HCV did not appear to hold or enhance the correlation with all HCV HIV (HCV HIV ART and 
HCV HIV NAIVE) groups displaying a Spearman r value of 0.0918 (P = 0.6423) and the HCV HIV NAIVE group a 
Spearman r value of -0.1094 (P = 0.7635). It is possible the correlation is lost due to the less advanced HIV 
disease stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.   
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Figure 108 Correlation of liver stiffness and frequency of Th1 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
. 
No correlations were demonstrated between Th1 cell frequencies and liver stiffness in HCV or HIV-1 
monoinfection. The HCV group, only HIV (HIV ART and HIV NAIVE) group and HIV NAIVE group displayed 
Spearman r values of -0.1995 (P = -0.3860), 0.0555 (P = 0.7516) and -0.0035 (P = 0.9888) respectively.  
The only correlation was demonstrated by the HCV HIV NAIVE group which demonstrated a Spearman r 
value of -0.6239 (P = 0.0538). Although non significant due to limited patient numbers it suggests some 
synergism in untreated HIV-1 infection and HCV infection leading to a correlation between Th1 cell 
frequencies and liver stiffness.  
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Figure 109 Correlation of liver stiffness and frequency of Th17 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
No correlations between Th17 cell frequencies and liver stiffness were observed when examining HCV 
infected individuals. A negative correlation was demonstrated in untreated HIV-1 monoinfection. While the 
only HIV (HIV ART and HIV NAIVE) groups displayed a Spearman r value of -0.3716 (P = 0.0332), the HIV 
NAIVE group displayed a Spearman r value of -0.4573 (P = 0.0490). The significance strengthened when 
observing all HIV NAIVE groups with a Spearman r value of -0.4306 (P = 0.0197).  
Coinfection with HIV-1/HCV did not appear to hold this correlation with the HCV HIV NAIVE group 
demonstrating a Spearman r value of -0.3318 (P = 0.0846). It is possible the correlation is lost due to the less 
advanced HIV disease stage of the individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.    
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Figure 110 Correlation of liver stiffness and frequency of Th22 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART group and HIV NAIVE group, HIV NAIVE group: includes HIV 
NAIVE group, all HIV NAIVE groups: includes HIV NAIVE group and HCV HIV NAIVE group. 
 
No correlations were observed when examining HCV infected individuals. A negative correlation was 
demonstrated between Th22 cell frequencies and liver stiffness in HIV-1 monoinfected individuals with only 
HIV (HIV ART and HIV NAIVE) groups displaying a Spearman r value of -0.4303 (P = 0.0140). Having untreated 
HIV-1 infection appeared to drive this correlation with a Spearman r value of -0.4019 (P = 0.0880) in the HIV 
NAIVE group. No correlations were observed when examining HCV infected individuals.  
In untreated HIV-1 infection, coinfection with HCV was not shown to hold the correlation with the HCV HIV 
NAIVE group displaying a Spearman r value of 0.1067 (P = 0.7692). This may be explained by the less 
advanced HIV-1 disease in individuals in the HCV HIV NAIVE group compared with the HIV NAIVE group.  
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6.3.3 Liver stiffness and CD4 T cell cytokines 
Table 32 Correlations between liver stiffness and CD4 T cell cytokines 
   HCV HIV HIV NAIVE HCV HIV NAIVE  r p 
Liver stiffness % CD4+IFN-γ+ cells - - - +++ -0.7784 0.0172 
 % CD4+IL-2+ cells - -
 
-
 
-   
 % CD4+IL-17A+ cells - - - -   
 % CD4+IL-21+ cells - - - ++ -0.5793 0.0793 
 % CD4+IL-22+ cells - - - -   
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.01) 
 
1 
r -0.4061, P = 0.0155 
 
No correlations were demonstrated between liver stiffness and frequencies of CD4+IL-2+, CD4+IL-17A+ or 
CD4+IL-22+ cells in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1).  
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Figure 111 Correlation of liver stiffness and frequency of CD4+IFN-γ+ cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
The HCV group did not display a correlation between frequency of IFN-γ+ CD4 T cells and liver stiffness 
(Spearman r -0.3975, P = 0.0743). No correlation was demonstrated in either the only HIV (HIV ART and HIV 
NAIVE) groups with a Spearman r value of -0.2016 (P = 0.2456), or the HIV NAIVE group with a Spearman r 
value of -0.3981 (P = 0.0914).  
The only correlation was demonstrated in coinfection of untreated HIV-1 with HCV. The HCV HIV NAIVE 
group displayed a negative correlation with a robust Spearman r value of -0.7782 (P = 0.0172). Although this 
was not significant, probably because of reduced numbers in this group, but there is the suggestion that 
coinfection results in synergism leading to a correlation between frequency of IFN-γ+ CD4 T cells and liver 
stiffness. 
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Figure 112 Correlation of liver stiffness and frequency of CD4+IL-21+ cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group 
 
HCV and HIV-1 monoinfection did not lead to a correlation between frequency of IL-21+ CD4 T cells and liver 
stiffness. The HCV group displayed a Spearman r value of 0.1978 (P = 0.4031), while the only HIV (HIV ART 
and HIV NAIVE) groups and the HIV NAIVE group displayed Spearman r values of -0.3438 (P = 0.0432) and 
0.0062 (P = 0.9800) respecitvely.  
The only correlation was seen in untreated HIV-1 in the context of coinfection with HCV. The HCV HIV NAIVE 
group demonstrated a Spearman r value of -0.5793 (P = 0.0793). Although this was not significant, probably 
because of reduced numbers in this group, but there is the suggestion that coinfection results in synergism 
leading to a correlation between frequency of IL-21+ CD4 T cells and liver stiffness. 
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6.3.4 Liver stiffness and CD4 T cell subset shifts 
Table 33 Correlations between liver stiffness and CD4 T cell subset shifts 
   HCV HIV HIV NAIVE HCV HIV NAIVE  r p 
Liver stiffness Th1:Th17 - - - ++ -0.6991 0.0245 
 Th1:Th22 - - - ++ -0.6869 0.0282 
 Th1:Treg - - - ++ -0.6687 0.0345 
 Th1Th17:Treg - - - - -0.3521 0.1519 
 Th17:Treg - - - - -0.3633 0.1154 
 Th22:Treg - - - - -0.2762 0.2524 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.0085) 
 
No correlations were demonstrated between liver stiffness and Th1Th17:Treg, Th17:Treg and Th22:Treg cell 
ratios in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection (Appendix 1).  
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Figure 113 Correlation of liver stiffness and Th1:Th17 cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlation was observed between Th1:Th17 cell ratios and liver stiffness in HCV monoinfection, HIV-1 
monoinfection, irrespective of ART status, and untreated HIV-1 monoinfection. The only correlation 
observed was in individuals with untreated HIV-1 infection in the context of HCV coinfection. The HCV HIV 
NAIVE group displayed a negative correlation with a Spearman r value of -0.6991 (P = 0.0245). Significance 
was not reached probably because of small numbers recruited to this group, but there is the suggestion that 
synergism between HCV and untreated HIV-1 infection leads to a negative correlation between Th1:Th17 cell 
ratios and liver stiffness. 
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Figure 114 Correlation of liver stiffness and Th1:Th22 cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlation was observed between Th1:Th22 cell ratios and liver stiffness in HCV monoinfection, HIV-1 
monoinfection, irrespective of ART status, and untreated HIV-1 monoinfection. The only correlation 
observed was in individuals with untreated HIV-1 infection in the context of HCV coinfection. The HCV HIV 
NAIVE group displayed a negative correlation with a Spearman r value of -0.6869 (P = 0.0282). Significance 
was not reached likely due to small numbers recruited to this group, but there is the suggestion that 
synergism between HCV and untreated HIV-1 infection leads to a negative correlation between Th1:Th22 cell 
ratios and liver stiffness. 
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Figure 115 Correlation of liver stiffness and Th1:Treg cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlation was observed between Th1:Treg cell ratios and liver stiffness in HCV monoinfection, HIV-1 
monoinfection, irrespective of ART status, and untreated HIV-1 monoinfection. The only correlation 
observed was in individuals with untreated HIV-1 infection in the context of HCV coinfection. The HCV HIV 
NAIVE group displayed a negative correlation with a Spearman r value of -0.6687 (P = 0.0345). Significance 
was not reached likely due to small numbers recruited to this group, but there is the suggestion that 
synergism between HCV and untreated HIV-1 infection leads to a negative correlation between Th1:Treg cell 
ratios and liver stiffness. 
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6.4 Conclusions 
6.4.1 Key findings 
In HIV-1 monoinfection liver stiffness correlated with cellular (CD38 ABC of CD8 T cells) and soluble 
(neopterin) markers of immune activation, but not microbial translocation (see table 34). IDO activity 
correlated positively with liver stiffness. Th17 and Th22 cells were the only CD4 T cells which correlated 
negatively with liver stiffness. 
In HIV-1/HCV coinfection liver stiffness was not shown to correlate with markers of immune activation or 
microbial translocation, while in HCV monoinfection HLA-DR+CD38hi CD8 T cell frequencies were positively 
correlated with liver stiffness. The positive correlation between IDO activity and liver stiffness was more 
robust than in either HIV-1 or HCV monoinfection. HCV monoinfection did not demonstrate any correlations 
between liver stiffness and CD4 T cell subsets, cytokines or subset shifts. Meanwhile HCV coinfection of 
untreated HIV-1 infection demonstrated negative correlations between phenotypic and functional Th1 (IFN-
γ+ CD4 T cells) cells and less robustly functional Th17 (IL-21+ CD4 T cells) cells. In addition shifts away from 
Th1 cells towards Th17, Th22 and Treg cells were negatively associated with liver stiffness. 
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Table 34 Summary of key findings: chapter 6 
Correlation HCV HIV NAIVE HCV HIV NAIVE 
Liver stiffness translocation ×* × ×** 
immune activation pos pos × 
IDO activity × pos pos 
Th1 × × neg 
Th1Th17 × × × 
Treg × × × 
Th17 × neg neg 
Th22 × neg × 
Th1:Treg × × neg 
Th1Th17:Treg × × × 
Th17:Treg × × × 
Th22:Treg × × × 
Th1:Th17 × × neg 
Th1:Th22 × × neg 
 
× correlation does not exist 
pos positive correlation exisits 
neg negative correlation exists 
= variable unchanged compared to control group 
 
Novel findings highlighted in green 
Different findings to previous highlighted in orange 
*  + Sandler et al., 2011 
**  + Balagopal et al., 2008 
  
239 | P a g e  
 
6.4.2 Discussion 
Correlations between indicies of microbial translocation and liver stiffness were not demonstrated in HIV-1 
infection, HCV infection or HIV-1/HCV coinfection. In HIV-1 monoinfection correlations were shown between 
liver stiffness and CD38 ABC of CD8 T cells (r 0.5385, P = 0.0007) and neopterin concentrations (r 0.4717, P = 
0.0037). The correlation with CD38 ABC of CD8 T cells was driven by untreated HIV-1 infection, while that 
with neopterin occurred irrespective of ART status. HCV monoinfection only demonstrated a positive 
correlation with one marker of microbial translocation (HLA-DR+CD38hi CD8 T cells). Coinfection did not 
demonstrate correlations with immune activation. This may be due to the less advanced HIV-1 disease stage 
in individuals in the HCV HIV NAIVE group compared to the HIV NAIVE group.  
HCV monoinfection did not result in any correlations between liver stiffness and CD4 T cell subsets, cytokines 
of subset shifts. HIV-1 monoinfection demonstrated inverse correlations with Th17 (r -0.4306, P = 0.0197) 
and Th22 (r -0.4303, P = 0.0140) cells. The correlation with Th17 cells was driven by untreated HIV-1 
infection, while the correlation with Th22 cells occurred irrespective of ART status. HIV-1/HCV coinfection 
displayed inverse correlations with functional and phenotypic Th1 (IFN-γ+ CD4 T cells) cells (r -0.6239, P = 
0.0539 and -0.7784, P = 0.0172) and less robustly functional Th17 (IL-21+ CD4 T cells) cells (r -0.5793, P = 
0.0793). While Th1Th17 and Treg cells did not correlate with liver stiffness in any disease group a marker of 
Treg cell activity did. IDO activity demonstrated positive correlations with liver stiffness. HCV monoinfection 
did not display correlations while both untreated HIV-1 monoinfection and HCV coinfection of untreated 
HIV-1 infection did with Spearman r values of 0.4705 (P = 0.0038) and 0.5228 (0.1210). 
CD4 T cell subset shifts between Th1Th17, Th17 or Th22 cells and Treg cells did not correlate with liver 
stiffness. However shifts in CD4 T cells from Treg, Th17 or Th22 cells towards Th1 cells were demonstrated to 
negatively correlate with liver stiffness only in the context of coinfection of untreated HIV-1 infection with 
HCV. 
6.4.3 Study limitations 
The main limitation of this study is its cross-sectional, rather than longitudinal, nature so that causality 
cannot be determined. As in the previous chapters the fact that individuals recruited to the HCV HIV NAIVE 
group appeared to have less advanced HIV-1 infection than the HIV NAIVE group means that correlations 
may not have been exposed. In addition the difficulty in recruiting to this group meant that statistical 
analyses may have been under powered.  
With regard to the measurement of liver fibrosis there are a number of limitations. Firstly the disease 
spectrum was relatively narrow. Any difference between variables is likely to be identified in comparing 
those with no liver disease to those with cirrhotic liver disease. However there were difficulties recruiting 
sufficient individuals with cirrhotic liver disease and thus individuals with mild to moderate liver disease 
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were also recruited. Secondly, with regard to transient elastography, there are still some concerns related to 
its accuracy and performance, a lack of standardised cut-off values for the designation of different stages of 
liver disease and difficulty in accurately defining non-cirrhotic liver fibrosis stages. This needs to be taken 
into account when interpreting the above results. 
6.4.4 Conclusions 
While correlations between liver stiffness and markers of microbial translocation were not demonstrated, 
increased levels of immune activation were associated with increased liver stiffness in HIV-1 monoinfection 
and HCV monoinfection. If microbial translocation is an indirect driver of liver fibrosis, via immune activation, 
rather than direct driver via products such as LPS, an association with liver stiffness would not necessarily be 
expected. However it is possible that either the indices used to define microbial translocation in this study or 
transient elastography used to define liver fibrosis are not sensitive or specific enough to allow an 
association to be shown. Lack of correlations in HIV-1/HCV coinfection may be due to less advanced HIV-1 
disease in the HCV HIV NAIVE group compared to the HIV NAIVE group, a lack of power or multiple causatory 
factors in coinfection weakening any association.  
Of the CD4 T cell subsets only reduced Th17 and Th22 cell frequencies were associated with increased levels 
of liver stiffness in HIV-1 infection. While HCV monoinfection did not appear to result in any associations 
between liver stiffness and phenotypic or functional CD4 T cells subsets, coinfection with HIV-1 did. An 
association between liver stiffness and reduced Th17 cells, but not Th22 cells, was demonstrated. In 
addition, in coinfection, depleted phenotypic and functional Th1 cells demonstrated more robust inverse 
correlations with liver stiffness. The importance of Th1 responses and liver stiffness in HIV-1/HCV coinfection 
was highlighted by the association between liver stiffness and a shift away from a Th1 response (towards 
Treg, Th17 and Th22 responses). While the shift towards Treg cells (away from Th1Th17, Th17 and Th22 
cells) was not associated with liver stiffness. The above results suggest that Th1 and Th17 cells, as opposed 
to other CD4 T cell subsets, are important to the development of liver fibrosis in HIV-1/HCV coinfection.  
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Chapter 7 General Conclusion 
7.1 Discussion 
7.1.1 Human Immunodeficiency Virus 
Our results have confirmed that infection with HIV-1 leads to increased systemic immune activation (HLA-
DR+CD38hi CD4 & CD8 T cells, CD38 ABC of CD8 T cells and neopterin) and an increase in microbial 
translocation (LBP and sCD14) neither of which are fully reversed by effective ART . A positive correlation 
between these markers of microbial translocation and immune activation has been demonstrated in 
untreated HIV-1 infection, suggesting that microbial translocation may be one of the contributory factors in 
driving immune activation. In this study, as in previous studies, correlations between microbial translocation 
and immune activation were modest, but this is unsurprising as multiple other factors such as; HIV, depletion 
of Treg cells, coinfection with opportunistic infections and lymph node fibrosis, are likely to contribute to 
immune activation.  
In addition we confirmed the preferential reduction of phenotypic (CCR4+CCR6+CD4 T cells) and functional 
(IL-17A+ and IL-21+ CD4 T cells) Th17 cells and demonstrated the finding of depleted phenotypic 
(CCR4+CCR6+CCR10+ CD4 T cells) and functional (IL-22+ CD4 T cells) Th22 cells, compared to other CD4 T cell 
subsets (Th1, Th1Th17 and Treg cells) in the periphery. Effective ART appeared to result in restoration of 
Th17 cells (functional and phenotypic), with only partial restoration of functional Th22 cells. Loss of IL-17A 
production may lead to reduced intestinal mucosal integrity with loss of: tight junctions, antimicrobial 
peptides, neutrophil recruitment and regulation of effector T cells in the gut. Diminished IL-21 may lead to 
exhaustion of CD8 T cells with loss of control of chronic infections and promote a shift from Th17 to Treg 
responses. While depletion of IL-22 may prevent early host defence against attaching and effacing bacterial 
gastrointestinal infections and prevent induction of LBP to LPS neutralising levels. Thus preferential 
depletions in these CD4 T cell subsets could lead to increased microbial translocation. Th17 and Th22 cells 
were the only CD4 T cell subsets shown to correlate negatively with both systemic immune activation and 
microbial translocation in HIV-1 infection. These correlations tended to be driven by untreated HIV-1 
infection, except for the correlation between Th22 cells and markers of microbial translocation which were 
present irrespective of ART status. This pilot data supports the suggestion that depletion of Th17 and Th22 
cells in HIV-1 infection contributes to the increased levels of microbial translocation and in turn increased 
immune activation seen in HIV-1 infection.  
We have demonstrated a shift towards Treg cells from Th1Th17, Th17 and Th22 cells, while the balance in 
Treg cells to Th1 cells was not altered. While shifts away from Th17 cells have previously been reported in 
HIV-1 infection, those from Th1Th17 and Th22 cells have not. Shifts towards Treg cells away from Th17 and 
Th22 (but not Th1 and Th1Th17) cells were associated with increased immune activation and microbial 
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translocation. In addition IDO, a marker of Treg cell activity, was positively correlated with immune 
activation and to a lesser extent microbial translocation. Whether this shift in CD4 T cells to predominant 
Treg cell responses, away from Th17 and Th22 cell responses, is a contributory cause or effect of immune 
activation in HIV-1 infection is unclear, but has been proposed as a mechanism through which immune 
activation can drive the development of fibrosis in peripheral tissues.  
HIV-1 infection was not shown to affect phenotypic Th1 cells, but in keeping with known literature we 
demonstrated a reduction in some Th1 cell responses in the form of IL-2+ CD4 T cells, which were not fully 
restored with effective ART. An altered balance between Th1 cells and Th17 (in contradiction to known 
literature) or Th22 cells was not demonstrated.  
Possible mechanisms for the loss of Th17 and Th22 cells in HIV-1 infection are still being investigated. It is 
possible that direct viral killing and / or redistribution of Th17 and Th22 cells to other tissues (eg GALT) may 
play a role. It remains unclear if frequencies in the periphery mirror those in the GALT or whether there is a 
homeostatic relationship between the two compartments. In addition IL-21 and IDO are thought to play 
important roles in the reciprocal relationship of Th17 and Treg cells. We have not demonstrated an 
association between IL-21+ CD4 T cells and the shift from Th17 to Treg cells. However we confirm increased 
IDO activity in untreated HIV-1 infection and an association between increased IDO activity and a shift 
towards Treg cells from Th17 and Th22 cells, but not Th1 or Th1Th17 cells. Increased IDO activity in HIV-1 
may explain the reduction in Th17 and Th22 cells and the shift towards Treg cells in untreated HIV-1 
infection.  
7.1.2 Hepatitis C Virus 
In HCV monoinfection this study has corroborated firstly a definitive increase in cellular (CD38 ABC of CD8 T 
cells) and soluble (neopterin) markers of immune activation and secondly a modest increase in microbial 
translocation via the measurement of the indirect markers LBP and sCD14. While LBP was not shown to 
correlate with immune activation in HCV monoinfection, sCD14 did display a modest positive correlation 
with both cellular (HLA-DR+CD38hi CD8 T cells) and soluble (neopterin) markers of immune activation.  
In addition we have verified the up regulation of Th1 cells, while demonstrating a shift towards Th1 
responses from Treg, Th17 and Th22 cells. HCV infection did not alter other CD4 T cell subset frequencies 
(Th1Th17, Treg, Th17 or Th22) or lead to a shift towards a Treg cell response. In HCV monoinfection only 
functional Th17 cells and phenotypic Th22 cells demonstrated weak inverse correlations with markers of 
immune activation. Th17 and Th22 cells were also shown to have inverse correlations with sCD14 (a marker 
of microbial translocation). These correlations were weaker than those seen in HIV-1 monoinfection implying 
a less prominent role for Th17 and Th22 cells in immune activation and microbial translocation in HCV 
monoinfection. Th22 cell frequencies in HCV monoinfection were shown to have a positive correlation with 
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LBP concentrations which is in keeping with previous studies demonstrating that IL-22 stimulates production 
of LBP (Wolk et al., 2007). This was supported by the correlation between LBP and the shift towards Th1 
responses away from Th22 responses. 
7.1.3 Human Immunodeficiency Virus and Hepatitis C Virus 
HIV-1/HCV coinfection led to a further significant increase in immune activation compared with HCV 
monoinfection, which was demonstrable in a broad number of cellular (HLA-DR+CD38hi CD4 & CD8 T cells 
and CD38 ABC of CD8 T cells) and soluble (neopterin) immune activation markers. In this study, contradictory 
to other recent studies, HIV-1/HCV coinfection did not demonstrate increased immune activation compared 
to HIV-1 monoinfection. This may be explained by the less advanced HIV disease in the HIV-1/HCV ART naive 
individuals compared with the HIV-1 ART naive individuals in this study. With respect to the markers of 
microbial translocation, LBP levels confirmed previous findings of a tendency to increased levels in HIV-
1/HCV coinfection compared to HC, while sCD14 showed increased levels compared to HC with a trend to 
increased levels compared to HCV monoinfection. We demonstrated a positive correlation between immune 
activation and microbial translocation in ART naive HIV-1/HCV coinfection, which was more robust than 
those correlations seen in both HIV-1 and HCV monoinfection. Therefore this pilot data supports the theory 
that in the context of coinfection there is increased microbial translocation which plays a more prominent 
role in driving immune activation than in either HCV or HIV-1 monoinfection. 
Infection with both untreated HIV-1 and HCV revealed a more complex and broad alteration of CD4 T cell 
subsets than either infection with HIV-1 or HCV alone. Coinfection led to reduced frequencies of Th1Th17, 
Th17 and Th22 cells compared to both HC and HCV monoinfection. The demonstration of reduced 
frequencies of IL-17A+, IL-21+ and IL-22+ CD4 T cells compared to HC and HCV monoinfected individuals 
further supports the depletion of Th17 and Th22 cells. Effective ART did not fully restore levels of functional 
Th17 or Th22 cells. These results highlight a comprehensive assault on CD4 T cell subsets in HIV-1/HCV 
coinfection, driven by HIV-1 infection, which is likely to impact on the natural history of HCV and may explain 
reduced rates of spontaneous clearance and increased HCV RNA titires. Depletion of phenotypic and 
functional Th17 cells appeared to be more marked in HIV-1/HCV coinfection than HIV-1 monoinfection. 
Weak negative correlations were seen between immune activation and functional Th17 or phenotypic Th22 
cells in HCV and HIV-1/HCV coinfection, suggesting that as in HIV-1 infection these CD4 T cell subsets play a 
role in immune activation. Unlike in HIV-1 monoinfection we did not demonstrate negative correlations 
between Th17 and Th22 cells and markers of microbial translocation. It is possible that this is due to the less 
advanced HIV-1 disease in the HIV-1/HCV ART naive individuals compared with the HIV-1 ART naive 
individuals in this study. This pilot data supports the suggestion that depletion of Th17 and Th22 cells (driven 
by HIV-1 infection) in HIV-1/HCV coinfection contributes to the increased levels of immune activation, 
possibly driven by increased microbial translocation.  
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In addition coinfection demonstrated a shift towards Treg cells and away from all other CD4 T cell subsets 
(Th1, Th1Th17, Th17 and Th22). These changes appear to be HIV-1 driven, rather than HCV driven, as HCV 
monoinfection did not demonstrate an alteration in the balance between Treg cells and other CD4 T cell 
subsets, where HIV-1 infection did.  Treg cells were shown to positively correlate with markers of microbial 
translocation (sCD14 and LBP). No such correlations were demonstrated in HIV-1 or HCV monoinfection.  In 
addition IDO, a marker of Treg cell activity, was positively correlated with immune activation and to a lesser 
extent microbial translocation. These were similar to correlations seen in HIV-1 monoinfection, but stronger 
than those in HCV monoinfection. The importance of the shift towards Treg cell responses, away from Th17 
and Th22 cell responses in driving increased immune activation and microbial translocation in coinfection 
was highlighted by the enhanced negative correlation between Th17:Treg and Th22:Treg cell ratios and 
cellular markers of immune activation (HLA-DR+CD38hi CD8 T cells and CD38 ABC of CD8 T cells) and 
microbial translocation (LBP) in HIV-1/HCV coinfection compared to HCV monoinfection. Thus in coinfection, 
both Th17 and Th22 cells may play a significant role in microbial translocation and immune activation while 
the shift towards Treg cells may contribute to down-regulating the immune response to HCV. However this 
research has highlighted the importance of Th1 cells in HIV-1/HCV coinfection. 
Compared to HCV monoinfection, coinfection was deficient in up regulation of phenotypic (CXCR3+CCR5+ 
CD4 T cells) and functional (IFN- γ+ and IL-2+ CD4 T cells) Th1 cells. The blunting of the Th1 response in HIV-
1/HCV coinfection compared to HCV is highlighted by a shift away from Th1 cells towards Treg, Th17 and 
Th22 cells. Th1 cells displayed the most robust negative correlations with all three markers of immune 
activation, while HIV-1 and HCV monoinfection displayed none. While HCV monoinfection did not 
demonstrate any correlations between immune activation and shifts in Th1 cells, HIV-1/HCV coinfection 
showed an association with immune activation and a shift away from Th1 cells towards Treg cells. In addition 
Th1:Th17 and Th1:Th22 cell ratios were shown to negatively correlate with immune activation, where in HIV-
1 monoinfection these correlations were positive. The shift from Th1 towards Th17 cells also correlated with 
microbial translocation. These data imply that failure to up regulate Th1 cells in HIV-1/HCV coinfection plays 
a pivotal role in the development of immune activation and possibly liver fibrosis. 
While Th22 cell frequencies in HCV monoinfection were shown to have a positive correlation with LBP 
concentrations and HIV-1 infection led to a negative correlation it is unsurprising that coinfection led to a 
loss of this positive correlation. A depletion of Th22 cells in HIV-1 infection suggests that in the context of 
coinfection with HCV LBP levels known to neutralise LPS may not be reached allowing LPS to lead to immune 
activation unhindered.  
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7.1.4 Liver fibrosis 
While correlations between liver stiffness and markers of microbial translocation were not demonstrated, 
increased levels of immune activation were associated with increased liver stiffness in HIV-1 monoinfection 
and HCV monoinfection. If microbial translocation is an indirect driver of liver fibrosis, via immune activation, 
rather than direct driver via products such as LPS, an association with liver stiffness would not necessarily be 
expected. However it is possible that either the indices used to define microbial translocation in this study or 
transient elastography used to define liver fibrosis are not sensitive or specific enough to allow an 
association to be shown. Lack of correlations in HIV-1/HCV coinfection may be due to less advanced HIV-1 
disease in the HCV HIV NAIVE group compared to the HIV NAIVE group, a lack of power or multiple causatory 
factors in coinfection weakening any association.  
Of the CD4 T cell subsets only reduced Th17 and Th22 cell frequencies were associated with increased levels 
of liver stiffness in HIV-1 infection. While HCV monoinfection did not appear to result in any associations 
between liver stiffness and phenotypic or functional CD4 T cells subsets, coinfection with HIV-1 did. An 
association between liver stiffness and reduced Th17 cells, but not Th22 cells, was demonstrated. In 
addition, in coinfection, depleted phenotypic and functional Th1 cells demonstrated more robust inverse 
correlations with liver stiffness. The importance of Th1 responses and liver stiffness in HIV-1/HCV coinfection 
was highlighted by the association between liver stiffness and a shift away from a Th1 response (towards 
Treg, Th17 and Th22 responses). While the shift towards Treg cells (away from Th1Th17, Th17 and Th22 
cells) was not associated with liver stiffness. The above results suggest that Th1 and Th17 cells, as opposed 
to other CD4 T cell subsets, are central to the development of liver fibrosis in HIV-1/HCV coinfection.  
  
246 | P a g e  
 
7.2 Study limitations 
Conclusions drawn from this research must be done while being aware of the limitations of the data 
presented. There are a number of noteworthy limitations to this study: 
 This is a pilot study and as such power calculations to determine appropriate sample size were not 
performed, therefore the sensitivity of this data is unknown. 
 The cross-sectional, rather than longitudinal, nature of the study means causality cannot be determined.  
 Due to difficulties in obtaining organ tissue, we have only analysed peripheral blood samples and have 
not paired these with tissue samples, therefore it is unknown if events in the periphery mirror those in 
either the gastrointestinal mucosal tissue or the liver.  
 An attempt was made, where possible, to match individuals recruited to each of the six study groups 
however: 
 Individuals in the HCV group tended to be older than those in the HC group 
 Individuals in the HCV HIV NAIVE group appeared to have less advanced HIV-1 infection (higher nadir 
CD4 T cell frequencies, a trend to increased absolute counts and frequencies of CD4 T cells and 
CD4:CD8 T cell ratios, normal Tn, Thtm and Them cell frequencies) than the HIV NAIVE group. This 
was due to present day clinical guidelines advising commencement of ART at an earlier stage in 
coinfection with HCV. The HCV HIV NAIVE group was therefore difficult to recruit to and individuals 
with higher CD4 counts were thus included. It is possible that due to this any differences in variables 
between HIV-1 infected individuals naive to ART and HIV-1/HCV coinfected individuals naive to ART 
are not discernable in this study. 
 Individuals in the HCV group had been diagnosed with HCV over twice as long as those individuals in 
the HCV HIV NAIVE group. 
 Identification of Treg cells is problematic due to the lack of standardised assays to measure levels and 
function of Treg cells and this study is open to criticism in the way in which we have identified T cells. As 
no consensus exists as to the definitive strategy to identify Treg cells we decided to adopt the approach 
our study group has the most experience with and one which has been used by other research groups 
(Hunt et al., 2011).  
 There are concerns over the accuracy of markers for measuring microbial translocation.  
 LPS and EndoCAb assays did not determine any significant differences between the study groups. 
This differs from published literature. It is possible that the assays were not successful due to 
methodological issues such as: sample collection, sample handling or errors within the assays. Other 
studies have had fewer study groups, with larger group numbers and significant overlap in results 
between groups. Therefore this pilot study may be underpowered to demonstrate differences. It is 
possible that these variables do not differ between study groups. Redd et al, in a longitudinal study 
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from Uganda, found no significant changes in LPS and EndoCAb during HIV-1 disease progression 
(Redd et al., 2009). 
 Our two remaining markers of microbial translocation were LBP, which is felt by some researchers to 
be a more reliable marker of microbial translocation than LPS because of its longer half life 
(Schumann and Latz, 2000), and sCD14 which is an indirect marker of microbial translocation being 
secreted by monocytes and macrophages upon LPS stimulation (Kitchens and Thompson, 2005). The 
difficulty with measuring indirect markers is that results may be complicated by the possibility of 
unknown confounding factors.  
 With regards to liver fibrosis there were a few concerns. 
 Firstly the disease spectrum was relatively narrow. Any difference between variables is likely to be 
identified in comparing those with no liver disease to those with cirrhotic liver disease. However 
there were difficulties recruiting sufficient individuals with cirrhotic liver disease and thus individuals 
with mild to moderate liver disease were also recruited. 
 Secondly, with regard to transient elastography, there are still some concerns related to its accuracy 
and performance, a lack of standardised cut-off values for the designation of different stages of liver 
disease and difficulty in accurately defining non-cirrhotic liver fibrosis stages. This needs to be taken 
into account when interpreting the above results. 
7.3 Future work 
Initially this data needs to be confirmed in cohorts from other centres. It would be important for future 
studies to be longitudinal in nature, with variables measured over multiple time points and clear endpoints 
to allow causality rather than purely associations to be determined. It would be useful to be able to pair 
peripheral blood samples with both liver and gut tissue to see if the changes in CD4 T cell subsets are 
paralleled in these tissues. It was beyond the scope of this research to look at HCV specific immune 
responses, as this would have required prolonged culture and stimulation to acquire sufficient cells, but 
forthcoming research may benefit from including such experiments. It would be important for future studies 
to look at multiple markers of microbial translocation: preferably direct markers, such as both LPS and 
16SrDNA. Finally future work would benefit from comparing extremes of disease. Although this may not be 
possible with regards to advanced HIV-1 coinfection with HCV as these individuals should be commenced on 
ART at an early stage, it would be important to study individuals with cirrhotic liver disease and compare 
variables to those with no liver disease. 
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7.4 Conclusions 
We have confirmed an association between microbial translocation and immune activation in HIV-1 
monoinfection. A preferential loss of Th17 and Th22 cells has been demonstrated and Th17 and Th22 cells 
have been shown to be the only CD4 T cell subsets that negatively correlate with both immune activation 
and microbial translocation, implying a role for the depletion of these two CD4 T cell subsets in the 
development of microbial translocation and immune activation in HIV-1 monoinfection. A possible 
mechanism for reduced Th17 and Th22 cells is increased IDO activity in untreated HIV-1 infection (see figure 
116). We not only demonstrated a shift towards Treg cells from both Th17 and Th22 cells in untreated HIV-1 
infection, but showed that these shifts were associated with microbial translocation, immune activation and 
increased IDO activity.  
Figure 116 Possible roles of Th17 and Th22 cells in HIV-1 pathogenesis 
 
HIV-1/HCV coinfection not only led to increased microbial translocation and immune activation than in HCV 
monoinfection, but also to more robust correlations between microbial translocation and immune activation 
than either HIV-1 or HCV monoinfection. This implies a more prominent role for microbial translocation 
driving immune activation.  
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Figure 117 Possible roles of Th17, Th22 and Th1 cells in HIV-1 pathogenesis 
 
Our data suggests involvement of Th17 and Th22 cells in driving microbial translocation, immune activation 
and liver fibrosis in HIV-1/HCV coinfection in keeping with our hypothesis, but in addition highlights the 
importance and possible involvement of Th1 responses (see figure 117). CD4 T cell subsets were more 
broadly affected than in either HIV-1 or HCV monoinfection, likely driven by HIV-1 infection. Th17 cell 
depletion was more marked than in HIV-1 monoinfection. Th1 frequencies were suppressed compared to 
HCV monoinfection and a shift in balance away from Th1 cells towards other CD4 T cell subsets including 
Th17 and Th22 cells was demonstrated. Only Th17, Th22 and Th1 cells were negatively associated with 
immune activation; these associations were more marked than those seen in HCV monoinfection. Loss of a 
positive correlation between Th22 cell frequencies and LBP concentrations suggests LBP levels known to 
neutralise LPS are not reached allowing LPS to lead to immune activation unhindered. Shifts towards Treg 
cells away from Th17 and Th22 cells were associated with microbial translocation and had enhanced 
associations with immune activation compared to both HIV-1 and HCV monoinfection. However, whereas 
HIV-1 monoinfection displayed associations between immune activaiton a shift away from Th1 and toward 
Th17 and Th22 cells, in HIV-1/HCV coinfection this association was reversed, but not as strong as the 
association with shifts away from Th17 and Th22 cells towards Treg cells. Shifts away from Th1 and towards 
Th17 and Th22 cells were not shown to be associated with microbial translocation. Evidence for associations 
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with the development of liver fibrosis was shown with Th1 and Th17 cells. Depletion of Th1 
(CD4+CXCR3+CCR5+ and CD4+IFN-γ+) cells and Th17 (CD4+IL-21+) cells and shifts away from Th1 cells 
(Th1:Th17, Th1:Th22 and Th1:Treg) were associated with increasing liver stiffness in HIV-1/HCV coinfection.   
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Appendices  
Appendix 1: Non significant correlations 
Immune activation and lipopolysaccaride 
Correlation of frequency of HLA-DR+CD38hi CD8 T cells and lipopolysaccharide concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between CD8+HLA-DR+CD38hi cell frequencies and lipopolysaccharide 
concentrations in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection.  
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Correlation of CD38 ABC of CD8+ T cells and lipopolysaccharide concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between CD38 ABC of CD8+ T cells and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of neopertin concentration and lipolysaccharride concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between neopterin concentrations and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Immune activation and Th1Th17 cells 
Correlation of frequency of HLA-DR+CD38hi CD8 T cells and frequency of Th1Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No true correlations were observed between Th1Th17 cell frequencies and HLA-DR+CD38hi CD8 T cell 
frequencies in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
  
a) Correlation of immune activation and frequency of Th1Th17 cells
(HCV group)
0 5 10 15 20
0
5
10
15
20
25
30
% CD8+HLA-DR+CD38hi T cells
%
 T
h
1
Th
1
7
 c
e
ll
b) Correlation of immune activation and frequency of Th1Th17 cells
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c) Correlation of immune activation and frequency of Th1Th17 cells
(HIV NAIVE group)
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d) Correlation of immune activation and frequency of Th1Th17 cells
(HCV HIV NAIVE group)
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Correlation of CD38 ABC of CD8 T cells and frequency of Th1Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No true correlations were observed between Th1Th17 cell frequencies and CD38 ABC of CD8 T cell 
frequencies in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a) Correlation of immune activation and frequency of Th1Th17 cells
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c) Correlation of immune activation and frequency of Th1Th17 cells
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d) Correlation of immune activation and frequency of Th1Th17 cells
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Correlation of neopterin and Th1Th17 cell frequency  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No true correlations were observed between Th1Th17 cell frequencies and neopterin in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection.  
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b) Correlation of immune activation and frequency of Th1Th17 cells
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c) Correlation of immune activation and frequency of Th1Th17 cells
(HIV NAIVE group)
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(HCV HIV NAIVE group)
0 10 20 30
0
5
10
15
Neopterin (nmol/L)
%
 T
h
1
Th
1
7
 c
e
lls Spearman r 0.2371
P = 0.1136
257 | P a g e  
 
Immune activation and Treg cells 
Correlation of frequency of HLA-DR+CD38hi CD8 T cells and frequency of Treg cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between CD8+HLA-DR+CD38hi cell frequencies and Treg cell 
frequencies in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of CD38 ABC of CD8+ T cells and frequency of Treg cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between CD38 ABC of CD8+ T cells and Treg cell frequencies in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of neopertin concentration and frequency of Treg cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between neopterin concentrations and Treg cell frequencies in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
  
a) Correlation of immune activation and frequency of Treg cells
(HCV group)
0 5 10 15 20 25
0
5
10
15
20
Neopterin (nmol/L)
%
 T
re
g 
ce
lls
b) Correlation of immune activation and frequency of Treg cells
(only HIV groups)
0 10 20 30 40 50 60
0
10
20
30
40
Neopterin (nmol/L)
%
 T
re
g 
ce
lls
c) Correlation of immune activation and frequency of Treg cells
(HIV NAIVE group)
0 10 20 30 40 50 60
0
5
10
15
20
Neopterin (nmol/L)
%
 T
re
g 
ce
lls
d) Correlation of immune activation and frequency of Treg cells
(HCV HIV NAIVE group)
0 10 20 30
0
5
10
15
20
Neopterin (nmol/L)
%
 T
re
g 
ce
lls
Spearman r -0.0351
P = 0.8799
Spearman r 0.0689
P = 0.6898
Spearman r 0.1985
P = 0.4015
Spearman r 0.2727
P = 0.4478
260 | P a g e  
 
Immune activation and IFN-γ+ CD4 T cells 
Correlation of frequency of HLA-DR+CD38hiCD8 T cells and frequency of IFN-γ+ CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between IFN-γ+ CD4 T cells cell frequencies and CD8+HLA-DR+CD38hi 
cell frequencies in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
 
 
 
 
 
 
a) Correlation of immune activation and CD4+IFN-g+ cells
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b) Correlation of immune activation and CD4+IFN-g+ cells
(only HIV groups)
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c) Correlation of immune activation and CD4+IFN-g+ cells
(HIV NAIVE group)
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d) Correlation of immune activation and CD4+IFN-g+ cells
(HCV HIV NAIVE group)
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Correlation of frequency of CD38 ABC of CD8 T cells and frequency of IFN-γ+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between IFN-γ+ CD4 T cells cell frequencies and CD38 ABC of CD8 T 
cells in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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c) Correlation of immune activation and CD4+IFN-g+ cells
(HIV NAIVE group)
0 1000 2000 3000 4000 5000 6000
0.0
2.5
5.0
7.5
10.0
12.5
15.0
CD38 ABC of CD8+ T cells
%
 C
D
4
+I
FN
-g
+ 
ce
lls
Spearman r 0.0636
P = 0.7841
Spearman r 0.1485
P = 0.3947
Spearman r 0.0526
P = 0.8306
d) Correlation of immune activation and CD4+IFN-g+ cells
(HCV HIV NAIVE group)
0 1000 2000 3000 4000 5000 6000
0
2
4
6
CD38 ABC of CD8+ T cells
%
 C
D
4
+I
FN
-g
+ 
ce
lls Spearman r 0.0526
P = 0.8306
262 | P a g e  
 
Correlation of neopterin and frequency of IFN-γ+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between IFN-γ+ CD4 T cells cell frequencies and neopterin 
concentrations in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Immune activation and IL-17A+ CD4 T cells 
Correlation of frequency of HLA-DR+CD38hiCD8 T cells and frequency of IL-17A+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between IL-17A+ CD4 T cells cell frequencies and CD8+HLA-DR+CD38hi 
cell frequencies in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
 
 
 
 
 
 
 
a) Correlation of immune activation and CD4+IL-17A+ cells
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b) Correlation of immune activation and CD4+IL-17A+ cells
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Correlation of frequency of neopterin and frequency of IL-17A+CD4 T cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between IL-17A+ CD4 T cells cell frequencies and CD8+HLA-DR+CD38hi 
cell frequencies in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Correlation of immune activation and CD4+IL-17A+ cells
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b) Correlation of immune activation and CD4+IL-17A+ cells
(only HIV groups)
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Immune activation and IL-21+ CD4 T cells  
Correlation of neopterin and frequency of IL-21+CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between IL-21+ CD4 T cells cell frequencies and neopterin 
concentration in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
 
 
  
a) Correlation of immune activation and CD4+IL-21+ cells
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Immune activation and Th1Th17:Treg cell ratio 
Correlation of frequency of HLA-DR+CD38hiCD8 T cells and Th1Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between HLA-DR+CD38hi CD8 T cell frequencies and Th1Th17:Treg cell 
ratios in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
 
 
 
 
 
 
 
a) Correlation of immune activation and Th1Th17:Treg  cell ratio
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b) Correlation of immune activation and Th1Th17:Treg  cell ratio
(only  HIV groups)
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c) Correlation of immune activation and Th1Th17:Treg  cell ratio
(HIV NAIVE group)
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d) Correlation of immune activation and Th1Th17:Treg  cell ratio
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Correlation of frequency of CD38 ABC of CD8 T cells and Th1Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between CD38 ABC of CD8 T cells and Th1Th17:Treg cell ratios in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
 
 
 
 
 
 
 
 
a) Correlation of immune activation and Th1Th17:Treg cell ratio
(HCV group)
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b) Correlation of immune activation and Th1Th17:Treg cell ratio
(only HIV groups)
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c) Correlation of immune activation and Th1Th17:Treg cell ratio
(HIV NAIVE group)
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d) Correlation of immune activation and Th1Th17:Treg cell ratio
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Correlation of neopterin and Th1Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between neopterin concentrations and Th1Th17:Treg cell ratios in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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b) Correlation of immune activation and Th1Th17:Treg cell ratio
(only  HIV groups)
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c) Correlation of immune activation and Th1Th17:Treg cell ratio
(HIV NAIVE group)
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Immune activation and Th1:Th17 cell ratio 
Correlation of frequency of HLA-DR+CD38hiCD8 T cells and Th1:Th17 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between HLA-DR+CD38hi CD8 T cell frequencies and Th1:Th17 cell 
ratios in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
 
 
 
 
 
 
a) Correlation of immune activation and Th1:Th17 cell ratio
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b) Correlation of immune activation and Th1:Th17 cell ratio
(only  HIV groups)
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c) Correlation of immune activation and Th1:Th17 cell ratio
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d) Correlation of immune activation and Th1:Th17 cell ratio
(HCV HIV NAIVE group)
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Immune activation and Th1:Th22 cell ratio 
Correlation of frequency of HLA-DR+CD38hiCD8 T cells and Th1:Th22 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between HLA-DR+CD38hi CD8 T cell frequencies and Th1:Th22 cell 
ratios in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
 
 
 
 
 
 
a) Correlation of immune activation and Th1:Th22 cell ratio
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b) Correlation of immune activation and Th1:Th22 cell ratio
(only HIV groups)
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c) Correlation of immune activation and Th1:Th22 cell ratio
(HIV NAIVE group)
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d) Correlation of immune activation and Th1:Th22 cell ratio
(HCV HIV NAIVE group)
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Microbial translocation and Th1 cells 
Correlation of lipopolysaccharide and frequency of Th1 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1 cell frequencies and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
  
d) Correlation of microbial translocation and frequency of Th1 cells
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Correlation of soluble CD14 and frequency of Th1 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1 cell frequencies and soluble CD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of lipopolysaccharide binding protein and frequency of Th1 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1 cell frequencies and LBP concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Microbial translocation and Th1Th17 cells 
Correlation of lipopolysaccharide and frequency of Th1Th17 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1Th17 cell frequencies and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
d) Correlation of microbial translocation and frequency of Th1Th17 cells
(HCV HIV NAIVE group)
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Correlation of soluble CD14 and frequency of Th1Th17 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1Th17 cell frequencies and soluble CD14 concentrations in 
HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of lipopolysaccharide binding protein and frequency of Th1Th17 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1Th17 cell frequencies and LBP concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
  
d) Correlation of microbial translocation and frequency of Th1Th17 cells
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b) Correlation of microbial translocation and frequency of Th1Th17 cells
(only HIV groups)
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Microbial translocation and Treg cells 
Correlation of lipoploysaccharide and frequency of Treg cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Treg cell frequencies and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of soluble CD14 and frequency of Treg cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Treg cell frequencies and sCD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Microbial translocation and Th17 cells 
Correlation of lipoploysaccharide and frequency of Th17 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th17 cell frequencies and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Microbial translocation and Th22 cells 
Correlation of lipoploysacchardie and frequency of Th22 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th22 cell frequencies and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Microbial translocation and CD4 T cell cytokines 
Correlations between markers of microbial translocation and CD4 T cell cytokines 
   HCV HIV HIV NAIVE HCV HIV NAIVE   r p 
IFN-γ LPS EU/ml - - -
1
 - 
1
-0.2603 
1
0.2818 
 sCD14 ng/ml -
2
 - - - 
2
-0.0994 
2
0.6681 
 LBP µg/ml - - -
3
 - 
3
0.3080 
3
0.1995 
        
IL-2 LPS EU/ml -
4
 - - - 
4
0.4027 
4
0.0703 
 sCD14 ng/ml - -
5 
- - 
5
-0.2946 
5
0.0858 
 LBP µg/ml - - -
6 
- 
6
-0.1913 
6
0.4327 
        
IL-17A LPS EU/ml - - -
7 
- 
7
0.1539 
7
0.5420 
 sCD14 ng/ml -
8 
- - - 
8
-0.1464 
8
0.5266 
 LBP µg/ml - - - -
9 9
0.1746 
9
0.6296 
        
IL-21 LPS EU/ml - - - -
10
 
10
0.5058 
10
0.1358 
 sCD14 ng/ml -
11
 - - - 
11
-0.4575 
11
0.0425 
 LBP µg/ml - - - -
12 12
0. 2711 
12
0. 1152 
        
IL-22 LPS EU/ml - - - -
13
 
13
0. 6918 
13
0. 0267 
 sCD14 ng/ml - - - -
14 14
0.4303 
14
0.2145 
 LBP µg/ml - - - -
15 
0.3212 0.3655 
 
HCV: HCV monoinfection, HIV: HIV monoinfection, irrespective of ART status, HIV NAIVE: HIV monoinfection naive to ART,  
HCV HIV NAIVE: HIV-1/HCV coinfection naive to ART 
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.01) 
  
282 | P a g e  
 
Microbial translocation and Th1:Treg cell ratio  
Correlation of lipopolysaccharide and Th1:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1:Treg cell ratios and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of soluble CD14 and Th1:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1:Treg cell ratios and sCD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Microbial translocation and Th1Th17:Treg cell ratio  
Correlation of lipopolysaccharide and Th1Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1Th17:Treg cell ratios and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of soluble CD14 and Th1Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1Th17:Treg cell ratios and sCD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of lipopolysaccharide binding protein and Th1Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1Th17:Treg cell ratios and LBP concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Microbial translocation and Th17:Treg cell ratio  
Correlation of lipopolysaccharide and Th17:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th17:Treg cell ratios and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Microbial translocation and Th22:Treg cell ratio  
Correlation of lipopolysaccharide and Th22:Treg cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th22:Treg cell ratios and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Microbial translocation and Th1:Th17 cell ratio  
Correlation of lipopolysaccharide and Th1:Th17 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1:Th17 cell ratios and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of soluble CD14 and Th1:Th17 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1:Th17 cell ratios and sCD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
 
  
a) Correlation of microbial translocation and Th1:Th17 cell ratio
(HCV group)
1000 2000 3000 4000 5000
0
1
2
3
4
5
sCD14 ng/ml
Th
1
:T
h
1
7
 c
e
ll 
ra
ti
o
b) Correlation of microbial translocation and Th1:Th17 cell ratio
(only HIV groups)
1000 2000 3000 4000 5000
0
1
2
3
sCD14 ng/ml
Th
1
:T
h
1
7
 c
e
ll 
ra
ti
o
c) Correlation of microbial translocation and Th1:Th17 cell ratio
(HIV NAIVE group)
1000 2000 3000 4000 5000
0
1
2
3
sCD14 ng/ml
Th
1
:T
h
1
7
 c
e
ll 
ra
ti
o
d) Correlation of microbial translocation and Th1:Th17 cell ratio
(HCV HIV NAIVE group)
1000 2000 3000 4000 5000
0.0
0.1
0.2
0.3
0.4
0.5
sCD14 ng/ml
Th
1
:T
h
1
7
 c
e
ll 
ra
ti
o
Spearman r -0.1083
P = 0.6494
Spearman r 0.2870
P = 0.2481
Spearman r 0.0618
P = 0.7370
Spearman r -0.1273
P = 0.7261
291 | P a g e  
 
Microbial translocation and Th1:Th22 cell ratio  
Correlation of lipopolysaccharide and Th1:Th22 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1:Th22 cell ratios and LPS concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of soluble CD14 and Th1:Th22 cell ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between Th1:Th22 cell ratios and sCD14 concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Indoleamine 2,3-dioxygenase activity and microbial translocation 
Correlation of lipopolysaccharide and IDO activity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between IDO activity and LPS concentrations in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Indoleamine 2,3-dioxygenase activity CD4 T cell subset shifts  
Correlation of IDO activity and Th1:Treg cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between KTR and Th1:Treg cell ratios in HCV monoinfection, HIV-1 
monoinfection or HIV-1/HCV coinfection.  
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Correlation of IDO activity and Th1Th17:Treg cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations where demonstrated between KTR and Th1Th17:Treg cell ratios in HCV monoinfection, HIV-1 
monoinfection or HIV-1/HCV coinfection. 
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IL-21 and CD4 T cell subset shifts  
Correlations between IL-21and CD4 T cell subsets shifts 
   HCV HIV HIV NAIVE HCV HIV   r p 
IL-21 Th1:Treg - - - -
1 1
0.3161 
1
0.3736 
 Th1Th17:Treg - - -
2 
- 
2
0.3326 
2
0.1641 
 Th17:Treg - -
3 
- - 
3
0.3260 
3
0.0687 
 Th22:Treg -
4 
- - - 
4
-0.2877 
4
0.2323 
 
HCV: HCV monoinfection, HIV: HIV monoinfection , irrespective of ART status,, HIV NAIVE: untreated HIV monoinfection,  
HCV HIV: HIV-1/HCV coinfection  
 
-: no correlation, +: correlation, ++: stronger correlation, +++: strongest correlation 
 
r: Spearman r value of strongest correlation (those in red r ≥ 0.4000), p: p value of strongest correlation (those in red P < 0.0125 for 
immune activation and microbial translocation and P < 0.0125 for CD4 T cell subset shifts) 
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Liver stiffness and microbial translocation 
Correlation of liver stiffness and lipopolysaccharide concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between liver stiffness and LPS concentrations in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection.  
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Correlation of liver stiffness and soluble CD14 concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between liver stiffness and sCD14 concentrations in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection.  
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Correlation of liver stiffness and lipopolysaccharide binding protein concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between liver stiffness and LBP concentrations in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection.  
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Liver stiffness and CD4 T cell subsets 
Correlation of liver stiffness and frequency of naive CD4 T cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between Thn cell frequencies and liver stiffness in HCV monoinfection, 
HIV-1 monoinfection or HIV-1/HCV coinfection.  
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Correlation of liver stiffness and frequency of Th1Th17 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between Th1Th17 cell frequencies and liver stiffness concentrations in 
HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of liver stiffness and frequency of Treg cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between Treg cell frequencies and liver stiffness concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Liver stiffness and CD4 T cell cytokines 
Correlation of liver stiffness and frequency of CD4+IL-2+ cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between the frequency of IL-21+ CD4 T cells and liver stiffness 
concentrations in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of liver stiffness and frequency of CD4+IL-17A+ cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, HIV NAIVE group: includes HIV NAIVE group, all HIV NAIVE groups: includes HIV NAIVE and HCV 
HIV NAIVE groups, HCV HIV NAIVE group: includes HCV HIV NAIVE group 
No correlations were demonstrated between the frequency of IL-17A+ CD4 T cells and liver stiffness 
concentrations in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of liver stiffness and frequency of CD4+IL-22+ cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group 
 
No correlations were demonstrated between the frequency of IL-22+ CD4 T cells and liver stiffness 
concentrations in HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Liver stiffness and CD4 T cell subset shifts 
Correlation of liver stiffness and Th1Th17:Treg cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between Th1Th17:Treg cell ratios and liver stiffness concentrations in 
HCV monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Correlation of liver stiffness and Th17:Treg cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between Th17:Treg cell ratios and liver stiffness concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
  
a) Correlation of liver stiffness and Th17:Treg cell ratio
(HCV group)
0 10 20 30 40
0.0
0.5
1.0
1.5
2.0
2.5
liver stiffness (KPa)
Th
1
7
:T
re
g 
ce
lls
b) Correlation of liver stiffness and Th17:Treg cell ratio
(only  HIV groups)
0 2 4 6 8 10
0.0
0.5
1.0
1.5
2.0
2.5
liver stiffness (KPa)
Th
1
7
:T
re
g 
ce
lls
c) Correlation of liver stiffness and Th17:Treg cell ratio
(HIV NAIVE group)
0 2 4 6 8 10
0.0
0.5
1.0
1.5
2.0
2.5
liver stiffness (KPa)
Th
1
7
:T
re
g 
ce
lls
d) Correlation of liver stiffness and Th17:Treg cell ratio
(HCV HIV NAIVE group)
0 3 6 9 12 15
0.0
0.2
0.4
0.6
0.8
1.0
liver stiffness (KPa)
Th
1
7
:T
re
g 
ce
lls
Spearman r -0.3633
P = 0.1154
Spearman r -0.2025
P = 0.2584
Spearman r -0.3289
P = 0.1619
Spearman r -0.3040
P = 0.3932
308 | P a g e  
 
Correlation of liver stiffness and Th22:Treg cell ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV group: includes HCV group, only HIV groups: includes HIV ART and HIV NAIVE groups, HIV NAIVE group: includes HIV NAIVE 
group, HCV HIV NAIVE group: includes HCV HIV NAIVE group. 
 
No correlations were demonstrated between Th22:Treg cell ratios and liver stiffness concentrations in HCV 
monoinfection, HIV-1 monoinfection or HIV-1/HCV coinfection. 
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Appendix 2: Review of literature on transient elastography as a tool to define 
severity of liver fibrosis 
The value of transient elastography for the assessment of the severity of liver fibrosis in chronic hepatitis, 
due to a number of different aetiologies, is under evaluation. In a meta-analysis (Talwalkar et al., 2007) 
based on seven studies the pooled estimates for the diagnosis of significant fibrosis (≥F2) were good: 
sensitivity 70% (95% CI, 67%-73%), specificity 84% (95% CI, 80%-88%), positive likelihood ratio 4.2 (95%CI, 
2.4-7.2) and negative likelihood ratio 0.31 (95% CI, 0.23-0.43). Estimates for the diagnosis of cirrhosis (F=4) 
were excellent: sensitivity 87% (95% CI, 84%-90%), specificity 91% (95% CI, 89%-92%), positive likelihood 
ratio 11.7 (95% CI, 7.9-17.1) negative likelihood ratio 0.14 (95% CI, 0.10-0.20). However a ‘cut-off effect’ was 
identified as an important cause of heterogenicity for pooled results. Reported cut-offs for cirrhosis range 
from 10.3 kPa in chronic hepatitis B to 17.3 kPa in chronic cholestatic diseases. Thus it appears that cut-off 
values should be specifically defined for each aetiology. 
Several studies have been carried out to look at the reliability of transient elastography for the diagnosis of 
fibrosis in patients with chronic hepatitis C alone. An initial study by Castera et al (Castera et al., 2005) 
showed that liver stiffness values correlated strongly with Metavir fibrosis stages. The area under the 
receiver operator characteristic curve (AUROC) was 0.83 for F≥2 using a cut-off value of 7.1 kPa. The best 
performances were observed for severe fibrosis (F≥3) and cirrhosis (F=4) with AUROCs of 0.90 and 0.95. The 
cut-off values used were 9.5 kPa for F≥3 and 12.5 kPa for F=4. Despite high AUROC values there was a 
substantial overlap of liver stiffness values observed between adjacent stages of hepatic fibrosis, particularly 
for lower stages. Arena et al (Arena et al., 2008) demonstrated that for a cut-off value of 7.8 kPa (F≥2), the 
liver stiffness had a PPV of 83%, an NPV of 79%, a sensitivity of 83% and a specificity of 82%. The positive 
likelihood ratio was 4.8 and the negative likelihood ratio was 0.2. Values were improved for determining the 
presence of severe fibrosis or cirrhosis (≥F3) with a cut-off value of 10.8 kPa having a PPV of 89%, an NPV of 
95%, a sensitivity of 91% and a specificity of 94%. There were markedly improved likelihood ratios of 14.27 
and 0.09. This study also revealed that necro-inflammatory activity at biopsy influences transient 
elastography values with liver stiffness values increasing on average by 1.7 kPa in those with A2-3 compared 
to A1 and by 2.4 kPa compared with A0. Hepatic steatosis was not shown to influence liver stiffness values. 
Sporea et al demonstrated that a cut-off value of 6.8 kPa was most accurate for discriminating between 
absent or mild fibrosis (F<2) and the presence of moderate and severe fibrosis (F≥2), compared with 7.2 kPa 
and 7.5 kPa. The liver stiffness had a PPV of 98%, an NPV of 30.1%, a sensitivity of 59.6% and a specificity of 
93.3% for the presence of significant fibrosis (≥F2 Metavir) (Sporea et al., 2008). Recently Calvaruso et al 
looked at discordance rates between transient elastrograpy and histology in 300 individuals with chronic 
HCV who had transient elastography and liver biopsy performed on the same day (Calvaruso et al., 2010). 
34% displayed discordance between elastography and histological results, but none were in individuals with 
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cirrhosis which was always correctly identified. Using a transient elastography cut off of 7.1 KPa, false 
negative results were almost four times as common as false positive results. Individuals with an AST of ≥ 1.5 
times the upper limit of normal were found to have much reduced discordance rates.  
A few studies have evaluated the performance of transient elastography in the diagnosis of fibrosis in HIV-
1/HCV coinfection, and performance was shown to be similar to that in HCV monoinfection (Vergara et al., 
2007, de Ledinghen et al., 2006). de Lendinghen et al used cut off values of 4.5 kPa (≥F2), 11.8 kPa (≥F3) and 
14.5 kPa (=F4). These gave sensitivities of 93%, 100% and 88.2%, specificities of 17.9%, 92.7% and 96.4% and 
AUROCs of 0.72, 0.91 and 0.97 respectively. Vergarar et al used only two cut off values; 7.2 kPa for ≥F2 
disease and 14.6 kPa for F=4. These gave sensitivities of 87% and 93%, specificities of 64% and 88%, with 
AUROCs of 0.87 and 0.95 respectively. A more recent study has confirmed similar AUROC results. Sanchez-
Conde et al used cut offs of <7 KPa (<F1), ≥11 KPa (≥F3) and ≥14 KPa (F4) which demonstrated an AUROC of 
0.80 to exclude fibrosis, 0.03 to identify advanced fibrosis and 0.99 to identify cirrhosis (Sanchez-Conde et 
al., 2010). Overall, the performance of transient elastography for the detection of liver disease among HCV 
and HIV-1/HCV coinfected patients appears to be an acceptable non invasive alternative to the error prone 
‘gold standard’ of liver biopsy.  
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Appendix 3: Study documentation 
Ethics and Research and Development Documentaion 
Ethical approval 
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Research and Development Approval 
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Patient information sheets and consent form 
Patient information sheet: FibroScan 
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Patient Information Sheet: HCV monoinfection 
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Patient Information Sheet: HIV monoinfection 
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Patient Information Sheet: HIV-1/HCV coinfection 
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Consent Form 
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